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Abstract 
Low  angiotensin  converting  enzyme  (ACE)  activity  is  associated  with  various 
cardiovascular phenotypes including reduced left ventricular (LV) hypertrophy, reduced 
cardiovascular events and enhanced metabolic efficiency, but precise mechanisms are 
unclear and direct genetic associations remain controversial.  ACE degrades kinins and 
promotes formation of angiotensin II. Combined genetic and in vitro studies were used 
to test the hypothesis that the previously observed effects may be through alterations in 
kinins or mitochondrial function via novel uncoupling proteins (UCPs).   
 
The -9 allele of the bradykinin β2 receptor BDKRB2+9/-9 gene variant is correlated 
with low kinin activity and was associated with lower prospective LV growth during 
strenuous physical exercise and lower prospective hypertensive cardiovascular risk, as 
well as increased efficiency of skeletal muscle contraction (delta efficiency) in healthy 
volunteers (P = 0.003, accounting for 11% of the inter-individual variability).   
  
Addition of angiotensin II to skeletal myocytes resulted in a 3.5 fold increase in oxygen 
consumption (P = 0.03). Incubation of isolated myocytes with an ACE inhibitor lead to 
mitochondrial membrane hyperpolarisation, suggesting mitochondrial coupling may be 
an important mediator of the cellular actions of ACE.   
 
A common promoter variant in the UCP2 gene was associated with a two-fold increase 
in prospective cardiovascular risk (P < 0.0001).  Variation in the UCP3/2 gene cluster 
accounted for 15% of the inter-individual endurance training related changes in delta 
efficiency  and  there  was  a  surprising,  but  consistent,  association  with  serum  ACE 
activity.  Finally, in vitro assays confirmed physiological downregulation of UCP2 in  
  5 
endothelial  cells  was  associated  with  increased  oxidative  stress  and  reduced  ACE 
mRNA. 
 
In  conclusion,  BDKRB2  may  mediate  some  of  the  beneficial  metabolic  and 
cardiovascular effects associated with low ACE activity, possibly through changes in 
mitochondrial  function.    Mitochondrial  coupling  appears  pivotal  in  cardiovascular 
(patho)physiology, possibly via oxidative stress or a novel ACE metabolic regulatory 
pathway.  UCPs may be a target for future cardiovascular interventions. 
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       CHAPTER ONE  
1  INTRODUCTION 
 
 
The endocrine renin-angiotensin-aldosterone system (RAAS) is involved in circulatory 
homeostasis and has been implicated in the pathogenesis of both coronary heart disease 
(CHD)  and  one  of  its  common  sequelae  -  the  syndrome  of  heart  failure  (SOLVD 
Investigators 1991; AIRE Study Investigators 1993; Yusuf et al. 2000; Fox et al. 2003).  
RAAS-modifying  drugs  improve  morbidity  and  mortality  in  both  these  disease 
processes through mechanisms beyond simple blood pressure reduction (Sleight et al. 
2001).    It  is  now  apparent  that  tissue  RAAS  exist,  whereby  the  components  (for 
example Angiotensin Converting Enzyme - ACE) are either generated locally within 
cells, tissues or organs or are actively sequestered from the circulation, and it has been 
hypothesised that antagonism of tissue RAAS is responsible for the observed benefits of 
RAAS-modifying drugs (Dzau et al. 2001).   
 
It  has  been  further  postulated  that  lower  ACE  activity,  either  as  a  consequence  of 
pharmacological manipulation or due to genetic variation, increases cellular metabolic 
efficiency (Montgomery et al. 1998), and that this may in fact may be responsible, at 
least in part, for the observed range of effects; from mortality and functional benefits in 
heart  failure  to  increased  efficiency  of  skeletal  muscle  contraction  and  enhanced 
endurance performance in athletes (Montgomery et al. 1998).  Could some of these 
metabolic effects be through the alteration of mitochondrial function?  Recent results 
support  the  existence  of  a  local  mitochondrial  RAAS:  components  of  the  RAAS, 
including ACE, have been localised to mitochondria (Yayama et al. 1995; Peters et al. 
1996; Clausmeyer et al. 1999) and ACE inhibition is of experimental benefit in other  
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situations where aberrations of mitochondrial function have been implicated, such as 
oxidative stress and ischaemia-reperfusion injury (Linz et al. 1986; Kingma et al. 1994; 
Berry  et  al.  2001).    However,  the  precise  underlying  mechanisms  of  such  putative 
actions are unclear, and may be a result of alterations in tissue levels of downstream 
effectors of the RAAS, such as kinins, or through novel mitochondrial pathways, such 
as through mitochondrial uncoupling proteins (UCPs).   
 
This thesis will examine whether common variation in the constitutive bradykinin β2 
receptor (BDKRB2) gene is also associated with similar cardiovascular and performance 
phenotypes to that previously reported for the ACE gene.  Secondly, in vitro assays will 
be used to test whether pharmacological manipulation of cellular ACE activity can alter 
mitochondrial coupling and the expression of mitochondrial UCPs.  If the RAAS can 
alter  cardiovascular  pathophysiology  through  changes  in  mitochondrial  activity,  can 
genetic differences in mitochondrial UCPs be directly associated with cardiovascular 
and performance phenotypes?  This hypothesis will also be tested, as will any detected 
associations between ACE and uncoupling proteins in vitro.   
 
1.1  CORONARY HEART DISEASE (CHD) 
By  the  beginning  of  the  21
st  century,  cardiovascular  disease  (CVD)  accounted  for 
almost one-half of all deaths in the developed world and one quarter of all deaths in the 
developing world (World Health Organisation 2002).  This represents a dramatic shift 
from  the  status  quo  in  the  19
th  century,  when  infectious  diseases  and  malnutrition 
represented  the  most  common  causes  of  death  worldwide.    CVD  includes  CHD, 
cerebrovascular disease and peripheral vascular disease, and it is predicted to become 
the major cause of morbidity and mortality worldwide, with an estimated 25 million 
deaths per year worldwide by 2020 (World Health Organisation 2002).  There are racial  
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variations  in  CVD  rates,  with  higher  rates  in  some  ethnic  minorities,  particularly 
amongst South Asians living in Western countries (Cappuccio 1997; Cappuccio et al. 
2002).  However, there is  now an explosion in CVD rates in  developing countries, 
which  is  thought  secondary  to  the  adoption  of  ‗westernised‘  lifestyles  (Zipes  et  al. 
2005).  Currently, in the UK, CVD is the leading cause of death overall and the leading 
cause  of  premature  death  in  adults  (British  Heart  Foundation  2006).    CHD  itself 
accounted for over 105000 deaths in 2004.  Recent advances in our understanding of 
this disease, coupled with advances in treatment, have led to a 44% reduction in deaths 
in adults under 65 years of age in the past 10 years (British Heart Foundation 2006).  
However, there is increasing morbidity from CHD, particularly in the elderly, with an 
estimated  2  million  sufferers  of  angina  and  almost  one  million  people  with  either 
definite or probable heart failure in the UK (British Heart Foundation 2006). 
 
1.1.1  Atherosclerosis (from Zipes et al. 2005 and reviewed by Libby 2002) 
Atherosclerosis is an inflammatory disease of the artery  (Ross 1999) and is caused by a 
complex interaction between environmental and genetic factors.  The word stems from 
the  Greek  ―athera‖  meaning  gruel  and,  although  its  presence  has  been  detected  in 
Egyptian mummies, it was nevertheless uncommon until modern times.  The increased 
prevalence of atherosclerotic disease has been thought to be a consequence of people 
surviving early mortality from infectious diseases together with lifestyle changes, such 
as the so-called atherogenic diet, and the inhalation of cigarette smoke. 
 
The normal artery consists of three concentric layers: the tunica intima, tunica media 
and the adventitia (Figure 1.1).  Innermost is the tunica intima, consisting of a single 
endothelial layer resting on a basement membrane of non-fibrillar collagens such as 
type  IV  collagen,  laminin  and  fibronectin,  and,  in  older  individuals,  there  is  an  
  35 
underlying layer of connective tissue and smooth muscle cells.  The endothelium is a 
highly specialised monolayer of cells which is in contact with the blood and maintains 
its  fluidity  through  the  expression  of  antithrombotic  cell  surface  molecules  such  as 
heparin-sulphate, thrombomodulin and prostacyclin (PGI2).  The intima is  separated 
from  the underlying tunica media by the internal  elastic lamina.  The tunica media 
consists of layers of smooth muscle cells separated by elastic laminae.  These layers are 
more pronounced in elastic arteries such as the aorta, which have a high compliance, 
allowing storage of the kinetic energy of systole as elastic energy, which it transmits 
during diastole.  The external elastic lamina separates the media from the adventitia, 
which is a supportive loose array of collagen fibrils where the vasa vasorum and nerve 
endings are located.   
 
The hallmark lesion of atherosclerosis is the fibrofatty plaque (Figure 1.1).  In early 
atherogenesis,  lipoprotein  particles,  particularly  low-density  lipoprotein  (LDL), 
accumulate in the intima.  This can be seen as the accumulation of fatty streaks in the 
great arteries and coronary arteries in as early as the second decade of life (Strong et al. 
1999).  Leucocytes, in the form of monocytes and T lymphocytes, are recruited into the 
intima,  first  by  circulating  leukocyte  adhesion  to  the  endothelium  via  adhesion 
molecules (such as VCAM-1 and selectins) then by migration towards chemokines such 
as monocyte chemoattractant protein (MCP-1).  Monocytes within the intima have the 
capacity  to  accumulate  lipid  via  scavenger  receptors  and  become  lipid-laden 
macrophages  or  ―foam  cells‖.    Macrophages  are  a  rich  source  of  pro-inflammatory 
mediators  and  also  recruit  T  lymphocytes  and  smooth  muscle  cells  to  the  plaque.  
Endothelial migration into plaque has been more recently recognised and results in the 
formation of neovessels.  The more mature plaque is formed by a complex interaction 
between pro- and anti-inflammatory signals between these resident cells.    
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Figure 1.1  The structure of the normal artery (left) and the genesis of the atherosclerotic plaque (right)  
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Extracellular matrix (interstitial collagens and proteoglycans) constitutes most of the 
advanced  plaque,  and  its  accumulation  is  a  balance  between  formation  by  smooth 
muscle cells and degradation by a family of proteins called matrix metalloproteinases 
(MMPs).   
 
 
1.1.2  The spectrum of disease in CHD 
The present consensus is that coronary atherosclerosis does not develop in a smooth, 
progressive manner, but rather during bursts of disease activity during an individual‘s 
life.  As a plaque increases in size, the artery first exhibits negative remodelling, with 
radial growth of the arterial wall away from the lumen and therefore relative protection 
of luminal diameter.  Once this ability of the artery to remodel is exceeded, further 
plaque  growth  encroaches  on  the  lumen  itself.    This  period  of  plaque  growth  is  a 
chronic  asymptomatic  phase.    Once  the  effective  luminal  diameter  is  reduced  by 
approximately 60-70%, often after several decades of plaque growth, the stenosis is 
likely to cause flow limitation during increased demand, such as during exercise.  This 
leads to the syndrome of chronic stable angina, where the onset of ischaemic chest 
pain is predictable and provokable by similar degrees of exertional or emotional stress. 
 
Acute myocardial infarction (MI) is the necrotic death of cardiac myocytes resulting 
from  an  abrupt  cessation  of  coronary  blood  flow,  usually  due  to  an  occlusion  by 
thrombosis  of  an  epicardial  coronary  artery  (Falk  1983;  Davies  et  al.  1989).    This 
usually presents as a prolonged episode of ischaemic chest pain, resulting in transmural 
infarction  with  clinical  sequelae,  ranging  from  ventricular  dysrhythmias  and  sudden 
cardiac death, to acute and chronic ventricular failure from pump or valvular failure, to 
myocardial rupture and aneurysm formation.  Incomplete, but critical occlusion of a  
  38 
coronary  artery  can  lead  to  the  syndromes  of  non-ST  elevation  MI  (NSTEMI, 
previously  non-Q  wave  infarction  or  subendocardial  infarction)  without  transmural 
infarction  and  unstable  (crescendo)  angina,  with  increased  frequency  or  severity  of 
angina occurring at lower thresholds of stress or at rest. 
 
It is now recognised that most cases of MI are caused by atherosclerotic lesions that 
were non-flow limiting at onset (Stary et al. 1995).  Physical disruption of a plaque 
(plaque rupture) or, less often, plaque erosion, results in its thrombogenic core coming 
into contact with the circulation, leading to thrombus generation which can occlude the 
entire lumen.  This finding has lead to the concept of the ‗vulnerable plaque‘.  A ‗stable 
plaque‘  has  a  large  fibrous  component  with  a  thick  fibrous  cap  and  small 
lipid/macrophage  core.    The  mechanical  strength  of  the  fibrous  cap  is  regulated  by 
plaque smooth muscle cell number and function (themselves regulated by T cells) and 
by matrix degradation by MMPs and cathepsins secreted by macrophages.  A large 
lipid/macrophage  core  will  make  the  plaque  more  vulnerable,  not  only  due  to  the 
increased biomechanical stress this causes in the shoulder regions of the plaque, but also 
due to the activated macrophages contained within, which generate pro-inflammatory 
cytokines (causing smooth muscle cell apoptosis) and matrix-degrading enzymes.   
 
It  is  likely  that  plaque  rupture  leads  more  often  to  subclinical  events,  whereby  the 
ensuing  thrombosis  does  not  lead  to  complete  luminal  occlusion  or  an  ischaemic 
syndrome,  but  rather  the  thrombus  propagation  is  controlled,  leading  to  plaque 
remodelling  and  progression  (Burke  et  al.  2001).    It  is  probably  these  sequential 
explosions in plaque growth that are responsible for progressive luminal loss.   
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Plaque erosion, on the other hand, has only been recently recognised and is another 
process which can lead to thrombus formation (Farb et al. 1996).  It is more common in 
younger adults, particularly women and smokers (Burke et al. 1997; Arbustini et al. 
1999). 
 
1.1.3  Risk factors for CHD 
A  risk  factor  is  a  characteristic  or  feature  of  an  individual  or  population  that  is 
associated with an increased chance of developing future disease.  Conventional and 
novel risk factors in the development of CHD are described in brief below. 
 
1.1.3.1   Conventional risk factors 
Long  recognised  independent  risk  factors  in  the  development  of  CHD  are  cigarette 
consumption  (smoking),  hypertension,  hyperlipidaemia,  the  presence  of  diabetes  or 
insulin resistance and obesity.  
 
Smoking is the singlemost modifiable risk factor for CHD and its effect on risk is dose-
dependent (Doyle et al. 1962; Zipes et al. 2005).  Smoking more than 20 cigarettes per 
day  increases  the  risk  of  CHD  by  two  to  three-fold.    There  are  many  adverse, 
atherogenic associations with smoking, including endothelial dysfunction (for example 
decreased endothelial nitric oxide (NO•) and increased monocyte-endothelial adhesion), 
oxidation of LDL cholesterol, an increase in biomarkers associated with CHD such as 
highly-sensitive  C-reactive  protein  (hsCRP),  ICAM-1,  fibrinogen  and  homocysteine, 
increased platelet aggregation and increased oxidative stress (Adams et al. 1997; Tracy 
et al. 1997; Fusegawa et al. 1999; Barua et al. 2003). 
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The prevalence of hypertension in the adult UK population is approximately 13% and 
increases with age.  The relative risk of CHD increases with the degree of hypertension 
when compared to normotensives (Kannel et al. 1969; Kannel et al. 1986; Hansson et 
al. 1993; Hansson 1996). 
 
The  universal  finding  of  cholesterol  within  atherosclerotic  plaque  outlined  the 
importance of circulating lipid in the pathogenesis of CHD.  However, it was not until 
prospective cohort studies in the 1950s that the relationship between serum cholesterol 
and  CHD  risk  was  confirmed  and  fully  accepted  (Kannel  et  al.  1964).    The  lipid 
transport  system  has  evolved  to  carry  hydrophobic  fats  in  the  aqueous  plasma.  
Lipoproteins are spherical particles consisting of a central core of cholesterol-ester and 
triglyceride within a cholesterol-phospholipid coating.  Highly evolutionary-conserved 
amphipathic apolipoproteins are also embedded in the lipoprotein coating and mediate 
the lipid  transport process.   These lipoproteins vary in  their size, density, lipid  and 
apolipoprotein  content.    Low  density  lipoprotein  (LDL)  is  the  main  carrier  of 
cholesterol,  containing  predominantly  cholesterol  ester  packaged  in  apolipoprotein 
B100.    LDL,  particularly  small  dense  LDL  (triglyceride  rich)  and  oxidised  LDL 
(oxLDL), is highly atherogenic, and levels correlate positively with CHD (Castelli et al. 
1986; 1986).  High density lipoprotein (HDL), whose protein content consists mainly of 
apolipoprotein  A1,  is  involved  with  cholesterol  efflux  from  tissue  targets  (e.g. 
endothelial cells).  HDL promotes reverse cholesterol transport and is antiatherogenic.  
Epidemiological studies have shown an inverse relationship between HDL and CHD 
risk (Yaari et al. 1981; Castelli et al. 1986).   
 
Early trials with drugs (bile-acid sequestrants, fibrates) with only modest reductions in 
LDL cholesterol reported only modest reductions in CHD risk.  However, several major  
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trials in patients using the ‗statin‘ class of drugs (HMG-CoA reductase inhibitors) have 
made possible aggressive reductions in serum LDL cholesterol, and have shown clear 
and reproducible beneficial reductions in CHD risk in both secondary (Scandinavian 
Simvastatin Survival Study Group 1994; Sacks et al. 1996; WoSCoPS Group 1997) and 
primary prevention trials (Shepherd et al. 1995; Downs et al. 1998; 2002). 
 
The presence of obesity promotes insulin resistance and dyslipidaemia but also predicts 
CHD risk (Garrison et al. 1980; MRFIT Research Group 1986).  There is a continuum 
between  the  onset  of  obesity  and  the  presence  of  the  metabolic  syndrome  (central 
obesity, hypertension, dyslipidaemia and insulin resistance).  Both insulin resistance and 
metabolic syndrome appear to confer an independent risk of CHD (Lakka et al. 2002; 
Sattar et al. 2003). 
 
The prevalence of diabetes is increasing worldwide at a dramatic rate.  It is estimated 
that diabetes affects 5% of the world‘s populace and its prevalence is doubling every 
generation, with an estimated 300 million people likely to be suffering from diabetes by 
2025 (King et al. 1998). At present there are 1.8 million people with diabetes in the UK 
(3% of the population) and this is set to increase to 3 million by 2010.  There are a 
further 1 million people with undiagnosed type 2 diabetes (Diabetes UK 2004).  Patients 
with diabetes have a two- to four-fold higher risk of developing CHD than matched 
non-diabetic individuals (Garcia et al. 1974; Stamler et al. 1993).  Indeed, by diagnosis, 
more than half of patients will already have CVD, and CVD accounts for 80% of all 
deaths in diabetic patients (Beckman et al. 2002).  Patients with diabetes but no prior 
history of CHD have the same level of future CHD risk as those non-diabetic patients 
with prior MI (Haffner et al. 1998). 
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The  metabolic  abnormalities  in  diabetes  and  in  the  pre-diabetic  state,  including 
hyperglycaemia,  insulin  resistance  and  dyslipidaemia,  render  arteries  susceptible  to 
atherosclerosis.    The  mechanisms  involved  are  complex  and  include  reduced 
bioavailability of nitric oxide (NO•) and endothelial dysfunction (Steinberg et al. 1996; 
Steinberg et al. 1997; Williams et al. 1998), increased reactive oxygen species (ROS) 
generation  through  enzymatic  and  non-enzymatic  processes  (Nishikawa  et  al.  2000; 
Brownlee 2001), and activation of protein kinase C (PKC) which has a vast array of 
actions  including  inactivation  of  the  endothelial  isoform  NO•  synthase  (eNOS), 
augmentation of endothelial tissue factor gene expression and the increased production 
of proinflammatory  cytokines  (Terry  et  al.  1996;  Koya et  al. 1998).  Diabetes also 
impairs  vascular  smooth  muscle  function  by  augmenting  the  production  of 
vasoconstrictors  such  as  endothelin  and  angiotensin  II  (Ang  II)  (Park  et  al.  2000; 
Beckman et al. 2002).  The accumulation of advanced glycation end products (AGEs), 
which are formed via the non-enzymatic glycation of macromolecules, may also disturb 
vascular function and accelerate atherosclerosis (Stitt et al. 1997; Brownlee 2000). 
 
1.1.3.2   Genetic factors 
There are strong genetic influences on the development of many of the classical risk 
factors for CHD, shown early on in twin studies (Feinleib et al. 1977; Austin et al. 
1987).    However,  family  history  is  a  strong  independent  risk  factor  for  CHD  itself 
(Snowden et al. 1982; Assmann et al. 1997);(1997; Hawe et al. 2003).  Further support 
for  a  genetic  contribution  to  CHD  risk  comes  from  twin  studies,  with  a  high 
concordance  for  age  of  onset  of  CHD  and  a  greater  risk  in  monozygotic  twins  in 
developing  CHD  at  a  young  age  compared  to  dizygotic  twins  (relative  risk  8.1 
compared with 3.8, respectively, (Marenberg et al. 1994).  Rarely, CHD arises from a 
single gene mutation, exemplified by familial hypercholesterolaemia (FH) which results  
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in elevated LDL cholesterol above the 95
th percentile (due predominantly to one of a 
number of mutations in the LDL receptor gene) and early-onset CHD in the 3
rd or 4
th 
decades.  The more common form of CHD is also thought to be partly heritable, arising 
from  the  interaction  between  common  environmental  exposure  (risk  factors)  and 
inheritance  of  many  disease  modifying  common  gene  variants  (polymorphisms),  all 
with small to moderate effect (Humphries et al. 2004). 
 
1.1.3.3   Novel risk factors  
Almost half of all MIs occur in patients without significant hyperlipidaemia (Ridker et 
al. 2002).  Even prediction models (for example based on the Framingham dataset) 
cannot  explain  approximately  1  in  5  CHD  events  using  ‗conventional‘  risk  factors.  
More  recently,  novel  risk  factors  have  been  associated  with  CHD,  such  as  those 
involved in inflammation and thrombosis.  One of the best studied examples is CRP - an 
acute phase reactant which plays a major role in the innate immune response and is used 
as a (laboratory) marker of inflammation.  It has now been shown in prospective studies 
using highly sensitive assays for CRP (hsCRP) that CRP is an independent risk factor 
for CHD (Kuller et al. 1996; Ridker et al. 1997; Tracy et al. 1997; Ridker et al. 1998; 
Koenig et al. 1999).  Whether CRP is directly atherogenic or is an epiphenomenon of 
the inflammatory process remains to be elucidated.  CRP is present in atherosclerotic 
plaque (Torzewski et al. 1998) where it may have several pro-atherosclerotic actions 
including  binding  oxidised  low  density  lipoprotein  (oxLDL)  (de  Beer  et  al.  1982), 
inducing  adhesion  molecule  expression  on  endothelium  (Pasceri  et  al.  2000)  and 
reducing NO• bioavailability (Venugopal et al. 2002)  
 
Fibrinogen is the precursor of fibrin and, in combination with thrombin, mediates the 
final  step  in  thrombus  formation  and  also  influences  platelet  aggregation,  plasma  
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viscosity and plasminogen binding.  Fibrinogen levels are correlated positively with 
smoking,  obesity,  LDL-cholesterol,  age  and  insulin  resistance/diabetes.    Elevated 
plasma fibrinogen levels are associated with a moderate increase in future CHD risk 
(Meade et al. 1986; Wilhelmsen et al. 2001). 
 
Other novel risk factors include inflammatory biomarkers, such as interleukin-6 (IL-6) 
which is the main cytokine stimulus for CRP (Ridker et al. 2000; Lindmark et al. 2001), 
CD40  ligand  (Schonbeck  et  al.  2001),  soluble  ICAM-1  (Malik  et  al.  2001)  and 
lipoprotein-associated  phospholipase  A2  (Blake  et  al.  2001)  amongst  others. 
Homocysteine is a sulphydryl-containing amino acid derived from the demethylation of 
methionine.    Patients  with  inherited  defects  in  methionine  metabolism  develop 
homocystinuria and have increased risk of both venous and arterial thrombosis, which 
may be as a result of endothelial dysfunction, increased oxidative stress and platelet 
activation  (Bellamy  et  al.  1998;  Welch  et  al.  1998).    Mildly  elevated  levels  of 
homocysteine are seen in the general population (usually related to dietary deficiency of 
folic acid), and have been associated with increased prospective CHD risk (Wald et al. 
2002).  Lipoprotein(a) consists of an LDL particle with its apolipoprotein B100 cross-
linked to  apolipoprotein(a)  which is  a highly complex molecule with  more than 25 
heritable forms.  Not only is it more atherogenic than LDL, but it also shares sequence 
homology  with  plasminogen  and  may  inhibit  endogenous  fibrinolysis  (Miles  et  al. 
1989).  Subjects with the top tertile of lipoprotein(a) levels are associated with a 1.6 fold 
increase in relative risk of CHD (Danesh et al. 2000). 
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1.2   HEART FAILURE 
 
1.2.1  Definition 
There  are  several  definitions  of  heart  failure.    In  essence,  heart  failure  is  a 
pathophysiological state said to be present when the heart is unable to pump blood at a 
rate commensurate with the requirements of the metabolising tissues, or can only do so 
in the face of elevated filling pressures.   
 
Heart failure is clinically defined by the European Society of Cardiology as: 
 
I.    Symptoms of heart failure (at rest or exertion) and 
II.  Objective evidence (preferably by echocardiography) of cardiac dysfunction 
(systolic/diastolic) (at rest) and  
III.  Response to treatment directed towards heart failure (in cases where the 
diagnosis is in doubt) 
                                                                      Criteria I and II must be fulfilled in all cases 
 
Heart failure has been defined by the American College of Cardiology/American Heart 
Association Task Force on practice guidelines as:  
―a complex clinical syndrome that can result from any structural or functional 
cardiac  disorder  that  impairs  the  ability  of  the  ventricle  to  fill  with  or  eject 
blood.‖ 
 
1.2.2  Epidemiology and causes 
 
Heart failure is a complex, multisystem disorder.  It is the final common manifestation 
of a number of disease processes that damage the heart, the most common being CHD  
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(Table 1.1).  Heart failure carries an overall 5 year mortality of 50% (Levy et al. 2002) 
and even with current treatments available, the one-year survival of patients with a new 
diagnosis of heart failure in London, UK is only 62% (Cowie et al. 2000).   
 
 
Table 1.1 The common causes of heart failure 
 
Coronary heart disease 
Hypertension 
Valvular heart disease 
Myocardial diseases 
(Idiopathic) dilated cardiomyopathy 
Viral 
Metabolic 
Infiltrative 
Inherited, e.g. Hypertrophic cardiomyopathy, 
       Fabry‘s, muscular dystrophy, ARVC, 
       mitochondrial myopathies 
Congenital heart disease 
Drug or toxin-induced 
Alcohol 
Cardiotoxic chemotherapy 
Tachymyopathy 
Pericardial disease 
High output failure (AV fistulae, thyrotoxicosis, Beriberi) 
 
 
 
Heart failure is a common condition and increases in prevalence with age.  It has a huge 
social and economic impact, with an estimated cost to the NHS of over £600 million in 
2000.  In the UK in 2001, heart failure was directly responsible for over 86000 hospital 
admissions and over 11500 deaths (data from www.heartstats.org).   
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1.2.3  Pathophysiology 
The cardinal manifestations of heart failure are dyspnoea, fatigue and fluid retention.  
These clinical symptoms and signs were initially explained by either backward (reverse) 
or  forward  pump  failure,  first  proposed  by  Hope  (1832)  and  Mackenzie  (1910), 
respectively.  In backward heart failure, it is suggested that ventricular end-diastolic 
volume (EDV) and pressure increase as a function of the inability of the cardiac muscle 
to shorten.  This then results in an increase in atrial volumes and pressures and these 
then result in an increase in upstream venous and capillary pressures.  This increase in 
pressure  results  in  increased  transudation  of  fluid  from  the  capillary  bed  into  the 
interstitium  causing  either  pulmonary  oedema  (in  the  case  of  left  ventricular 
dysfunction)  or  peripheral  interstitial  tissue/organ  oedema  (in  right  ventricular 
dysfunction).  In left ventricular failure, forward pump failure results in reduced cardiac 
Figure 1.2.  Diagram showing the interrelationship between ventricular end-diastolic volume 
(EDV) and stroke volume (SV).  The points at which symptomatic dyspnoea and pulmonary 
oedema  develop  are  represented  on  the  x-axis.    At  rest,  an  increase  in  EDV  results  in 
increasing SV due to increased myocardial contractility.  This relationship is shifted to the left 
during exercise (for example walking shown as moving from A to B) when adrenergic stimuli 
and tachycardia augment cardiac output.  With the development of heart failure, the curve is 
shifted down and to the right with higher filling pressures and lower SV developed, and with 
symptoms at rest and lower myocardial reserve (adapted from Zipes et al 2005).   
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output and relative hypoperfusion of vital organs such as the heart, gut, kidneys and 
brain. 
 
These explanations were, however, overly simplistic.  Early on in heart failure, the heart 
depends on several adaptive mechanisms to maintain its pumping action.  The most 
important are the Frank-Starling mechanism (in which an increase in preload results in 
an  increase  in  contractility,  Figure  1.2),  neuroendocrine  activation  (including  an 
increase in sympathetic drive, in endothelin and natriuretic peptide release and in RAAS 
activation)  and  myocardial  remodelling.    When  cardiac  output  is  depressed,  arterial 
pressure is maintained by systemic vasoconstriction and salt and water retention by a 
number of neurohormones.  These mechanisms appear to be important for the short term 
gain  in  acute  circulatory  failure  but  are  deleterious  in  chronic  heart  failure  (CHF), 
contributing to oedema formation but also having direct adverse effects on the heart 
(Figure  1.3).    Generalised  adrenergic  stimulation  and  parasympathetic  withdrawal 
results  in  vasoconstriction,  stimulates  myocardial  contractility  and  tachycardia  and 
promotes  sodium  retention  and  renin  secretion  from  the  juxtaglomerulus  apparatus 
(JGA) in the kidney.   
 
Activation  of  the  sympathetic  nervous  system  (SNS)  is  the  primary  mechanism  for 
increasing cardiac output in the normal heart via an increase in contractility and heart 
rate  (Bristow  1984).    The  mechanism  for  this  increased  contractility  has  been  well 
characterised, involving activation of β-adrenergic receptors and subsequent activation 
of adenylate cyclase, increase in cAMP and protein kinase A and phosphorylation of 
calcium regulatory proteins (Li et al. 2000).  This results in increased calcium influx 
into  cardiomyocytes,  increased  calcium  flux  through  the  sarcoplasmic  reticulum, 
decreasing inhibition of the cardiac isoform of the sarcoplasmic-endoplasmic reticulum  
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calcium uptake pump (SERCA2a) and decreased binding to troponin.  The increase in 
cardiac contractility and relaxation occurs at the expense of an increase in myocardial 
energy demand (Houser et al. 2003).   
 
A  characteristic  feature  of  heart  failure  is  the  activation  of  the  SNS  coupled  with 
blunting  of  the  normal  adrenergic  effects  on  myocyte  contractility.    Epinephrine  is 
exceptionally cardiotoxic at levels found in the failing human heart, levels of which are 
elevated three-fold at rest, but also rise rapidly during exercise (Chidsey et al. 1962; 
Grassi  et  al.  1995).    These  elevated  levels  are  thought  to  result  in  receptor 
desensitisation,  possibly  as  a  cardioprotective  mechanism,  with  reduced  β1  receptor 
density and uncoupling of β2 receptors from downstream effector molecules with  a 
resultant reduction in inotropic responsiveness (Bristow 1993).  However, the enhanced 
Figure 1.3.  Maladaptive mechanisms in heart failure include sympathetic (SNS) activation and 
RAAS  activation.    In  the  traditional  endocrine  model  of  RAAS  activation,  renal-derived  renin 
cleaves hepatic-derived angiotensinogen to generate circulating angiotensin I.  This is cleaved by 
ACE in the pulmonary circulation to generate the vasoconstrictor angiotensin II which stimulates 
adrenal aldosterone release.  However, tissue RAAS systems also exist (see section 1.4).  
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epinephrine levels promote apoptosis via β receptors and hypertrophy via upregulated α 
receptors  contributing  to  cell  death  and  negative  remodelling  (Milano  et  al.  1994; 
Communal  et  al.  1998).    The  augmented  adrenergic  drive  may  also  precipitate 
myocardial ischaemia, ventricular dysrhythmia and sudden cardiac death. 
 
Relative  renal  hypoperfusion  in  heart  failure  results  in  renin  secretion  from  the 
juxtaglomerular apparatus, with subsequent generation of Ang II and aldosterone, which 
promote systemic vasoconstriction and further salt and water retention as a protective 
mechanism  to  increase  systemic  blood  pressure  and  hence  renal  perfusion  pressure 
(Figure  1.3).    These  effects  may  be  deleterious  both  acutely  and  in  the  long-term, 
leading to oedema formation.  Furthermore, Ang II and aldosterone have direct effects 
on the heart, including cardiomyocyte necrosis (Tan et al. 1991), apoptosis (Leri et al. 
1998; Mano et al. 2004), hypertrophy (Sadoshima et al. 1993; Karmazyn et al. 2003) 
and myocardial fibrosis (Weber et al. 1991). 
 
In the compensated phase of CHF, ventricular remodelling  - comprising changes in 
mass,  volume,  shape  and  composition  -  results  in  hypertrophy  (pressure  overloaded 
ventricle) and dilatation (volume overloaded) (Jacob et al. 1998; Francis 2001; Zipes et 
al. 2005).  When the haemodynamic stress on the failing heart is prolonged, however, 
myocardial contractility becomes further depressed, with the redevelopment of overt 
heart failure (Houser et al. 2000).  Remodelling at the cellular level is characterised by 
myocyte hypertrophy and elongation, changes in myocyte phenotype with re-expression 
of foetal genes, abnormalities in calcium handling, myocyte necrosis and apoptosis and 
myocardial fibrosis (Anversa et al. 1997; Olivetti et al. 1997; Houser et al. 2000). 
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1.2.4  Central vs. peripheral abnormalities in chronic heart failure 
The mammalian heart is an obligate aerobic organ, consuming approximately 8-15 ml 
O2.min
-1.100 g tissue at rest but rising to more than 70 ml O2.min
-1.100 g tissue during 
vigorous exercise.  Molecular O2 itself is a double-edged sword: not only is it essential 
to maintain normal energy requirements, but is also central to the generation of ROS.  
For over 20 years, an ‗oxygen-wasting‘ contractile phenotype has been identified in the 
failing heart, suggestive of metabolic inefficiency (Horak et al. 1983; Buser et al. 1989; 
Sawyer et al. 2000), but the idea that the failing heart is energy-starved is decades old 
(Olson  et  al.  1951).  More  recently,  the  use  of  positron  emission  tomography  has 
confirmed such an increased inefficiency of energy utilisation in the failing human heart 
(Bengel  et  al.  2000;  Taylor  et  al.  2001),  to  which  impaired  mitochondrial  function 
seems a fundamental contributor in animals (Sabbah et al. 1992; Lesnefsky et al. 2001; 
Liu et al. 2001; Marin-Garcia et al. 2001; Casademont et al. 2002) and humans (Sharov 
et al. 2000). 
 
Figure 1.4.  ATP synthesising and utilising reactions in the cardiomyocyte.  
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1.2.4.1  Normal cardiac metabolism. 
Energy derived from adenosine triphosphate (ATP) hydrolysis provides the majority of 
the  energetic  requirement  in  the  healthy  adult  human  heart  (Figure  1.4),  with 
approximately  two-thirds  used  for  contractile  work  (hydrolysed  by  the  actomyosin-
ATPase) and one-third used by ion pumps such as the sarcoplasmic reticulum Ca
2+-
ATPase and the sarcolemmal Na
+/K
+-ATPase (Suga 1990).  In the healthy heart, ATP 
hydrolysis is matched to ATP re-synthesis, with the concentration of ATP, [ATP], kept 
relatively constant at approximately 10 mmol.L
-1 even during periods of increased ATP 
turnover.  ATP-requiring processes are inhibited by the products of ATP hydrolysis: 
namely adenosine diphosphate (ADP) and inorganic phosphate (Pi).   
 
To  understand  this  process  further  one  must  consider  basic  thermodynamics.  An 
increase in disorder of a system, entropy, is the driving force for a reaction in an isolated 
system such as the Universe.  In a closed system such as a cell, a reaction will occur 
spontaneously  if  the  entropy  of  that  system  plus  its  surroundings  increases.    An 
assessment of the entropy change in the surroundings (or Universe) caused by energy 
flow across the boundary of a closed system can be made under constant temperature 
and pressure, as it is equal to the flow of heat or enthalpy out of the closed system.  The 
Gibbs  energy  change,  ΔG,  is  the  quantitative  measure  of  the  driving  force  for  this 
reaction and is defined by the Gibbs-Helmholtz equation: 
ΔG=ΔH – TΔS 
ΔG = Gibbs energy change, ΔH = enthalpy change, T = temperature 
ΔS = entropy change of the system 
 
ΔG is at a minimum for a particular reaction when the mixture of reactants and products 
are at equilibrium, whereas increasing displacement of the reactants and products from 
equilibrium results in an increase in ΔG.  The ΔG required for ATP synthesis (also 
known as the phosphorylation potential) is obtained from the ΔG for ATP hydrolysis by  
  53 
changing the sign.  Intracellular [ATP], [ADP] and [Pi] in normal ventricular tissue are 
approximately 10 mmol.L
-1, <50 μmol.L
-1 and <1 mmol.L
-1, respectively.   
 
The heart uses energy reserve systems to maintain a high ΔG for ATP hydrolysis to 
drive ATPase reactions during variations in work output.  The primary energy reserve 
compound  in  the heart is  phosphocreatine (PCr), which is  present  in  concentrations 
twice that of ATP. The enzyme creatine kinase (CK) transfers the phosphoryl group 
between  PCr  and  ADP  at  a  rate  10-times  faster  than  the  rate  of  ATP  synthesis  by 
oxidative phosphorylation, maintaining [ATP] during conditions of acute stress, such as 
ischaemia, but  also  maintaining a high ΔG for ATP  hydrolysis by maintaining low 
levels of ADP and Pi.  The enzyme adenylate kinase also functions to maintain high 
Figure 1.5.  Cartoon depiction of myocardial metabolism.  The major fuel substrates 
in the healthy adult heart are free fatty acids (60-90%) and pyruvate (10-40%).  Pyruvate 
dehydrogenase  (PDH)  -  an  irreversible  step  in  pyruvate  metabolism  -  is  positively 
regulated  by  PDH  phosphatase  and  negatively  by  PDH  kinase.    Carnitine 
palmitoyltransferase  I  and  II  catalyse  transfer  of  long  chain  fatty  acyl  CoA  into  the 
mitochondrial matrix and are key regulators of fatty acid metabolism.  
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levels  of  ATP  by  transferring  phosphoryl  groups  amongst  the  adenine  nucleotides: 
2ADP  ATP + AMP. 
 
Almost all (98%) of the ATP resynthesis requirements of the human heart under aerobic 
conditions  originates  from  oxidative  phosphorylation  (Figures  1.4-1.5  and  section 
1.5.3), with the remaining fraction (2%) arising from glycolysis (Stanley et al. 2002).  
The substrates for oxidative phosphorylation are the reducing equivalents, nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2).  These in turn 
can be generated by either the β-oxidation of fatty acids, glycolysis, the oxidation of 
pyruvate or the Krebs cycle.  At birth, the human heart switches from glucose as a 
substrate to fatty acid as the predominant substrate.  In the healthy human heart in the 
fed state, about 60–90% of mitochondrial ATP generation comes from beta-oxidation of 
free fatty acids, and 10–40% originates from pyruvate.  Free fatty acids are esterified by 
long-chain fatty acyl-CoA synthetase with coenzyme A to form long-chain fatty acyl-
CoA,  which  is  transferred  across  the  mitochondrial  membranes  by  three  carnitine 
dependent  enzymes  (CPT-I,  CPT-II  and  carnitine  acylcarnitine  translocase)  yielding 
long-chain acyl-CoA in the mitochondrial matrix for β-oxidation.  Successive spirals 
through  the  β-oxidation  pathway  then  generates  one  acetyl-CoA  and  one 
NADH/FADH2 pair.   
 
Glucose and lactate are converted to pyruvate in the cytosol and subsequently oxidised 
to  CO2  in  the  mitochondria.    The  GLUT1  and  GLUT4  isoforms  of  the  glucose 
transporter family are responsible for glucose uptake into cardiomyocytes.   Glucose 
uptake  depends  on  the  cell  transmembrane  glucose  gradient  and  density  of  glucose 
transporters.    Thereafter,  glucose  is  locked  within  the  cell  by  phosphorylation  by 
hexokinase to form glucose 6-phosphate, and then either stored as glycogen or enters  
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the glycolytic pathway, which itself produces 2 NADH + 2ATP + pyruvate for each 
glucose molecule.  Lactate supplies approximately 50% of the pyruvate oxidised by the 
healthy heart at rest (Gertz et al. 1988), being taken up and rapidly oxidised by lactate 
dehydrogenase.  During exercise, lactate can become the predominant fuel for the heart 
(Gertz et al. 1988; Stanley et al. 2002). 
 
Pyruvate decarboxylation is the key irreversible step in carbohydrate metabolism and is 
under  metabolic  control.    This  step  is  catalysed  by  pyruvate  dehydrogenase  (PDH) 
which  is  itself  activated  by  phosphorylation.    PDH  phosphorylation  status  is  under 
complex control by a specific PDH kinase and by PDH phosphatase (Figure 1.5).  This 
enzyme complex, and thus pyruvate oxidation, is negatively regulated by free fatty acids 
and by the presence of acetyl CoA and NADH, whereas promotion of carbohydrate 
metabolism at the level of PDH results in less fatty acid oxidation via inhibition of CPT-
I through elevated malonyl-CoA levels. 
 
 
1.2.4.2  Cardiac muscle metabolic abnormalities in heart failure 
There  is  increasing  evidence  that  cardiac  substrate  utilisation  is  critical  for  cardiac 
function  (Stanley  et  al.  2002).    Indeed,  defects  in  enzymes  involved  in  fatty  acid 
oxidation cause childhood cardiomyopathies (Kelly et al. 1994), and pharmacological 
inhibition of cardiac fatty acid import induces cardiac lipid accumulation and causes 
rapid  death  in  peroxisome  proliferator  activator  receptor  α  (PPARa)-knockout  mice 
(Djouadi  et  al.  1998).    Transgenic  mice  that  overexpress  long-chain  acyl-CoA 
synthetase  and  take  up  excess  long  chain  fatty  acids  initially  exhibit  cardiac 
hypertrophy,  followed  by  LV  dysfunction  and  death  (Chiu  et  al.  2001).    The 
hyperadrenergic  state  of  CCF  causes  an  increase  in  circulating  free  fatty  acid  
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concentration paralleled by a 50% increase in myocardial lipid oxidation and a 60% 
reduction in carbohydrate oxidation (Paolisso et al. 1994).  Fatty acids inhibit pyruvate 
dehydrogenase (vide supra) resulting in reduced pyruvate oxidation and intracellular 
lactate accumulation.  Fatty acids generate more ATP per mol of substrate, but at the 
expense of a greater oxygen requirement per mol of ATP than either glucose or lactate 
(Nicholls et al. 2002), and also induce a proton leak across the inner mitochondrial 
membrane (Borst et al.  1962), increasing cardiac oxygen consumption for the same 
amount of cardiac external work in both the isolated (Challoner et al. 1966) and whole 
animal  model  (Mjos  1971),  resulting  in  an  even  lower  actual  ratio  of  ATP:oxygen 
consumed than that predicted (Brand et al. 1994).   
 
Mitochondria  form  40%  of  the  dry  weight  of  the  heart,  and  primary  mitochondrial 
defects result in diverse forms of cardiac dysfunction (Casademont et al. 2002).  A 
secondary decrease in PCr, ATP and mitochondrial function has long been observed in 
both  the hypertrophied  and failing heart  (Schwartz et  al.  1962;  Wollenberger  et  al. 
1965; Chandler et al. 1967; Lindenmayer et al. 1968; Sanbe et al. 1995).  PCr decreases 
in the failing heart because of a mismatch in ATP supply and demand, followed by up 
to 60% loss of the total creatine pool and decreases in both muscle and alterations in the 
amounts of the different CK isoforms.  Myocardial creatine depletion and the decrease 
in  the  [PCr]/[ATP]  ratio  measured  by  NMR  predicts  CHF  severity  and  prognosis 
(Conway et al. 1991; Neubauer et al. 1997; Nakae et al. 2003).  From human biopsy 
and 
31P NMR studies in patients, [ATP] is 25-30% lower in CHF (Starling et al. 1998; 
Beer  et  al.  2002).    Animal  models  of  CHF  suggest  the  decline  in  [ATP]  is 
approximately 0.35% per day and is caused by a loss of the total adenine nucleotide 
pool (Shen et al. 1999) with a resultant increase in [ADP], thereby lowering ΔG≈ATP.  A 
consequence of the rise in [ADP] is an increase in cytosolic [AMP] from the adenylate  
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kinase reaction (Shen et al. 1999) which itself is a ‗double-edged sword‘.  High [AMP] 
activates AMP kinase (AMPK) leading to activation of the ―low fuel warning system‖, 
switching off  ATP  consuming pathways  such  as  fatty acid  and sterol  synthesis  and 
activating ATP generating pathways such as fatty acid oxidation and enhanced glucose 
uptake  (Hardie  et  al.  1997)  and  promoting  mitochondrial  biogenesis  via  increased 
PPARγ- co-activator (PGC-1α) expression (Zong et al. 2002).  High [AMP] activates a 
specific cytosolic nucleotidase, which converts AMP to adenosine, and may lead to 
gradual reduction in the total adenine pool (Bak et al. 1994). 
 
In CHF, both morphological and metabolic mitochondrial abnormalities are present, 
with a loss of overall capacity for oxidative phosphorylation.  Such abnormalities in 
mitochondrial function are not confined to the myocardium.  Indeed, they may occur in 
diffuse cell types, where they may also lead to symptom progression (Minotti et al. 
1991; Harridge et al. 1996; Kong et al. 2001; Marin-Garcia et al. 2001). This may be 
especially true for skeletal muscle. 
 
 
1.2.4.3  Skeletal muscle metabolic abnormalities in heart failure 
The severe exertional handicap in CHF represents one of the best predictors of mortality 
(Clark et al. 1996), but is not explained by the limitations in central haemodynamic 
performance (Brown et al. 1954; Katsuki et al. 1995; McKelvie et al. 1995; Clark et al. 
1996).   In CHF, exercise limitation  occurs  in  the absence of pulmonary  congestion 
(Clark et al. 1996), correlates poorly with the degree of left ventricular dysfunction 
(Sullivan et al. 1995) and occurs well before the limits of cardiopulmonary reserve have 
been reached (Jondeau et al. 1992).  There is a lack of correlation between the peak rate 
of oxygen uptake (VO2) and LV filling pressures (Fink et al. 1986).  Conversely, it has  
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been  long  observed  that  successful  improvement  of  the  central  haemodynamic 
correlates of CHF with vasodilators, inotropes or cardiac transplantation results only in 
a gradual improvement in patient exercise capacity over weeks or months (Maskin et al. 
1983; Drexler et al. 1989).   
 
 
In healthy individuals, the addition of arm exercise to maximal leg exercise to increase 
the  exercising  muscle  bulk,  does  not  result  in  an  increase  in  VO2,  suggesting  that 
cardiac output and oxygen delivery are maximal and that exercise capacity is therefore 
limited  by  cardiac  output.    Conversely,  in  patients  with  CHF,  the  addition  of  arm 
exercise to maximal leg exercise does result in an increase in VO2, suggesting that the 
major determinant of exercise capacity in CHF is the ability of exercising muscle to 
extract oxygen rather than a limitation of oxygen supply (Jondeau et al. 1992).  This 
suggests  that  peripheral  rather  than  central  factors  may  be  more  important  in 
determining exercise performance in CHF. 
 
 
An  increase  in  the  slope  of  the  relation  between  ventilation  and  carbon  dioxide 
production (VE/VCO2 slope) is also seen in CHF (Higginbotham et al. 1983; Franciosa et 
al. 1984).  However, several lines of evidence suggest that the abnormal ventilatory 
drive  in  CHF  is  not  as  a  consequence  of  increased  CO2-drive  (Rubin  et  al.  1982; 
Franciosa et al. 1984; Clark et al. 1992) with a tendency to hyperventilation (Rajfer et 
al. 1987) with little or no change on arterial blood gases (Clark et al. 1994). 
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Non-pulmonary,  peripheral  causes  are  the  likely  explanation  for  the  abnormal 
ventilation seen in CHF.  Increased peripheral vasoconstriction is observed in CHF, 
with increased activation of the sympathetic nervous system (vide supra) and RAAS, 
and decreased muscle blood flow during exercise (Lindsay et al. 1996), coupled with 
endothelial dysfunction (sec 1.4.3).  However, it is thought that abnormalities of skeletal 
muscle are the major determinant of both the symptoms and the abnormal ventilatory 
drive seen (Clark et al. 1996) – the muscle hypothesis of CHF (Figure 1.6). 
 
Figure 1.6.  Muscle hypothesis of chronic heart failure (adapted from 
Coats & Clark 1994).  
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Several different abnormalities in skeletal muscle have been described in heart failure.  
There is generalised muscle atrophy coupled with reduced capillarisation (Lipkin et al. 
1988; Sullivan et al. 1990; Drexler et al. 1992).  Although there may be an overall 
change in capillary density (Drexler et al. 1992; De Sousa et al. 2000),  reductions in 
resting muscle blood flow, and in exercise-induced increases in muscle blood flow have 
also been observed (Sullivan et al. 1991; Lindsay et al. 1996), which may be as a result 
of  decreased  microvascular  distensibility  (Sorensen  et  al.  1999),  reduced  NO 
bioavailability and  an increase in  vasoconstrictor tone from  RAAS and sympathetic 
overactivity (Drexler et al. 1988).  A shift from fatigue resistant muscle  to fatiguable 
type  II fibre types occurs (Drexler et al. 1992), with the proportion of oxidative to 
glycolytic fibres being significantly correlated with VO2 max in CHF patients (Mancini 
et al. 1989). 
 
Intrinsic defects in metabolic function of skeletal muscle unrelated to oxygen supply 
may be responsible for the observed limitation in exercise capacity (Minotti et al. 1991; 
Harridge et al. 1996), making muscles less resistant to fatigue (Harridge et al. 1996) and 
resulting in decreased metabolic or mitochondrial efficiency (Massie et al. 1987; Massie 
et al. 1988; Mancini et al. 1994; Kemp et al. 1996).  The resultant impairment of muscle 
endurance  performance  correlates  closely  with  both  reduced  functional  capacity 
(Minotti et al. 1991) and maximal oxygen uptake (Harridge et al. 1996).  Compared to 
controls, oxidative capacity is reduced by 30% in CHF patients but "effective functional 
muscle  mass"  by  up  to  65%  (Kemp  et  al.  1996).    Resting  lower  limb  oxygen 
consumption is raised despite reduced muscle mass (Opasich et al. 1997), suggestive of  
a wasteful phenotype. 
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There is a reduction in the activity of oxidative enzymes (Sullivan et al. 1990; Opasich 
et al. 1996; Mettauer et al. 2001) and early reliance on anaerobic metabolism during 
exercise (Sullivan et al. 1991).  Abnormalities at the mitochondrial level may explain 
the observed increased lactate production (Sullivan et al. 1989; Opasich et al. 1997), the 
increased  phosphocreatine  (PCr)  depletion  and  intracellular  acidosis  (Massie  et  al. 
1987; Mancini et al. 1994), and the decreased rate of ATP resynthesis (Mancini et al. 
1994;  Clark  et  al.  1996).    The  number,  volume  and  effective  surface  area  of 
mitochondria are reduced in CHF, irrespective of aetiology (Drexler et al. 1992).  A 
46% reduction in mitochondrial creatine kinase (mi-CK) content has been observed in 
patients  with  CHF  (Hambrecht et  al. 1999).  A similar reduction in  mi-CK protein 
content  was  observed  in  animals  with  CHF,  together  with  a  marked  reduction  in 
mitochondrial oxidative capacity in both type I and type II muscle fibres, as well as a 
decrease in the control of mitochondrial respiration by mitochondrial kinases (adenylate 
kinase and mi-CK) in oxidative fibres  (De Sousa et al. 2000).   
 
Two reflex mechanisms may be responsible for non-central ventilatory drive in CHF:  
the  muscle  ergo-  or  metaboreflexes  and  the  arterial  chemoreflexes.    The  ergoreflex 
system  consists  of  intramuscular  unmyelinated  or  small  myelinated  nerve  endings 
sensitive to the metabolic state of exercising skeletal muscle which reflexly stimulate 
ventilation  (Clark  et  al. 1996).  These ergoreflex afferents  appear sensitive to  local 
prostaglandin (Scott et al. 2002) and bradykinin (Scott et al. 2004) generation.  An 
overactivation  of  these  neural  afferents  may  reflexly  increase  sympathetic  activity 
(Notarius et al. 2001), vasoconstriction (Hammond et al. 2000) and ventilatory drive 
(Piepoli et al. 1996) and is therefore implicated in the dyspnoea associated with CHF, 
and  is  responsive  to  exercise  training  (Piepoli  et  al.  1996).    Similarly,  augmented  
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peripheral hypoxic and central CO2-sensitivity has been reported in CHF (Chua et al. 
1996). 
 
 
1.2.5  Treatments 
Treatments for CHF are aimed at symptomatic relief and improving prognosis, as well 
as reducing the risk of further exacerbation of disease by treating risk factors.  Drugs 
which target the neurohormonal maladaptations have shown clear long term benefits, 
with  ACE  inhibitors  (ACEi)  and  selective  β1-adrenergic  receptor  antagonists  (beta-
blockers) forming the cornerstones of therapy.  Treatment of patients with heart failure 
(mostly post MI) with ACEi significantly reduce mortality (CONSENSUS Trial Study 
Group 1987; SOLVD Investigators 1991; Pfeffer et al. 1992; AIRE Study Investigators 
1993; Kober et al. 1995).  Antagonism of the downstream effectors of the RAAS has 
also  been  effective  in  the  treatment  of  heart  failure,  with  Ang  II  type  1  receptor 
antagonists (ARBs) shown to be as effective as ACEi in the treatment of heart failure, 
reducing mortality and morbidity as well as hospitalisations (Pitt et al. 1997; Pitt et al. 
2000; Cohn et al. 2001; Granger et al. 2003), and with aldosterone antagonism also 
providing additional mortality benefit (Pitt et al. 1999; Pitt et al. 2003).   Selective beta-
blockade has been shown in randomised placebo-controlled trials to reduce mortality 
(CIBIS-II 1999; MERIT-HF 1999; Packer et al. 2002) and hospitalisation from heart 
failure (Packer et al. 2002). 
 
Other  drug  therapies  such  as  loop  diuretics  and  nitrovasodilators  may  provide 
symptomatic  relief  in  heart  failure.    Nitrovasodilators  may  be  of  specific  mortality 
benefit in African-American patients with advanced heart failure (Taylor et al. 2004) 
and  have  been  much  publicised  as  specific  pharmacogenomic  or  ethno- 
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pharmacotherapeutic  agents  (Rahemtulla  et  al.  2005).    However,  this  trial  was  not 
randomised according to race, so it is far too early to draw any such conclusions.   
 
Mechanical therapies to improve cardiac output, which are reserved for severe heart 
failure that is refractory to maximal medical therapy, include cardiac resynchronisation 
therapy with bi- or tri-ventricular pacing to assist inter- and intra-ventricular systolic 
dyssynchrony (Abraham et al. 2002), and implantable ventricular assist devices in end-
stage heart failure as bridging therapy to cardiac transplantation (Rose et al. 2001).   
 
Whilst traditional targets for therapeutic intervention (such as pre-  and afterload, or 
salt/water  balance)  may  be  exhausted,  future  therapies  might  target  the  metabolic 
inefficiency of cardiac and skeletal muscles.  Indeed, some therapies may already be 
acting  through  this  mechanism.    For  instance,  regular  moderate  exercise  training 
improves exercise tolerance in CHF patients (Afzal et al. 1998; Tyni-Lenne et al. 1998) 
not  through  changes  in  limb  blood  flow  (Hambrecht  et  al.  1997),  but  through 
improvements in muscle metabolism (Stratton et al. 1994; Brunotte et al. 1995) and 
metabolic  efficiency  (Kemp  et  al.  1996),  including  ultrastructural  changes  in 
mitochondria resulting in increased mitochondrial oxidative capacity (Hambrecht et al. 
1997).  ACE inhibition may work in a similar way (section 1.6). 
 
1.3    GENETIC ASSOCIATION STUDIES 
Genetic diseases are the extreme manifestation of genetic variation.  Common diseases, 
such  as  CHD,  have  a  complex  pathogenesis,  arising  from  interaction  between 
environment factors (risk) and common variation in multiple genes or gene-products – 
the common disease-common variant theory (Lander 1996; Risch et al. 1996; Collins et 
al. 1997).  It has long been appreciated that there is common sequence variation in the  
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human genome and the extent of this variation has become appreciable recently with 
sequencing of the entire genome (Lander et al. 2001; Venter et al. 2001).  Common 
genetic  variability  allows  for  subtle  variation  in  the  expression  or  activity  of  the 
encoded protein which is compatible with health and explains subtle interindividual 
differences in phenotype or physiological responses (Hingorani 2001).  Without this 
genetic variability, a single environmental factor (e.g. smoking) would expect to have 
an identical effect in any two, otherwise matched, individuals, and response (or disease 
risk)  would  be  directly  proportional  to  the  extent  of  the  environmental  stimulus 
(Stephens et al. 2003).  
 
Most stable variation in the human genome occurs in the form of single nucleotide 
polymorphisms (SNP).  Recent mapping of the human genome uncovered 1.42 million 
SNPs  with  an  average  frequency  of  one  SNP  every  1.9kb  (Lander  et  al.  2001; 
Sachidanandam et al. 2001; Venter et al. 2001).  Individual genes vary markedly in 
their nucleotide diversity (Cargill et al. 1999), with 39% of genes containing 10 or more 
SNPs  (Sachidanandam  et  al.  2001).    SNPs  represent  about  90%  of  the  common 
variation in the genome, with sequence insertion/ deletion polymorphisms and variable 
repeat elements providing the rest (Altshuler et al. 2000; Sachidanandam et al. 2001).  
SNPs are stable, as the sequence variation arises through a single mutation event in the 
history of the population making the likelihood of recurrent mutation at the same site 
low.  Common SNPs, by definition, have a minor ―variant‖ allele frequency greater than 
1% and may occur in coding and non-coding sequences.   
 
A  major  difficulty  arises  when  trying  to  assess  functionality  of  a  common  variant.  
Functional genetic polymorphism may result in phenotypic changes in gene transcript 
levels or gene product.  Initial estimates suggest that there are 22287 genes in the human  
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genome (www.sanger.ac.uk), with approximately 60000 SNPs occurring within exonic 
sequences (Sachidanandam et al. 2001).  Non-conservative coding SNPs (resulting in an 
amino acid change in the gene product and therefore change in structure or function of a 
protein), appear to have been selected against during human history, being found at a 
lower allele frequency than to be expected compared to conservative or synonymous 
SNPs (Cargill et al. 1999).  The majority of SNPs occur outside the coding regions of 
genes, and some of these will be within sequences with important regulatory function, 
such  as  the  gene  promoter,  and  such  variation  may  be  the  key  primary  effect 
contributing  to  phenotypic  variation  in  humans  (Stranger  et  al.  2007).    Indeed 
phenotypic variability in mRNA transcript levels may represent an intermediate stage 
between common genetic variation and complex traits.  It was recently confirmed that 
there is a genetic contribution to this variability (Cheung et al. 2003). 
 
These functional gene polymorphisms account for much of the biological diversity in 
homeostatic systems. One hypothesis is that the disease-susceptibility alleles included in 
this variation have persisted at moderate frequency because they have been selectively 
neutral, at least until the recent emergence of technological advancements creating the 
environment required for disease manifestation (Doris 2002). 
 
In  order  to  determine  the  genetic  risk  profile  of  a  subject  we  must  therefore  use  a 
polygenic  strategy,  and  it  is  only  by  the  simultaneous  analysis  of  functional  gene 
polymorphisms at several loci, or by stratifying by the presence of an environmental 
factor, that such an understanding can be obtained (gene-environment approach). 
 
Different tools are available in the study of common disease causing candidate genes.  
Linkage analysis can be a powerful tool in mapping disease genes (Lander et al. 1994).   
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In such an approach, the recombination fraction between two genetic loci is estimated 
using genotype data from collections of related individuals with family members who 
manifest  a  complex  trait  or  disease  (e.g.  hypertension,  CHD).    The  recombination 
fraction is the probability that recombination (during meiosis) will take place between 2 
loci, ranging between 0 (no recombination – loci are very close) and 0.5 (essentially 
random assortment because loci are far apart or on different chromosomes).  In linkage 
analysis, one locus is known (e.g. genotyped SNP) and the other is unobserved (the 
disease locus).  The test therefore examines the co-inheritance with the complex trait of 
several widely-distributed genetic markers, in order to infer the genomic position of the 
allele(s) contributing to that trait. 
 
Linkage disequilibrium (LD) refers to a non-random relationship between two alleles, 
typically  because  they  are  close  together  on  a  chromosome  and  less  likely  to  be 
separated by gene recombination.  The degree of LD also reflects human population 
history  as  it  is  influenced  by  recombination,  by  the  historical  size  and  pattern  of 
expansion and contraction of the population, by migration followed by admixture, by 
selection and by random drift.  A common standardised measure of LD is D’ (Lewontin 
1964).    D’  ranges  between  0  (two  loci  are  completely  unlinked,  e.g.  different 
chromosomes) and 1 (the two loci are never seen separately). 
 
Gene  association  studies  look  for  statistical  association  between  common  genetic 
variants and a complex trait.  Typically, case-control studies have been used to assess 
the impact of genetic variation in candidate genes on the presence of CHD (Hingorani 
2001; Stephens et al. 2003).  In such studies, the frequency of a genetic variant  in 
unaffected controls is compared with that in a sample of unrelated cases.  This approach 
has potentially greater statistical power than linkage-based designs (Risch et al. 1996).   
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However,  statistical  power  can  be  reduced  by  several  factors  including  a  lower 
frequency of the variant allele, genotyping error, phenotyping error (including locus 
heterogeneity)  and  strength  of  association  between  variant  genotype  and  phenotype 
(genotype relative risk or effect size).  False positives may arise in this approach for 
several reasons: as a function of sample size, because the gene variant under study may 
not be directly functional but may be in LD with other SNPs or neighbouring variants 
which  are  functional,  or  because  of  population  stratification  or  undetected  ethnic 
admixture,  both  of  which  may  alter  allele  frequencies  (Montgomery  et  al.  2002; 
Montgomery et al. 2003). 
 
 
 
1.4  RENIN ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)  
 
The first chapter in the story of the RAAS was penned by Tigerstedt and Bergman at the 
end of the 19
th Century in their description of a pressor agent produced by the renal 
cortex (Tigerstedt et al. 1898) termed renin, and later identified as an aspartyl protease 
which cleaves the α2 globulin angiotensinogen to yield the decapeptide, angiotensin I 
(Ang I).  Subsequently elucidated, the endocrine RAAS was ascribed the sole function 
of maintaining circulatory homeostasis.  However, it has now become clear that local 
tissue RAAS also exist, where they have paracrine, autocrine and intracrine (‗between 
cells‘ and ‗intracellular‘) roles.  
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1.4.1.  Tissue ACE 
The RAAS and Kallikrein-Kinin System (KKS) are intimately enmeshed at the tissue 
level  (Figure  1.7).  First  isolated  in  1956,  the  158kDa  zinc  metalloproteinase 
Angiotensin I Converting Enzyme (ACE; kininase II) plays a pivotal role in both the 
RAAS and KKS:  it acts as a dipeptidyl carboxypeptidase, removing the C-terminal 
dipeptide from Ang I to form Ang II, from the vasodilator nonapeptide bradykinin (BK) 
to form BK(1-7), and from BK(1-7) to form BK(1-5).  Kinetic studies have shown that 
the preferred substrate for ACE is BK (Jaspard et al. 1993).   
 
ACE can exist in two forms: a somatic form containing two homologous zinc-binding 
catalytic domains arising from tandem gene duplication, and a truncated testicular form 
containing only the C-terminal catalytic domain which is critical to fertility.  ACE is 
anchored to the plasma membrane of cells by its C-terminus, which is subsequently 
cleaved by ACE secretase to yield circulating ACE (Wei et al. 1991).  The somatic ACE 
promoter  has  a  typical  TATA  box,  3  Sp1  binding  sites,  4  glucocorticoid  response 
elements and an early growth response-1 (egr-1) factor response element.  Endothelial 
ACE mRNA is induced by steroids within 4 hours of treatment (Dasarathy et al. 1992).  
ACE  gene  expression  is  also  upregulated  by  a  variety  of  factors  such  as  vascular 
endothelial  growth  factor  (Saijonmaa  et  al.  2001)  and  atrial  natriuretic  peptide 
(Saijonmaa et al. 1998) via secondary messengers such as protein kinases, cyclic GMPs 
and  MAP  kinases.    Protein  kinase  C  (PKC)  activation  upregulates  ACE  gene 
expression, possibly via egr-1, and may be a common pathway through which a variety 
of mechanisms  (shear  stress  and hypoxia) can activate endothelial cells  (Iwai et  al. 
1987; Villard et al. 1998). 
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The ACE-related carboxymonopeptidase ACE2 is  a homologue of ACE, discovered 
only recently (Donoghue et al. 2000; Tipnis et al. 2000).  It is an 89.6kDa endothelial-
bound  enzyme  whose  expression  appears  limited  to  the  heart  and  renal  vasculature 
(Donoghue et al. 2000; Tipnis et al. 2000).  It has a single zinc-binding catalytic domain 
which shares 40% sequence homology with the ACE catalytic domains (Donoghue et 
al. 2000).  ACE2 can cleave Ang I to inactive Ang(1-9) (Donoghue et al. 2000; Vickers 
et al. 2002), can generate vasodilator Ang(1-7) from Ang II (Crackower et al. 2002; 
Vickers et al. 2002) and can also cleave kinin and opioid peptides (Vickers et al. 2002).  
The  ACE2  knockout  mouse  has  cardiac  dysfunction,  but  the  ACE/ACE2  double 
knockout has a normal cardiac phenotype (Crackower et al. 2002).  Therefore the ACE 
and ACE2 enzymes may counterregulate one another.  
 
Circulating ACE contributes less than 10% of total body ACE, and it is now recognised 
that the largest proportion of ACE is to be found in tissue compartments (Cushman et 
al.  1971).    Other  RAAS  components  have  also  been  identified  in  diverse  tissues 
Figure 1.7.  The Renin-Angiotensin and Kallikrein-Kinin Systems 
Angiotensinogen 
Angiotensin I 
Angiotensin II 
AT1R  AT2R 
Angiotensin (1-9) 
Angiotensin (1-7)  Bradykinin 
Lys-BK 
des-Arg
9-BK 
des-Arg
9-Lys-BK 
B2R  B1R 
Inactive  Inactive 
Renin 
ACE  ACE  ACE 
ACE2 
ACE2 
ACE2 
Kininase I  
  70 
including those of the heart (Danser 1996; Neri Serneri et al. 1996), vasculature (Dzau 
1993), brain (Saavedra 1992; Hilbers et al. 1999), lung (Pieruzzi et al. 1995), kidney 
(Alhenc-Gelas et al. 1989; Harris et al. 1996; Zhuo et al. 1998) and pancreas (Sernia 
2001; Lam et al. 2002), as well as in adipose tissue (Jonsson et al. 1994; Schling et al. 
1999), and skeletal muscle (Reneland et al. 1994).   
 
In some situations, complete RAAS seem to exist: in others, local generation of some 
RAAS  components  is  supplemented  by  the  uptake  of  others  from  the  circulation 
(Danser et al. 1999).  Local RAAS may influence the inflammatory process (Brull et al. 
2002).  Indeed macrophages contain an active RAAS (Eklund et al. 1987; Potter et al. 
1998;  Sun  et  al.  2001)  which  here,  as  elsewhere,  may  drive  synthesis  of 
proinflammatory cytokines such as IL-6 (Schieffer et al. 2000; Keidar  et al. 2001).  
Fibrotic responses in tissues such as heart (Weber et al. 2000; Sun et al. 2001), lung 
(Marshall et al. 2000) and kidney (Mezzano et al. 2001) are similarly RAAS-dependent.  
 
Several hundred thousand patient years of experience underscore the safety and efficacy 
of pharmacological ACE inhibition in CHF (CONSENSUS Trial Study Group 1987; 
Flather et al. 2000) and after myocardial infarction (Pfeffer et al. 1992).  ACEi reduce 
the generation of Ang II, reduce degradation of BK (Swartz et al. 1980) and mediate 
cross-talk between membrane-bound ACE and the bradykinin β2 receptor (BDKRB2), 
leading to a reduction in BDKRB2 desensitisation, reduced receptor endocytosis and an 
increase in BK-receptor affinity (Minshall et al. 1997).  More recently, fundamental 
roles  of  ACEi  in  vascular  disease  modification,  beyond  circulatory  homeostasis 
(Fonarow  et  al.  1992),  have  been  confirmed  by  the  Heart  Outcome  Prevention 
Evaluation (HOPE) study (Yusuf et al. 2000).  In this randomised controlled trial of 
9297  high  risk  patients  with  established  atherosclerotic  disease,  the  ACEi  ramipril  
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significantly  decreased  the  incidence  of  MI,  stroke  and  death  from  cardiovascular 
causes, as well as the incidence of new-onset diabetes and diabetic complications. It 
also induced regression of, and inhibited development of, left ventricular hypertrophy 
(LVH).  Minor associated reductions in blood pressure (3/2 mmHg) explain, at most, 
only one-third of these benefits (Mancini et al. 2001; Sleight et al. 2001).  Such effects 
may be mediated through inhibition  of tissue, rather than circulating,  ACE activity.  
Similar benefits were later confirmed in a large multicentre, placebo-controlled trial of 
patients with CHD but without clinical heart failure (Fox et al. 2003). 
 
 
1.4.2.  Receptors for angiotensin II and kinins 
 
Ang II acts via two different types of G-protein-coupled receptors (GPCRs) – the Ang II 
type 1 (AT1R) and type 2 (AT2R) receptors.  Ang II is the effector peptide of the RAAS 
cascade,  acting  via  the  AT1R  to  cause  potent  vasoconstriction,  renal  salt  and  water 
retention  via  stimulated  secretion  of  aldosterone,  fibrosis,  cell  proliferation, 
inflammation and reactive oxygen species (ROS) generation.  The AT2R is thought to 
oppose the actions of the AT1R (Matsubara 1998). 
 
Kinins are a family of peptides, whose original functions in pain, inflammation and 
thrombosis  have been  extended to  vasodilatation and metabolism  (Scholkens 1996).  
Kinins are released from the precursor glycoproteins ‗low molecular weight‘ or ‗high 
molecular weight‘ kininogen (LMWK and  HMWK, respectively  – both coded by  a 
single kininogen gene by alternative splicing) by serine proteases termed kallikreins.  
Plasma kallikrein catalyses the conversion of kininogens to BK (Arg
1-Pro
2-Pro
3-Gly
4-
Phe
5-Ser
6-Pro
7-Phe
8-Arg
9) and tissue kallikreins catalyse the conversion of kininogens  
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to Lys-BK (also termed kallidin) which differs only by the addition of an N-terminal 
lysine (Lys
1-Arg
2-Pro
3-Pro
4-Gly
5-Phe
6-Ser
7-Pro
8-Phe
9-Arg
10).  The subsequent cleavage 
of the C-terminal arginine residue by carboxy-peptidase yields the active fragments des-
Arg
9-BK and Lys-des-Arg
9-BK. 
 
Intact  kinins  and  their  fragments  act  upon  β1  and  β2  G-protein  coupled  cell-surface 
receptors  (termed  BDKRB1  and  BDKRB2,  respectively),  which  share  only  36% 
sequence homology and differ greatly in their expression and pharmacology (Regoli et 
al. 1997).  Thus, the constitutive BDKRB2 is expressed in diverse cell types including 
the endothelium, myocardium and skeletal muscle, and is responsive to intact kinin 
peptides (Faussner et al. 1999).  Conversely, the inducible BDKRB1 is activated by C-
terminal  arginine-deficient  kinin  fragments  (Faussner  et  al.  1999).    Kinin  receptor 
activation leads to calcium-dependent nitric oxide (NO•) and prostaglandin release. 
 
Animal  studies  have  suggested  that  kinins  have  cardioprotective  effects,  including 
immediate protection of the myocardium from ischemia-reperfusion injuries (Yang et 
al. 1997; Zhang et al. 1997; Kitakaze et al. 1998; Su et al. 2000) and, in the longer-
term, a reduction in left ventricular hypertrophy (LVH) and prevention of heart failure  
(Linz et al. 1992; Linz et al. 1993; Ishigai et al. 1997; Liu et al. 1997).  Kinin receptor 
activation  may  also  play  a  role  in  the  modulation  of  atherosclerotic  risk  through 
promotion of microangiogenesis  (Parenti et al. 2001), inhibition of vascular smooth 
muscle cell growth (Murakami et al. 1999), coronary vasodilatation (Su et al. 2000),  
increased  local  NO·  synthesis  (Kichuk  et  al.  1996),  and  anti-thrombotic  actions 
(Schmaier 2000).  Reduced kinin degradation may therefore contribute to the beneficial 
effects of ACE inhibition on vascular risk, LVH and heart failure (Linz et al. 1995), but 
this is unproven in humans.  
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1.4.3.  Nitric oxide (NO•) 
It was as early as 1867 that Brunton first reported the use of amyl nitrite for the relief of 
angina (Brunton 1908).  He also noted that glyceryl trinitrate (GTN, nitroglycerin) had a 
similar  effect,  but  felt  unable  to  work  with  this  compound  because  of  the  terrible 
headaches it caused.  Over a century passed before there was more interest in nitrous 
compounds and their effects on the circulation.  In 1980, it was shown that endothelial 
cells were necessary for the acetyl choline-induced relaxation of rabbit aorta (Furchgott 
et al. 1980), but that the artery denuded of endothelium still responded to exogenous 
GTN.  The endogenous mediator of this effect was termed endothelium derived relaxing 
factor (EDRF) (Furchgott et al. 1980) and later proven to be NO• (Ignarro et al. 1987; 
Palmer et al. 1987).  
 
Figure 1.8.  Cartoon depiction of classical nitric oxide (NO•) generation within endothelial cells 
by nitric oxide synthase (NOS).  NO• can diffuse across the plasma membrane to act on soluble 
guanylyl cyclase to form cGMP within adjacent smooth muscle cells to promote vasodilatation.  
NOS can become uncoupled by reactive oxygen species (ROS), low levels of BH4 or high levels of 
AMDA to generate further ROS.  See text for discussion.  
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NO• is a diffusible, lipophilic, highly reactive gaseous molecule with a short half life 
(<4 seconds in biological solutions).  It is rapidly oxidised to nitrite and then nitrate by 
oxygenated haemoglobin before being excreted into the urine (Moncada et al. 1993).  
NO• is synthesized from the amino acid L-arginine by different isoforms of nitric oxide 
synthase  (NOS)  (including  constitutive  neuronal  type  1  isoform  (nNOS,  or  NOS1), 
inducible type 2 isoform (iNOS or NOS2) and constitutive endothelial type 3 isoform 
(eNOS or NOS3)),  yielding L-citrulline as a byproduct (Figure 1.8).  Several co-factors 
are  required  for  NO•  biosynthesis,  including  nicotinamide  adenine  dinucleotide 
phosphate  (NADPH),  flavin  mononucleotide  (FMN),  flavin  adenine  dinucleotide 
(FAD), tetrahydrobiopterin (BH4), and calmodulin.  NOS has two catalytic domains 
consisting of a C-terminal reductase where NADPH, FMN, and FAD bind, and an N-
terminal  oxygenase  domain  where  heme,  BH4,  oxygen  and  L-arginine  bind.  The 
catalytic  mechanisms  of  NOS  involve  flavin-mediated  electron  transport  from  C-
terminal–bound NADPH to the N-terminal heme centre, where oxygen is reduced and 
incorporated into the guanidine group of L-arginine, yielding NO• and L-citrulline. 
 
An important physiological target of NO• is the heme protein soluble guanylyl cyclase.  
NO• diffuses across the endothelial cell membrane and activates guanylyl cyclase by 
interacting  with  its  heme,  generating  cyclic  guanosine-3‘,5-monophosphate  (cGMP) 
from guanosine triphosphate (GTP).  As a second messenger, cGMP mediates many of 
the  biological  effects  of  NO•  including  the  control  of  vascular  tone  and  platelet 
function.  Subcellular NO• signal transduction is complex, involving cGMP-dependent 
protein kinases (PKGs) and cGMP-stimulated and cGMP-inhibited cyclic nucleotide 
phosphodiesterases  (cGsPDE  and  cGiPDE,  respectively).  PKG-dependent  signal 
transduction  involves  the  phosphorylation  of  various  targets,  whereas  cGsPDE-  and 
cGiPDE-dependent  pathways  involve  decreases  or  increases  (respectively)  in  cAMP  
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levels.  In addition, NO• has other molecular targets which include metal and thiol-
centred proteins and DNA, supporting additional reactions with key enzymes or ion 
channels.    NO•  also  interacts  with  enzymes  of  the  mitochondrial  respiratory  chain 
(Brown et al. 1994; Cleeter et al. 1994). 
 
Impaired synthesis or bioavailability of NO• may underlie the endothelial dysfunction 
seen in individuals with cardiovascular risk factors but without clinical CHD (smokers, 
hypertensives,  hypercholesterolaemics),  and  may  predispose  to  the  development  of 
atherosclerosis (Calver et al. 1992; Chowienczyk et al. 1992; Celermajer et al. 1993; 
Cooke et al. 1997).  NO• bioavailability can be reduced by several factors, including a 
reduction in cofactors for NOS, for example reduced BH4 as seen early in endothelial 
dysfunction, diabetes and hypercholesterolaemia.   
 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NOS which has 
been found to be increased in atherosclerotic disease, hypertension, diabetes and chronic 
renal  failure.    ADMA  is  formed  from  L-arginine  by  the  protein  methylase-I  and 
subsequently  metabolised  by  dimethylarginine  dimethylaminohydrolase  (DDAH)  to 
produce citrulline (Vallance et al. 1992).   
 
There are also important interactions between NO• and ROS.  Superoxide (O2•
-) can 
react  with  equimolar  concentrations  of  NO•  to  form  peroxynitrite  (ONOO
-),  thus 
reducing the bioavailability of NO•.  Peroxynitrite at high concentrations is highly toxic 
producing protein nitration and oxidation and irreversible inhibition of mitochondrial 
electron transport (Beckman et al. 1990; Radi et al. 1994).  NOS can also become a 
potent  generator  of  ROS  (Figure  1.8):  in  relative  substrate  (L-arginine)  or  cofactor 
(BH4)  deficiency,  NOS  can  become  ‗uncoupled‘,  generating  O2•
-  and  peroxynitrite  
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(Mayer et al. 1997; Xia et al. 1997).  Peroxynitrite itself can directly or indirectly (by 
rapidly  metabolising  BH4  to  BH2)  uncouple  NOS,  thereby  perpetuating  ROS 
generation (Zou et al. 2002). 
 
It has become increasingly apparent that NO• has divergent roles.  The effects of NO• 
depends on several factors including the cellular source and targets of NO• as well as 
target cell redox/antioxidant status, the amount of NO• released or studied, stimuli such 
as coronary flow rate and heart rate or co-existing neurohumoral stimuli, or the presence 
of immune activation or disease (Shah et al. 2000).  For example, NO• has positive and 
negative inotropic responses at low and high concentrations, respectively (Mohan et al. 
1996) and a similar biphasic response is seen with respect to apoptosis  (Kim et al. 
1999).    Exposure  to  bacterial  lipopolysaccharide  (LPS)  or  cytokines  such  as  TNFα 
results in increased vascular iNOS expression and the resultant NO• has bactericidal, 
antiviral  and leukostatic effects.   Endotoxaemia rapidly  results  in  hypotension,  with 
dysregulation of vasomotor tone and myocardial depression, and excess NO• generation 
is directly implicated in the pathogenesis of septic shock in both animals and humans 
(Petros et al. 1991). 
 
NO•  has  also  been  implicated  in  the  development  of  LVH  and  heart  failure.  
Endogeneous NO• has a small baseline inotropic effect in the human heart in vivo which 
is  lost  in  patients  with  heart  failure  (Cotton  et  al.  2001).    eNOS  and  nNOS  are 
constitutively expressed in the human heart, but the expression pattern may change in 
heart failure, with an increase in cytokine-induced calcium-insensitive iNOS expression 
(de Belder et al. 1993; Drexler et al. 1998).  Cardiac eNOS and iNOS gene expression 
correlates positively with indices of cardiac performance in heart failure and negatively 
with the severity of LV dysfunction (Heymes et al. 1999).  However, cardiac iNOS  
  77 
expression  in  the  failing  heart  has  also  been  implicated  in  blunting  β-adrenoceptor 
responsiveness in vitro (Hare et al. 1998) and in vivo (Drexler et al. 1998) .  Paracrine 
NO• release from the coronary microvasculature enhances myocardial relaxation and 
diastolic LV function and reduces myocardial oxygen consumption (Shah et al. 2000).  
In  animal  models  of  LVH,  NO•-dependent  LV  relaxation  is  markedly  impaired 
independent of coronary flow (MacCarthy et al. 2000).  This may be due to a significant 
increase in superoxide generated by NADPH oxidase which can be acutely reversed by 
administration  of  antioxidants  (MacCarthy  et  al.  2001).    The  precise  spatial  and 
temporal expression patterns of the NOS isoforms and relationship to cardiac failure 
remains controversial at present (Drexler 1999; Shah et al. 2000). 
 
 
 
 
 
1.5  MITOCHONDRIA 
 
1.5.1  Overview 
The endosymbiosis hypothesis suggests that mitochondria are organelles derived from 
ancient protobacteria about 1500 million years ago (Lang et al. 1997).  Mitochondria 
play a critical role in survival of the ‗host‘ cell; they house energy-yielding oxidative 
reactions,  metabolise amino acids,  fatty acids  and ketone bodies,  and  are  central  in 
calcium  homeostasis,  oxidative  stress  and  the  process  of  programmed  cell  death  or 
apoptosis.   
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The mitochondrion (Figure 1.9) consists of an outer membrane and an inner membrane 
which define the intermembranous space and the inner matrix (Graff et al. 1999).  The 
inner  membrane  is  a  sophisticated  energy-transducing  membrane  and  is  folded  into 
cristae,  increasing  its  surface  area.    All  energy-transducing  membranes  contain  two 
types of proton pump.  In the case of the mitochondrion, it contains ‗primary pumps‘ 
known  as  the  electron  transport  chain  (ETC)  which  consist  of  four  complexes 
(numbered I to IV) that catalyse the transfer of electrons from substrates to the final 
acceptor, molecular oxygen (Figure 1.9).  These are coupled to highly evolutionary-
conserved  ‗secondary‘  pumps  termed  ATP  synthase  (F1.Fo-ATPase  or  complex  V) 
which are seen as ‗knob-like‘ structures on the matrix side of the inner membrane on 
electron microscopy, consisting of a proton channel (Fo subunit) and an ATP synthase 
(F1 subunit).  If the secondary pump were in isolation, it would hydrolyse ATP to ADP 
and Pi.   
 
The mitochondrial matrix contains 2-10 copies of a 16,569 base pair circular molecule 
of  double  stranded  DNA  (mitochondrial  or  mtDNA)  which  is  distinct  from  nuclear 
DNA.  Human mtDNA encodes 37 genes:  22 encoding transfer RNAs, 2 ribosomal 
RNAs and 13 polypeptides which are components of the ETC or ATP synthase. The 
ETC complexes contain at least 70 nuclear-encoded peptides, which are synthesised 
within  the  cell  cytoplasm  and  targeted  to  the  mitochondrion  using  specific  import 
pathways. 
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Figure 1.9.  Cross section through a mitochondrion, showing the inner and outer membranes.  A section of inner membrane has been magnified to show the complexes of 
the electron transport chain which generate an electrochemical gradient by transporting protons (H
+) out of the matrix during a series of redox reactions depicted.  H
+ re-
enters the matrix through FOF1-ATPase down this gradient, providing energy for generation of ATP.  ATP exits the matrix through the ADP/ATP translocator. 
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1.5.2  Mitochondrial metabolism (reviewed in (Nicholls et al. 2002) 
Oxidative phosphorylation is the process by which oxidation of the reducing equivalents 
NADH, FADH and succinate is coupled to the generation of ATP in the mitochondrion 
(Figure  1.9).    NADH,  FADH  and  succinate  (derived  from  the  oxidation  of  fuel 
substrate) transfer electrons into the respiratory chain (ETC) and ultimately to O2.  The 
ensuing  series  of  redox  reactions  releases  free-energy  which  is  used  to  translocate 
protons (H
+) at complexes I, III and IV, out of the mitochondrial matrix and into the 
intermembranous space.  The outer membrane contains proteins, termed porins, which 
render it freely permeable to molecules up to 10kDa in weight.  The inner membrane is 
permeable only to gases such as O2 and carbon dioxide (CO2) and certain lipophilic 
compounds (discussed later).  Hence the translocation of H
+ across the inner membrane 
results in an electrochemical gradient (ΔμH+) or proton motive force (PMF, ΔP) which 
drives the ATP synthase to synthesise ATP from ADP and Pi.  This process has been 
termed  the  chemiosmotic  theory  of  energy  transduction  (Mitchell  et  al.  1967).    ΔP 
consists of two components: a H
+ gradient (pH gradient or ΔpH) and a gradient due to 
the electrical potential generated between the matrix and intermembranous space (Δψm).  
In  the  mitochondrion,  the  ΔpH  component  is  small,  only  0.5pH  units,  and  Δψm 
approximates ΔP. 
 
The  ETC  can  be  thought  of  as  a  ‗proton  circuit‘  analogous  to  an  electrical  circuit 
(Nicholls  et  al.  2002)  (Figure  1.10).  Both  circuits  have  generators  of  a  potential 
difference (expressed in volts) used to perform useful work.  The current flowing (I) is 
defined by Ohm‘s Law, V = I x R, where R is the resistance of the circuit (inverse of 
conductance).  Both circuits can be shorted and the potential falls if the current drawn 
increases.  A typical Δψm achieved is 200mV, equivalent to a charge of 300000V.cm
-1 
across  the  inner  membrane.    Ionophores  are  lipophilic  compounds  which  possess  a  
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hydrophilic core, able to carry or shield charge within.  They can therefore enter a 
charged lipid bilayer, such as the inner membrane, and act as mobile charge carriers or 
channel formers and are used to study membrane properties. 
 
Protonphores, or uncouplers, are molecules which can insert into lipid bilayers.  They 
contain extensive π-orbital rings, which allow them to dissociate their proton charge, 
facilitating proton cycling across the inner mitochondrial membrane, increasing proton 
conductance and collapsing Δψm. The rate of proton flow can be estimated from the 
respiration rate of mitochondria measured, for example, with an oxygen electrode.   
 
 
Figure 1.10.  The mitochondrial proton circuit is analogous to an electrical 
circuit (after Nicholls and Ferguson 2002).  Voltage (V) is equivalent to proton 
motive force (Δp); current (I) is equivalent to proton flux (JH+); conductance, 
resistance and short circuits can be derived. 
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Classically, five states of respiration are recognised in isolated mitochondria according 
to  the  availability  of  substrate,  ADP  and  O2,  presented  in  Figure  1.11.    Maximal 
respiration occurs (state 3) under optimal conditions when substrate, ADP and O2 are all 
available. That any respiration occurs during state 4 is due to the inherent ‗proton leak‘ 
of  the  inner  membrane,  whereby  any  leak  of  protons  is  counterbalanced  by  proton 
extrusion  by  the  respiratory  chain  (see  chapter  1.7.1).    Protonphore  uncouplers  can 
initialise  rapid  respiration,  similar  to  state  3,  by  collapsing  Δψm,  driving  futile 
respiration.  In this situation, glycolytically formed ATP is further depleted by reversal 
of the ATP synthase.  The respiratory control ratio is defined as state 3 (or uncoupled) 
divided by state 4 respiration (absence of uncoupler) and is related to the integrity or 
efficiency of the mitochondria.   
 
 
1.5.3  Measuring mitochondrial membrane potential in living intact cells 
Traditionally,  respiration  was  measured  in  isolated  mitochondria  using  an  oxygen 
(Clark) electrode (Nicholls et al. 2002), but studying mitochondrial function in intact 
cells remained problematic until recently (Griffiths 2000; Duchen et al. 2003).  The 
explosion of knowledge in this area has been aided by the development of fluorescent 
dyes  and  fluorescence  technologies,  which  have  been  used  to  measure  Δψm, 
intramitochondrial calcium, redox state, ROS generation, apoptosis and mitochondrial 
distribution and movement within cells.  
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Lipophilic cationic compounds will concentrate within mitochondria, which are more 
negatively charged than the surrounding cytoplasm, according to Nernstian principles 
(Emaus et al. 1986; Duchen et al. 2003):   
[C]i/[C]o = e
-FΔψm/RT 
where [C]i is the concentration of cations inside and [C]o is the concentration of cations 
outside the mitochondria, R is the gas constant, T is the temperature in degrees Kelvin 
Figure 1.11.  States of respiration in isolated mitochondria.  Changes are related to 
changes in membrane potential (Nicholls 2002). 
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and  F  is  the  Faraday  constant.    This  characteristic  has  been  exploited  to  develop 
fluorescent  lipophilic  cationic  dyes  which  will  concentrate  within  mitochondria 
according to the magnitude of Δψm.  At very low probe concentrations, fluorescence 
intensity  is  proportional  to  dye  concentration.    However,  some  important  problems 
exist.  Firstly, as dye concentration within a compartment increases, the fluorescence 
fails to increase because of the phenomenon of ―quenching‖: the dye is thought to form 
multimers,  with  energy  transferred  between  molecules  rather  than  expressed  as 
fluorescence  (Duchen  et  al.  2003).    Secondly,  the  dye  will  concentrate  in  the  cell 
cytoplasm  according  to  the  plasma  membrane  potential  (Δψp)  and  then  within 
mitochondria according to Δψm.  Thirdly, an ideal fluorescent dye would not bind to any 
mitochondrial component, but  be free to  move according to  changes  in  Δψm.  This 
binding would cause apparent deviation from Nernstian behaviour and would lead to 
enhanced mitochondrial accumulation (Rottenberg 1984; LaNoue et al. 1986).  Lastly, 
almost all of these fluorescent probes are photosensitising agents and prolonged laser 
illumination can cause phototoxicity leading to mitochondrial oxidative damage and 
depolarisation (Duchen et al. 2003). 
 
Many of the dyes first used were developed during a systematic search for dyes which 
would enable measurement of Δψ in neurones (Cohen et al. 1978).  Several types of dye 
are now available for study including rhodamines (Farkas et al. 1989; Duchen et al. 
1998;  Floryk  et  al.  1999;  Diaz  et  al.  2000;  Ward  et  al.  2000),  rosamines,  and  
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carbocyanine  derivatives.    Two  of  these  fluorescent  probes  are  discussed  in  greater 
detail below. 
 
1.5.3.1.  TMRM 
The  rhodamine  derivatives  TMRE  (tetramethylrhodamine  ethyl  ester)  and  TMRM 
(tetramethylrhodamine methyl  ester) have been used extensively to measure Δψm in 
living cells (Duchen et al. 1998; Antonicka et al. 1999; Floryk et al. 1999; Scaduto et 
al. 1999; Collins et al. 2000; Diaz et al. 2000; Ward et al. 2000; Krieger et al. 2002; 
Michelakis  et  al.  2002;  Michelakis  et  al.  2002).    Both  dyes  equilibriate  rapidly 
according  to  the  magnitude  of  Δψm.  However,  TMRM  demonstrates  much  less 
mitochondrial toxicity and less mitochondrial binding than TMRE at the same dose 
(Scaduto  et  al.  1999).    TMRM  fluorescence  demonstrates  red  spectral  shift  on 
accumulation in mitochondria, with maximal mitochondrial red fluorescence at 573nm 
(Scaduto  et  al.  1999).    The  chemical  structure  and  excitation/emission  spectra  of 
TMRM is shown in Figure 1.12. 
 
Figure 1.12.  Chemical structure and excitation/emission spectra for TMRM  
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1.5.3.2.   JC-1 
JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide, Figure 
1.13) is a carbocyanine derivative, which has been used widely to measure Δψm (Reers 
et al. 1991; Smiley et al. 1991; Cossarizza et al. 1993; Di Lisa et al. 1995; Cossarizza et 
al. 1996; Nuydens et al. 1999; Mathur et al. 2000; Minners et al. 2001; Michelakis et al. 
2002; Michelakis et al. 2002).  It exhibits dual fluorescence:  at low concentrations, JC-
1 exists as a monomer which fluoresces green (peak fluorescence 527nm); at higher 
concentration (>0.1M in solution or upon mitochondrial concentration), it forms so-
called ―J-aggregates‖ which exhibit red ―resonance fluorescence‖ at a peak of 590nm.  
The ratio of red/green fluorescence has been used for potentiometric assessment of Δψm 
(Reers et al. 1991; Michelakis et al. 2002) and has been found to be more reliable than 
several other compounds, such as DiOC6, Rhodamine 123 and CMXRos, being less 
Figure 1.13.  Chemical structure and excitation/emission spectra for JC-1  
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sensitive to changes in Δψp (Salvioli et al. 1997; Mathur et al. 2000).  J-aggregates are 
slow to disperse and therefore JC-1 does not give a dynamic representation of Δψm 
(Smiley et al. 1991) 
 
 
1.5.4  Defects in mitochondrial metabolism 
Mutations  in  mtDNA  result  in  neurological,  myopathic  and  cardiomyopathic 
abnormalities (Graff et al. 1999).  Not only is mtDNA highly susceptible to damage 
because it lacks protective histones and effective DNA repair mechanisms, but it also 
resides within an environment prone to ROS generation (Shigenaga et al. 1994; Graff et 
al. 1999; Ide et al. 2001).  mtDNA is almost exclusively inherited from the mother, but 
typically several allelic forms are inherited.  Each mitochondrion contains 2-10 copies 
of  mtDNA,  and  each  cell  can  contain  up  to  10
4  mitochondria.    Heteroplasmy  (the 
coexistence of more than one type of mtDNA within a cell, tissue, or organism) explains 
why  there  is  variation  in  which  cells  within  a  tissue,  or  which  tissues  within  an 
individual, are affected by a mtDNA mutation, and also the variable penetrance.  The 
propensity  for  the  CNS  or  myocardium  to  be  affected  probably  reflects  the  high 
metabolic demand within these tissues and possibly also higher oxidative stress within 
these tissues (two-hit phenomenon).   
 
Oxidative damage to mtDNA, mitochondrial protein and lipid accumulates as a function 
of age.  A decrease in respiratory rate of mitochondria isolated from ageing tissues is 
also seen, allied with a generalised decline in ETC complex and cytochrome c oxidase 
activity, perpetuating further oxidative damage.  These processes are thought to be a 
major determinant in the decline of organ function attributable to ageing (Shigenaga et 
al. 1994).  
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1.5.5  ACE and mitochondria 
A handful of studies have localised components of the RAAS in mitochondria, mostly 
in relation to aldosterone biosynthesis which is highly energy dependent.  Ang II and 
potassium regulate the synthesis and secretion of aldosterone from adrenal mitochondria 
via  calcium.    Physiological  concentrations  of  Ang  II  induce  oscillating  cytoplasmic 
calcium  signals  (Quinn  et  al.  1988;  Kramer  1990),  associated  with  parallel 
mitochondrial calcium and NAD(P)H oscillations (Pralong et al. 1994; Rohacs et al. 
1997).  This activates mitochondrial respiration and the generated ATP is used to drive 
aldosterone  biosynthesis  (Xu  et  al.  1991;  Kowluru  et  al.  1995).    Extra-adrenal 
production of aldosterone has been found in the heart (Young et al. 2000), vasculature 
(Hatakeyama et al. 1994) and brain (Gomez-Sanchez et al. 1997), and the mechanism of 
production  and  secretion  are  presumed  at  present  to  be  the  same  as  in  adrenal 
glomerulosa cells.  Most of the components of the RAAS have been located in adrenal 
cells (Hilbers et al. 1999; Mazzocchi et al. 2000).  Interestingly, biochemically active 
renin has been found within adrenal mitochondria, located in inclusion bodies of high 
electron  density  (Peters  et  al.  1996)  and  targeted  to  mitochondria  rather  than  the 
cytoplasm by alternative transcription and splicing of the renin gene (Clausmeyer et al. 
1999).  Ang II droplets have also been immunolocalised within rat brain, liver, and 
adrenal mitochondria (Erdmann et al. 1996).  
 
In  a  study  of  the  effects  of  ACE  inhibition  on  ageing,  enalapril  was  added  to  the 
drinking  water  of  CF1  mice  shortly  after  weaning  until  death  (approximately  24 
months(Ferder et al. 1993).  Enalapril treatment was associated with longevity, lower 
cardiac  weight,  lower  myocardial  and  glomerular  sclerosis  and,  interestingly,  an 
increase in the number of mitochondria in cardiomyocytes and hepatocytes.  In a further 
study, Ferder et al again found a protective effect of enalapril on cardiac mitochondrial  
  89 
number with ageing in the CF1 mouse, an effect which was significant by 18 months.  
This  effect  was  related  to  higher  mitochondrial  superoxide  dismutase,  higher 
cardiomyocyte replicative capacity (marked by higher cyclin expression) and reduced 
apoptosis (Ferder et al. 1998). 
 
 
1.6  OXIDATIVE STRESS 
 
ROS, including superoxide (O2•
-), hydrogen peroxide (H2O2), hydroxyl radicals (HO•), 
NO•  and peroxynitrite (ONOO
-), are important  mediators of both  physiological  and 
pathological  processes.    ROS  can  damage  cellular  macromolecules  including  DNA, 
protein  and  lipid  and  have  been  implicated  in  ageing,  atherosclerosis,  diabetes, 
tumourogenesis  and  neurodegeneration  (Shigenaga  et  al.  1994;  Ide  et  al.  2001).  
Oxidative  stress  refers  to  an  imbalance  between  the  production  of  ROS  and  the 
endogenous antioxidant defence mechanisms, and this may result in toxicity to lipids, 
DNA or protein.   
 
As discussed above, ROS include O2•
-, H2O2, HO•, NO• and ONOO
- , as well as lipid 
radicals.  Any one ROS has the potential to generate more ROS via chain reactions.  For 
instance ROS may react with cell membrane fatty acids to produce a fatty acid peroxyl 
radical (R-COO•) that can attack adjacent fatty acid side chains and produce other lipid 
radicals,  which  may  accumulate  to  have  deleterious  effects  on  cell  and  organelle 
integrity such as membrane leak, dysfunction of membrane-bound receptors, as well as 
cytotoxicity and mutagenesis (Herbst et al. 1999).  ROS may modify proteins to cause 
enzyme inactivation or protein denaturation (Stadtman et al. 2003).  ROS may also 
contribute to mutagenesis of DNA by inducing strand breaks, purine oxidation, protein- 
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DNA cross-linking and chromatin remodelling to affect gene expression (Konat et al. 
2003).  Oxidative  stress  may  thus  contribute  to  age-related  changes  in  the 
cardiovascular system, but this remains the subject of debate (Lakatta 2003). 
 
ROS  are  not  solely  deleterious,  having  important  physiological  roles.    They  have 
important  modulatory  roles  through  redox-sensitive  proteins  and  enzymes  to  effect 
cytokine, growth factor, and hormone action and secretion, ion transport, transcription, 
neuromodulation and apoptosis (Finkel 1999).  These effects may be imparted by action 
on tyrosine-phosphatases which have a redox-sensitive cysteine residue at the active site 
(Hecht et al. 1992), dimerisation of receptors or enzymes at redox-sensitive cysteine 
cross-bridges (Finkel 1999), altering protein-protein interaction (Wang et al. 1996) and 
direct effects on transcription factors such as nuclear factor Κβ (NF-Κβ) (Schreck et al. 
1991).   
 
As mentioned above, atherosclerosis is now thought to be an inflammatory disease and 
abnormalities of redox signalling may be a contributing factor (Ross 1999; Libby 2002; 
Harrison et  al. 2003).  ROS  appear to  promote all stages  of atherogenesis, through 
reduced endothelial-dependent vasodilatation (Rubanyi et al. 1986), lipid peroxidation 
(Steinberg et al. 1996), increased platelet aggregation and monocyte adhesion (Marui et 
al. 1993), endothelial cell apoptosis (Herbst et al. 1999), vascular smooth muscle cell 
hypertrophy (Zafari et al. 1998; Harrison et al. 2003) and plaque instability caused by 
MMP activation (Rajagopalan et al. 1996).  There is also a growing body of evidence 
that  ROS  production  in  response  to  traditional  risk  factors  such  as  hypertension, 
hypercholesterolaemia and diabetes results in alteration in signal transduction pathways 
in target cells, thereby altering a plethora of genes implicated in atherogenesis such as 
inflammatory gene transcription (Sen et al. 1996; Kunsch et al. 1999).  In this regard,  
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both the transcription factors NF-Κβ and activator protein-1 (AP-1) are redox sensitive 
(Ares et al. 1995).  Indeed, AP-1 is activated by a variety of ROS, including superoxide, 
H2O2, oxLDL and the lipid peroxidation product 4-hydroxy-2-nonenal.  NF-kB was the 
first eukaryotic transcription factor shown to respond directly to oxidative stress and its 
activation  mechanisms,  which  directly  lead  to  NF-Κβ  nuclear  translocation,  involve 
ROS as a common step (Schreck et al. 1991).  However, the ROS that activate NF-Κβ 
are  more  restricted  to  hydroperoxidases,  such  as  H2O2.    NF-Κβ  has  been  directly 
implicated  in  atherogenesis,  and  activated  NF-Κβ  is  specifically  localised  in 
atherosclerotic but not healthy vessels (Brand et al. 1996).  
 
Increased ROS production or decreased antioxidant activity may favour LVH.  Ang II, 
TNFα  and  adrenergic  stimulation  all  induce  ROS-dependent  cardiomyocyte 
hypertrophy  (Nakamura  et  al.  1998;  Amin  et  al.  2001)  and  partial  inhibition  of 
cytoplasmic CuZn-SOD (SOD 1) also induces cardiomyocyte hypertrophy (Siwik et al. 
1999).  Ang II induces cardiomyocyte hypertrophy in a non-pressor dependent manner 
via NAD(P)H oxidase ROS production (Bendall et al. 2002).   Graded increases in ROS 
induce a graded phenotype shift in cardiac myocytes, from hypertrophy and induction of 
foetal gene expression at low levels to apoptosis at high levels of oxidative stress (Siwik 
et al. 1999; Pimentel et al. 2001).  Mechanical strain may also induce ROS-dependent 
cardiomyocyte hypertrophy via MAP kinase (Pimentel et al. 2001).   
 
ROS have been implicated in the pathophysiology of CCF.  Elevated levels of ROS 
have been found in both animal models of heart failure (Hill et al. 1996) and in clinical 
trials of heart failure treatment (McMurray et al. 1993; Keith et al. 1998; Yucel et al. 
1998), and may contribute to the endothelial dysfunction identified in CCF (Kubo et al. 
1991) and to post infarct myocardial remodelling due to effects on hypertrophy, fibrosis  
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(via MMP activation) and apoptosis (Spinale 2002; Sabri et al. 2003).  ONOO
- may 
inhibit  mitochondrial  substrate  supply  via  inactivation  of  the  Kreb‘s  cycle  enzyme 
aconitase (Castro et al. 1994) and can inhibit mitochondrial electron transport, with the 
potential  to  generate  further  ROS  from  the  ETC  (Radi  et  al.  1994),  with  marked 
depression  of  myocardial  contractile  function  and  reduced  cardiac  efficiency  in  the 
isolated perfused rat heart (Schulz et al. 1997).  O2•
- can rapidly and irreversibly inhibit 
calcium-induced force generation in isolated rat cardiomyocytes (Miller et al. 1995).   
 
NO• has a plethora of roles in the myocardium (see section 1.4.3) including effects on 
myocardial diastolic and systolic function and oxygen consumption (Shah et al. 2000) 
and  cardiac  NOS  isoform  expression  correlates  positively  with  indices  of  cardiac 
performance  in  heart  failure  and  negatively  with  the  severity  of  LV  dysfunction 
(Heymes et al. 1999). 
 
Despite this wealth of data, clinical trials of  antioxidants in patients at high risk of 
cardiovascular disease have yielded disappointing results (Hennekens et al. 1996; Yusuf 
et  al.  2000)  and  it  remains  speculative  whether  oxidative  stress  is  causal  or  an 
epiphenomenon of cardiovascular diseases. 
 
 
1.6.1  Mitochondrial ROS generation 
Mitochondria are the major cellular source of ROS (Chance et al. 1979) (Figure 1.14).  
Quantitative data on isolated mitochondria suggest that 2-6% of total O2 consumption is 
due to O2•
- production.  O2 appears to have access to the electron donating sites in 
complexes I and III, to allow formation of O2•
-.  At complex III, this tendency increases 
as Δψm increases, for instance as mitochondria move from state 3 to state 4 respiration.   
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O2•
-  generated  at  the  quinine-binding  site  of  complex  III  is  released  into  the 
intermembranous space, as it cannot cross the inner membrane because of the negative 
Δψm.    O2•
-  generated  in  this  way  is  probably  detoxified  by  cytoplasmic  Cu-Zn-
superoxide dismutase (CuZn-SOD or SOD1). 
 
Mitochondria have also developed elaborate enzyme systems to protect against ETC-
generated ROS.  Complex I is thought responsible for most of the ROS within the 
mitochondrial matrix.  This O2•
- is first reduced to diffusible H2O2 by the mitochondrial 
manganese-dependent  isoform  of  superoxide  dismutase  (Mn-SOD  or  SOD2).    The 
mouse  homozygous  SOD2  knockout  show  neonatal  lethality  due  to  selective 
mitochondrial  injury  resulting  in  dilated  cardiomyopathy,  neuronal  degeneration, 
accumulation of lipid in liver and skeletal muscle and metabolic acidosis (Li et al. 1995; 
Lebovitz et al. 1996) emphasising the toxicity of mitochondrial ROS.   
 
The glutathione couple (GSSG/GSH representing the oxidised and reduced forms) is 
responsible  for  detoxifying  H2O2  to  water  via  the  enzyme  glutathione  peroxidase.  
Glutathione is maintained in a reduced state at the expense of nicotinamide adenine 
dinucleotide  phosphate  (NADPH)  via  glutathione  reductase.    Furthermore,  a  highly 
reduced  NADP
+  pool  is  maintained  at  the  expense  of  NADH  by  the  ΔP-driven 
mitochondrial transhydrogenase.  Thioredoxin and thioredoxin reductase form another 
redox  regulatory  couple  which  can  catalyze  the  regeneration  of  many  antioxidant 
molecules, including ubiquinone (Q10) and ascorbic acid, and as such constitute an 
important  antioxidant  defence  against  ROS.  Thioredoxin  reductase  gene  deletion 
results in congenital cardiac abnormalities and a severe dilated cardiomyopathy (Conrad 
et al. 2004).  Non-enzymatic antioxidants include the vitamins E, C and β-carotene, 
ubiquinone, lipoic acid, and urate (Nordberg et al. 2001).   
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1.6.2  Non-mitochondrial sources of oxidative stress 
Important  non-mitochondrial  sources  of  cellular  ROS  in  the  myocardium  and 
endothelial cells include NAD(P)H oxidase, xanthine oxidase and NOS (Figure 1.15).  
The  membrane-bound,  non-phagocytic  NAD(P)H  oxidase  is  a  flavocytochrome  b 
heterodimer which is a major source of intracellular ROS generation from endothelial 
cells, vascular smooth muscle cells and cardiomyocytes.  This process is regulated by 
Ang II via the AT1R, shear stress and by cytokines such as TNFα and platelet derived 
Figure 1.14.  Reactive oxygen species (ROS) are generated at complexes I and III of 
the electron transport chain.  Superoxide dismutase and the glutathione reductase 
systems  form  part  of  the  mitochondrial  defence  against  ROS.    Other  non-
mitochondrial sources of ROS, such as xanthine oxidase are also shown (adapted 
from Nicholls and Ferguson 2002).  
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growth factor (PDGF) (Rajagopalan et  al.  1996;  Zhang  et  al. 1999;  Harrison  et  al. 
2003).    Receptor  binding  activates  protein  kinase  C  (PKC)  which  both  directly 
stimulates  ROS  from  NAD(P)H  oxidase,  and  indirectly  via  transactivation  of  the 
endothelial growth factor receptor (EGFR), which causes further assembly of NAD(P)H 
oxidase subunits over a period of hours (Figure 1.15).   
 
Several  studies  have  shown  that  NAD(P)H  oxidase  mediates  Ang  II–induced 
hypertension and ROS generation (Rajagopalan et al. 1996; Ushio-Fukai et al. 1998; 
Zhang  et  al.  1999).    This  cascade  is  important  in  transducing  Ang  II  intracellular 
signalling to mediate cellular hypertrophy/proliferation/migration/apoptosis (Griendling 
et al. 2000), as well as in endothelial dysfunction and atherogenesis (Harrison et al. 
2003)  and  in  part  explains  endothelial  ROS  generation  in  both  diabetes  and 
hypercholesterolaemia (Guzik et al. 2000; Brownlee 2001).  Ang II – NAD(P)H oxidase 
mediated ROS production is reduced by ACE inhibition and AT1R antagonism,  and is 
enhanced by AT2R antagonism (Zhang et al. 1999).   
 
Xanthine oxidoreductase catalyses the oxidation of xanthine and hypoxanthine during 
purine metabolism and can exist in two forms:  xanthine dehydrogenase which reduces 
NAD
+  and  xanthine  oxidase  which  reduces  molecular  oxygen  to  generate  O2•
-  and 
H2O2.  There is some evidence that ROS generated by xanthine oxidase on endothelial 
cells  may  reduce  NO•  bioavailability  and  its  activity  is  increased  in  patients  with 
atherosclerosis (Harrison et al. 2003).  NOS uncoupling to generate ROS was discussed 
in section 1.43.  
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1.7  RAAS AND METABOLISM 
 
There  is  now  a  wealth  of  evidence  that  ACEi  improve  morbidity  and  mortality  in 
cardiovascular disease.  Early, large clinical trials showed a reduction in mortality and 
mortality associated with ACEi treatment of patients with severe (NYHA class IV) to 
moderate (class II-III) heart failure (CONSENSUS Trial Study Group 1987; SOLVD 
Investigators 1991).  ACEi therapy appeared to prevent further left ventricular dilatation 
and dysfunction compared to conventional therapy (SOLVD Investigators 1991).  These 
benefits were extended to patients treated with ACEi post-MI who had a left ventricular 
ejection fraction below 40% but without overt heart failure (Pfeffer et al. 1992) and then 
Figure  1.15.    Angiotensin  II  (Ang  II)  activation  of  membrane  bound  NAD(P)H 
oxidase system.  Ang II type 1 receptor binding activates protein kinase C (PKC) 
which  can  either  directly  stimulate  ROS  generation  from  NAD(P)H  or  via 
transactivation  of  other  growth  promoting  receptors,  such  as  endothelial  growth 
factor  receptor  (EGFR)  and  insulin-like  growth  factor  receptor  (IGFR),  via  the 
tyrosine kinase cSrc, causing further assembly of NAD(P)H oxidase subunits (rac, 
gp91phox, p22phox, p47phox, p67phox) over a period of hours, protein synthesis and 
cell growth and proliferation. 
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to any patient post-MI who had any clinical evidence of heart failure (either transient or 
ongoing) (AIRE Study Investigators 1993).  However, no reduction in mortality was 
seen when enalapril was  started within 24hours  of MI in  the  CONSENSUS  II trial 
(Swedberg et al. 1992). 
 
The HyC (Hydralazine vs. Captopril) trial in 1992 pointed to a role of ACE inhibition in 
CCF beyond blood pressure reduction (Fonarow et al. 1992).  117 patients with severe 
CCF  were  randomised  to  either  captopril  or  vasodilator  therapy  (hydralazine  plus 
nitrate).  The haemodynamic status was then closely matched using invasive monitoring 
in the two groups.  Captopril treatment conferred a significant survival benefit, with 
projected one year survival rates of 81% and 51% in captopril and hydralazine groups, 
respectively.    The  HOPE  Study  (Flather  et  al.  2000)  further  focussed  the  idea  that 
inhibition of ACE has biological effects above and beyond those associated with simple 
systemic blood pressure reduction (Dzau et al. 2001; Mathew et al. 2001).   
 
Quality of life, in particular dyspnoea, has also been reported to be improved by ACEi 
treatment in heart failure (Rector et al. 1993; Rogers et al. 1994).  Exertional dyspnoea, 
which is  characterised  by narrow and rapid  respiration during  exercise, is  the main 
symptom of patients with CHF.  In a small study of patients with CHF, ACEi therapy 
for one week was associated with a decrease in the ratio of minute ventilation to expired 
CO2, a marker of excessive ventilation during exercise.  In those patients with the least 
exercise  capacity,  ACEi  improved  excess  ventilation  without  an  increase  in  peak 
oxygen consumption (VO2) (Kitaoka et al. 2000).  
 
ACEi also reduce the decline in physical function and exercise capacity in patients with 
CHF (Gambassi et al. 2000).  ACEi were shown to have a dramatic effect in a study of  
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755 women from the Women‘s Health and Ageing Study who had hypertension but not 
CHF:  subjects on ACEi showed a  lower decline in muscle strength  and in mean 
walking  speed  over  3  years  compared  with  women  who  received  other  or  no 
antihypertensives (Onder et al. 2002).  This effect in elderly women suggested a dose-
dependent relationship of ACEi with physical function. 
 
Forearm oxygen consumption during maximal exercise is lower in patients with severe 
CCF, and is increased by the administration of the ACEi captopril (Imaizumi et al. 
1990).    In  rats  with  CCF,  muscle  ATP  and  PCr  levels  decline  more  quickly  with 
exercise than in controls, and lactate levels rise faster. Six weeks of an ACEi reverses 
these effects,  suggesting that ACE inhibition  may  restore skeletal muscle metabolic 
efficiency (Yamaguchi et al. 1999). 
 
These studies suggest that the benefit of ACE inhibition may not be simply due to 
central (cardiac), but also due to peripheral factors, such as alterations in or preservation 
of skeletal muscle function due to alterations in tissue RAAS.  Genetic studies have 
provided further evidence to support a role for peripheral tissue RAAS in metabolic 
efficiency (vide infra).   
 
1.7.1  The ACE gene and physical performance 
Global indices of human athletic performance (Rankinen et al. 2002), as well as more 
precise measures of human skeletal muscle function (Thomis et al. 1998), are strongly 
influenced by genetic as well as environmental factors.  To date, few genetic loci of 
influence have been identified (Yang et al. 2003).  One such is the gene for angiotensin-
I converting enzyme (ACE) (Montgomery et al. 1998; Myerson et al. 1999; Folland et 
al. 2000; Williams et al. 2000; Woods et al. 2001).  
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A common variant in the human gene for ACE exists in which the presence (Insertion or 
I), rather than the absence (Deletion or D), of a 287bp Alu repeat sequence in intron 16 
is  associated  with  lower  circulating  (Rigat  et  al.  1990)  and  tissue  ACE  activity 
(Costerousse et al. 1993; Danser et al. 1995).  The ACE I/D gene variant is therefore a 
useful  marker  for  ACE  activity,  accounting  for  up  to  50%  of  the  inter-individual 
variation in activity (Rigat et al. 1990). 
 
Montgomery et al have performed a series of prospective gene-environment studies to 
test the hypothesis that low muscle ACE activity, as marked by the ACE I allele, is 
associated  with  endurance  performance.    A  homogeneous  human  population  was 
selected  (i.e.  young  healthy  adult,  male,  white  Caucasians),  thus  limiting  genetic 
heterogeneity  and  differences  in  previous  environmental  exposures,  both  of  which 
would serve to limit the power of any subsequent test.  A uniform or near-uniform 
stimulus was then applied to all study participants and any phenotypic changes related 
to differences in a candidate gene.  This approach has also been termed ―stressing the 
genotype‖.    Using  such  an  approach,    the  maximum  duration  of  repetitive  elbow 
flexions whilst holding a 15kg bar bell (the phenotype) was assessed before and after 
10 weeks of military training (the uniform stressor) in 78 young healthy male British 
army recruits (homogeneous population) (Montgomery et al. 1998).  There was no 
difference  in  performance  by  ACE  I/D  genotype  pre-training,  but  the  change  in 
performance  following  training  was  highly  genotype  dependent,  with  II  individuals 
improving on average by 66.2% and DD individuals by 5.9% (P=0.001).  In a follow-up 
study, the efficiency of muscular contraction was better quantified by measuring delta 
efficiency (DE; the percentage ratio of the change in work performed per minute to the 
change  in  energy  expended  per  minute)  during  bicycle  ergometry  using  the  same  
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stimulus of 11 weeks military training in 58 training-naïve male recruits (Williams et al. 
2000).  Again, the baseline efficiency was identical by ACE genotype pre-training (II 
24.5% and DD 24.9% delta efficient).  However, training related benefits were highly 
ACE I/D genotype dependent, with II gaining muscular efficiency (percentage increase 
in efficiency 8.62% in II and -0.39% in DD; P<0.025).   
 
Further  association  studies  have  shown  a  predilection  for  ACE  I  allele  carriers  for 
endurance  sports  or  extreme  performance,  including  high  altitude  mountaineering 
without  oxygen  (Montgomery  et  al.  1998),  elite  rowers  (Gayagay  et  al.  1998)  and 
distance-running  events  amongst  British  Olympic  athletes  (Myerson  et  al.  1999).  
Professional athletes from mixed sporting disciplines have also been shown to have an 
excess of the I allele (Alvarez et al. 2000). 
 
The  I  allele  has  also  been  associated  with  a  greater  anabolic  response  to  exercise 
training (Montgomery et al. 1999).  Conversely, the D allele has been associated with 
greater skeletal muscle strength gain following isometric strength-training (Folland et 
al. 2000) and with predominantly explosive / anaerobic sports (Myerson et al. 1999).    
Clinical studies have shown an association of the ACE D allele with a disturbance in 
peripheral  oxygen  utilisation  and  hyperlactataemia  during  exercise  in  patients  with 
COPD (Kanazawa et al. 2002), and the D allele was a strong, independent predictor of 
severe hypoglycaemia in patients with type 1 diabetes (Pedersen-Bjergaard et al. 2001).   
 
However, there is some contradictory evidence regarding the influence of the ACE gene 
I/D polymorphism on endurance performance, but these studies used heterogeneous, 
rather than homogeneous, study groups which may have diluted any genotypic effect 
(Karjalainen et al. 1999; Rieder et al. 1999; Taylor et al. 1999; Rankinen et al. 2000).  
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1.7.2  RAAS and metabolic efficiency in cardiac and skeletal muscle 
How  might  some  of  these  metabolic  differences  be  explained?    The  downstream 
effector  peptides  angiotensin  II  and  bradykinin  may  both  be  responsible  for  the 
metabolic effects of ACE.  Angiotensin II has recognized effects on metabolism (Brink 
et al. 1996) and is a recognized growth factor necessary for the hypertrophy of skeletal 
muscle in response to mechanical load (Gordon et al. 2001).  Levels of bradykinin are 
dependent on ACE genotype (Murphey et al. 2000) and may influence skeletal muscle 
glucose  uptake    and  muscle  blood  flow  (Wicklmayr  et  al.  1983)  as  well  as 
mitochondrial  oxygen  utilisation  (Moncada  et  al.  2002).    Some  of  these  effects  of 
bradykinin have been shown to be dependent on the constitutive B2 receptor (BDKRB2) 
(Taguchi et al. 2000).   
 
There are no human data relating these downstream effectors to physical performance.  
Much of the data arise from animal models of heart disease, which suggest that ACE 
inhibition not only preserves cardiac function, but also levels of high energy phosphates 
and  indices  of  mitochondrial  function  in  acute  ischaemia  (Watanabe  et  al.  1997; 
Divisova et al. 2001), chronic CHF (Nascimben et al. 1995; Sanbe et al. 1995; Hugel et 
al. 1999) and left ventricular hypertrophy (Gohlke et al. 1994).  The beneficial effects 
of ACEi on myocardial metabolism may be kinin mediated (Linz et al. 1996).  Kinins 
are released from ischemic hearts (Hashimoto et al. 1977), whilst BK perfusion during 
ischaemia improves cardiac function and myocardial energy metabolism  (Linz et al. 
1987) and metabolic benefits of ACEi in hypertrophy are BDKRB2 dependent (Gohlke 
et al. 1994).  Ang II, acting via the AT1R, mediates cardiac fibrosis and hypertrophy 
(Kato  et  al.  1991).    However,  the  protective  effect  of  AT1R  blockade  on  the 
myocardium may be due to unopposed stimulation of AT2R, which is kinin and NO• 
dependent (Gohlke et al. 1998; Jalowy et al. 1998).  Perfusion with a combination of an  
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ACEi  and  an  AT1R  antagonist  may  have  an  additive  benefit  on  ATP  levels  and 
intracellular pH during ischaemia (Kawabata et al. 2000).  It was originally suggested 
some ACEi such as captopril  had free radical scavenging activity, explained by the 
sulphydryl  group  in  their  structure,  and  that  this  helped  attenuate  myocardial 
dysfunction  during  reperfusion  injury  (Westin  et  al.  1988).    However,  this  seems 
unlikely  since  this  cardioprotection  has  been  extended  to  other  non-sulphydryl-
containing ACEi, suggesting a direct effect on tissue RAAS (Rabkin 1992), which may 
also be dependent on NO• synthesis via the BDKRB2 (Jin et al. 1998). 
 
Skeletal muscle also contains a complete kallikrein-kinin system (Mayfield et al. 1996), 
can liberate kinins locally (Langberg et al. 2002), and expresses functional BDKRB2 
(Figueroa  et  al.  1996; Rabito et  al. 1996).   BK is  thus  generated within  exercising 
skeletal muscle (Langberg et al. 2002), can increase skeletal muscle glucose uptake 
(Wicklmayr  et  al.  1979)  and  produces  an  endothelial-dependent  increase  in  muscle 
blood flow (Wicklmayr et al. 1983).  In fact, through the BDKRB2 (Taguchi et al. 
2000), BK enhances insulin-stimulated tyrosine kinase activity of the insulin receptor, 
which  stimulates  phosphorylation  of  insulin  receptor  substrate-1  with  subsequent 
GLUT-4 translocation in adipose (Isami et al. 1996), cardiac (Rett et al. 1996) and 
skeletal muscle tissue during exercise (Motoshima et al. 2000).  Thus ACE inhibition 
can  increase  skeletal  muscle  glucose  uptake,  insulin  sensitivity  and  GLUT-4 
translocation  (Henriksen  et  al.  1995;  Jacob  et  al.  1996)  via  BDKRB2  agonism 
(Henriksen et al. 1999).  Indeed, ACEi have been associated with hypoglycaemia in 
diabetic patients (Herings et al. 1995) and the ACE I/D polymorphism has also been 
associated  with  decreased  insulin  resistance  and  baseline  insulin  levels  in  diabetes 
(Katsuya et al. 1995; Panahloo et al. 1995; Kennon et al. 1999; Takezako et al. 1999). 
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BDKRB2 activation can lead to transient rises in inositol 1,4,5-trisphosphate (Rabito et 
al. 1996), which is involved in excitation-coupling of skeletal muscle via increases in 
cytoplasmic  calcium  (Hidalgo  et  al.  1989;  Lopez  et  al.  1991;  Foster  1994).    This 
process is enhanced by both insulin  (Kudoh et  al. 2000) and by inhibition of ACE 
(Kudoh et al. 2000).  Conversely, chronic Ang II infusion in rats has been shown to 
induce  cachexia  with  profound  skeletal  muscle  wasting  (Brink  et  al.  1996),  due  to 
enhanced  protein  catabolism,  with  concomitant  downregulation  of  skeletal  muscle 
insulin-like growth factor 1 (IGF-1) and IGF-1 binding proteins (Brink et al. 2001), and 
increased energy expenditure and changes in oxygen consumption associated with a 
metabolic cachexia (Cassis et al. 2002).   Skeletal muscle does express Ang II receptors 
(Stoll et al. 1995; Rabito et al. 1996), and paracrine adipose RAAS may play a role in 
the mobilization of triglycerides as a metabolic fuel (Goldman et al. 1987; Campbell et 
al. 1993; Hennes et al. 1996; Jones et al. 1997).  Moreover, ACEi (Flather et al. 2000) 
and ARBs (Dahlof et al. 2002) have both been associated with a reduction in the risk of 
developing type II diabetes in patients at high risk of CHD events. 
 
Could the mitochondrial effects of ACE inhibition be mediated by NO•?  NO• is both a 
vasodilator and a second messenger which, at physiological (nanomolar) concentrations, 
reversibly inhibits cytochrome c oxidase (complex IV) in competition with O2 (Brown 
et al. 1994; Cleeter et al. 1994).  It thus reduces O2 uptake in skeletal muscle and heart 
mitochondria (Cleeter et al. 1994; Poderoso et al. 1996) and in heart submitochondrial 
particles isolated from the rat heart (Poderoso et al. 1996).   It has been suggested that 
the interplay between NO• and O2 allows cytochrome c oxidase to act as an O2 sensor 
within cells, with the affinity of NO• for cytochrome c oxidase dependent on the O2 
tension (Clementi et al. 1999).  The large amount of NO• induced by cytokines such as 
TNFα and IF-γ via iNOS, is able to inhibit mitochondrial respiration in vascular smooth  
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muscle cells (Geng et al. 1992).  NO• donors also have the potential to reversibly inhibit 
oxygen utilisation in rat skeletal mitochondria (Cleeter et al. 1994).  Tissue and whole 
animal  studies  have  shown  that  kinins  can  suppress  oxygen  consumption  via 
endogenous NO• in skeletal (Shen et al. 1995) and cardiac muscle (Zhang et al. 1997), 
an effect mimicked by ACEi and prevented by blockade of BDKRB2  (Zhang et al. 
1997).    Poderoso  observed  a  dose-dependent  reduction  in  myocardial  oxygen 
consumption and release of H2O2 when isolated rat heart was perfused with bradykinin 
(Poderoso et al. 1998).  Co-administration with enalapril resulted in further reductions 
in oxygen uptake.  Moreover, bradykinin, the ACEi ramiprilat, calcium channel blocker 
amlodipine, and the neutral endopeptidase inhibitor thiorphan, all stimulate endogenous 
NO• release while significantly decreasing oxygen consumption in failing human heart 
tissue explanted at transplantation (Loke et al. 1999).  This effect is attenuated in the 
presence of a NOS inhibitor.  Vavrinkova et al demonstrated that 4 weeks pre treatment 
with the ACEi captopril was associated with a significant reduction in the content of 
free radical forms of the mitochondrial respiratory chain during ischaemia in isolated rat 
hearts  perfused  with  L-arginine  and  that  this  was  associated  with  enhanced  NO• 
formation (Divisova et al. 2001).  NO• modulation of mitochondrial respiration and 
membrane potential can have protective effects in apoptosis (Beltran et al. 2000) and 
ischaemia-reperfusion injury (Rakhit et al. 2001). 
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1.8  UNCOUPLING PROTEINS (UCPs) 
 
1.8.1  Overview 
Not all of the energy released by oxidation of fuel substrate by the ETC generates ATP, 
implying that the coupling of respiration to ATP synthesis is imperfect.  A basal leak of 
protons is found in all mitochondria and is responsible for state 4 respiration (section 
1.2.2), when all the available ADP has already been converted to ATP (Nicholls et al. 
2002).  In resting hepatocytes and skeletal muscle, this proton leak is responsible for up 
to 20-30% and 50% of oxygen consumption, respectively, and together may contribute 
up to 20-30% of basal metabolic rate (Rolfe et al. 1996).  Moreover, differences in 
skeletal  muscle  energy  expenditure  accounts  for  the  majority  of  the  observed 
interindividual variation in both basal and exercising metabolic rate (Zurlo et al. 1990; 
Ravussin et al. 1992).  
 
Endothermic  organisms  can  produce  facultative  heat  in  a  cold  environment  from 
skeletal muscle and brown adipose tissue (BAT); termed shivering and non-shivering 
thermogenesis, respectively.  Uncoupling of respiration resulting in ‗wasteful energy‘ or 
theromogenesis  would  therefore  be  important  for  energy  balance  and  body  weight 
control, and may be particularly important in metabolic diseases such as obesity and 
diabetes.    Indeed,  the  mitochondrial  uncoupler  dinitrophenol  was  shown  to  greatly 
increase metabolic rate in patients (Cutting et al. 1932) and was widely prescribed in the 
USA in the 1930s as a treatment for obesity, until it was discredited due to its narrow 
‗therapeutic  window‘  and  its  significant  hepatic,  cardiac,  nerve,  muscle  (and  other) 
toxicities, as well as blindness and fatal malignant hyperpyrexia (Colman 2007). 
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BAT makes an important contribution to non-shivering thermogenesis in mammals and 
is regulated principally by the SNS (Himms-Hagen 1990).  In humans, this process is 
important at birth and in infancy, but reduces in importance as BAT atrophies to 2% of 
total body adipose tissue mass in adults.  In BAT, energy derived from fuel substrate is 
not used to generate ATP, but is dissipated via proton leak to generate useful heat.  
Interest in the high thermogenic capacity of BAT began in the 1960s, when BAT was 
shown to have a high density of mitochondria which respired rapidly, but displayed no 
respiratory control (Nicholls 2001).  The proton leak or conductance was subsequently 
shown to be nucleotide-sensitive and activated by fatty acids, but it was not until 1977 
that  the  protein  responsible,  thermogenin  or  uncoupling  protein  (UCP,  later  termed 
UCP1),  was  identified  and  shown  to  constitute  up  to  10%  of  inner  mitochondrial 
membrane protein content (Heaton et al. 1978).  BAT from UCP1 knockout mice have 
low spontaneous respiration (Enerback et al. 1997).  It is now accepted that UCP1 is 
exclusively responsible for non-shivering thermogenesis in BAT (Krauss et al. 2005).   
 
UCP1 expression is, however, limited to BAT, so the search for UCP1 homologues 
which might be responsible for the protein leak observed in tissues other than BAT was 
spurred.  UCP2 and UCP3 were subsequently cloned in 1997 (Boss et al. 1997; Fleury 
et al. 1997; Gimeno et al. 1997; Gong et al. 1997; Solanes et al. 1997; Vidal-Puig et al. 
1997) and found to have 59% and 57% amino acid sequence homology with UCP1, 
respectively.  The UCP2/UCP3 gene locus has been mapped to human chromosomal 
region 11q13, with the UCP2 gene 7kB downstream from the UCP3 gene, a region that 
has  been  linked  to  hyperinsulinaemia  and  obesity  in  humans  (Fleury  et  al.  1997).   
UCP2 and UCP3 themselves share 72% sequence homology.  It is now thought that 
UCP2 is in fact the ancestral UCP, and that UCP3 was caused by a gene duplication 
event (Borecky et al. 2001).  
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UCPs belong to the mitochondrial anion-carrier superfamily, which has been described 
across various animal and plant species and includes the adenine nuclear translocator 
(ATP/ADP  translocator;  ANT),  dicarboxylate,  citrate,  carnitine  and 
oxoglutarate/maleate carriers, as well as the mammalian homologues UCP1-5 (Borecky 
et  al.  2001).    The  UCPs  are  nuclear-encoded,  mitochondrial-targeted  proteins.  
Phylogenetic analysis (Figure 1.16) suggests that there is a subfamily of closely related 
UCPs, consisting of UCP1, UCP2, UCP3 and bird UCPs (Borecky et al. 2001).  UCP4 
and  UCP5  (brain  mitochondrial  carrier  protein  1,  BMCP1)  share  lower  sequence 
homology  with  UCP1  (30%  and  33%,  respectively)  and  do  not  appear  to  be  true 
members of the UCP sub-family (Mao et al. 1999; Yu et al. 2000).    
 
Figure 1.16.   Phylogenetic tree of the mitochondrial anion-carrier superfamily 
(adapted from Borecky 2001).  
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Figure 1.17.  Postulated tripartite structure of uncoupling proteins.  The conserved arginine residues shown are necessary for nucleotide 
binding. 
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1.8.1.1 Structure 
 
UCP  1,  2  and  3  contain  306,  308  and  311  amino  acid  residues,  bearing  tripartite 
structures containing signature motifs for mitochondrial carrier proteins (Figure 1.17).  
The  crystal  structure  has  not  been  determined.  However,  each  of  the  three  repeat 
domains consists of two transmembrane, hydrophobic α-helices linked by hydrophilic 
loops.  The central matrix-facing loop is important for membrane insertion, as there is 
no typical N-terminal mitochondrial targeting sequence (Schleiff et al. 2000) and, once 
inserted in the inner mitochondrial membrane, UCPs are thought to dimerise (Lin et al. 
1980). 
Figure 1.18.  Possible mechanisms of uncoupling protein proton translocation 
 
A.  Proton buffering model.  UCPs can translocate protons directly, but fatty acid 
anion can facilitate this process. 
 
B.  Fatty acid cycling model.  Fatty acid anions can pass from the matrix through 
the  UCP  channel,  becoming  protonated  in  the  intermembrane  space.    The 
protonated  fatty  acid  is  then  able  to  flip-flop  back  through  the  inner 
membrane, releasing protons on the matrix side. 
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Most is known about the function of UCP1.  Mutational analysis suggests that the UCP 
helices together form a hydrophilic channel with the loops controlling access (gating 
domains) (Arechaga et al. 2001). Site-directed mutagenesis has suggested nucleotide 
binding  domains  within  the  transmembrane  α-helices  at  three  conserved  arginine 
residues (Arg 83, Arg 182 and Arg 276), binding to which results in a conformational 
change in the pore and inhibition of function (Modriansky et al. 1997).  
 
UCP1 can transport protons and several anions, such as chloride and nitrate (Nicholls et 
al. 1973; Nicholls 1974).  The exact mechanism of proton transport is unknown but is 
fatty  acid  sensitive.    Two  main  hypotheses  exist.    In  the  first  model,  proposed  by 
Klingenberg and known as the ―proton buffering model‖, it is suggested that UCP1 
actually  transports  protons,  and  fatty  acids  provide  an  essential  free  carboxy  group 
which augment proton  movement  through the  channel  (Figure 1.18A).  The second 
model, proposed by  Garlid  and termed the ―fatty-acid  cycling model‖  suggests that 
UCP1 transports charged fatty acid anions to the intermembrane space, which would 
otherwise be confined to the matrix.  On the positively charged outer face of the inner 
mitochondrial membrane, the fatty acid anions can accept protons.  In their protonated, 
hydrophobic  form,  the  fatty  acids  can  flip-flop  back  directly  through  the  inner 
membrane to release protons on the matrix side to complete the circuit (Figure 1.18B).  
It has been suggested that both of these mechanisms may exist (Ricquier et al. 2000); 
with a proton pathway accounting for spontaneous respiration in state 4 which could be 
further enhanced by small concentrations of fatty acids.  At higher concentrations, fatty 
acid cycling may occur as described above.   
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1.8.2  Uncoupling protein 2 
 
In contrast to UCP1, UCP2 is expressed ubiquitously at the mRNA level (Fleury et al. 
1997; Gimeno et al. 1997), in particular in cells of the immune system, white adipose 
tissue (WAT), skeletal and cardiac muscle, brain, lung and liver.  Studies with specific 
antibodies have been difficult, and it has been suggested that UCP2 protein expression 
may be somewhat restricted in mice (to the spleen, stomach, lung and gonadal WAT) 
(Pecqueur et al. 2001) but has also been found in the heart (Murray et al. 2004) and 
liver (Taniguchi et al. 2002) in humans.  To date, no study has shown the presence of 
any  UCP within endothelial  cells.    However,  UCP2 mRNA content of any  adipose 
tissue examined was 3-4x higher in the stromal-vascular fraction (rich in endothelial 
cells,  pre-adipocytes,  fibroblasts  and  monocyte/macrophages)  than  in  the  adipocyte 
fraction (Prunet-Marcassus et al. 1999).  The amount of UCP2 mRNA increases during 
adipocyte differentiation (Do et al. 1999), so the excess mRNA in the stromal-vascular 
fraction must be due to the expression of UCP2 in non-adipocyte cell types.  In the same 
study, UCP3 mRNA was found only in adipocyte fractions.   
 
 
1.8.2.1  Gene structure 
The human UCP2 (hUCP2) gene consists of 8 exons, of which exons 1 and 2 are non-
coding (Pecqueur et al. 1999).  The 3.3kb promoter differs significantly from those of 
the hUCP1 and hUCP3 genes, lacking a typical TATA or CAAT box (Tu et al. 1999).  
The transcription start site is preceded by a GC rich region with multiple Sp-1 binding 
sites  and AP-1 and AP-2 motifs.  This  region  contains  a strong,  cis-acting positive 
regulatory element (-141 to -65) which may underlie the ubiquitous expression of UCP2 
(Tu  et  al.  1999),  analogous  to  the  situation  in  the  mouse  (Yoshitomi  et  al.  1999).     
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Several consensus sequences exist for transcription control elements, such as C/EBP-
beta (important for IL6 gene expression), CREB-1 (cAMP response element binding 
protein 1), 2 PPREs (PPARγ response elements), two TREs (thyroid hormone response 
elements), MyoD (muscle regulatory protein) and NF-кB (Tu et al. 1999).  Promoter 
construct work has delineated regions containing further positive (-1398 to -884) and 
negative (-3271 to -1398, -1398 to -884, -884 to -141) control elements (Tu et al. 1999).   
 
1.8.2.2  Regulation 
Due to a lack of specific antibodies for UCP2, much work has focussed on changes in 
UCP2  mRNA  expression  in  response  to  metabolic  challenges.    UCP2  mRNA 
expression  is  upregulated  by  an  increase  in  circulating  free  fatty  acids  in  rodent 
oxidative skeletal muscle (Samec et al. 1998; Samec et al. 1999; Vettor et al. 2002) and 
heart (Vettor et al. 2002).  A similar response at the mRNA level has been shown in 
humans after lipid infusion and a high fat diet in WAT (Nisoli et al. 2000) and skeletal 
muscle (Schrauwen et al. 2001), respectively, and plasma free fatty acid levels have 
been  positively  correlated  with  UCP2  protein  levels  in  human  heart  (Murray  et  al. 
2004).  Hence, metabolic perturbations which result in an increase in circulating free 
fatty acids increase UCP2 mRNA expression.  As such, cold exposure, fasting and fat 
feeding  increase  UCP2  mRNA  to  varying  degrees  in  WAT  and  skeletal  muscle  of 
rodents (Boss et al. 1997; Matsuda et al. 1997; Samec et al. 1998; Weigle et al. 1998; 
Gong et al. 1999). 
 
Similarly, in humans, UCP2 expression is upregulated by fasting in WAT (Millet et al. 
1997).  PPARs may mediate the transcriptional effects of fatty acids on UCP2 mRNA 
expression.  PPARγ agonists increase UCP2 mRNA levels in adipocytes and skeletal 
myocytes in vitro in some (Aubert et al. 1997; Camirand et al. 1998) but not all studies  
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(Kelly et al. 1998).  PPARα agonists appear to have limited effects in vitro, increasing 
liver UCP2 mRNA expression only (Kelly et al. 1998).  
 
Norepinephrine  or  β3-agonism  does  not  appear  to  alter  UCP2  mRNA  expression  in 
murine WAT, but 3 weeks of β3-agonism in mice decreased skeletal and cardiac muscle 
UCP2 mRNA expression together with a decrease in circulating free fatty acids and 
insulin (Aubert et al. 1997; Yoshitomi et al. 1998).  As to be expected, tri-iodothyronine 
(T3) increased UCP2 mRNA expression in WAT, skeletal and cardiac muscle in rodents 
(Lanni et al. 1997; Masaki et al. 1997; Lanni et al. 1999) and in WAT and skeletal 
muscle in humans (Barbe et al. 2001).   
 
In rats, an 8 week endurance training programme was associated with 54% and 41% 
decreases in UCP2 mRNA expression in heart and tibialis anterior (type IIa and IIb fast 
twitch  fibres)  muscle,  respectively,  with  no  associated  changes  in  WAT  and  soleus 
(slow  twitch)  muscle  (Boss  et  al.  1998).    Denervation  increased  UCP2  mRNA 
expression in mixed muscle (gastrocnemius) in both the rat and mouse (Cortright et al. 
1999).  In the same study, only acute exercise in the mouse increased UCP2 mRNA 
expression, whereas chronic exercise had no effect in rats (Cortright et al. 1999).  The 
differences  may  have  been  produced  by  differences  in  concomitant  feeding  in  the 
experimental protocols. 
 
1.8.2.3  Function 
Unlike UCP1, the precise function of UCP2 remains to be elucidated and is the matter 
of much debate.  UCP2 has been implicated in the development of diabetes and obesity 
(O'Rahilly 2001).  UCP2 is expressed in pancreatic islet β cells and overexpression can 
lead to a reduction in glucose-stimulated insulin secretion (GSIS) – an ATP-dependent  
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process  (Chan  et  al.  1999).    UCP2  knockout  mice  exhibit  markedly  increased 
circulating insulin levels, and islets isolated from these animals have enhanced GSIS 
(Zhang et al. 2001).   Overexpression in mice of the human UCP2 gene was associated 
with reduced fat mass, with a tendency to increased basal metabolic rate, but with no 
effects on thermoregulatory feeding behaviour (Horvath et al. 2003).  However, the 
UCP2  knockout  mouse  is  not  obese  and  has  a  normal  response  to  cold  exposure 
(Arsenijevic et al. 2000), suggesting an alternative function. 
 
Many of the early cell overexpression studies suggested that UCP2 was an uncoupler of 
mitochondrial respiration (Fleury et al. 1997; Gimeno et al. 1997; Chan et al. 1999; 
Jaburek et  al. 1999; Rial et  al.  1999; Teshima et  al. 2003).   However, it has  been 
demonstrated  that  UCP  overexpression  results  in  non-physiological  uncoupling  of 
mitochondria, either because the high levels of expression causes perturbation of inner 
mitochondrial  membrane  integrity  or  because  of  incorrect  membrane  insertion 
(Heidkaemper et al. 2000; Stuart et al. 2001; Stuart et al. 2001).  In contrast, isolated 
thymocytes from UCP2 knockout mice were shown to have higher Δψm and ATP levels 
than thymocytes isolated from wild-type animals (Krauss et al. 2002).  It was calculated 
that up to 50% of the basal proton leak was dependent on the expression of UCP2. 
 
Gene deletional studies and the ubiquitous expression of UCP2 suggest the primary role 
may not be thermogenesis (Arsenijevic et al. 2000; Couplan et al. 2002).  An alternative 
conclusion from the widespread expression and electrochemical actions of UCP2 is that 
it  is  a  plausible  and  powerful  regulator  of  mitochondrial  ROS  production  (Negre-
Salvayre  et  al.  1997;  Casteilla  et  al.  2001).    In  keeping  with  this  proposal,  UCP2 
expression is induced by oxidative stress (Lee et al. 1999; Pecqueur et al. 2001) and 
UCP-induced proton conductance is activated by O2•
- (Echtay et al. 2002; Echtay et al.  
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2002).  The O2•
-  activated uncoupling is, predictably, dependent on the presence of 
fatty acids and inhibited by purine nucleotides (Echtay et al. 2002) and occurs from the 
matrix  side  of  the  mitochondria  (Echtay  et  al.  2002)  directly  activating  proton 
conductance, rather than by futile cycling of reactive species through UCPs.  UCP2 may 
therefore  be  involved  in  inflammatory  processes  through  ROS  generation.  
Mitochondria  isolated  from  UCP2  knockout  mice  are  resistant  to  infection  from 
toxoplasmosis  and  their  macrophages  generate  more  ROS  than  wild-type  mice 
(Arsenijevic et al. 2000).  UCP2 protein is increased (at the transcriptional level) by 
inflammatory cytokines and endotoxin in hepatocytes and pulmonary tissue (Pecqueur 
et al. 2001). 
 
 
1.8.3  Uncoupling protein 3 
 
UCP3 has 73% sequence homology with UCP2 but its mRNA expression in humans 
and rodents is limited predominantly to skeletal muscle and BAT, with smaller amounts 
in WAT and in cardiac tissue (Boss et al. 1997; Larkin et al. 1997; Vidal-Puig et al. 
1997).  The human UCP3 gene consists of 7 exons, the first of which is not translated 
(Solanes et al. 1997).  Human UCP3 mRNA exists in two forms, UCP3S (short) and 
UCP3L (long) due to the presence of translation termination (TGA) codons in exon 6 
and 7, respectively, which appear to be transcribed in equal amounts (Solanes et al. 
1997).  UCP3L codes the 312 amino acid protein, whereas UCP3S codes a putative 275 
amino acid protein lacking the last transmembrane domain which is not transcribed 
(Solanes et al. 1997).   
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1.8.3.1  Gene structure 
The human UCP3 promoter contains several potential binding sites for muscle-specific 
factors (E Box, MyoD, MEF2), CAAT boxes, PPREs and a TRE containing a CRE-like 
element (Acin et al. 1999; Tu et al. 1999).  A consensus sequence for a TATA box is 
present at position -45 from initiation of transcription.  There are no GC rich SP-1 
regions.  Strong negatively and enhancing cis-acting regions were found between -2983 
to -1585 and -982 to -622 in the promoter, respectively (Tu et al. 1999). 
 
1.8.3.2  Regulation 
As is the case for UCP2, the study of UCP3 protein expression has also been hampered 
by a lack of specific antibodies, and again, most work has focussed on UCP3 mRNA 
expression.  Its expression in skeletal muscle is upregulated in a similar way to UCP2 
by fatty acids, in both rodents (Samec et al. 1998; Weigle et al. 1998; Hwang et al. 
1999;  Samec  et  al.  1999;  Vettor  et  al.  2002;  Costello  et  al.  2003)  and  humans 
(Schrauwen  et  al.  2001).    A  feedback  loop  involving  fatty  acid  supply,  UCP3  and 
mitochondrial fatty oxidation has been suggested, and may vary according to muscle 
fibre type (Samec et al. 1999).  Hence, high fat feeding and fasting/calorie restriction 
have been associated with elevations of UCP3 mRNA in skeletal muscle in rodents 
(Boss et al. 1998; Gong et al. 1999), and with elevations of both UCP3 mRNA and 
protein in humans in some (Millet et al. 1997; Hesselink et al. 2003), but not all studies 
(Pedersen et al. 2000; Cameron-Smith et al. 2003). 
 
In humans and rodents, UCP3 mRNA in skeletal muscle is upregulated during treatment 
with thyroxine, and downregulated following endurance training (Larkin et al. 1997; 
Boss et al. 1998; Cortright et al. 1999; Schrauwen et al. 1999; Masaki et al. 2000).  In 
humans, UCP3 mRNA expression correlates negatively with maximal aerobic power  
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(Schrauwen et al. 1999).  UCP3 protein content differs according to muscle fibre type 
(most abundant in type 2b fast glycolytic > type 2a fast oxidative-glycolytic >type 1 
slow oxidative fibres) (Hesselink et al. 2001) and is 46% lower in the skeletal muscle of 
endurance  trained  cyclists  compared  to  healthy  untrained  men,  although  the  same 
hierarchy of content exists (Russell et al. 2003).  Skeletal muscle mitochondrial density 
is  known  to  increase  during  endurance  training  secondary  to  neo-mitochondrial 
biogenesis (Freyssenet et al. 1996).  Fernström et al demonstrated that vastus lateralis 
muscle mitochondrial volume increased by 47% during a 6 week endurance training 
programme  in  healthy  men,  but  relative  UCP3  protein  content  and  uncoupled 
mitochondrial respiration decreased by 53% and 18%, respectively  (Fernstrom et al. 
2004). 
 
Adrenergic stimulation may also increase muscle UCP3 mRNA expression, but there 
has been conflicting data in both rodents (Gomez-Ambrosi et al. 1999; Nagase et al. 
2001; Nakamura et al. 2001) and in humans (Boivin et al. 2000; Hoeks et al. 2003).  
Leptin  administration  increases  skeletal  muscle  UCP3  mRNA  expression  (Gomez-
Ambrosi et al. 1999) and this effect may be thyroid hormone-dependent (Cusin et al. 
2000).  PPARγ agonists decrease UCP3 mRNA expression skeletal myocytes in culture 
(Cabrero et al. 2000), but their administration in vivo increased UCP3 expression in 
BAT  but  not  in  skeletal  muscle  or  WAT  (Kelly  et  al.  1998).    In  contrast,  PPARα 
activation  (with  bezafibrate  or  Wy-14  643)  increased  UCP3  mRNA  threefold  in 
adipocytes in culture (Cabrero et al. 2000), but had no effect on skeletal myocytes in 
culture without the presence of exogenous fatty acids (Cabrero et al. 2000).   
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1.8.3.3  Function 
As  is  the  case  with  UCP2,  the  precise  function  of  UCP3  is  unclear.  The  hUCP3 
overexpressing (UCP3tg) mouse produces approximately 66 times more UCP3 and is 
hyperphagic but lean, with less adipose tissue (Clapham et al. 2000).  Isolated skeletal 
muscle  mitochondria  from  these  UCP3tg  mice  have  an  increase  in  mitochondrial 
uncoupling (Clapham et al. 2000).  Indeed isometric stress-testing in isolated soleus 
muscle from the UCP3tg mouse has the same contractile performance as muscle from 
wild-type animals, but produces greater heat energy (i.e. is less efficient) (Curtin et al. 
2002).  However, it has been shown that UCP3 overexpression studies suffer from the 
same  controversy  as  those  of  UCP1  and  UCP2  overexpression  (vide  supra),  as 
uncontrolled uncoupling ensues (Cadenas et al. 2002; Harper et al. 2002).   
 
The study of UCP3 gene deletion (UCP3ko) mice, produced independently by several 
laboratories, has shed some light on function.  Isolated skeletal muscle mitochondria 
from  these  animals  were  shown  to  have  increased  mitochondrial  coupling  due  to 
reduced  proton  leak  (state  4  respiration)  and  increased  ATP/ADP  ratios  by  two 
independent  groups  (Gong  et  al.  2000;  Vidal-Puig  et  al.  2000)  but  not  by  a  third 
(Cadenas et al. 2002).  However, these animals exhibit no obvious phenotype, with no 
difference in body weight, resting energy expenditure (fed or fasting), or response to 
exhaustive exercise and cold temperature compared to wild-type mice (Vidal-Puig et al. 
1997; Gong et al. 2000). 
 
In  line  with  observations  with  UCP2,  isolated  skeletal  muscle  mitochondria  from 
UCP3ko mice produced significantly more ROS as assessed by a lucigenin assay and by 
mitochondrial  aconitase  activity    (Vidal-Puig  et  al.  1997)  and  superoxide  induced  
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proton conductance in isolated skeletal muscle mitochondria through a UCP3 dependent 
mechanism (Echtay et al. 2002).  
 
Few studies have examined the role of UCP3 protein in human skeletal muscle.  In one 
such small study, dietary manipulation was used to alter skeletal muscle UCP3 content:  
ingestion of a high fat diet resulted in an elevation of UCP3 protein compared to a low 
fat diet (Hesselink et al. 2003).  High-intensity exercise with limb blood flow occlusion 
was  used to deplete the primary muscle energy reserve  compound,  phosphocreatine 
(PCr),  and  the  PCr  resynthesis  rate  was  measured  biochemically  as  a  marker  of 
efficiency of ATP generation.  There was no difference in PCr resynthesis rate between 
the high and low fat dietary groups, leading the authors to conclude that an increase in 
UCP3 content within the physiological range did not affect mitochondrial coupling in 
vivo in human skeletal muscle (Hesselink et al. 2003).  However, there was a positive 
linear  association  between  UCP3  protein  content  and  PCr  resynthesis  rate  overall, 
suggesting that the authors were measuring a surrogate marker of total mitochondrial 
protein or volume rather than the relative amount of UCP3.  Indeed, the relationship 
between UCP3 protein content and PCr resynthesis rate appeared to change during high 
fat feeding compared to normal diet, but the study was not powered to detect such a 
difference (N=6 subjects).  In support of this counter-argument, it has been shown that 
during 6 weeks of endurance training, total UCP3 protein remains unchanged in human 
skeletal  muscle,  but  when  indexed  to  a  marker  of  mitochondrial  volume  (citrate 
synthase),  the  relative  amount  of  UCP3  protein  decreased  significantly  by  53% 
(Fernstrom et al. 2004).   The data overall remain inconclusive.   
 
A further alternative hypothesis is that UCP3 protein functions to remove fatty acid 
anions from the mitochondrial matrix as part of a detoxifying mechanism.  This may be  
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either to remove excess fatty acid anion oversupply which would accumulate passively 
within the matrix according to Δψm (Schrauwen 2003), or alternatively as part of a fatty 
acid cycle, whereby intramitochondrial fatty acyl-CoAs release the CoA moiety (by the 
action of thioesterase) during periods of increased bursts of mitochondrial Kreb‘s cycle 
and β-oxidation activity with resultant surplus matrix fatty acid anion which must be 
removed (Himms-Hagen 2001). 
 
 
1.8.4  Cardiac UCPs 
Some controversy exists as to whether UCPs are expressed within the heart and, if so, 
what function they may serve.  Certainly, both UCP2 and UCP3 have been consistently 
shown  to  be  expressed  at  the  mRNA  level  in  the  heart,  although  UCP2  mRNA  is 
expressed at a much higher level than UCP3 mRNA in both the rodent and human heart 
(Boss et al. 1997; Fleury et al. 1997; Gimeno et al. 1997; Vidal-Puig et al. 1997).  As 
stated above, research into protein expression in the heart has been hampered by the 
lack of specific antibodies.  Western blot analysis using sensitive antibodies failed to 
detect UCP2 protein in the mouse (Pecqueur et al. 2001).  However, both UCP2 and 
UCP3 protein has been detected in the rat (Boehm et al. 2001) and, more recently, 
UCP2 protein was detected in human right atrial tissue samples (Murray et al. 2004).   
 
Changes  in  UCP2  or  UCP3  expression  may  be  associated  with  an  alteration  in  the 
balance between cardiac glucose and fatty acid utilisation.  In rodent studies, cardiac 
UCP2 mRNA levels are present in low level in the foetus and increase shortly after 
birth, mirroring the rise in fatty acid utilisation in the heart (Van Der Lee et al. 2000).  
Cardiac UCP2 mRNA levels are five fold higher in the adult than before birth.  In 
contrast, UCP3 mRNA levels are undetectable in the foetus and rise in concert with  
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suckling  in  the  newborn  in  a  fatty  acid-dependent  manner,  declining  once  chow  is 
introduced (Skarka et al. 2003).  In vitro administration of fatty acids induce UCP2 
mRNA expression in isolated neonatal cardiomyocytes and both tri-iodothyronine and 
phenylephrine induced UCP2 mRNA expression in a fatty acid dependent manner (Van 
Der Lee et al. 2000).  However, elevation of serum free fatty acids (by high fat feeding, 
fasting or induction of diabetes) increases cardiac UCP3 mRNA in the rat in a PPARα-
dependent manner but does not alter cardiac UCP2 mRNA (Depre et al. 2000; Van Der 
Lee et al. 2000; Van der Lee et al. 2001; Young et al. 2001).  
 
Both UCP2 and UCP3 mRNA and protein expression in the rat heart are increased in 
models  of  pressure  overload  in  a  fatty  acid-dependent  manner  (stroke-prone 
hypertensive  rat,  aortic  constriction,  chronic  aortic  regurgitation),  and  decreased  by 
pressure unloading and by acute aortic regurgitation (Fukunaga et al. 2000; Noma et al. 
2001; Young et al. 2001).  During acute volume overload in acute aortic regurgitation, 
UCP2 mRNA was reduced by 53% by 3 days and was inversely proportional to LV 
diastolic dimension (Noma et al. 2001).  In contrast, UCP2 mRNA was increased 3.8 
fold by 100 days in the left ventricle in the chronic phase of heart failure (Noma et al. 
2001).  The degree of  LV dysfunction, together with  the increase in  UCP2 mRNA 
expression was mitigated by treatment with an ACEi (Murakami et al. 2000; Murakami 
et al. 2002).  Similarly, cardiac UCP2 mRNA expression was increased in different 
mouse  models  of  dilated  cardiomyopathy  caused  by  genetic  enhancement  of  β-
adrenoceptor signalling (Gaussin et al. 2003).  
 
Cardiac UCP mRNA levels have been regulated by hormones, inflammatory mediators 
and hypoxia.  Induction of hyperthyroidism in rats to induce a physiological alteration 
in mitochondrial function, resulted in a 32% and 48% increase in UCP2 and UCP3  
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protein respectively, combined with a 71-100% increase in palmitate-induced proton 
leak and a 38% overall decrease in cardiac efficiency (work performed by unit oxygen 
consumed) (Boehm et al. 2001).  TNFα administration in rats reduced UCP2 and UCP3 
mRNA expression in the heart (Young et al. 2001).  Isolated cardiac mitochondria from 
male  Wistar  rats  which  had  spent  one  week  in  a  hypobaric  hypoxic  (11%  O2) 
environment  showed  similar  reductions  in  rates  of  oxygen  consumption  and  ATP 
synthesis without a change in mitochondrial coupling (respiratory control ratio).  There 
was no change in UCP2 mRNA levels, but a 63% decrease in cardiac UCP3 mRNA 
levels,  together  with  decreases  in  mRNA  level  of  enzymes  involved  in  fatty  acid 
metabolism (Essop et al. 2004).   
 
In  vitro  UCP2  gene  overexpression  using  an  adenoviral  vector  resulted  in  an 
approximately two-fold increase in UCP2 protein level in isolated rat cardiomyocytes, a 
partial depolarisation of Δψm and decreased cell death, calcium overload and loss of 
Δψm  in  response  to  oxidative  stress  (Teshima  et  al.  2003).    No  cardiac  phenotypic 
alterations  have  been  reported  in  mouse  models  of  either  UCP2  or  UCP3  gene 
overexpression 
 
There  have  been  few  human  studies  to  date.    UCP2,  but  not  UCP3,  mRNA  was 
significantly reduced in the left ventricle of patients with severe left ventricular failure 
(ejection  fraction  <20%)  due  to  dilated  cardiomyopathy  (idiopathic,  ischaemic  or 
peripartum).  This was in concert with a change to a foetal metabolic gene profile with 
down-regulation of enzymes involved in both lipid and glucose metabolism (Razeghi et 
al. 2001).  Murray et al demonstrated the presence of both UCP2 and UCP3 protein in 
the hearts of patients (n=39) undergoing elective coronary artery bypass grafting with 
impaired  LV  systolic  function  (mean  46±10%).    Both  UCP2  and  UCP3  protein  
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concentrations  were  positively  correlated  with  fasting  plasma  free  fatty  acid 
concentrations  but  not  with  the  presence  of  clinical  heart  failure,  diabetes  or  drug 
treatment with ACEi, β blockers or statins (Murray et al. 2004).  
 
 
1.8.5  Genetic variants of UCP2 and UCP3 
The  UCP3/UCP2  locus  has  shown  positive  association  with  resting  metabolic  rate 
(Bouchard et al. 1997) and is in a region that has been associated with diabetes and 
obesity (Fleury et al. 1997).  Several common variants have been described in both 
genes (Figure 1.19).  In UCP2, a common exon 4 variant (+164C>T) exists that encodes 
an  amino  acid  change  (Ala55Val),  in  which  the  heterozygote  state  (Ala/Val)  was 
associated with higher sleeping metabolic rate in a sample of Pima Indians (Walder et 
al. 1998), but no association with metabolic indices or body mass was found in other 
ethnic groups (Urhammer et al. 1997; Kubota et al. 1998; Otabe et al. 1998; Yanovski 
et al. 2000).  The positive data in the large sample of Pima Indians may have been 
because of significant linkage disequilibrium (LD) with an exon 8, 3‘UTR 45 base pair 
insertion  deletion  (ins/del)  variant.    The  heterozygote  state  was  associated  with 
increased sleeping metabolic rate in the Pima Indian sample (Walder et al. 1998), higher 
body mass index (BMI) in South Indian women and higher leptin in obese European 
women (Cassell et al. 1999) and childhood obesity (Yanovski et al. 2000).  However no 
associations have been reported with obesity in men (Dalgaard et al. 1999) or with the 
presence of diabetes (Walder et al. 1998; Cassell et al. 1999).   
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Recently, a common, functional promoter variant has been described (Esterbauer et al. 
2001), UCP2-866G>A, which is in complete LD with a second promoter variant (-
2723T>A), and explains 71% of the variation in mRNA transcript ratio of the exon 8 
ins/del variant.  The -866G>A variant is at the junction between negative and positive 
cis-acting  DNA  regions,  and  within  a  region  containing  binding  sites  for  hypoxia, 
inflammation and pancreatic β-cell-specific binding factors.  The rare (A) allele has 
been  associated  with  lower  gene  transcription  (repression)  in  somatic  non-β  cells 
(Krempler et al. 2002), but more effective gene transcription in pancreatic β cells with 
Figure  1.19.    Human  UCP2/UCP3  gene  locus  (chromosome  11q13)  and  common 
variants 
 
1 kb 
+1  +1 
Exons  I  II  III  IV  V  VI  VII  I  II  III 
IV 
V 
VI 
VII 
VIII 
ATG  TGAS  TGAL  TGA  ATGS  ATG 
UCP3  UCP2 
-866 
G>A 
-2723 
T>A 
45bp 
ins/del 
-55 
C>T 
Ala 55 
Val 
Thr 99 
Thr 
100% 
LD 
UCP3 mRNA has two forms:  a short (S) form due to translation termination at a 
premature stop codon in exon 6 or a long (L) form due to termination in exon 7 
which codes for UCP 3 protein.  A premature translation start codon exists in 
UCP2 exon 2 (ATG s) which is not thought to give rise to an mRNA species.  
Common gene variants known to be in linkage disequilibrium (LD) are joined by 
arrows.    Interrupted  red  line  signifies  UCP2 -866G>A  variant  explains  70% 
variation in mRNA transcript ratio seen in exon 8 45bp ins/del heterozygotes.  
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reduced  markers  of  β  cell  function  (Krempler  et  al.  2002)  as  well  as  measures  of 
reduced GSIS (Sesti et al. 2003).  The A allele has been associated with protection from 
obesity (Esterbauer et al. 2001), but is associated with the presence of diabetes in obese 
subjects (Krempler et al. 2002). 
 
A common promoter variant has also been described in the UCP3 gene (-55C>T) which 
is in LD with the UCP2 exon 8 ins/del polymorphism (Cassell et al. 2000).  The variant 
allele has been associated with obesity in a recessive manner in several studies (Cassell 
et al. 2000; Otabe et al. 2000; Halsall et al. 2001) and higher LDL-cholesterol in a large 
sample from the MONICA study (Meirhaeghe et al. 2000).  Silent sequence changes 
(C99T, C200T) and rare variants (+5G>A, -155C>T) have been described (Cassell et al. 
1999; Otabe et al. 2000).  Rare dysfunctional mutations have been described in African-
American patients with morbid obesity and diabetes (Argyropoulos et al. 1998). 
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Table 1.2.  Published studies of common variants in the human UCP2 gene and association with various phenotypes 
Author (Year)  UCP2 variant  Study group (n)   Phenotype  Association 
Klannermark (1998)  Ala55Val  
 
Caucasian  (55  with  metabolic 
syndrome, 51 controls) 
BMI,  resting  energy 
expenditure 
No association 
Urhammer (1998)  Ala55Val  
 
Caucasian  (144  juvenile  onset 
obesity,  up  to  369  healthy 
controls) 
Obesity,  insulin 
resistance 
No association 
Otabe (1998)  Ala55Val  
3‘ UTR 45bp D/I 
Rare: 
5‘UTR Exon 1 C
19>T 
5‘UTR Exon 1 C
27>G 
5‘UTR Exon 2 C
97>T 
Exon 4 Gly85Ser 
Caucasians: 
Controls (210 – 226) 
Obese (44 – 966) 
Obesity  No associations 
Kubota (1998)  Ala55Val  
Ala232Thr 
Japanese (470)  Obesity, type 2 Diabetes  No associations 
Walder (1998)  Ala55Val  
3‘ UTR 45bp D/I 
Pima Indians (82) 
 
 
 
 
Pima Indians (790) 
Sleeping  and  daily 
metabolic  rate  (SMR, 
DMR) 
 
 
Diabetes, obesity 
Ala/Val  higher  SMR 
(P=0.007) 
D/I  higher  SMR  (P=0.02), 
DMR (P= 0.04) 
 
No associations 
Cassell (1999)  3‘ UTR 45bp D/I  South Indian (708) 
UK Caucasian (247) 
Obesity, type 2 diabetes, 
leptin 
II raised BMI in South Indian 
Women (P=0.018) 
 
DI  lowest  leptin  in  obese 
Caucasian women (P=0.006) 
Dalgaard (1999)   3‘ UTR 45bp D/I  Danish  Caucasian  men  (791 
obese; 915 lean) 
Body mass index  No association   
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Table 1.2.(contd).   Published studies of common variants in the human UCP2 gene and association with various phenotypes (contd.)  
Nordfors (2000)  3‘ UTR 45bp D/I  Swedish Caucasian (41)  Body  fat  accumulation 
during peritoneal dialysis 
DD  increase  in  body  fat 
and body weight (P<0.05) 
Evans (2000)  3‘ UTR 45bp D/I  German Caucasians (579)  Morbid obesity, BMI  I  allele  increased  in 
obesity  and  higher  BMI 
(P=0.002, 0.005) 
Yanovski (2000)  3‘ UTR 45bp D/I  Children age 6-10 years (105) 
African American, Caucasian, 
Asian 
BMI,  body  fat,  resting 
energy expenditure 
DD  lower  BMI,  lower 
body fat. 
Esterbauer (2001)  -866G>A  Danish Caucasian (340 obese, 
256 lean) 
 
 
German Caucasian (791) 
 
Obesity / BMI   AA  reduced  risk  of 
obesity  (RR  0.61  P  = 
0.007) 
 
GG  increases  population 
risk of obesity by ~ 15% 
Buemann (2001)  Ala55Val  
 
Caucasian  (8  Ala/Ala,  8 
Val/Val) 
Incremental  exercise 
efficiency  (energy 
expenditure  at  increasing 
workload) 
Efficiency  higher  in 
Val/Val (P<0.05) 
Kimm (2002)  3‘ UTR 45bp D/I 
Ala55Val  
African American (77) 
Caucasian (75) 
Resting  energy 
expenditure 
No association 
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Table 1.3.  Published studies of common variants in the human UCP3 gene and association with various phenotypes 
Author (Year)  UCP3 variant  Study group (n)   Phenotype  Association 
Meirhaeghe (2000)  -55C>T  
 
French Caucasian (116 obese, 
up to 718 controls, 171 type 2 
diabetes) 
Type  2  diabetes,  obesity, 
lipids 
CC  increased  risk  of 
diabetes  (P<0.05),  TT 
higher LDL (P=0.001) 
Urhammer (1998)  Tyr99Tyr 
Tyr200Tyr 
Rare: 
Gly84Ser 
4 intron 3 variants 
 
 
Caucasian (156 juvenile onset 
obesity,  up  to  380  healthy 
controls) 
Obesity, insulin resistance  No association 
Otabe (2000)  -55C>T 
Tyr99Tyr  
Rare: 
+5G>A 
-155C>T 
-439A Ins 
Exon 4 Gly85Ser 
Caucasians: 
Controls (231) 
Obese (401) 
Obesity  -55TT higher BMI in lean 
(P=0.03)  and  obese 
(P=0.003) 
No other associations 
Walder (1998)  Tyr99Tyr  Pima Indians (82) 
 
 
 
Pima Indians (790) 
Sleeping  and  daily 
metabolic  rate  (SMR, 
DMR) 
 
Diabetes, obesity 
No associations 
Cassell (1999)  -55C>T  South Indian (540) 
UK Caucasian (150) 
BMI,  waist-to-hip  ratio, 
type 2 diabetes 
CC  lower  waist-to-hip 
ratio in women.  
No association with BMI, 
type  2  diabetes  and  no 
associations in men. 
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Table 1.3 (contd)  Published studies of common variants in the human UCP3 gene and association with various phenotypes. 
 
 
Argyropoulos 1998  Val102Ile 
Rare: 
R143X 
Exon  6  splice-donor 
mutation 
Several ethnic populations 
Mende tribe of Sierra Leone 
African-Americans 
Caucasians 
 
Obesity, type 2 diabetes  Rare mutations associated 
with  morbid  obesity  and 
diabetes 
Kimm (2002)  -55C>T 
Tyr99Tyr 
Val102Ile 
Tyr210Tyr 
African American (77) 
Caucasian (75) 
RER  Tyr210Tyr  associated 
with  RER  in  African-
American women 
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1.9  SUMMARY 
The RAAS is important in normal cardiovascular physiology and is implicated in the 
genesis of CHD and in the perpetuation of heart failure.  Heart failure is associated with 
ultrastructural, metabolic and mitochondrial abnormalities of both cardiac (central) and 
skeletal (peripheral) muscle, leading to an intrinsic deficiency of fatigue resistance and 
endurance  performance.    ACE  inhibitors,  and  other  therapies  which  modulate  the 
RAAS, are of proven clinical benefit in CHD and heart failure, through downstream 
mechanisms which have not been clearly defined, but may include improvements in 
mitochondrial  function.    Genetic  studies  suggest  ACE  is  involved  in  the  metabolic 
efficiency of skeletal muscle.  Novel inner mitochondrial proteins, UCPs, have been 
described which uncouple mitochondrial respiration from the generation of ATP and 
may be involved in muscle contractile efficiency and also may protect against oxidative 
stress.   
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1.10  HYPOTHESES & AIMS OF THIS THESIS 
 
 
1.10.1  Hypotheses 
 
i.  The  association  of  low  ACE  activity  with  improved  cardiovascular 
mortality and morbidity is mediated, in part, by elevated kinin activity. 
 
ii.  The  association  of  low  ACE  activity  with  increased  skeletal  muscle 
efficiency is mediated, in part, by elevated kinin activity. 
 
iii.  Reduction of ACE activity increases the coupling of substrate oxidation 
to  ATP  generation  within  mitochondria  of  both  cardiac  and  skeletal 
muscle. 
 
iv.  ACE modifies mitochondrial function, either directly or indirectly via 
downstream effectors such as kinins or angiotensins or through novel 
pathways such as uncoupling proteins. 
 
v.  Mitochondria are an important source of cellular ROS generation and, as 
such, may be fundamental in the genesis of atherosclerotic disease and 
cardiac growth.  
 
vi.  Uncoupling  proteins  2  and  3  have  a  role  in  cardiac  and  skeletal 
physiology and pathophysiology. 
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1.10.2  Aims 
 
i.  To  use  the  prospective  gene-environment  approach  to  test  the  hypothesis  that 
bradykinin,  acting  via  the  constitutive  β2  receptor  (BDKRB2),  is  an  important 
regulator  of  human  cardiac  physiology  and  pathophysiology.  A  functional 
promoter variant in the  BDKRB2 gene (BDKRB2 +9/-9) has been described, in 
which the -9 allele is associated with higher mRNA and receptor activity.  We 
would expect that the -9 allele would be associated with prospective LV growth in 
response  to  physical  exercise  and  lower  prospective  CHD  risk,  particularly  in 
hypertensive individuals. 
ii.  Similarly, common functional promoter variants exist in both the human UCP2 and 
UCP3 genes.  The UCP2-866A (as opposed to G) allele is associated with lower 
gene transcription in somatic non-β cells and would be expected to be associated 
with elevated ROS and increased prospective CHD risk.  The UCP3-55T allele 
(rather  than  C)  has  been  associated  with  obesity  phenotypes  and  may  also  be 
associated with CHD risk.  If UCP2 and UCP3 influence cardiac metabolism and 
ROS  generation,  then  UCP2/UCP3  genotypes  may  also  be  associated  with 
prospective LV growth. We aim to test this hypothesis. 
iii.  To  use  prospective  gene-environment  studies  to  test  the  hypothesis  that  the 
BDKRB2  and  uncoupling  proteins  2  and  3  are  important  regulator  of  muscle 
efficiency. 
iv.  To  examine  intermediate  phenotypes  in  these  studies,  including  inflammatory 
markers, in relation to variation in the UCP2/UCP3 gene locus. 
v.  To  examine  the  effect  of  the  RAAS  on  mitochondrial  coupling  by  assessing 
mitochondrial membrane potential and oxygen consumption in whole live cells. 
vi.  To  examine  the  in  vitro  relationship  between  ACE  and  uncoupling  proteins.12 
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 CHAPTER TWO  
2  MATERIALS & METHODS 
 
 
2.1.  HUMAN STUDIES 
Local ethics committees gave approval for each study.  All study subjects gave written, 
informed consent.  I carried out genotyping and data analysis for all studies, unless 
otherwise stated. 
 
2.1.1.  Bassingbourn (Big Heart) 2 Study (BH2) 
This was a prospective gene-environment study of the effects of exercise as a stimulus 
to heart growth.  It has been previously shown that intense physical exercise amongst 
military  recruits  is  an  effective  model  for  studying  gene-environment  interaction 
(Montgomery  et  al.  1996).  Subjects  comprised  141  Caucasian  male  British  Army 
recruits  from  the  Bassingbourn  (Big  Heart)  2  Study  (Myerson  et  al.  2001)  who 
completed  11  weeks  of  basic  army  training.    Genomic  DNA  was  isolated  from 
peripheral blood leukocytes.  Subjects were selected by homozygosity for the ACE I/D 
gene  variant  (section  2.3)  and  randomised  to  receive  either  placebo  or  a  low  dose 
(25mg) of the AT1R antagonist, losartan.  Baseline age, height and body mass were 
recorded.    Left  ventricular  mass  and  cardiac  dimensions  were  assessed  by  cardiac 
magnetic resonance imaging (CMR) before and after training.  Body composition was 
assessed in 117 recruits by whole body MRI and lean body mass calculated.  Dr Saul 
Myerson was responsible for subject recruitment and CMR scanning.  For this thesis, 
subjects were further genotyped for the BDKRB2 (+9/-9), UCP2-866G>A and UCP3-
55C>T promoter variants (section 2.3). 
 12 
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2.1.2.  Second Northwick Park Heart Study (NPHSII)   
This is a prospective study of subjects comprising 3012 unrelated healthy Caucasian 
middle-aged men (mean age 56.1 + 3.5 years) recruited from nine UK general practices 
who, at the time of my studies, had been followed for a median of 10.2 years (range 9 
days  to  13.3  years).    At  recruitment,  subjects  were  devoid  of  a  history  of  prior 
myocardial  infarction  (MI),  cerebrovascular  disease,  life  threatening  malignancy  or 
regular medication with aspirin or anticoagulants.  A 5ml EDTA blood sample was 
drawn, from which genomic leukocyte DNA was extracted by salting out (section 2.2).  
Genotypes were subsequently determined using polymerase chain reaction amplification 
(PCR) and confirmed by two independent technicians blind to subject outcome, with 
discrepancies resolved by repeat genotyping (section 2.3).  Subjects were subsequently 
divided according to the principles of Mendelian randomisation at study onset. Entry 
systolic and diastolic (Korotkoff V) blood pressures (SBP and DBP respectively) were 
recorded twice with a random zero mercury sphygmomanometer after the subject had 
been seated for 5 minutes, and mean values used in the statistical analysis.  Systolic and 
diastolic hypertension was defined as SBP≥160mmHg and DBP≥95mmHg respectively, 
according to the accepted criteria at trial conception (World Health Organisation 1962; 
Miller et al. 1995), and was reported to the subject‘s general practitioner for action.  
Baseline  demographics  and  conventional  risk  factors  for  CHD  were  documented.  
Patients  were  monitored  with  annual  examinations  and  regular  review  of  medical 
records.  Those who moved from their recruitment location were similarly followed up.  
Deaths  were  recorded  through  the  UK  National  Health  Service  Central  Register.  
Information  for  events  presenting  clinically  /  symptomatically  were  assembled  by 
systematic enquiries through the participating practices, hospitals attended and for fatal 
events through coroners‘ offices.  CHD events were defined as sudden cardiac death, 12 
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symptomatic MI (based on history, ECG, cardiac enzymes and pathology that were 
assessed by an independent reviewer who classified events by criteria of the World 
Health Organization (1976), silent MI (the appearance of a new major Q wave on the 
follow up ECG, using Minnesota codes 11,12.1 to 12.7, 12.8 plus 51 or 52 (Prineas et al. 
1982)), or coronary revascularisation (either surgical or percutaneous).  In addition, any 
(rare) subclinical events were identified though routine electrocardiography at baseline 
and the sixth annual examination.  Time to first coronary event was recorded, yielding 
only one event per subject.  The likelihood of detecting any component endpoint event 
is thus considered equal across all sites.  At the time of my analysis, there had been 204 
events comprising 148 (72.5%) acute MI, 38 (18.6%) coronary revascularisation and 18 
(8.8%) silent MI.   
 
 
2.1.3.  University College diabetes and cardiovascular disease study (UDACS) 
Consecutive subjects attending the outpatient diabetes clinic were recruited by Dr JW 
Stephens  to  the  University  College  Diabetes  and  Cardiovascular  Disease  Study 
(UDACS).    Analyses  were  confined  to  Caucasian  men  only  (n=465;  mean  age 
61.113.3 years).  Baseline characteristics are presented in the results chapter 6 (Table 
6.17).    Presence  of  CHD  was  defined  as  either  a  history  of  angina,  documented 
myocardial  infarction  (MI)  or  coronary  revascularisation  (percutaneous  or  surgical).  
Genomic DNA was isolated from peripheral blood leukocytes (section 2.2).  Venous 
blood was also drawn from a left forearm vein for measurement of serum ACE activity 
(section  2.1.9)  and  assays  for  assessment  of  plasma  markers  of  oxidative  stress 
(Appendix 4).  
 
 12 
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2.1.4.  Human physical performance  
Healthy  subjects  were  drawn  from  two  sources  and  were  free  from  significant 
cardiorespiratory  or  musculoskeletal  disease  and  were  taking  no  medication.  
Recruitment and the exercise training programme were supervised by Dr Alun Williams 
(University of Staffordshire).  
 
Males were drawn from consecutive Caucasian male British army recruits, selected for 
homozygosity for the ACE I/D variant, and studied at the start and end of 11 weeks of 
basic  army  training  (Williams  et  al.  2000).    This  training  is  target-orientated  and 
comprises  a  mixture  of  upper  body  strength,  and  lower  limb  strength/strength–
endurance exercise of graded workload. Recruits are tested to ensure that they have 
reached a set of minimum standards at the end of the training period. 
 
Fifty  healthy  female  Caucasian  volunteers  (aged  range  18-39)  who  had  not  been 
involved  in  any  structured  training  programme  during  the  previous  6  months,  were 
recruited from the student and staff populations of the University of Staffordshire.  They 
underwent  an  8  week  endurance  training  program  consisting  of  3  non-supervised 
sessions  per  week  at  70-80%  of  maximum  heart  rate  (as  derived  from  the  test  of 
maximal oxygen uptake), with 20 minute sessions for weeks 1-4 increased to 30 minute 
sessions for weeks 5-8.  Subjects were trained to regulate their exercise intensity using a 
Polar™ heart rate monitor (Polar Electro, Kempele, Finland) and regular contact was 
maintained throughout training to ensure compliance. 
 
Measures of height and body mass were taken at baseline and after endurance training.  
Resting blood samples were drawn from a superficial forearm vein before and after 12 
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training.  Genomic DNA was extracted from 5ml whole blood (section 2.2).  Serum was 
separated from 10ml whole blood by centrifugation at 1500g for 10 minutes and was 
stored at -20°C until analysis for serum ACE activity (section 2.1.9).   
 
Delta efficiency (DE) is a measure of efficiency of skeletal muscle contraction and is 
the ratio of the external work performed to the internal energy expended.  DE was 
assessed  during  cycle  ergometry  before  and  after  training  (Cooke,  1996).    Briefly, 
subjects  cycled  on  an  electrically  braked  cycle  ergometer  (Lode  RehcorTM,  Lode, 
Netherlands) at 60 r.p.m. at external power outputs of 40, 60 and 80 W for 4 min per 
stage.  Expired air was analysed breath-by-breath using an Oxycon analyser (Mijnhardt, 
Netherlands)  and  heart  rate  was  monitored  telemetrically  (Polar  Electro™,  Polar, 
Kempele, Finland).  A conversion factor dependent on respiratory exchange ratio was 
applied to the oxygen uptake measured, to give rate of energy expenditure (Brouwer, 
1957).  DE was calculated as: 
 
Δ work performed per min 
Δ energy expended per min 
 
 
 
 
2.1.5.  British Olympic athletes (Williams, Dhamrait et al 2004)  
All 1,086 athletes selected for competition by the British Olympic Association were 
contacted in 1998 (Myerson et al. 1999).  Of the 495 respondents, 91 were elite runners 
(48 men, 43 women;  79 Caucasian) who competed over 12 distances ranging from 
100m to 100km (sprinters to ultramarathon runners).  Genomic DNA was isolated from 
buccal cells (section 2.2).  The twelve distance running events were grouped according 
to  the  type  of  muscle  metabolism  involved  (Newsholme  et  al.  1992):  ≤200  m 
x100 % 12 
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(predominantly anaerobic), 400–3,000 m (mixed aerobic and anaerobic), and ≥5,000m 
(predominantly aerobic or endurance trained).  This segregation was confirmed by two 
independent  sources  (D.  Jones,  Professor  of  Sport  and  Exercise  Physiology, 
Birmingham University, and R. Godfrey, Chief Physiologist, British Olympic Medical 
Centre).    Individuals  were  genotyped  for  the  ACE  I/D,  BDKRB2  (+9/-9),  UCP2-
866G>A  and  UCP3-55C>T  gene  variants.    Genotype  and  haplotype  effects  were 
examined by grouping according to distance run. 
 
 
 
2.1.6.  Systemic  inflammatory  response  to  intense  physical  exercise.    The 
Bassingbourn (Big Heart) 3 Study 
This was  a prospective gene-environment study of the effects of strenuous physical 
activity on serum markers of acute inflammation and on serum ACE activity. Every 
fortnight,  new  recruits  start  an  11-week  period  of  basic  army  training  designed  to 
emphasise physical fitness.  At the end of this period, recruited soldiers embark on an 
intensive 48 hour final military exercise (FME), with free access to water to prevent 
dehydration.  Constraints  on  recruit  availability  meant  that  only  a  maximum  of  6 
individuals per fortnightly recruitment could be accurately and prospectively studied at 
the  latter  time  points  during  basic  training  in  order  to  take  serial  blood  samples 
following FME, without disrupting the troop‘s training program.   
 
The study was  performed at  the Army Training Regiment,  Bassingbourn, UK, with 
recruitment, venesection and sample handling carried out by Dr David Brull and myself.  
Between January 2000 and January 2001, consecutive Caucasian male recruits were 
asked to participate.  The study sample consisted of 250 healthy male Caucasian British 12 
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Army recruits (mean age 19.4 ± 2.2 years) (Brull et al. 2002; Brull et al. 2003).  Venous 
blood was drawn as part of the recruits‘ initial routine medical examination.  Blood was 
also taken for DNA extraction (10ml EDTA) and for serum analysis (4.5ml citrated 
sample)  at  baseline,  6  weeks  (during  a  rest  week)  and  immediately  (2  hours)  after 
returning from FME.  Citrated samples were centrifuged (3000g, 10 min) and the serum 
aspirated, aliquoted and transported (2hr, 4°C), then immediately frozen at          –20°C 
for subsequent analysis for serum IL6, fibrinogen, CRP and ACE activity.   
 
Serum ACE activity was assayed by Dr Peter Gohlke (U. Kiel, Germany, section 2.1.9).  
CRP,  IL-6  and  fibrinogen  were  measured  by  staff  blind  to  all  subject  data  in  the 
laboratory of Professor GDO Lowe, Department of Medicine, University of Glasgow, 
UK.    hsCRP  was  measured  on  a  BN  Prospec®  System  (Dade  Behring,  Germany), 
which  is  an  automated  analyser  using  nephelometry.    Interassay  and  intraassay 
coefficients of variation were <4% and <2%, respectively, with a detection limit of 
0.20mg.L
-1.    IL-6  concentration  was  measured  using  a  commercial  assay  (R&D 
Systems, UK).  Interassay and intraassay coefficients of variation were 5% and 3%, 
respectively,  with  a  detection  limit  of  0.70pg.mL
-1.    Fibrinogen  concentration  was 
determined using a semi-automated Clauss assay (MDA-180 coagulometer, Organon 
Teknika, Cambridge), using the manufacturer‘s reagents  and calibrated with the 7th 
British Standard (NIBSC).  Individuals were genotyped for the ACE I/D, BDKRB2 (+9/-
9),  UCP2-866G>A and  UCP3-55C>T  gene variants  and data  analysed  according to 
genotype.   
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2.1.7.  Republic of South Africa (RSA) study 
Subjects were 200 unrelated male black South African volunteers recruited from the 
Xhosa  ethnic  group  during  2002-3  from  a  local  community  centre  in  Cape  Town.  
Recruitment was carried out by Dr B. Rayner (Division of Hypertension, Groote Schuur 
Hospital, University of Cape Town, Republic of South Africa).  Subjects were healthy 
and  not  on  regular  medication  (mean  age  39.8±10.0  years).    Mean  resting  blood 
pressure was SBP 120.9±14.9mmHg and DBP 78.6±11.0mmHg.  Venous blood was 
obtained at rest from the antecubital fossa from all subjects for genomic DNA extraction 
(section 2.2) and measurement of serum ACE activity (section 2.1.9).  I carried out 
DNA extraction, genotyping and data analysis. 
 
 
2.1.8.  Danish type 1 diabetics hypoglycaemia study 
The study  consisted of 262 consecutive adult (≥ 18  years old; mean age 45.513.7 
years;  117  female)  type  1  diabetic  patients  drawn  from  the  outpatients  department 
Hillerød Hospital, Denmark by Dr Ulrik Pedersen-Bjergaard and colleagues (Pedersen-
Bjergaard et al. 2001).  These patients had had diabetes for more than 2 years, with type 
1  diabetes  defined  as  need  for  insulin  treatment  from  the  time  of  diagnosis  and 
unstimulated C-peptide concentrations below 300 pmol.L
-1 or stimulated (venous blood 
glucose  concentration  >12mmol.L
-1)  C-peptide  concentrations  below  600  pmol.L
-1.  
These patients were part of a wider study examining the association of ACE activity and 
hypoglycaemic events.  Blood was drawn for extraction of DNA and for measurement 
of serum ACE activity using a kinetic assay (Sigma Diagnostics, St Louis, MO, USA). 
The  within-assay  and  between-assay  variabilities  were  13%  and  11%.    I  extracted 
genomic DNA, and performed genotyping and data analysis. 
 12 
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2.1.9.  Serum ACE activity  
Serum  ACE  activity  was  assayed  by  Dr  Peter  Gohlke  (Institute  of  Pharmacology, 
University of Kiel, Germany) by a modified fluorometric method using carbobenzoxy-
phenyl-alanyl-histidyl-leucine (Z-phe-his-leu) as a substrate (Depierre et al. 1975) for 
all  studies  apart  from  the  Danish  Hypoglycaemia  study.  Interassay  and  intraassay 
coefficients of variation were 13% and 11%, respectively. 
 
 
2.2.  DNA EXTRACTION 
 
2.2.1.  Materials for DNA extraction 
All reagents were supplied by Sigma (Poole, UK) and were as follows: 
  1M MgCl2: 20.33 MgCl2 dissolved in 100ml dH2O; 
  1M Tris pH 7.5: 12.11g Tris made up to 100ml in dH2O, pH corrected to 7.5 
and autoclaved; 
  Sucrose lysis mix: 109.54g sucrose. 5ml 1M MgCl2, 10ml Tris pH 7.5, 10ml 
Triton-X-100, made up to 1000ml in dH2O and stored at 4ºC; 
  0.5M Na2EDTA: 37.22g EDTA, up to 200ml in dH2O, adjust with NaOH to pH 
8.0; 
  10% SDS: 10g Sodium dodecyl sulphate , made up to 100ml dH2O; 
  Nuclear lysis mix: 1ml Tris-HCl pH 8.2, 2.34g NaCl, 0.4ml 0.5M Na2EDTA pH 
8.0, 10ml 10% SDS, made up to 90ml in dH2O; 
  5M sodium perchlorate: 70.24g sodium perchlorate, up to 100ml in dH2O; 
  TE buffer pH 7.6: 1.21g Tris, 0.37g EDTA, made up to 100ml dH2O. 
 
 12 
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2.2.2.  DNA Extraction Protocol from peripheral blood leucocytes 
Genomic  DNA  was  extracted  from  5ml  potassium-EDTA  or  citrated  anticoagulated 
blood  using  a  salting  out  method  (Miller  et  al.  1988).    Samples  were  meticulously 
logged and entered into a double-password protected computer database. 
 
2.2.2.1.  Cell and Nuclear Lysis 
1.  3-5ml blood was added to a 30ml polypropylene tube, to which 20ml of ice-cold 
sucrose lysis buffer was added. 
2.  The mixture was inverted several times to ensure thorough mixing. 
3.  The resulting suspension was centrifuged at 1300g (10 000rpm in Sorvall RC5 
centrifuge  using  SA-600  rotor)  at  4°C  for  10  minutes.    The  supernatant  was 
carefully decanted and discarded without disturbing the pellet into waste tubes. 
4.  The pellet was resuspended in 20ml sucrose lysis buffer using a Pasteur pipette, 
mixed as before and centrifuged at 1300g for 10 minutes.  The supernatant was 
carefully discarded once more. 
5.  The pellet was resuspended in 2ml nuclear lysis buffer using a Pasteur pipette. 
 
2.2.2.2.  Deproteinisation & extraction 
1.  1ml 5M sodium perchlorate was added and the suspension mixed by inverting at 
least 10 times by hand.  The suspension was transferred to shaker for 10 minutes. 
2.  2ml  of  ice-cold  chloroform  (-20°C)  was  added  using  a  glass  pipette  and  the 
suspension mixed by inversion 10 times by hand. 
3.  The suspension was then centrifuged at 1300g for 3 minutes. 
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2.2.2.3.  DNA precipitation 
1.  The upper aqueous phase (containing the DNA) was transferred by pipetting to a 
fresh 15ml polypropylene tube without disturbing the organic phase. 
2.  10ml cold (-20°C) 100% ethanol was added slowly down the side of the tube to 
the aqueous phase, and the tube inverted gently to precipitate the DNA. 
3.  A sterile pipette was used to carefully spool and remove the white ―woolly‖ DNA, 
washed  quickly  in  fresh  70%  ethanol  and  plunged  into  a  sterile  microtube 
containing 1ml TE buffer 
4.  The DNA was allowed to dissolve by incubating overnight at 37°C.  
5.  If  no  DNA  was  seen  to  precipitate,  the  DNA  mixture  was  cooled  to  -20ºC 
overnight.    The  mixture  was  subsequently  centrifuged  at  1300g  and  the 
supernatant decanted off quickly without disturbing the pellet.  The pelleted DNA 
was allowed to air dry prior to the addition of 0.5ml TE buffer and the DNA 
allowed  to  dissolve  overnight  at  37°C.    The  resulting  DNA  suspension  was 
transferred to a sterile microtube. 
6.  The microtubes were arranged in 96 well boxes and stored at -20ºC. 
 
 
2.2.3.  DNA extraction protocol from saline mouthwash (buccal cells) 
Lysis Buffer consisted of 1000ml dH2O containing 400mM Tris, 50mM EDTA, 150mM 
NaCl and 1% SDS.  DNA extraction from buccal cells was a similar process to that 
from blood leucocytes, although the vessels used were scaled down to 1.5ml eppendorrf 
containers: 
1.  A  universal  container  containing  10ml  saline  mouthwash  was  centrifuged  at 
3000rpm for 3 minutes to pellet the cheek cells. 12 
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2.  The saline supernatant was discarded and the cell pellet resuspended in 500μl 
lysis buffer.  The resulting solution was transferred to a 1.5ml eppendorrf. 
3.  150μl 5M sodium perchlorate was added followed by 500μl chloroform.  The 
mixture was shaken vigorously. 
4.  The mixture was centrifuged at 1400rpm for 3 minutes, resulting in the formation 
of an aqueous (DNA) layer above a chloroform (organic) layer. 
5.  The 500μl aqueous layer was carefully drawn off into a second 1.5ml eppendorrf. 
6.  1000μl of 100% ethanol was added and the eppendorrf slowly inverted 10 times to 
precipitate the DNA. 
7.  The DNA was pelleted by centrifuging the mixture for 2 minutes at 14000rpm and 
the supernatant discarded. 
8.  The DNA was allowed to air dry for 10 minutes. 
9.  500μl sterile distilled water was added and the sample left at 37ºC for 24 hours 
and stored at 4ºC (for 2 weeks) before analysis. 
 
 
2.3.  HIGH THROUGHPUT GENOTYPING FOR COMMON VARIATION IN 
HUMAN STUDIES 
 
2.3.1.  PCR amplification of a target DNA sequence 
Genotyping  involves  amplifying  a  target  DNA  sequence  by  PCR.    This  requires  a 
unique  set  of  oligonucleotide  sequences  (termed  ‗primers‘)  designed  to  be 
complementary to either end (5‘ and 3‘) of the target DNA sequence and are termed 
forward and reverse.  These are approximately 20 bases long.  The temperature (Tm) at 
which these primers anneal to the target sequence is unique and is a function of the 
sequence.  Genomic DNA is initially heated to 95ºC to ‗melt‘ the DNA into single 12 
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strands.  The DNA is then allowed to cool and, as it does so, the primers will anneal to 
the target sequence.  A DNA polymerase will then synthesise a single strand from the 3‘ 
end of each primer by the addition of nucleotides complementary to the target sequence, 
taking approximately 3 to 5 minutes depending on the size of the target sequence.  To 
separate the two strands of DNA (target and new complementary sequence) the strands 
must be again heated to a higher temperature (typically 95ºC).  As the reactant mix is 
further cooled, excess primer anneals to the target sequence.  This cycle of annealing, 
extension and melting is repeated, typically 30 times, thereby exponentially amplifying 
the target DNA sequence.  This process is mechanised by virtue of a computerised 
thermal cycler block which can rapidly cycle through preset temperatures by means of 
heater elements and cooling fans.   
 
If the genetic variation under investigation involves the absence or presence of a short 
sequence  of  DNA,  a  so-called  insertion/deletion  polymorphism,  then  the  amplified 
alleles  will  accordingly  vary  in  length.    Potentially,  these  alleles  can  be  directly 
discerned  by  gel  electrophoresis.  Genetic  variations  involving  a  difference  in  a 
nucleotide  (‗single  nucleotide  polymorphism‘  or  SNP)  can  be  discerned  utilising 
restriction endonucleases.  These are bacterial enzymes which cut dsDNA at a specific 
short  sequence  (usually  4-6bp  long)  that  it  recognises.    A  restriction  enzyme  can 
therefore be chosen which will splice at the SNP site of just one of the variant alleles.  
The  resulting  differences  in  DNA  fragment  sizes  can  be  discerned  by  gel 
electrophoresis. 
 
2.3.2.  PCR experimental protocol 
Dissolved genomic DNA samples were prepared in a 96 well format for subsequent 
Microtitre Array Diagonal Gel Electrophoresis (MADGE).  The order was recorded on 12 
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paper  and  electronic  array  sheets  and  the  identical  format  was  replicated  on  DNA 
storage  arrays,  DNA  working  arrays  and  PCR  plates  through  to  the  gels  used  for 
electrophoresis.  DNA was diluted to 45ng.μl
-1 in 96 well working arrays, leaving at 
least 4 out of the 96 wells blank.  These arrays were centrifuged at 200g for 1 minute to 
ensure the DNA was at the bottom of the wells to prevent cross-contamination.  A 
Finnipippete  multichannel  dispenser  (Life  Sciences,  Basingstoke,  UK)  was  used  to 
transfer 2.5μl of each sample DNA into a  96 well PCR plate (Omniplate, Hybaid).  
Positive control DNA samples of known genotype were added to 2 out of the 4 blank 
wells, leaving two blank wells (negative controls).  The plates were centrifuged at 200g 
for 1 minute to ensure the DNA was at the bottom of the wells and the DNA then dried 
on a 96 well thermal cycler block (MJ Tetrad DNA Engine Thermocycler) at 80ºC for 
10 minutes.  
 
Table 2.1  PCR mix for 100 reactions 
 
 
  Genotype 
Reagent (μl)  ACE I/D 
BDKRB2 
(+9/-9) 
UCP2-
866G>A 
UCP3-
55C>T 
UCP2 D/I 
Polmix  200  200  200  200  200 
Magnesium 50mmol.l
-1  60  100  100  100  100 
Forward primer  2.75  8  8  8  8 
Reverse primer  1.5  8  8  8  8 
Third primer  7.5         
dH2O  1620  1617  1617  1617  1617 
Taq polymerase 5u/µl  4  7  7  7  7 
BSA  -  60  60  60  60 
W1 (1%)  100         12 
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20μl of PCR mix (unique for each genetic variant; Table 2.1) was added to each well of 
the PCR plate using an automatic Biohit repeating dispenser (Alpha Laboratories, UK).  
The PCR mix contains forward and reverse primers, ‗Polmix‘ (containing 50mM KCl, 
10mM Tris-HCl (pH 8.3) and 0.2mM of each of the nucleotides dATP, dGTP, dTTP, 
dCTP), Thermus aquaticus (Taq) DNA polymerase and magnesium (a cofactor required 
for DNA polymerase).  Taq polymerase is a thermostable DNA polymerase (isolated 
from thermophiles which exist in thermal vents on the oceanic floor) which remains 
active at the high temperatures required for the denaturation-naturation cycles.  
 
Each sample was overlaid with 20μl mineral oil to prevent evaporation.  Plates were 
then sealed with sterile clear plastic adhesive lids and again centrifuged at 200g for 1 
minute prior to PCR amplification on an MJ Tetrad. 
 
 
2.3.3.  MADGE 
DNA fragments in the PCR product were separated using electrophoresis on a non-
denaturing polyacrylamide gel using MADGE (Day et al. 1995).  MADGE consists of 
an open arrangement of 8x12 wells each 2mm deep and arranged at an angle of 71.2º to 
the short axis of the array, but perpendicular to the long axis of the Perspex formers.  
Thus,  the  maximum  track  length  is  26.5mm  allowing  sufficient  travel  for  genotype 
resolution.  All 96 wells can therefore be seen on a single gel (Figure 2.1). 
 
MADGE gels were made up in batches as follows.  Glass plates (160x100x2mm) were 
rigorously  cleaned  and  hand-dried  using  70%  ethanol.    Once  dry,  2  ml  of  γ-
methacryloypropyltrimethoxysilane (‗sticky silane‘) was spread across the plates and 
left to air dry.  Silane was used to ensure the gel adhered to the glass plate.   12 
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The gel was made using 5ml 10xTBE, 12.2mls 30% acrylamide-bisacrylamide (ratio 
19:1,  Protogel  National  Diagnostics,  Hull,  UK),  32.5mls  dH2O  and  150μl  N‘-
tetramethylethylenediamine (TEMED, BDH, Leicestershire, UK).   Polymerisation of 
the gel was initiated by the addition of 150μl 25% ammonium persulphate (APS, BDH, 
Leicestershire,  UK).    TBE  (10x  Tris-Boric  acid-ethylenediaminetetraacetic  acid) 
contained: 0.9M Tris, 0.9M orthoboric acid and 0.2M ethylendiaminetetraacetic acid 
(all from BDH, Leicestershire, UK). 
 
Immediately  after  the  addition  of  APS,  the  solution  was  poured  into  the  perspex 
MADGE  former  and  a  glass  plate  (silanised  face  down)  was  then  carefully  placed 
Figure 2.1.  Example of a MADGE gel.  96 genomic DNA samples (including 4 blanks) 
have been amplified by PCR for the UCP2D/I variant.  The gel was then loaded with 
each  individual  PCR  product.    The  wells  are  arranged  in  a  12x9  grid  with  lanes 
arranged at 71.2º to the short axis which enables more samples to run on a single gel.   
 
1       2        3        4       5       6        7        8        9      10      11      12 
A 
B
C 
D 
E 
F 
G 
H 
II  
homozygote  DD 
homozygote 
ID Heterozygote with  
* heteroduplex band  
* 
Gel lane in which 
product from well 
G9 will run during 
electrophoresis.  
DNA products 
will separate 
according to size. 
Current applied in 
this direction  
 12 
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across the liquid surface without trapping any air bubbles.  A 0.5kg weight was placed 
on top of the plate to aid adherence of the gel and the gel allowed to set for 15 minutes.  
Excess gel was trimmed off and the gel-plate was lifted off the former.  MADGE gels 
were stored in 1xTBE. 
 
The MADGE gels were stained with ethidium bromide prior to loading (1000ml 1xTBE 
containing 100μl ethidium bromide for 20 minutes).  5μl PCR product was mixed with 
2μl  formamide  dye  (98%  formamide,  10mmol.l
-1  EDTA,  0.025%  xylene  cyanol, 
0.025% bromophenol blue) in a fresh round-bottomed 96 well plate.  5μl of this mixture 
was  transferred  into  the  wells  of  the  MADGE  gel  which  had  been  placed  in  an 
electrophoresis tank containing 1L of 1xTBE.  120V was applied across the gel for 
approximately 50 minutes or until genotypes were distinguishable.  The gel was viewed 
using the Gene Snap gel documentation system under UV light. 
 
 
 
2.3.4.  Genotyping for variation in the ACE, BDKRB2, UCP2 and UCP3 genes 
 
2.3.4.1.  ACE I/D Variant 
Reagents  were  optimised  (Table  2.1)  and  published  primers  (Table  2.2)  were  used 
(Evans et al. 1994).  The PCR conditions were: 
  95C   5 min 
 
  95C   45 sec 
  54C   45 sec       35 cycles 
  72C   30 sec 
 
  72C   5 min 
 12 
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and  yielded two products that could be resolved on MADGE (7.5% gel):  an 84bp 
product (D allele) and a 65bp product (I allele). 
 
2.3.4.2.  BDKRB2 (+9/-9) Ins/Del variant  
The  Bassingbourn  2  study  volunteers  were  genotyped  for  the  BDKRB2  (+9/-9) 
polymorphism by Dr J Erdmann, with products resolved on a heteroduplex gel (Lung et 
al. 1997).  For all subsequent studies, genotyping was carried out using a MADGE 
system with primers (Table 2.2) and reagents (Table 2.1) designed and optimised by Dr 
John Payne.  This yielded a 100bp (deletion) and 109bp (insertion) fragments that could 
be  discerned  by  MADGE  using  a  7.5%  gel,  with  a  third  heteroduplex  band  in 
heterozygotes (209bp). 
 
 
2.3.4.3.  UCP3-55C>T variant 
Published  primers  were  used  (Cassell  et  al.  2000).    Reagents  and  conditions  were 
optimised for MADGE (Table 2.1).  PCR conditions were as follows: 
 
95ºC for 4mins 
95ºC for 40s 
55ºC for 30s  30 cycles 
72ºC for 1m 
72º for 5 mins 
 
The 194bp product was digested overnight at 37ºC with the restriction enzyme BsuR1 to 
yield 110, 64, 20bp fragments for the C allele and 110 and 84bp fragments for the T 
allele.  For 100 reactions, 60μl BsuR1 was mixed with 300μl buffer R
+ and 640μl dH2O. 
 12 
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2.3.4.4.  UCP2-866G>A variant (Esterbauer et al. 2001) 
Primer sequences were a kind gift from Harald Esterbauer (Department of Laboratory 
Medicine,  Landeskliniken  Salzburg,  Austria;  Table  2.2).    The  PCR  reagents  were 
optimised for a 7.5% MADGE (Table 2.1) and conditions were as follows: 
 
95ºC for 4mins 
95ºC for 40s 
65ºC for 30s  30 cycles 
72ºC for 1min 
72º for 5 mins 
 
Mlu1 breaks dsDNA at the following recognition sequence, found only in the G allele: 
 
 
5’-A  CGCGT 
3’-TGCGC  A 
 
On digestion, the 360bp PCR product would therefore yield 290+70bp fragments in G 
allele carriers only.  For 100 digestion reactions, 20μl Mlu1 was mixed with 150μl 
buffer R
+ and this diluted with 320μl dH2O.  5μl of this mixture was added to 10μl PCR 
product and incubated overnight at 30C.  5µl of the resulting digestion mixture was 
mixed with  2μl  formamide dye  and loaded on  an ethidium stained MADGE  gel  as 
above. 
 
 
 
2.3.4.5.  UCP2Del/Ins variant 
Primers were as previously published (Cassell et al. 1999); Table 2.2).  Reagents (Table 
2.1) and conditions were optimised for 7.5% MADGE: 
Mlu1 12 
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95ºC for 3 mins 
95ºC for 30s 
65ºC for 30s  35 cycles 
72ºC for 30s 
72º for 5 mins 
 
The PCR  yielded a  412bp (deletion) and  457bp (insertion)  fragments  that could  be 
discerned  by  MADGE  using  a  7.5%  gel,  with  a  third  heteroduplex  band  in 
heterozygotes. 
 
 
2.4.  CELL CULTURE 
 
Cell culture was performed in a dedicated tissue culture suite (Rayne Institute, UCL). 
Gloves, cell culture dedicated laboratory coats and overshoes were worn at all times.  
Sterility was maintained by handling all open cell culture media, cultureware and liquid 
materials within a class II microbiological safety cabinet with unidirectional laminar 
downflow (Envair (UK) Ltd).  Surfaces were cleaned with 1% Virkon and 70% ethanol 
solutions.  Materials for use within the laminar flow hoods were pre-sprayed with 70% 
ethanol.  Contaminating fluids such as used culture media were removed with suction 
into  1%  Virkon  containing  vessels  and  stored  therein  for  at  least  24  hours  before 
disposal.  Cells were cultured in Galaxy R CO2 incubators (Wolf Laboratories, UK), 
humidified and set to 5% CO2, 37°C unless otherwise stated. 
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Table 2.2.  Forward and reverse primers for genotyping common gene variants. 
 
 
Gene variant  Forward primer  Reverse primer  Restriction enzyme or 3
rd primer 
BDKRB2 (+9,-9) 
5‘-TCTGGCTTCTGGGCTCCGAG-
3‘ 
5‘-AGCGGCATGGGCACTTCAGT-
3‘  - 
UCP3-55C>T 
5‘-GGATAAGGTTTCAGGTCAGGC-
3‘ 
5‘-AAGGGATGAGGGAGGAGAAA-
3‘  BsuR1 
UCP2-866G>A 
5‘-CACGCTGCTTCTGCCAGGAC -
3‘ 
5‘-AGGCGTCAGGAGATGGACCG -
3‘  Mlu1 
UCP2 Del/Ins 
5‘-CAGTGAGGGAAGTGGGAGG-
3‘ 
5‘-GGGGCAGGACGAAGATTC-
3‘  - 
ACE  I/D 
5'–CATCCTTTCTCCCATTTCTC-
3'  5'-TCGGATTACAGCCCTGATACAG-
3'  5'-ATTTCAGAGCTGGAATAAAATT- 
3' 
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2.4.1.  General cell culture methods for immortalised cell lines 
 
2.4.1.1.  Thawing and seeding cells for culture  
A  single  cryotube  (Nunc™,  Fisher  Scientific,  UK)  containing  0.5ml  frozen  cell 
suspension, stored in the vapour phase of liquid Nitrogen (-170°C), was thawed for 1 
minute in a 37°C water bath (Grant Instruments,Cambridge, UK).  The cell suspension 
was diluted into 5ml of warm (37°C) growth medium contained in a 50ml centrifuge 
tube  and  then  immediately  pelleted  by  centrifuging  at  1000rpm  for  5  minutes 
(Eppendorrf centrifuge 5804R).  The supernatant was removed and the pellet gently 
resuspended in 5ml warm growth media (37°C).  The resultant suspension was then 
added to a 75ml culture flask containing 15ml warm growth medium which had been 
allowed to equilibriate with a humidified 5% CO2, 37°C atmosphere for 10 minutes in 
the incubator.  Once the cells were adequately dispersed, the flask was placed in an 
incubator at 37°C, in a 5% CO2 humidified atmosphere.  Every 2-3 days, growth media 
was suctioned off with a sterile glass pipette and replaced with fresh media. 
 
Adherent cells were split at subconfluency either at a ratio of 1:3 or from 75cm
2 into 
175cm
2 flasks.  First, growth media was removed by suction, cells washed with PBS, 
and 1-2ml trypsin-EDTA (GIBCO BRL) added.  Once the cells had detached (usually 
within 1-2 minutes), the cell suspension was removed to a 50ml centrifuge tube and 
centrifuged at 1000rpm for 5 minutes.  The supernatant was then discarded and the cell 
pellet resuspended in 5ml warmed (37°C) growth medium.  The cell suspension was 
then divided as above or added to a 175cm
2 flask with a 40ml final volume of growth 
media. 
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2.4.1.2.  Cryopreservation of cells 
Following trypsinisation, cells were resuspended in cell freezing media (GIBCO BRL) 
at a concentration of 10
6cells.ml
-1 and 0.5ml of this cell suspension was then aliquoted 
into  cryotubes.    The  cryotubes  were  immediately  stored  at  -80°C  for  24  hours  and 
thereafter moved to -170°C in liquid nitrogen for long-term storage. 
 
2.4.2.  Growing characteristics of C2C12 cell line 
The C2 cell line was originated by selective serial passage of myoblasts obtained from 
the thigh muscle of 2 month old normal mice, prepared 70 hours after crush injury 
(Yaffe et al. 1977).  The C2C12 subclone was derived by further passaging (Blau et al. 
1985)  and  was  shown  to  differentiate  rapidly  and  to  produce  extensive  myotubes 
expressing characteristic muscle proteins.  The C2C12 cell line was obtained from ATCC 
(product CRL-1772, ATCC-LGC, Teddington, UK). 
 
Myoblast growth medium consisted of Dulbecco‘s Modified Eagle‘s Medium (DMEM) 
containing  4500mg.L
-1  D-glucose  (Sigma  D6429)  supplemented  with  penicillin  and 
streptomycin at a final concentration of 100u.ml
-1 (GIBCOBRL No 15140-122) and 
10% heat-inactivated foetal bovine serum (GIBCOBRL 10106-169).  Myoblasts were 
differentiated  into  myotubes  at  confluency  by  changing  to  serum  deprived 
(differentiation) media consisting of DMEM containing 4500mg.L
-1 D-glucose (Sigma 
D6429)  supplemented  with  penicillin  and  streptomycin  at  a  final  concentration  of 
100u.ml
-1 (GIBCOBRL No 15140-122) and 2% horse serum (Sigma Cat No H1138). 
 
2.4.3.  Growing characteristics of H9C2 
The H9C2 cardiomyoblast cell line was originally derived from embryonic heart tissue 
using selective serial passage (Kimes et al. 1976).  The cell line was a kind gift from 12 
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Professor D. Yellon (Hatter Institute, UCL).  Growth media was identical to that used 
for  C2C12  myoblast  culture.    Differentiated  H9C2  cardiomyoblasts  are  of  a  similar 
phenotype to skeletal myotubes (Kimes et al. 1976) and were not used in subsequent 
experiments. 
 
 
2.4.4.  Culture of primary cells 
 
2.4.4.1.  Adult ventricular cardiomyocytes isolated from the Sprague Dawley rat 
All experiments were conducted in accordance with the animal
 care guidelines of the 
Ethics  Committee  of  University  College  London,
  adhering  to  the  United  Kingdom 
Home  Office  Animals  (Scientific  Procedures)
  Act  of  1986.  Adult  ventricular 
cardiomyocytes  were  isolated  using  retrograde  perfusion  in  a  modified  Langendorff 
apparatus  (Stemmer  et  al.  1991)  in  the  laboratory,  and  under  the  supervision,  of 
Professor Yellon (Hatter Institute, UCL).  Isolation buffers were prepared as follows: 
 
Buffer 1 (1000ml) 
Reagents  mM  g.L
-1  MWt 
Sterile distilled water 1000ml        
Sodium chloride  (BDH)  116.3  6.8  58.44 
Potassium chloride (BDH)  5.4  0.4  74.55 
Magnesium sulphate (BDH)  0.4  0.1  246.48 
HEPES (BDH)  20.0  4.76  238.3 
Sodium dihydrogen orthophosphate (BDH)  0.9  0.12  137.99 
D-Glucose (BDH)*  5.6  1  180.16 
 
Buffer 1 was adjusted to pH 7.35-7.4 and sterilised by autoclaving.   
* Sterile filtered D-glucose was added after autoclaving. 12 
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Buffer 2 (200ml/heart) 
Buffer 1 +  3.3µM EGTA (132µl 5mM EGTA pH 7.4) 
    1mg.ml
-1 (0.2g) bovine serum albumin (fraction V fatty acid free) 
 
Buffer 3 (200ml) 
Buffer 1 +  1mg/ml (0.2g) collagenase  
    25µM (50µl of 100mM) CaCl2 
 
Buffer 4 (200ml) 
Buffer 1 +   50µM (100µl of 100mM) CaCl2  
 
Buffer 5 (200ml) – Restoration Buffer 
Reagents   
Buffer 1 +    
BSA   2g 
Na pyruvate (kept at 4C)  10mg 
5.0mM Taurine  125mg 
2.0mM Carnitine  64mg 
1.0mM Creatine  131mg 
75µM CaCl2  150µl of 100mM 
 
 
 
Buffers were oxygenated with 100% oxygen.  Adult male Sprague Dawley rats (SDR) 
were fed ad libitum and kept at a 12hour day/night cycle.  SDR (300-350g) underwent 
terminal anaesthesia with an intraperitoneal injection containing 0.7ml phenobarbitone 
(60mg.ml
-1) and 0.3ml sodium heparin (1000u.ml
-1).  The heart was rapidly excised, 
arrested in chilled (4°C) Buffer 1 and mounted on an aortic cannula.  The heart was 12 
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perfused (in a non-circulating manner) with calcium-free Buffer 2 (warmed to 37°C) for 
5 minutes, followed by 1mg.ml
-1 Type 2 collagenase (Buffer 3) for 10 minutes (37°C).  
During this time, the heart assumes a globular shape, yellows and softens.  Finally, the 
heart  was  perfused  with  50μM  calcium  Buffer  4  for  5  minutes  (37ﾰC),  before  the 
ventricles  were  excised  and  minced  in  oxygenated  restoration  Buffer  5  (37°C).  
Dispersed cardiomyocytes were recovered and any remaining intact ventricular tissue 
underwent  further  cycles  of  digestion  with  collagenase  (Buffer  3)  at  37°C  with 
subsequent  recovery  of  dispersed  cardiomyocytes  by  aspiration  and  centrifugation 
(1000rpm 5 minutes).  Isolated cardiomyocytes were resuspended in 25ml oxygenated 
restoration Buffer 5 and the calcium concentration increased stepwise with aliquots of 
50μl 100mM calcium chloride solution at 5 minute intervals to a final concentration of 
1.25mM.  Cardiomyocytes were then ready for use in subsequent experiments. 
 
 
2.4.4.2.  Isolated human ventricular cardiomyocytes 
Isolated  human  ventricular  myocytes  were  obtained  from  the  laboratory  of  Dr  Sian 
Harding  (National  Heart  and  Lung  Institute,  Imperial  College  School  of  Medicine, 
London,  United  Kingdom).    Ventricular  myocardium  was  obtained  from  explanted 
human  hearts  comprising  recipient  hearts  with  chronic  end-stage  heart  failure 
(ischaemic  or  dilated  cardiomyopathy).    Myocytes  had  been  isolated  by  enzymatic 
digestion of left or right ventricular myocardium (Harding et al. 1992; Davies et al. 
1995; Peeters et al. 1995) and only rod shaped cells were used in the confocal studies.   
Cells were incubated in M199 medium (GIBCOBRL) supplemented with human insulin 
1μM, creatine 5mmol, taurine 5mmol, carnitine 5mmol, 0.2% BSA (no ascorbate). 
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2.4.4.3.  Culture of human umbilical vein endothelial cells (HUVECs) 
Human  umbilical  vein  endothelial  cells  (HUVECs)  were  obtained  from  PromoCell 
(Catalogue number C-12200, Heidelberg, Germany) at passage 2.  They were cultured 
in  tissue  culture  vessels  coated  with  1%  gelatine  (GIBCOBRL)  at  37°C  with  an 
atmosphere  of  20%  O2 and  5%  CO2.   The  culture  medium  was  endothelial  growth 
medium  (EGM™  BulletKits
®  Cambrex  Clonetics,  Wokingham,  Cat  No  CC-3124) 
containing bovine brain extract (with heparin), human endothelial growth factor, 1000 
units of gentamicin and amphotericin B and supplemented with 10% heat-inactivated 
bovine calf serum (BCS, GIBCOBRL).  HUVECs at passage 3-5 at confluence were 
used in  experiments,  having been seeded to  Nunclon™Δ 6 well culture dishes at  a 
density of 5000 cells.cm
-2.  Cells achieved 80% subconfluency with standard growth 
medium and then incubated in serum-free EGM™ for 48 hours to confluency prior to 
all experiments.  For experiments in prolonged hypoxia, cells were incubated in  an 
atmosphere of 5% O2 and 5%CO2. 
 
 
2.5.  MEASURING MITOCHONDRIAL FUNCTION IN LIVE CELLS 
 
Novel approaches using fluorescent indicators have been recently applied to the study of 
mitochondrial  function  in  vitro.    These  approaches  coupled  to  digital  imaging 
fluorescence  microscopy  or  flow  cytometry  are  allowing  new  insights  into 
mitochondrial  physiology  and  pathophysiology  such  as  apoptosis,  free  radical 
generation,  intramitochondrial  calcium  and  cell  death.    In  this  thesis,  both  flow 
cytometry  and  confocal  microscopy  have  been  used  to  study  alterations  in 
mitochondrial membrane potential (Δψm) and ROS generation.  The fluorescent probes 
TMRM and JC-1 were obtained from Molecular Probes (Eugene, Oregon). 12 
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2.5.1.  Flow cytometric measurement of Δψm 
 
2.5.1.1.  Principles of flow cytometry 
Flow  cytometry  is  a  powerful  tool  for  measuring  the  physical  and  fluorescent 
characteristics  of  individual  cells  from  a  homogeneous  population,  sampled  at  high 
speed (up to 10000 cells.s
-1).  Fluorescently labelled (e.g. mitochondrial or antibody-
conjugated)  cells  in  suspension  are  passed  through  an  argon  laser  light  within  a 
pressurised fluidic stream.  Hydrodynamic focussing ensures that the incident argon 
laser light (488nm) hits the cells, one cell at a time,  The incident laser light is scattered 
in  all directions  and is  registered on various detectors set  at  different  angles to  the 
incident light.  The forward scatter (FSC) detector is set directly in front of the laser and 
detects cell size.  Cells passing through the beam will scatter light in a forward direction 
Figure 2.2.  Overview of a flow cytometer.  Cells are focussed through a laser light at 
the  interrogation  point  where  cell  size,  structural  complexity  and  fluorescence 
characteristics are measured and recorded for subsequent analysis (see text). 12 
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which is proportional to cell size.  A detector converts this light into an electrical signal 
which is further amplified and registered by the attached computer.  The side scatter 
(SSC) detector is  set  at 90° to both the incident  laser light  and FSC.   SSC detects 
scattered light as a cell passes through the beam, and therefore gives an indication of 
granularity  or  structural  complexity  of  the  cell,  being  particularly  important  in 
differentiating leucocytes. 
 
A further series of filters and dichroiic mirrors is also set at 90° to the incident laser 
light.  The filters allow fluorescent light of particular wavelengths to pass through.  This 
range of wavelengths is termed the bandpass width.  The first dichroiic mirror allows all 
light above 560nm to pass directly through, but light below this wavelength is reflected 
at  90° through a 535-560nm  bandpass  filter, which only  allows  green  light  to  pass 
through.  This light will then be detected on the FL-1–green or ‗fluorescein‘ channel.  
Similar arrangements  allow detection of orange-red (FL-2) and far-red (FL-3) light.  
Again each signal can be amplified to allow detection.  The signal is transmitted to a 
computer  for  data  collection.    For  a  sample  of  10000  cells  labelled  with  2 
fluorochromes, 40000 data points will be collected.  In these experiments, FACScan and 
FACSCalibur (Becton Dickinson, Oxford, UK) flow cytometers were used, attached to 
a G4 computer (Apple Macintosh) using Cell Quest and Cell Quest Pro Software for 
acquisition and analysis of data.  WinMDI (for flow cytometry; version 2.8) freeware 
was used for further data analyses and data presentation. 
 
2.5.1.2.  Flow cytometric analysis of Δψm  
Adherent cell lines were seeded at 0.5x10
5 cells per well in 6-well plates, grown to 
confluency and treated with appropriate intervention or vehicle.  Thereafter, the cells 
were  washed  twice  with  2ml  warmed  Krebs‘  solution  and  then  incubated  with 12 
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potentiometric fluorochrome (in Krebs‘ solution) in the dark at 37ﾰC (5% CO2).  After 
this period, the cells were washed once in Kreb‘s solution and detached with 0.5ml 
trypsin/EDTA.    Once  detached,  trypsinisation  was  halted  by  the  addition  of  0.5ml 
cooled (4°C) trypsin-neutralising solution and the cell suspension pipetted into a 5ml 
round-bottomed falcon tube (Becton Dickinson, Oxford, UK) and then placed in ice and 
kept in the dark for transfer to the flow cytometer and immediately analysed. 
 
 
Table 2.3.  Typical flow cytometer detector settings for analysis of Δψm in live cells 
using JC-1 fluorescent dye 
 
Parameter  Detector  Voltage  Amp Gain  Mode 
P1  FSC  E-1  4.87  Lin 
P2  SSC  280  5.41  Lin 
P3  FL-1  420  1  Log 
P4  FL-2  385  1  Log 
P5  FL-3  150  1  Log 
FSC threshold 400; Compensation: FL-1 minus 1.5% FL2 and FL-2 minus 35.3% FL1 
 
 
 
2.5.2.  Confocal scanning laser microscopic measurement of Δψm 
Confocal  laser  scanning  microscopy  (CLSM)  uses  similar  fluorescent  technology  to 
flow cytometry.  However, CLSM allows more detailed examination of a magnified 
field of view, for example a histological section or live single cells grown on coverslips.  
CLSM uses a conventional, high powered microscope attached to a computer.  The 
sample is illuminated by laser light, from a selection of lasers, which is focussed at a 
specific point and focal plane within the specimen and scans across the specimen in a 
series of lines to build up the image.  The laser wavelengths can also be selected to 
match the excitation / emission properties of the fluorescent probes used.  The light 12 
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emitted  by  the  specimen  is  captured  through  an  objective  lens,  and  is  transmitted 
through a series of dichroiic mirrors and filters to detectors in a similar manner to the 
flow cytometer discussed above.  Again, the fluorescence signal can be amplified by 
photomultiplier tubes (PMT) and thereafter converted to a digital signal at a detector 
which is then sent to the computer.  The CLSM is software driven.  The software is used 
to acquire the image.  Indeed, the image can be captured at any focal plane, rotated and 
digitally zoomed before capture.  The strength of the laser light can be reduced by 
reducing the power and also the iris size of the shutter above the specimen.  This would 
also have the effect of improving focus and reduce laser photobleaching of the specimen 
as well as oxidant and thermal stress.  The emitted light signal can be post processed by 
amplification  by  the  PMTs  and  digital  amplification  to  aid  image  capture  and  also 
reduce the strength of laser light needed. 
 
The CLSM therefore allows a field of cells to be captured at low magnitude (x20), or 
single cells at higher magnitude (x40) and intracellular examination (x60 and above).  
This therefore allows separation of mitochondrial from cytoplasmic signal and single 
cell-based physiological responses to be tested.  However, it is slower and materials 
more expensive than flow cytometry.  CLSM and flow are therefore complementary. 
 
In these experiments, a Nikon Eclipse TS100 inverted microscope attached to a Bio-Rad 
Radiance2000 confocal system was used.  This has 3 lasers: an argon laser capable of 
emitting laser light at 4 different wavelengths (457, 476, 488, 514nm), a helium-neon 
laser (543nm) and a krypton laser (637nm).  Images were acquired using LaserSharp 
2000 software, and analysed using LaserPix and LaserVox software (Bio-Rad, UK) as 
appropriate.  
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For live cell experiments, adherent cells were seeded to 2 well quartz-glass chamber 
slides  (Nunc™,  Fisher  Scientific,  UK)  at  10
3  cells  per  well.    For  cardiomyocyte 
experiment,  chambers  were  pre-coated  with  150µl  laminin  (30μg.ml
-1;  Roche, 
Mannheim, Germany). 
 
2.5.3.  Measurement of cellular ROS generation 
Cell monolayers were washed with Krebs medium and then incubated with either DCF-
DA at a final concentration of 1 μM or DHE at 10 μM.  The cells were then washed in 
Krebs medium and suspended in solution in order to be analysed by flow cytometry.  
Cells were excited by an argon laser at 488nm and DCF-DA fluorescence measured in 
the green (FL1) channel and DHE fluorescence in the red (FL2) channel. 
 
To  manipulate  Δψm,  cells  were  pre-treated  with  mClCCP  (Mathur  et  al.  2000)  or 
nigericin (Keij et al. 2000; Zhang et al. 2001).  To increase cellular OS, cells were 
treated with mClCCP (Nishikawa et al. 2000), high glucose (Nishikawa et al. 2000), 
rotenone (Duranteau et al. 1998; Pearlstein et al. 2002), menadione (Roychowdhury et 
al. 2002) or incubated in a hypoxic environment (Pearlstein et al. 2002).   
 
2.5.4.  Measurement of in vitro ACE activity 
Cell culture media was aspirated and immediately frozen at -20ºC.  ACE activity was 
subsequently measured by Dr P Göhlke as above (section 2.1.9). 
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Figure 2.3.  ‘Optics’ folder within the Laser Sharp confocal microscopy software.  This gives a graphic representation of the settings used to 
obtain a confocal image.  To the right are the percentage power outputs of the lasers in use as well as the wavelength of the laser light.  This 
light is reflected onto the specimen.  Emitted light then passes back through a series of mirrors and then to dichroiic mirrors with subsequent 
filtering  of  light  to  allow  detection  of  certain  emitted  fluorescence  wavelengths  (see  text).    This  confocal  system  is  set  to  detect  green 
fluorescence which is reflected at the first dichroiic mirror (reflects light below 560nm) through a green light filter (515±30nm) to PMT1.  Red-
orange fluorescence is reflected at the second dichroiic mirror and through the red filter (590±70nm) to PMT2.  Far red signal is detected at 
PMT3. 12 
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Figure 2.4.  Laser Sharp imaging software during live confocal image acquisition.  The scanning parameters are in the folder to 
the right.  The laser scanning line speed, laser power, iris size as well as post processing digital zoom and image orientation are 
seen.  The image (H9C2 myoblasts) acquired is to the left with the greyscale image above the red colourised image. 12 
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2.5.5.  Measurement of cellular oxygen consumption 
Cellular O2 consumption was measured using the OxySpot system (Rosser et al. 1998; 
Knopp  et  al.  1999).    Cells  were  grown  to  confluency  as  described.    Cells  were 
trypsinised and concentration of cells calculated using a haemocytometer.  Cells were 
resuspended in aerated Kreb‘s solution containing 10% albumin at 4x10
6 cells per ml.  
The cell suspension was placed in a 3 cm
3 disposable glass cuvette, containing 37.5 mg 
of palladium mesotetra  porphyrin  (Medical  systems,  via Digitimer, Welwyn Garden 
City, UK) and a magnetic stirrer (micro magnetic flea, Fisher Scientific).   
 
The cuvette was then sealed with a rubber stopper to prevent the entry of atmospheric 
oxygen and placed within a dark chamber with the tip of the fibre optic cable from the 
OxySpot system (Medical Systems Corp.) abutting against the side.  A 22 gauge needle 
(Sherwood Medical) was pushed through the stopper and filled with medium to form an 
effective diffusion barrier.  Drug additions were through a second needle.  Continuous 
uniform mixing was achieved with the magnetic stirrer.  Oxygen tension was measured 
Figure  2.5.    Cartoon  depiction  of  oxyspot  system  to  measure  cellular  oxygen 
consumption (described fully in the text). 
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by the oxygen dependent quenching of porphyrin phosphorescence (Vanderkooi et al. 
1986; Lo et al. 1996) using the OxySpot.  In these experiments the phosphorescence 
half-life of five flashes delivered by the fibreoptic cable were averaged.  Measurements 
of oxygen tension were recorded every 10 s once oxygen tension had fallen to 60 torr, 
the  upper  limit  of  accuracy  using  this  porphyrin,  and  were  continued  until  oxygen 
consumption had ceased, or for 30 minutes. Oxygen consumption at room temperature 
was calculated from the rate of fall of oxygen tension in the sealed cuvette (torr.s
-1).  
Respiratory  control  ratio  was  calculated  as  the  uncoupled  rate  /  baseline  oxygen 
consumption rate. 
 
 
2.6.  MEASUREMENT OF mRNA 
 
2.6.1.  RNA isolation 
All materials were handled with gloves, pipettes and Eppendorrfs autoclaved prior to 
use for RNA work only, and benchspace cleaned meticulously with 70% ethanol.  RNA 
was isolated from cells grown in 6 well plates using the RNeasy® Mini Kit (Qiagen, 
Crawley, UK) spin protocol.  This entails the use of a high-salt buffer system which 
allows up to 100 μg of RNA longer than 200 bases to bind a silica-gel-based membrane 
within an RNeasy® mini column.  Briefly 350 μl lysis buffer (‗Buffer RLT‘) was added 
directly to cells in culture, and resultant cellular suspension homogenised for 2 minutes 
by pipetting and added to a labelled eppendorrf.  350 μl of 70% ethanol was added and 
the  suspension  mixed  well.    The  sample  was  then  added  to  a  spin-column,  and 
centrifuged for 15s at ≥ 10000 rpm.  The flow-through was discarded.  350 μl of Buffer 
RW1 was added to the spin column, and the sample centrifuged for 15s at ≥ 10000 rpm 
to wash.  80μl DNase I solution (Qiagen, Crawley, UK) was added directly to the silica-12 
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gel membrane of the spin column for 15 minutes followed by a second RW1 wash.  The 
sample was then washed twice with 500 μl Buffer RPE.  Finally, the RNA was eluted 
with 50 μl RNase-free water added directly to the silica-gel membrane with subsequent 
centrifugation for 1 minute at ≥ 10000 rpm into a fresh eppendorrf.  The RNA was 
stored at -80°C.     
 
 
2.6.2.  cDNA synthesis 
The concentration of RNA was determined by measuring the absorption at 260 nm 
(A260) in a spectrophorimeter.  Then 1.5 μg RNA was added to 2 μl random primers 
(pd[N]6; Pharmacia) and the reaction volume made up to 12 μl with RNase-free dH2O.  
The sample was heated to 70°C for 5 minutes and then chilled on ice for 1 minute.  4 μl 
1
st strand buffer (Invitrogen), 2 μl 0.1M DTT (Invitrogen) and 1 μl 10mM dNTP mix 
(Gibco BRL) was mixed in gently and the sample centrifuged, followed by incubation 
at  42°C for 2 minutes.  After this  stage, 1 μl Superscript™  II  reverse transcriptase 
(Invitrogen)  was  added,  the  sample  mixed  and  incubated  at  42°C  for  1  hour.    The 
incubation temperature was increased to 55°C for 5 minutes with subsequent addition of 
1 μl RNaseH (Invitrogen) and further incubation for 10 minutes at 55ﾰC.  Resultant 
cDNA samples were stored at -20°C. 
 
2.6.3.  Design of primers 
Forward and reverse primers were designed using Oligo (v 3.4) and LightCycler Probe 
Design Software (v.1.0, Idaho Technology Inc.).  DNA/cDNA sequences were obtained 
from  the  National  Centre  for  Biotechnology  Information  (NCBI)  public  database 
(www.ncbi.nlm.nih.gov./PubMed) and exon-exon boundaries identified.  Primers were 
typically 20mer  and either crossed exon-exon boundaries  or the  amplified sequence 12 
  170 
would have at least one intervening intronic sequence to avoid amplification of genomic 
DNA.  Primers were designed for polymerase chain reaction (PCR) conditions of ≥ 3.0 
mmol.l
-1 for use with the LightCycler®. 
 
 
 
Table 2.4.  Source of DNA sequences for primer design 
 
cDNA sequence  Accession number  cDNA sequence  Accession number 
Human GAPDH  J04038  Mouse UCP3  AF032902 
Human UCP2  NM_003355 / AF019409  Mouse ACE  M55333 
Human UCP3  U84763 / AF050113  Rat GAPDH  AF106860 
Human ACE  J04144  Rat UCP2  AB017043 
Mouse GAPDH  NM_008084  Rat UCP3  U92069 
Mouse UCP2  AB012159  Rat ACE  U03734 
 
 
2.6.4.  Reverse-transcription (RT)-PCR 
RT-PCR was performed on DNA Engine Tetrad thermal cyclers (MJ Research, now 
Bio-Rad, USA).  1 μl cDNA was used in 20 μl reaction volume.  Primers were added at 
8pmol per reaction.  ‗Polmix‘ buffer containing 0.2mM dNTPs, 50mM KCL and 10mM 
Tris-HCl (pH 8.3) was added.  PCR was optimised using temperature gradients and 
magnesium titrations (2.0 – 5.0mM, ≥3.0mM for Light Cycler® work).  5 μl RT-PCR 
product was mixed with 2 μl of MADGE dye, loaded alongside a 1kB DNA ladder 
(GIBCO BRL) on 1-2% agarose gels (stained with ethidium bromide) in a gel tank 
containing 1% TRIS.  Appropriate current was applied for 30-45 minutes and gels were 12 
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visualised with UV light (GeneSnap gel documentation system, SynGene, Cambridge, 
UK). 
 
2.6.5.  Quantitative real-time RT-PCR using the LightCycler® 
The LightCycler® (Roche, Mannheim, Germany) was used to perform quantitative real-
time PCR.  cDNA was amplified using ‗FastStart DNA Master SYBR Green I‘ (Roche).  
This  is  a  ready-to-use  reaction  mix,  containing  FastStart  Taq  DNA  polymerase  (a 
modified form of thermostable recombinant Taq polymerase, whose activity is blocked 
by heat-labile blocking groups at room temperature, preventing non-specific binding of 
primers)  and  SYBR  Green  I  dye,  which  binds  specifically  to  DNA  and  whose 
fluorescence is proportional to the quantity of DNA.  The LightCycler® has a motorised 
32 sample carousel, with a heating coil/rapid air cooling system for rapid temperature 
ramping and microvolume fluorimetry system to measure sample fluorescence.  The 
machine is connected to a computer and data acquired and analysed on LightCycler 
Software (v.3.0, Roche).  Quantification in the log-linear phase of PCR amplification is 
calibrator normalised with PCR efficiency correction using the LightCycler Relative 
Quantification Software (‗RelQuant‘ v.1.0, Roche).  Standards were prepared from both 
target and reference (GAPDH) DNA sequences, by serial dilution from a starting known 
concentration (1:10, 1:100, 1:1000…etc.).  The standards were then run in triplicate by 
RT-PCR, and a standard curve plotted and exported to RelQuant (Appendix 4).  The 
samples were then run in triplicate with target and reference calibrators and negative 
controls,  with  results  exported  for  analysis  on  RelQuant  software  using  the  relative 
standard curves. 
 
 
 12 
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2.7.  STATISTICAL ANALYSES 
I  conducted  all  statistical  analyses  using  Microsoft®  Excel  (Microsoft  Corporation 
2002), SPSS for Windows v.10 (SPSS Inc. Chicago, USA) and Graphpad Prism v3.00 
(Graphpad  Software  Inc.)  on  double-password  protected  databases.    Log-
transformations were conducted for data which were not normally distributed.   Data are 
represented as mean ±standard deviation unless otherwise stated.  Two-sided tests were 
performed throughout.  For genetic studies, allele frequencies were estimated by gene 
counting. A χ
2 test was used to compare the observed numbers of each genotype with 
those expected for a population in Hardy-Weinberg equilibrium. Linkage disequilibrium 
between sites in pairwise combination was estimated (Chakravarti et al. 1984).  One 
way analysis of variance (ANOVA) and linear trend analysis was used to assess the 
effect  of  genotypes  on  baseline  characteristics,  using  either  the  raw  values  or  log 
transformed values, as appropriate.  One-way analysis of covariance (ANCOVA) was 
performed to test for confounders.  Univariate and multivariate analysis was used to 
measure  significance  of  association.    Pearson‘s  correlation  coefficient  was  used  to 
assess the degree of correlation. 
 
Complex analysis for the NPHSII study was performed by Jackie Cooper and Emma 
Hawe (departmental biostatisticians, Cardiovascular Genetics, UCL) using ‗Intercooled 
STATA‘ software (version 7.0, STATA Corporation, Texas, USA) under my direction.  
Data are reported for those individuals amongst whom high-throughput genotyping was 
successful.  There was no evidence of heteroscedacity between groups, considered via 
Bartlett‘s test.  Survival analysis with respect to genotypes was carried out using Cox‘s 
proportional hazards model, thus allowing for varying follow-up intervals and censoring 
due to competing events.  For this modelling, ‗failure time‘ was taken as the time to the 
first CHD event.  The significance of the parameters in the Cox model was assessed 12 
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using the Likelihood Ratio (LR) Test.  95% confidence intervals (CI) for the estimates 
were calculated from the standard errors assuming a normal distribution.  Results are 
presented as hazard ratios (HR) with their corresponding 95% CI and CHD event rate 
per 1000 patient years calculated from survival analysis.  To allow for differences in 
baseline data according to age and practice, age was included as  a covariate in the 
model and data stratified by practice (using the strata option in STATA).  To adjust for 
established  CHD  risk  factors,  BMI,  blood  pressure,  smoking,  diabetes,  cholesterol, 
triglyceride,  fibrinogen  and  CRP  were  also  included  as  covariates  in  the  model.  
Interactions were considered as deviations from multiplicative effects in the survival 
model.  The assumption of proportional hazards was checked by testing for a non-zero 
slope  in  a  generalized  linear  regression  of  the  scaled  Schoenfeld  residuals  on  time 
(using the stphtest command in STATA).  The relative excess risk due to interaction 
(RERI) was used as a measure of deviation from additive effects.  A value of zero 
represents  no  deviation  from  additive  effects,  and  95%  CI  were  calculated  using 
bootstrapping (Assmann et al. 1996).   
 
No adjustment was made for multiplicity of testing.  Whilst making such an adjustment 
reduces the type I error, it leads to increases in the type II error, and fewer errors of 
interpretation occur when no adjustment is made (Rothman 1990).  In all cases a P 
value of <0.05 was considered statistically significant. IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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 RESULTS CHAPTER THREE  
 
 
3  IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION 
IN THE BRADYKININ B2 RECEPTOR AND PROSPECTIVE 
CARDIOVASCULAR PHENOTYPES? 
 
Coronary heart disease (CHD) is caused by a complex interaction between environment 
(risk) and genetic background resulting in atherosclerosis, a progressive inflammatory 
disease  of  the  large  arteries,  associated  with  the  deposition  of  lipid  plaques  in  the 
arterial wall characterised by episodic erosion or rupture complicated by thrombosis and 
remodelling.  Left ventricular hypertrophy (LVH) itself is an independent risk factor for 
CHD  (Levy  et  al.  1990)  with  several  determinants  including  age,  race,  sex,  blood 
pressure  and  body  mass.    Even  after  correcting  for  such  confounders,  twin  studies 
suggest that more than 50% of LV mass in the adult has a genetic component (Swan et 
al. 2003). 
 
CHD  and  LVH  are  thus  both  complex  disorders  with  multifactorial  pathogenesis 
including a strong genetic component (Marenberg et al. 1994; Swan et al. 2003) which 
is rarely monogenic. More commonly, both will have a polygenic component, with each 
functional genetic variant contributing a variable, often minor, amount to overall risk.  
Without  genetic  variation,  the  change  in  phenotype  or  disease  risk  as  a  result  of 
exposure to the same environmental stimulus (such as smoking or hypertension) would 
be identical in all humans or directly proportional to the extent of the environmental 
stimulus.   
 
Prospective  gene-environment  studies  test  the  interaction  between  a  given 
environmental stimulus and common sequence genetic variation (polymorphism) with IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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resultant  differences  in  phenotypic  expression.    Carriage  of  each  genetic  variant  is 
subject to Mendelian randomisation.  
 
ACE activity plays an important role in the development of both LVH and CHD, and 
pharmacological inhibition of ACE activity has proven benefits in preventing coronary 
events and in the regression of LVH (Pfeffer et al. 1992; Yusuf et al. 2000; Fox et al. 
2003).  It has been accepted that many of these observations are due to alterations in 
angiotensin II generation, but bradykinin is the preferred substrate of ACE (Jaspard et 
al. 1993).  A common genetic variation in the human ACE gene exists in which the D 
allele (rather than I) is associated with higher circulating (Rigat et al. 1990) and tissue 
ACE activity (Costerousse et al. 1993; Danser et al. 1995).  The ACE D allele has been 
associated with prospective LV growth (Montgomery et al. 1997; Myerson et al. 2001; 
Jamshidi et al. 2002) and with CHD (Cambien et al. 1992).  I tested the hypothesis that 
genetic variation in the constitutive bradykinin B2 receptor (BDKRB2) may similarly 
be associated with LVH and CHD using a gene-environment approach in a prospective 
army training model of LV growth and in a large prospective study of healthy UK men. 
 
 
 
3.1  BASSINGBOURN (BIG HEART) 2 STUDY AND BDKRB2 +9/-9 GENE 
VARIANT  
The baseline characteristics are shown in Table 3.1 of the 141/212 study subjects who 
completed army training.  There was no difference in baseline characteristics between 
those who entered and those who completed the study.  There was no effect of losartan 
therapy on baseline characteristics or on LV mass change during exercise (Myerson et IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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al. 2001);  therefore  BDKRB2 genotype analyses  combined both  losartan-treated and 
untreated subjects. 
 
Basic training was associated with a significant prospective increase in LV mass (8.4 
±13.9g P<0.001), LV stroke volume (5.0 ±16.4ml P<0.001) and RV stroke volume (5.0 
±14.5ml P<0.001). 
 
Table 3.1.  Baseline characteristics of Big Heart 2 Study subjects 
 
Trait  Mean (SD) 
Age (years)  19.6 (2.4) 
Systolic blood pressure (mmHg)  117.6 (11.7) 
Diastolic blood pressure (mmHg)  66.1 (10.5) 
Body mass index (kg.m
-2)  23.1 (2.2) 
Lean mass (kg)  58.8 (6.0) 
Adipose tissue (kg)  12.2 (3.9) 
LV mass (g)  183.9 (25.1) 
BDKRB2 +9+9/+9-9/-9-9 (n) 
-9 allele frequency 
33 / 60 / 16 
0.422 [0.356-0.488] IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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Of the study subjects, 109/141 (77%) were successfully genotyped for the BDKRB2 
(+9/-9)  gene  variant.    The  genotype  frequency  (Table  3.2)  was  consistent  with  the 
Hardy-Weinberg equilibrium (χ
2=1.8; P=0.18) and rare (-9) allele frequency (0.422) 
was similar to previous reports (Houle et al. 2000).  The (-9) allele frequency was 0.49 
and similar to previous published reports for a white Caucasian population (Lung et al. 
1997; Brull et al. 2001).  There was no association between BDKRB2 genotype and any 
baseline  characteristic  including  LV  mass  (Table  3.3).    In  particular  there  was  no 
association with DBP or SBP. 
 
BDKRB2 genotype was associated with LV growth response (a gain of 4.6 ±11.3g vs. 
8.3 ±13.1g vs. 13.7 ±13.9g for the 16, 60 and 33 individuals of -9/-9 , -9/+9 and +9/+9 
genotypes respectively: ANOVA P=0.06, linear trend  P=0.02; Table 3.3, Figure 3.1)  
and this persisted after adjustment for lean body mass (Brull et al. 2001). 
 
BDKRB2 +9/+9 subjects had larger right and left end-diastolic and end-systolic volumes 
after  training,  reflected  in  greater  increases  in  stroke  volume  related  to  training, 
significant for the right ventricle (Table 3.3).   
 
As previously published, ACE genotype was significantly associated with prospective 
LV  growth  (ACE  II  4.3  ±14.1g  vs.  DD  11.5  ±12.9g  P=0.02).    Tests  for  statistical 
interaction demonstrated that ACE and BDKRB2 genotypes interacted additively, with 
growth being greatest amongst those of DD/+9+9 genotype (lowest kinin and BDKRB2 
activity),  and  least  amongst  those  of  II/-9-9  genotype  (highest  kinin  and  BDKRB2 
levels):  15.7  ±14.2g  vs.  –1.4  ±10.7g  respectively:  P=0.009  for  comparison  of 
homozygotes: P=0.003 across all genotypes; Figure 3.2). Although the numbers were 
small,  subgroup  analysis  suggested  evidence  of  biological  interaction  when  the IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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influence  of  BDKRB2  genotype  was  examined  separately  according  to  ACE 
homozygosity.  Amongst those of II genotype, LV growth rose by –1.4 ±10.7g, 6.2 
±11.6g  and  11.5  ±13.6g  for  those  of  BDKRB2  -9/-9,  -9/+9  and  +9/+9  genotype 
respectively (P=0.02). However, such a gradient was far less clear (9.3 ±10.7g, 9.7 
±14.1g and 15.7 ±14.2g) amongst those of DD genotype, and failed to reach statistical 
significance (P= 0.18). 
 
 
Table 3.2.  Baseline characteristics of Big Heart 2 Study sample by BDKRB2 +9/-9 
gene variant 
 
Trait 
BDKRB2 +/-9 Genotype 
+9/+9 
n = 33 
+9/-9 
n = 60 
-9/-9 
n = 16 
Age (years)  19.3 (2.1)  19.6 (2.2)  19.8 (2.4) 
Systolic blood pressure (mmHg)  117.0 (11.9)  118.4 (10.7)  121.6 (10.4) 
Diastolic blood pressure (mmHg)  63.2 (8.9)  64.8 (10.4)  68.5 (9.2) 
Body mass index (kg.m
-2)  22.9 (1.9)  23.2 (2.2)  22.7 (2.4) 
Lean mass (kg)  58.4 (4.1)  59.3 (6.7)  55.8 (6.1) 
Adipose tissue mass (kg)  11.7 (4.1)  12.4 (3.8)  11.3 (3.7) 
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Table 3.3.  Training related changes in cardiac parameters by BDKRB2 +9/-9 
genotype and ACE/BDKRB2 haplotypes 
 
Cardiac traits  
BDKRB2 +9/-9 Genotype   
P 
ANOVA 
 
P 
Linear 
-9/-9  -9/+9  +9/+9 
LV mass pre-training (g)  180.0 (19.8)  184.2 (27.3)  181.9 (24.6)  0.82  0.93 
LVMI
LM pre-training (x10
-3)  3.25 (0.26)  3.13 (0.35)  3.11 (0.39)  0.43  0.27 
LV mass post training (g)  184.6 (22.0)  192.5 (28.2)  195.6 (22.8)  0.38  0.19 
LVMI
LM post training (x10
-3)  3.26 (0.35)  3.16 (0.36)  3.30 (0.34)  0.24  0.47 
Change in LV mass (g)  4.6 (11.3)   8.3 (13.1)  13.7 (13.9)  0.06  0.02 
Change in LV mass (%)  2.7 (6.4)   4.8 (7.2)  8.1 (8.5)  0.04  0.01 
Change in LVMI
LM (%)  0.1 (5.3)  2.3 (7.7)  5.8 (9.1)  0.06  0.02 
Change in LV stroke volume 
(%)  2.36 (27.0)  10.8 (23.5)  13.5 (19.1)  0.28  0.14 
Change in RV stroke volume 
(%)  3.1 (23.1)  8.8 (21.2)  16.5 (18.0)  0.08  0.03 
  BDKRB2 / ACE haplotypes * 
P 
ANOVA 
P 
Linear 
trend    -9-9 II 
N=7 
-9-9 DD 
N=9 
+9+9 II 
N=16 
+9+9 DD 
N=17 
LV mass pre-training (g)  176.0 
(21.2) 
183.1 
(19.4) 
181.4 
(24.5) 
182.5 
(25.4)  0.8  0.7 
LVMI
LM pre-training (x10
-3)  3.20 (0.32)  3.28 (0.24)  3.10 (0.41)  3.12 (0.37)  0.4  0.1 
LV mass post training (g)  174.6 
(15.1) 
192.4 
(24.1) 
192.9 
(26.2) 
198.2 
(19.6)  0.9  0.5 
LVMI
LM post training (x10
-3)  3.14 (0.35)  3.35 (0.35)  3.21 (0.36)  3.38 (0.31)  0.3  0.3 
LV mass change (g)  -1.4 (10.8)  9.3 (10.7)  11.5 (13.6)  15.7 (14.2)  0.07  0.003 
LV mass change (%)  -0.4 (6.0)  5.0 (6.0)  6.6 (7.9)  9.4 (9.1)  0.05  0.001 
LV MI
LM change (%)  -1.9 (5.0)  1.6 (5.3)  3.6 (7.5)  8.0 (10.2)  0.03  0.001 
* Homozygotes only shown, statistics calculated on all genotypes 
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Figure 3.1.  Proportional change in LV mass as assessed by CMR according to 
BDKRB2 +9/-9 genotype in the BH2 study. 
Figure 3.2.  Proportional change in LV mass as assessed by CMR in the BH2 study 
in recruits grouped according to BDKRB2 +9/-9 and ACE I/D genotypes. 
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3.2  NPHSII AND THE BDKB2 GENE VARIANT (DHAMRAIT ET AL. 2003) 
 
BDKRB2  genotype  was  obtained  for  2364  (87.4%)  participants  and  genotype 
frequencies  were  as  expected  for  a  population  in  Hardy-Weinberg  equilibrium 
(χ
2=0.003; P=0.96; Table 3.4).  There was no difference in baseline characteristics in 
those genotyped and those not successfully genotyped for the BDKRB2.  The (-9) allele 
frequency was 0.49 and similar to previous published reports for a white Caucasian 
population  (Lung  et  al.  1997)  and  to  the  BH2  study  (Brull,  Dhamrait  et  al  2001).  
Baseline characteristics did not vary by BDKRB2 genotype.  In particular, there was no 
association with DBP or SBP.  The (-9) allele frequency was 0.50 and 0.48 amongst 
normotensives and subjects with systolic hypertension at baseline (P=0.59) and there 
was no association with the development of hypertension over the follow up period.  
There was no difference in BDKRB2 genotype between cases and controls (-9 allele 
frequency 0.51 and 0.49 respectively, P=0.20). 
 
Cardiovascular  event  probability  in  relation  to  increasing  systolic  blood  pressure  is 
shown in Figure 3.3a, demonstrating the expected strong relationship between elevated 
blood pressure and CHD event rate.  For further analysis of the effects of genotype in 
relation to hypertension, subjects were also divided into normotensive or hypertensive 
(SBP≥160mmHg, DBP≥95mmHg) groups as defined at the onset of the trial (Miller et 
al. 1995).  
 
Coronary  event  probability  in  relation  to  increasing  SBP  in  subjects  divided  by 
homozygosity  for  the  BDKRB2  variant  is  depicted  in  Figure  3.3b.  Risk  increased 
significantly with increasing blood pressure in (+9,+9) and (+9,-9) groups, but there was 
no  significant  increase  risk  amongst  (-9,-9)  carriers  (hazard  ratio  for  a  1  standard IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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deviation increase in SBP 1.58 [1.18-2.11]; P=0.002, 1.33 [1.09-1.61]; P=0.004 and 
1.12[0.82-1.52]; P=0.47 for (+9,+9), (+9,-9) and (-9,-9) respectively).  There was no 
significant  association  between  BDKRB2  genotype  and  cardiovascular  events  in  the 
study overall.  Amongst normotensives, compared to the (+9,+9) men, the CHD event 
rate tended to be higher in those carrying one or more (-9) alleles (HR 1.67 [1.05–2.64]; 
P=0.03) and this effect was statistically significant in the larger (+9,-9) heterozygote 
group normotensive at baseline (HR (+9,+9): 1.0; (+9,-9): 1.70 [1.05–2.74];p=0.03).  
However, as shown in Table 3.5, hypertension significantly increased the cardiovascular 
risk in BDKRB2(+9,+9) individuals when compared to their normotensive counterparts 
(HR 3.51 [1.69-7.28]; P=0.001 and HR 2.65 [1.31 – 5.38]; P=0.007 for systolic and 
diastolic hypertension respectively), but not in BDKRB2(-9,-9) homozygotes (HR 1.25 
[0.51-3.04];  P=0.63  and  HR  1.23  [0.62  –  2.44];  P=0.55  for  systolic  and  diastolic 
hypertension respectively, with P=0.21 for the interaction of BDKRB2 genotype, SBP 
and risk).   Risk estimates for homozygotes remained significant after adjustment for 
other CHD risk factors (Table 3.5) and when CHD events were confined to acute (fatal 
and non-fatal) MI events. 
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Table 3.4.  Baseline characteristics of men from NPHS II according to BDKRB2(+9, -9) genotype. 
 
Trait 
BDKRB2(+9, -9) genotype 
(+9,+9) 
n = 607 
(+9,-9) 
n = 1183 
(-9,-9) 
n = 574  Probability 
Age (years)  55.8 (3.4)  56.1 (3.5)  56.0 (3.5)  0.23 
Systolic blood pressure (mmHg)  138.3 (20.0)  137.9 (18.9)  137.9 (19.4)  0.92 
Diastolic blood pressure (mmHg)  84.6 (12.0)  84.2 (10.7)  84.6 (12.2)  0.69 
Body mass index (kg.m
-2)  26.2 (3.3)  26.5 (3.6)  26.5 (3.4)  0.24 
Current smoking % (n)  29.2% (177)  31.0% (365)  26.1% (150)  0.13 
Diabetes % (n)  2.1% (13)  2.1% (25)  2.6% (15)  0.79 
Cholesterol (mmol.l
-1)  5.75 (1.01)  5.76 (1.01)  5.68 (1.00)  0.32 
Triglyceride (mmol.l
-1) *  1.78 (0.95)  1.79 (0.94)  1.77 (0.94)  0.95 
 
Data are mean (SD) unless otherwise stated.  
*For triglyceride, the mean is geometric (approximate SD). 
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Table 3.5. Coronary heart disease (CHD) events in subjects stratified by presence of systolic hypertension (SBP≥160mmHg) by BDKRB2(+9,-
9) genotypes.  Relative hypertensive risk is CHD risk of hypertensive vs. normotensive subjects within each respective genotype group. 
 
BDKRB2 
Genotype 
Normotensives 
SBP<160mmHg 
Events / Total No. 
(Events per 1000 
patient years) 
Hypertensives 
SBP>160mmHg 
Events / Total No. 
(Events per 1000 
patient years) 
 
Relative  
Hypertensive Risk* 
 [95% CI] 
 
Probability 
 
Adjusted 
Relative  
Hypertensive Risk
† 
 (95% CI) 
 
Probability 
 
 (+9,+9) 
 
 
(+9,-9) 
 
 
(-9,-9) 
 
22 / 514 (4.6) 
 
 
73 / 1016 (7.8) 
 
 
33 / 498 (7.2) 
 
13 / 93 (16.0) 
 
 
22 / 165 (16.0) 
 
 
6 / 76 (8.8) 
 
3.51 
[1.69 – 7.28] 
 
1.87 
[1.15 – 3.03] 
 
1.25 
[0.51 – 3.04] 
 
0.001 
 
 
0.01 
 
 
0.63 
 
3.17 
[1.46 – 6.87] 
 
1.49 
[0.90 – 2.46] 
 
1.15 
[0.46 – 2.88] 
 
0.003 
 
 
0.12 
 
 
0.77 
 
* Risk adjusted for age and smoking for BDKRB2 genotypes.  
† Risk adjusted for age, practice, smoking, diabetes, body mass index, cholesterol, triglycerides. 
SBP indicates systolic blood pressure; BDKRB2, bradykinin B2 receptor. IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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Figure 3.3.  Association between systolic blood pressure at recruitment in NPHS II 
and CHD amongst  
 
a.  all subjects 
b.  men stratified by homozygosity for the BDKRB2 (+9,-9) variant 
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3.3  DISCUSSION 
 
The BDKRB2 (+9/-9) gene variant was associated with both prospective LV growth and 
prospective CHD risk. 
 
BDKRB2(+9/-9) and prospective LV growth 
To  date,  few  genetic  loci  have  been  associated  with  prospective  LV  growth 
(Montgomery  et  al.  1997;  Myerson  et  al.  2001;  Jamshidi  et  al.  2002).    That  now 
reported for the  BDKRB2 (+9/-9) polymorphism  contributed to  4% of the  observed 
interindividual variability.  These data provide important mechanistic insight.  Both LV 
ACE activity (Danser et al. 1995) and circulating kinin concentrations (Murphey et al. 
2000)  are  dependent  on  ACE  genotype.    The  resultant  difference  in  local  kinin 
concentration acts upon genetically (BDKRB2 genotype) determined levels of receptor 
(Lung et al. 1997).  These data demonstrate a role for BDKRB2 genotype in determining 
LV growth response, and suggest that alterations in kinin concentrations (marked by the 
ACE genotype) and kinin-receptor transcription (marked by BDKRB2 genotype) interact 
biologically in an additive way.  These data support those from in vivo animal and in 
vitro  cell  culture  studies  that  kinins  exert  antitrophic  effects  through  the  BDKRB2 
present on cardiomyocytes (Linz et al. 1996) and vascular endothelial cells (Rosenkranz 
et al. 1999).  In animal models, the antihypertrophic effects of ACE inhibition may be 
substantially accounted for by increases in local kinin levels (Zhu et al. 1996) whereas 
BDKRB2  gene  knockout  mice  develop  LVH  (Emanueli  et  al.  1999).    These  data 
therefore  support a role for bradykinin in  the  regulation of  human  LV  growth, and 
suggest that the effects of ACE could be partly mediated through alterations in kinin 
concentrations.  Nonetheless, care must be taken in the extrapolation of these findings to 
the genesis of pathological hypertrophy, in which the magnitude of the role of kinins IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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might differ. These data could also have implications for the treatment of patients with 
pathological LVH.   
 
The development of LVH is an independent risk factor for CHD (Levy et al. 1990) and 
its development has been shown to be ACE I/D genotype dependent (Montgomery et al. 
1997; Myerson et al. 2001).  This study has now shown that BDKRB2(+9/-9) genotype 
is  also  associated  with  prospective  LV  growth  in  healthy  adult  men  undergoing 
strenuous  physical  exercise,  with  a  significant  interaction  with  ACE  I/D  genotype.  
Could  BDKRB2(+9/-9)  genotype  also  be  associated  with  prospective  CHD  risk, 
particularly in individuals in whom a hypertrophic stimulus, such as hypertension, is 
present?    In  NPHSII,  the  cardiovascular  risk  associated  with  hypertension  amongst 
middle-aged men was influenced by functional variation in the BDKRB2 gene: CHD 
risk climbed steeply as blood pressure increased in the presence of the BDKRB2(+9) 
allele – an effect not identified amongst those homozygous for the BDKRB2(-9) allele.  
The impact of genotype was exemplified by the substantial elevation of risk amongst 
those suffering systolic hypertension (≥160mmHg, as dichotomously defined at trial 
inception  some  14  years  ago).    Even  when  modern  definitions  are  applied  (e.g. 
SBP≥140mmHg)  the  impact  of  genotype  on  risk  remained  statistically  significant.  
These findings persisted after multivariate adjustment for all potential confounders, and 
genotype  was  unrelated  to  the  presence  or  development  of  hypertension  itself,  in 
keeping with past observations (Gainer et al. 2000).  These are the first prospective data 
to demonstrate a role for the BDKRB2 in pathogenesis of human coronary vascular 
disease.  
 
Genotype strongly influenced the CHD risk associated with hypertension, whilst risk 
was genotype-independent amongst normotensives.  These observations are consistent IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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with  the  previously-reported  excess  frequency  of  another  BDKRB2  polymorphism 
(BDKRB2-58C  rather  than  -58T)  amongst  hypertensive  (rather  than  normotensive) 
sufferers of acute MI (Aoki et al. 2001).  Such a phenomenon may relate to a genotype-
dependent  difference  in  (potentially  protective)  receptor  upregulation  in  the 
hypertensive state.  Plaque growth and risk of rupture correlate strongly with the levels 
of pro-inflammatory markers, through which ‗classical‘ risk factors may partly mediate 
their effects (Farmer et al. 2002).  Hypertension is similarly associated with a systemic 
(Koenig et al. 1999) and local vascular (Parissis et al. 2000) inflammatory response 
which, through interleukin-driven activation of NF-κβ, induces (potentially protective) 
vascular BDKRB1 expression (Ni et al. 1998).  Indeed, β1 (and, to a lesser extent β2) 
receptors  are  highly  expressed  in  the  atheromatous  plaque  (Raidoo  et  al.  1997).  
Whether BDKRB2 expression may be similarly modulated is, however, not known. 
 
Altered activity in the human coronary vascular KKS (Kichuk et al. 1996) might also 
underlie these findings.  Kallikreins catalyse the conversion of kininogens to autacoid 
peptide kinins such as bradykinin and Lys-bradykinin, whose subsequent cleavage of 
the C-terminal arginine residue by carboxy-peptidase yields the fragments des-Arg
9-
bradykinin and Lys-des-Arg
9-bradykinin.  Intact kinins and their fragments act upon the 
β1 and β2   G-protein coupled cell-surface receptors, which share only 36% sequence 
homology and differ greatly in their expression and pharmacology (Regoli et al. 1997).  
Thus, the constitutive BDKRB2 is expressed in diverse cell types including those of the 
endothelium,  and  is  responsive  to  intact  kinin  peptides  (Faussner  et  al.  1999).  
Conversely, the inducible BDKRB1 is activated by C-terminal arginine-deficient kinin 
fragments (Faussner et al. 1999).  The (-9) variant of the BDKRB2 gene is associated 
with greater BDKRB2 gene promoter activity (Braun et al. 1996) and mRNA expression 
(Lung et al. 1997).  These functional effects may underlie the reported associations with IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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clinical disease states: the BDKRB2(-9) allele is associated with symptomatic hereditary 
angioedema in cases of C1 inhibitor deficiency (Lung et al. 1997) and now with lower 
cardiac physiological hypertrophic responses. 
 
These data offer some insight into the mechanisms of atherosclerosis, with the genotype 
predicted  to  lead  to  higher  BDKRB2  expression/activity  seemingly  associated  with 
reduced cardiovascular risk in the hypertensive state.  KKS protection may be mediated 
through a number of potential mechanisms including BDKRB2-mediated inhibition of 
vascular smooth muscle cell growth (Murakami et al. 1999), coronary vasodilatation 
(Su et al. 2000), and local nitric oxide synthesis (Kichuk et al. 1996).  KKS activation 
also  exerts  a  potent  anti-thrombotic  role.    Factor  XII  activation  and  prekallikrein 
activation participate in a positive feedback loop, leading to rapid bradykinin release 
(Schmaier 2000). This stimulates formation of tissue plasminogen activator and nitric 
oxide release, whilst kininogen breakdown products act as antithrombins.  KKS activity 
therefore exerts antiadhesive, anticoagulant, and profibrinolytic effects, and can inhibit 
platelet activation at low thrombin concentrations (Colman et al. 1999). Thus, kinins 
(and, via this mechanism, the use of ACEi) may prevent coronary thrombosis (Schmaier 
2000).  
 
These  results  also  offer  important  insight  into  the  mechanisms  underlying  the 
cardiovascular protective action of drugs which target the RAAS.  Treatment with ACEi 
not only impairs kinin degradation, raising  kinin levels in vivo (Swartz et al. 1980), but 
also mediates cross-talk between membrane-bound ACE and the BDKRB2, leading to a 
reduction in BDKRB2 desensitisation, reduced receptor endocytosis and an increase in 
bradykinin receptor affinity (Minshall et al. 1997).   Moreover, selective AT1R blockade 
also raises tissue kinin levels and may influence crosstalk (through heterodimerisation) IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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between AT1 receptors and bradykinin receptors (AbdAlla et al. 2000).  These data 
would suggest that these phenomena may contribute to the marked vasculoprotective 
effects associated with ACE inhibition (Yusuf et al. 2000) and, perhaps, with ARB use 
(Dahlof et al. 2002). Such data suggest potential gains in cardiovascular risk reduction 
from the combined use of ARBs with ACEi, or from the use of newer drugs, such as the 
neutral endopeptidase-ACEi class, which greatly increase kinin levels. 
 
A  drawback  of  the  study  is  that  no  detailed  information  about  the  specific 
cardiovascular  medication  received  at  baseline  and  after  enrolment  is  currently 
available.    However,  the  use  of  specific  RAAS  antagonists  was  uncommon  in  the 
timeframe of study (NPHSII was started in 1989), since their putative role in primary 
prevention had not yet been elucidated.  No treated hypertensives, nor patients with 
heart failure, were included at the onset of the study.  The study was initiated well over 
20 years ago and, at this time, these were the only two indications for therapy with 
ACEi,  and  ARBs  were  not  yet  available.  Thus,  there  was  no  potential  for 
pharmacogenomic interaction at the outset. Similarly, the onset of heart failure (leading 
to ACEi treatment) would have necessitated development of one of the documented 
clinical endpoints (such as myocardial infarction), and as such could not have operated 
as a confounder.  Meanwhile, the use for other reasons (such as diabetic nephropathy, or 
primary cardiovascular prevention) was not accepted during most of this timeframe and 
would, in any event, have applied to only a few individuals.  Thus, it is unlikely that 
therapy with these (or other) agents could account for any differences observed, given 
that prescription would have had to have been strongly predicated by genotype to act as 
a  significant  confounder-  and  most  indications  for  treatment  would  have  been 
documented  as  a  study  endpoint.    Evidently,  however,  one  might  postulate  that 
hypertension itself may have been an active confounder leading to pharmacogenomic IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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interaction.  However, this is unlikely: analysis shows no association of the candidate 
genotypes  with  hypertension-  whether  defined  as  a  categorical  variable,  or  as  a 
continuous trait.  In support of the lack of confounding associations, the survival plots 
indicate divergence by genotype early on in the trial.  Nonetheless, pharmacogenomic 
studies would be warranted given the mechanistic implications of the data. 
 
In  summary,  I  have  presented  novel  associations  between  the  BDKRB2(+9)  allele 
(associated with reduced receptor mRNA expression) and both an enhanced prospective 
human  left  ventricular  hypertrophic  response  and  with  prospective  coronary  artery 
disease  only  amongst  hypertensives.    This  suggests  common  mechanisms  through 
which the deleterious effects of hypertension on LVH and CHD may be mediated. THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
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 RESULTS CHAPTER FOUR  
 
 
4  THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
PERFORMANCE. 
4.   
 
In Chapter 3, novel associations between genetic variation in the BDKRB2 and both 
prospective human left ventricular hypertrophic response and prospective hypertensive 
CHD risk were described, providing insight into the mechanism of action of ACEi in 
heart  disease.    Pharmacological  inhibition  of  ACE  has  long  been  associated  with 
reductions in cardiovascular mortality and morbidity, but it is now clear that ACEi have 
biological effects beyond simple blood pressure reduction (Flather et al. 2000; Dzau et 
al. 2001;  Mathew et  al. 2001), including additional metabolic effects  as  detailed in 
Section 1.7.  Both animal and human studies suggest an improvement in metabolic 
efficiency  of  both  skeletal  and  cardiac  muscle  following  treatment  with  ACEi 
(Imaizumi et al. 1990; Gohlke et al. 1994; Nascimben et al. 1995; Sanbe et al. 1995; 
Watanabe et al. 1997; Hugel et al. 1999; Yamaguchi et al. 1999; Gambassi et al. 2000; 
Divisova et al. 2001; Onder et al. 2002).  Could an increase in local kinin activity be 
responsible for some of these observations?  Prospective gene-environment studies are a 
useful tool that can answer some of these questions. 
 
Global indices of human athletic performance (Rankinen et al. 2002), as well as more 
precise measures of human skeletal muscle function (Thomis et al. 1998), are strongly 
influenced by genetic as well as environmental factors.  To date, few genetic loci of 
influence have been identified (Yang et al. 2003).  One such is the gene for angiotensin-
I converting enzyme (ACE) (Montgomery et al. 1998; Myerson et al. 1999; Folland et THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
PERFORMANCE. 
  193 
al. 2000; Williams et al. 2000; Woods et al. 2001).  As detailed in Section 1.7.1, a 
common genetic variation in the human ACE gene exists in which the I allele (rather 
than D) is associated with lower circulating (Rigat et al. 1990) and tissue ACE activity 
(Costerousse et al. 1993; Danser et al. 1995).  The ACE I allele has been associated with 
an  anabolic  response  to  exercise  training  (Montgomery  et  al.  1999)  and  with  an 
increased training-related gain in fatigue resistance (Montgomery et al. 1998) and in 
contractile efficiency (Williams et al. 2000), whereas the D-allele has been associated 
with improvements in strength (Folland et al. 2000).  Similarly, the I-allele is associated 
with elite endurance performance at both sea-level (Myerson et al. 1999) and at altitude 
(Montgomery et al. 1998), and the D-allele with performance over shorter distances in 
runners, rowers, and swimmers (Myerson et al. 1999; Brull et al. 2001).   
 
However, there is some contradictory evidence regarding the influence of the ACE gene 
on endurance performance (Taylor et al. 1999; Rankinen et al. 2000).  Serum ACE 
activity appears to remain relatively constant during both acute and prolonged exercise 
with regards to ACE genotype (Woods et al. 2004; Huang et al. 2007), but it is not 
known  whether  tissue  ACE  activity  remains  constant  for  an  individual  or  changes 
during  exercise  training  and  if  any  changes  are  ACE  I/D  genotype  dependent.  
Furthermore,  the  ACE  gene  is  separated  by  approximately  370kb  from  the  growth 
hormone gene cluster, and it has been postulated that some of the observed effects may 
be due to linkage disequilibrium with genes within this cluster.  Phenotype associations 
with  the  downstream  effector  peptides  of  the  RAAS,  such  as  angiotensin  II  and 
bradykinin, may help to strengthen any such association with ACE.  However, there are 
no such human data relating the BDKRB2 to physical performance. 
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If the effects of ACE on human skeletal muscle function and its role in influencing more 
global  aspects  of  performance  are  mediated  through  bradykinin,  then  we  might 
anticipate  BDKRB2  genotype  to  be  similarly  associated  with  muscle  function  and 
performance.  A prospective gene-environment approach was therefore used to test the 
hypotheses  that  common  variation  in  the  BDKRB2  gene  is  associated  with  skeletal 
muscle  contractile  efficiency  and  with  competitive  running  distance  in  Olympic 
standard athletes. 
 
 
4.1.  HUMAN PHYSICAL PERFORMANCE  
Subjects  were  drawn  from  two  sources:    young  healthy  male  British  army  recruits 
undergoing  basic  army  training  and  young  healthy  female  volunteers  from  the 
University of Staffordshire who underwent an endurance training programme (Methods 
section  2.1.4).    Of  the  131  subjects  (89  male,  42  female)  who  had  baseline  delta 
efficiency (DE) measured, 85 (65%) subjects completed training (either basic army or 
structured).  There was no difference in baseline characteristics (male age 19.4 ±2.5yr, 
height 1.78 ±0.06m, body mass index [BMI] 22.8±2.4 kg.m
-2; female age 23.2 ±6.2yr, 
height 1.66 ±0.06m, BMI 24.3 ±3.1kg.m
-2) between those who did and did not complete 
training.  Of those with complete data, mean DE was 24.6 ±2.6%, and there was no 
association of gender, age, height, mass or BMI with either DE or change in DE.  DE 
and change in DE were normally distributed (Figure 4.1) 
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Figure 4.1.  Distribution of baseline delta efficiency and training related changes in 
delta efficiency. 
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Table 4.1.  Baseline delta efficiency according to BDKRB2 (+9/-9) genotype in the 
study subjects overall and in those homozygous for the ACE I/D polymorphism. 
 
BDKRB2 
Genotype 
Delta efficiency% (sd; n) 
ACE DD, n=45  ACE II, n=52  Overall, n=115 
 
+9+9 
 
23.45 (2.81; 8) 
 
24.34 (2.51; 11) 
 
23.84 (2.41; 25) 
+9-9  24.06 (3.15; 12)  24.26 (2.41; 32)  24.25 (2.81; 61) 
-9-9  25.30 (1.65; 15)  27.41 (2.61; 9)  26.05 (2.26; 29) 
 
+9 allele 
 
23.90 (3.03; 20) 
 
24.28 (2.41; 43) 
 
24.13 (2.69; 86) 
 
ANOVA 
0.233  0.005  0.003 
Linear trend  0.097  0.013  0.002 
+9 allele vs. -9-9  0.104  0.0008  0.001 THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
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 BDKRB2  (+9/-9)  genotyping  was  successful  in  115/131  (88%,  with  42  female)  of 
subjects  with  genotype  distribution  (29  vs.  61  vs.  25  for  -9/-9  vs.  -9/+9  vs.  +9/+9) 
consistent with Hardy-Weinberg equilibrium (Table 4.1) and similar to that previously 
reported (Braun et al. 1996; Lung et al. 1997) and to the Bassingbourn 2 and NPHSII 
studies  (Chapter  3).    Age,  height,  mass  and  BMI  were  independent  of  BDKRB2 
genotype.   
 
DE prior to training was highly significantly associated with BDKRB2 genotype (24 
±3% vs. 24 ±3% vs. 26 ±2% for those of +9/+9 vs. +9/-9 vs. -9/-9 genotype respectively, 
P = 0.003 by ANOVA, P = 0.001 for +9 allele vs. -9/-9 carriers; Table 4.1).  This 
significance increased after adjustment for sex (P = 0.0008 for ANOVA), and the data 
remained significant after adjustment for all demographic data (P = 0.003 for ANOVA).   
Multivariate analysis, including sex as a covariate, suggested that BDKRB2 genotype 
accounted for 11% of the inter-individual variability in pre-training DE.  There was no 
association between BDKRB2 genotype and training related changes in DE. 
 
 
 
As previously reported, there was no association between ACE genotype and DE at 
baseline  (Williams  et  al.  2000).    We  sought  to  examine  whether  there  was  any 
biological interaction between ACE and BDKRB2 genotypes in influencing DE prior to 
training (Table 4.1; Figure 4.2).  Amongst the 45 of ACE DD genotype, there was no 
significant difference in DE according to BDKRB2 -9/-9 homozygotes (24 ±3% vs. 24 
±3%  vs.  25  ±2%  for  +9/+9  vs.  +9/-9  vs.  -9/-9,  respectively).    However,  BDKRB2 
genotype  significantly  influenced  DE  for  those  individuals  who  were  of  ACE  II 
genotype (24 ±3% vs. 24 ±2% vs. 27 ±3% for +9/+9 vs. +9/-9 vs. -9/-9 respectively, P = THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
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0.005 by ANOVA, P = 0.0008 for +9 allele vs. -9/-9 carriers).  DE was associated with 
ACE/BDKRB2  ranked  genotypes  (P=0.004  for  linear  trend  adjusted  for  gender, 
genotype  groups  ranked  according  to  Figure  4.2).    DE  was  significantly  higher  in 
individuals with the highest predicted kinin receptor activity (ACE II, BDKRB2 -9/-9) 
compared  to  lowest  kinin  receptor  activity  (ACE  DD,  BDKRB2  +9/+9;  P  =  0.0007 
ANOVA adjusted for gender).  
 
 
 
Figure 4.2.   Baseline delta efficiency according to BDKRB2 (+9/-9) genotype in 
study subjects homozygous for the ACE I/D polymorphism 
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4.2.  BRITISH OLYMPIC ATHLETES 
 
DNA was available for 86/91 (95%) of the original sample of elite runners drawn from 
athletes selected for competition by the British Olympic Association in 1998 (Methods 
2.1.5).  Nine athletes were of Afro-Caribbean descent of whom, 7 competed at track 
disciplines deemed to be predominantly anaerobic (<400m distance) and two competed 
at middle distance (400-3000m). 
 
The  BDKRB2  (+9/-9)  genotype  distribution  was  consistent  with  Hardy-Weinberg 
equilibrium and rare (-9) allele frequency (0.46 [0.39-0.54]) similar to previous reports 
(Braun et al. 1996; Lung et al. 1997; Brull et al. 2001).  Amongst the 81 runners, 
analysis revealed a linear trend of increasing -9 allele frequency with distance run.  The 
proportion of -9 alleles increased from 0.382 to 0.412 to 0.569 for those athletes running 
≤200 m (n
 = 17), 400-3000 m (n = 35), and ≥5000 m (n = 29), respectively
 (P=0.04 for 
comparison of ≤5000 m vs. ≥5000 m).  ACE and BDKRB2 combined genotype analysis 
demonstrated a significant relationship with distance run (≤5000 m vs. ≥5000 m) both 
overall (P=0.001 Fisher‘s exact test) and for Caucasians only (P=0.003), with a greater 
proportion of ‗low kinin receptor activity‘ (ACE D and BDKRB2 +9 allele) activity in 
events shorter than 5000 m and, conversely, a greater proportion of ‗high kinin receptor 
activity‘  combined  genotypes  (ACE  I  and  BDKRB2  -9  alleles)  competing  in  events 
greater than 5000 m (Figure 4.3). 
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Figure 4.3.  ACE/BDKRB2 combined genotypes by running distance in BOA study 
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4.3  DISCUSSION 
 
There were highly significant associations between the BDKRB2 -9 (rather than +9) 
allele  and  skeletal  muscle  metabolic  efficiency,  and  also  with  endurance  athletic 
performance.    Moreover,  these  associations  were  greatest  amongst  individuals  with 
highest kinin receptor activity as marked by the ACE I (high kinin ligand generation) 
allele (Murphey et al. 2000) and BDKRB2 -9 (high receptor expression) allele (Lung et 
al. 1997).  Such data support recent linkage analyses which suggest an effect of a locus 
near to the BDKRB2 gene on performance-related phenotypes such as cardiac output 
and stroke volume (Feitosa et al. 2002).  
 
Such data are important for two reasons.  Firstly, it has been suggested that the ACE I/D 
polymorphism is in strong allelic association with functional variants in adjacent genes THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
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(such as that for growth hormone, GH), and that these (and not ACE phenotype) are 
responsible for the observed associations with ACE genotype (Rankinen et al. 2000).  
However, these data suggest this is not the case, given the demonstration of a similar 
(and biologically plausible) effect of a downstream receptor.  In this regard, these data 
support past studies suggesting such linkage disequilibrium to be unlikely (Montgomery 
et al. 1998; Williams et al. 2000).  Secondly, the ACE I-allele has been associated with 
increased metabolic efficiency (Williams et al. 2000) and with endurance performance 
(Gayagay et al. 1998; Montgomery et al. 1998; Myerson et al. 1999), and these are the 
first  data  to  implicate  a  specific  underlying  mechanism.    At  least  some  of  these 
associations  between  ACE  genotype  and  performance  seem  mediated  through 
alterations in kinin activity at the BDKRB2, given that the ACE I-allele is associated 
with increased kinin activity (Murphey et al. 2000), and that a genetic marker of higher 
kinin receptor expression (Braun et al. 1996; Lung et al. 1997) is  now associated with 
the same performance phenotypes.  Association with other genetic variants (such as the 
-58C>T  promoter  variant)  or  haplotypes  in  the  BDKRB2  gene  should  be  sought  as 
confirmation  of  these  data.    Further  in  vivo  work  is  also  required  to  relate  the 
ACE/BDKRB2  haplotypes  to  kinin  metabolism  and  responses.    However,  these 
haplotypic  data  do  support  our  previous  observation  relating  these  ACE/BDKRB2 
haplotypes to prospective exercise-induced left ventricular growth (Brull et al. 2001).   
 
Skeletal muscle contains a complete KKS (Mayfield et al. 1996), can liberate kinins 
locally (Langberg et al. 2002), and expresses functional B2 receptors (Figueroa et al. 
1996; Rabito et al. 1996).  However, it is not yet clear precisely how kinin activity 
affects  the  endurance  performance  phenotypes  studied  here.    Bradykinin  generated 
within exercising skeletal muscle (Langberg et al. 2002) may influence muscle blood THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
PERFORMANCE. 
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flow and skeletal muscle glucose uptake (Wicklmayr et al. 1983).  In fact, through the 
BDKRB2 (Taguchi et al. 2000), bradykinin enhances insulin-stimulated tyrosine kinase 
activity  of  the  insulin  receptor,  with  subsequent  GLUT-4  translocation  in  skeletal 
muscle tissue during exercise (Taguchi et al. 2000).  BDKRB2 activation can lead to 
transient rises in inositol 1,4,5-trisphosphate (Rabito et al. 1996), which is involved in 
excitation-coupling of skeletal muscle (Hidalgo et al. 1989; Foster 1994) via increases 
in cytoplasmic calcium (Lopez et al. 1991).  This process is enhanced by both insulin 
(Kudoh et al. 2000) and by inhibition of ACE (Kudoh et al. 2000).  Bradykinin-induced 
nitric  oxide  (NO•)  generation  may  also  modulate  mitochondrial  respiratory  control 
(Moncada et al. 2002).  NO• is a vasodilator which, at physiological concentrations, 
reversibly inhibits cytochrome c oxidase (mitochondrial complex IV) in competition 
with oxygen (Cleeter et al. 1994) and thus reduces oxygen uptake in skeletal muscle and 
heart mitochondria (Cleeter et al. 1994; Poderoso et al. 1996).  It has been suggested 
that the interplay between NO• and oxygen allows cytochrome c oxidase to act as an 
oxygen sensor within cells (Clementi et al. 1999).  NO donors have also been shown to 
reversibly inhibit oxygen utilization in rat skeletal muscle mitochondria (Cleeter et al. 
1994).  Tissue and whole animal studies have shown that kinins can suppress oxygen 
consumption via endogenous NO• production in skeletal (Shen et al. 1995) and cardiac 
muscle (Zhang et al. 1997), an effect mimicked by ACE inhibition and prevented by 
blockade of BDKRB2 (Zhang et al. 1997).  It may also be that BDKRB2 genotype 
influences skeletal muscle fibre type.  The relative proportion of Type I (slow-twitch, 
oxidative) to type IIA (fast, oxidative) and type IIB (fast glycolytic) skeletal muscle 
fibres has a strong influence on propensity to endurance or sprint performance (Coyle et 
al. 1992), and also influences DE (Coyle et al. 1992), whilst ACE I/D genotype has 
recently been associated with fibre type distribution (Zhang et al. 2003).  THE BRADYKININ B2 RECEPTOR GENE AND HUMAN 
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Conversely, such a role for bradykinin does not exclude a contribution for Ang II in 
mediating the effects of ACE.  Chronic Ang II infusion results in profound metabolic 
cachexia in rodents (Brink et al. 1996) with muscle catabolism and increased energy 
expenditure allied with  changes  in  oxygen consumption  (Cassis et  al. 2002).  As a 
powerful growth factor, it is also necessary for the hypertrophy of skeletal muscle in 
response to mechanical load (Gordon et al. 2001).  
 
Further studies are required to confirm these observations amongst other comparable 
groups  of  athletes.    The  association  of  genotype  with  relative  ranked  performance 
amongst endurance athletes should also be sought.  Such studies should also include 
those  of  other  ages  and  race.    The  small  number  of  ACE  ID  heterozygotes  (n=18) 
restricted the ability to assess the combined ACE/BDKRB2 genotypic association with 
DE within this group.  This inability in no way weakens the observations, but further 
studies should be performed if allele co-dominant influences on genotype response are 
to be sought.  In addition, no single gene will determine (exclusively) propensity to a 
given  sporting  discipline,  and  any  association  does  not  demonstrate  the  underlying 
mechanism of causation. By combining association study of phenotype class with a 
mechanistic study, we have attempted to overcome such problems.  However, these data 
do suggest that bradykinin, acting via the BDKRB2, has a role in regulating skeletal 
muscle performance.  The implications of such findings go beyond sports alone, and 
may  extend  to  the  management  of  patients  with  cardiovascular,  respiratory  and 
metabolic diseases, in which muscle function is adversely affected.  THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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 RESULTS CHAPTER FIVE  
 
5  THE EFFECT OF ACE-INHIBITION ON MYOCYTE 
MITOCHONDRIAL FUNCTION 
 
 
Low  ACE  activity,  such  as  that  resulting  from  ACEi  treatment  in  animal  studies 
(Gohlke et al. 1994; Nascimben et al. 1995; Sanbe et al. 1995; Watanabe et al. 1997; 
Hugel et al. 1999; Divisova et al. 2001) or as marked by the ACE I allele in human 
genetic studies (Montgomery et al. 1999; Myerson et al. 1999; Williams et al. 2000), is 
associated with enhanced metabolic efficiency. However, the mechanisms responsible 
have yet to be elucidated.  I have hypothesised that some of these associations may be 
through  alterations  in  mitochondrial  metabolism.    Uncoupling  proteins  are  nuclear-
encoded inner mitochondrial membrane proteins which are associated closely with the 
electron  transport  chain  and  may  serve  to  negatively  regulate  mitochondrial  ATP 
production by dissipating Δψm (Pecqueur et al. 2001; Echtay et al. 2002).  As such, 
UCPs may be potential mediators of any putative mitochondrial actions of ACE. 
 
To test these hypothesis, in vitro assays were established for measuring Δψm in live cells 
by  direct  (confocal  microscopy)  and  indirect  (flow  cytometry)  visualisation  using 
fluorescent mitochondrial potentiometric probes.  The effect of ACEi treatment on Δψm 
was tested in both skeletal and cardiac myocytes and in both cell lines and primary cell 
cultures.  The effect of ACEi on skeletal myocyte UCP3 expression was measured. The 
response of cellular oxygen consumption to ACEi was also studied. THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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5.1  FLOW CYTOMETRY 
 
5.1.1.  Baseline characteristics  
Preliminary  experiments  were  conducted  with  C2C12  undifferentiated  myoblasts  and 
preadipocytes because of their ease of culture.  Cytometer PMT settings (voltage, gain) 
were  adjusted  until  C2C12  blasts  were  localised  on  the  linear  FSC  (size)  and  SSC 
(granularity) scales (Figures 5.1, 5.2).  The FSC threshold was set at 200 to exclude the 
majority of cellular debris.  The contour plot (Figure 5.2) demonstrates the homogeneity 
of spatial characteristics of this population. 
 
 
 
 
 
Figure 5.1.  Dot plot representation of murine C2C12 myoblasts cells analysed by flow 
cytometer,  with  granularity  (Side  s catter  SSC)  plotted  on  the y -axis  vs.  cell  size 
(Forward scatter FSC) on the x-axis. Each dot represents one cell event (N= 10000).   THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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5.1.2.  TMRM mitochondrial probe 
 
5.1.2.1.   Dose titration 
C2C12 myoblasts were incubated with the mitochondrial probe TMRM and red (FL-2) 
fluorescence analysed.  Figure 5.3 shows a three-dimensional representation of spatial 
characteristics (FSC on x-axis, SSC on y-axis) and mitochondrial TMRM fluorescence 
(TMRM z-axis).  Figure 5.4 shows the same population of cells on a histogram plot, 
with TMRM fluorescence normally distributed on a logarithmic scale.  Compensation 
was adjusted to ensure that detected FL-1 (green fluorescence) from spectral overlap 
was within the first log decade. 
Figure  5.2.    Flow  cytometric  contour  map  of  the  same  C2C12  blasts  (events  of 
similar occurrence are joined  by lines  of similar  colour).   Most frequent areas 
(highest density in Fig 5.1) are brown to least frequent, blue. (N=10 000) THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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Figure 5.3.  A 3D density plot of TMRM staining characteristics of C2C12 blasts.  
Size (FSC) and granularity (SSC) are on linear x- and y-axes, respectively, and 
TMRM red fluorescence on the logarithmic z-axis. 
 
Figure 5.4.  TMRM fluorescence of C2C12 blasts expressed on a histogram plot, 
with number of events (cells; y-axis) against TMRM fluorescence (FL-2; x-axis; 
logarithmic scale, arbitrary units). THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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C2C12  myoblasts  were  incubated  with  increasing  concentrations  of  TMRM  for  30 
minutes (Figure 5.5).  Increasing TMRM concentration was associated with increasing 
red fluorescence, due to increased mitochondrial uptake of dye. 
 
 
 
 
 
 
 
Figure  5.5.    Contour  plots  of  C2C12  blasts  incubated  with  increasing 
concentrations of TMRM for 30 minutes.  An increase in TMRM red fluorescence 
(FL-2) is seen on the logarithmic y-axis. (N=10 000 per plot). THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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5.1.2.2.  The effect of mClCCP on cellular TMRM fluorescence 
 
C2C12  blasts  were  incubated  with  increasing  doses  of  TMRM,  followed  by 
trypsinisation  and  resuspension  in  Kreb‘s  Buffer  containing  the  mitochondrial 
respiratory uncoupler mClCCP at a final concentration of 20 nM.  This resulted in a 
mean loss of FL-2 fluorescence at lower concentrations of TMRM (e.g. -47± 4% at 1.0 
μM TMRM; P < 0.003; Figure 5.6). This trend of loss of TMRM fluorescence was, 
however,  reversed  at  higher  concentrations  of  TMRM,  with  a  net  gain  in  cellular 
fluorescence, at doses greater than 2 μM (Figures 5.7 & 5.8), due to the phenomenon of 
quenching (Duchen et al. 2003). 
 
 
 
Figure  5.6.    Flow  cytometric  analysis  of  TMRM  stained  C2C12  cells.    Control 
(coupled) cells are shown in the red histogram.  Treatment with the mitochondrial 
respiratory  uncoupler  mClCCP  (blue  histogram)  results  in  a  left  shift  in 
fluorescence. 
Uncoupling THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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Figure 5.7.  Flow cytometric measurement of TMRM fluorescence in untreated 
(coupled) and mClCCP-treated (uncoupled) C2C12 myoblasts. (N=3 at each point) 
Figure  5.8.    Relative  change  in  TMRM  fluorescence  in  C2C12  myoblasts  after 
treatment with 20 nM mClCCP (10000 cells).  At lower loading doses of TMRM, 
uncoupling  results  in  a  reduction  of  fluorescence,  whereas  at  higher  doses, 
uncoupling induces an increase in fluorescence due to quenching. 
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5.1.3.    JC-1 mitochondrial probe 
 
5.1.3.1.   Dose titrations 
JC-1  exists  as  a  monomer  at  low  concentrations  (or  at  low  Δψm)  and  forms  ―J-
aggregates‖ at higher concentrations (in aqueous solutions above 0.1μM or at higher 
Δψm).    The  monomer  absorption/emission  maxima  in  aqueous  solutions  are 
510nm/527nm.  Monomer fluorescence was therefore detected in the flow cytometer 
green (FL-1) channel following excitation at 488nm with its Argon laser.  J-aggregates 
are excitable over a wide range from 485nm to its absorption maxima at 593nm, with 
emission maxima at 595nm and can therefore be detected on the FL-2 (red) channel.  
There was spectral overlap between the emission wavelengths of the JC-1 monomers 
and aggregates, so fluorescence compensations were carefully set to minimise ‗bleed-
through‘. 
 
Preliminary work with a preadipocyte cell line demonstrated that the degree of both 
aggregate (orange) and monomer (green) fluorescence was a factor of the concentration 
of JC-1 probe and of the incubation time with the probe (Figures 5.9-5.12).  At low JC-1 
concentrations  (<0.5-1.0  μM),  cells  predominantly  exhibited  monomer  fluorescence, 
and  the  proportion  of  cells  that  took  up  the  dye  (and  fluoresced  green)  increased 
according  to  concentration  and  duration  of  incubation  with  dye.    At  higher  probe 
concentrations, more cells achieved aggregate fluorescence at the expense of monomer 
fluorescence, and this effect was more pronounced the longer the dye was left to reach 
equilibrium.   The ratio of JC-1 aggregate to monomer fluorescence (JC-1 A:M) was 
more reproducible and reflected the overall dye fluorescence characteristics. THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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Figure  5.9.    Proportion  of  pre-adipocytes  demonstrating  green  and  orange 
fluorescence when incubated with increasing concentrations of JC-1 for 15 minutes 
(10000 cells at each concentration). 
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Figure  5.10.    Proportion  of  pre-adipocytes  demonstrating  green  and  orange 
fluorescence  when  incubated  with  increasing    concentrations  of  JC-1  for  60 
minutes (N=10000 cells at each concentration). 
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Figure  5.11.    Proportion  of  preadipocytes  (total  N=10000)  exhibiting  green 
monomer fluorescence incubated with increasing dose of JC-1 (varying time and 
concentrations). 
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Figure  5.12.    Proportion  of  preadipocytes  (total  N=10000)  exhibiting  orange 
aggregate fluorescence incubated with increasing dose of JC-1 (varying time and 
concentrations). 
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5.1.3.2.  JC-1 and manipulation of Δψm 
It was found that the addition of uncoupler after incubating the cells with JC-1 resulted 
in  very  little  change  in  aggregate  fluorescence,  in  stark  contrast  to  the  uncoupler-
induced  changes  seen  in  TMRM  fluorescence.    This  difference  is  probably  due  to 
aggregates being slow to disassociate following acute changes in Δψm.  It was therefore 
decided to add uncoupler for 15 minutes before addition of JC-1. 
 
Figure 5.13 shows a series of dot plot representations of flow cytometric analysis of 
C2C12 myotubes incubated with increasing concentrations of JC-1 (37°C, 30 minutes), 
with the comparative plots below of C2C12 myotubes pre-treated with 20 nM mClCCP.  
Again,  the  FL1  and  FL2  channels  have  been  optimised  by  compensating  to  reduce 
spectral overlap.  As can be seen, the control population (no dye) predominates in the 
first log decade.  Thereafter, increasing doses of JC-1 result in increasing monomer 
fluorescence  (FL-1  green  channel,  x-axis),  followed  by  increasing  aggregate 
fluorescence  (FL-2  orange,  y-axis).    Uncoupling  with  mClCCP  prior  to  JC-1  cell 
loading resulted in greater monomer (green) fluorescence at the expense of aggregate 
fluorescence signal and also of the total number of cells exhibiting either fluorescence.  
The uncoupler-induced collapse of Δψm therefore prevents subsequent mitochondrial 
loading and concentrating of JC-1.  In C2C12 myotubes, addition of a low concentration 
of mClCCP (5 μM) resulted in complete loss of Δψm (99.2 ±0.2% reduction in JC-1 
A:M fluorescence, P < 0.0000001, N=3; Figure 5.15).  H9C2 cardiac blasts showed 
greater aggregate formation at a lower concentration of JC-1 (Figure 5.14).  Again, pre-
treatment  with  uncoupler  (20  µl  mClCCP)  resulted  in  an  increase  in  monomer 
fluorescence  and  a  decrease  in  aggregate  fluorescence.    The  proportion  of  cells 
achieving aggregate fluorescence began to plateau at 2.5-5.0 µM JC-1 (graph Figure 
5.14).THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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Figure 5.13.  Dot plot series. Upper panel: murine C2C12 myotubes incubated for 30 mins at 37°C with increasing concentrations of the mitochondrial 
probe JC-1 followed by 2 channel flow cytometric analysis.  Monomer fluorescence emission was detected in the FL-1 channel (x-axis) and aggregate 
fluorescence emission in the Fl-2 channel (y-axis).  Quadrants have been drawn which best reflect monomer emission and aggregate emission.  The 
percentage of cells within each quadrant is shown in their respective corners.  As the concentration of JC-1 increased, the monomer fluorescence 
increased, with the development of aggregate fluorescence above 0.5 μM JC-1.  A greater proportion of cells achieve aggregate fluorescence at higher 
JC-1 concentrations.  Lower panel: pre-treatment with 20 μM mClCCP results in an increase in monomer fluorescence at the expense of both a 
decrease in aggregate fluorescence and number of cells with aggregate fluorescence (N=10000 each panel).  
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Figure 5.14.  Dot plot series showing (upper panels) rat H9C2 cardiac blasts incubated for 30 mins at 37C with increasing concentrations of the 
mitochondrial probe JC-1 followed by 2 channel flow cytometric analysis.  Monomer fluorescence emission was detected in the FL-1 channel (x-axis) 
and aggregate fluorescence emission in the Fl-2 channel (y-axis).  H9C2 cells appear to form JC-1 aggregates more readily than myotubes.  The lower 
panels show the result of pretreatment with the uncoupler mClCCP.  The graph demonstrates the proportion of cells with aggregate fluorescence with 
increasing concentration of JC-1 (N=10000 for each panel). 
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The ionophore nigericin was used to induce a slight inner mitochondrial membrane 
hyperpolarisation.  It catalyses the electroneutral exchange of K
+ for H
+, equalising their 
respective  gradients  across  the  membrane,  thereby  increasing  Δψm  (Section  1.5.2).  
Addition of a 10μM nigericin for 1 hour to C2C12 myotubes resulted in a 24 ±12% 
increase in JC-1 A:M fluorescence (P = 0.03; N=3; Figure 5.15). 
 
 
5.1.4.    ACE inhibitor effects on Δψm assessed in whole cells by flow cytometry 
 
5.1.4.1.  TMRM 
Δψm was measured in C2C12 skeletal myotubes using a low dose (0.1 µM) of TMRM for 
30 minutes.  Treatment of C2C12 myotubes with 10 µM ramiprilat for 24h resulted in a 
significant increase in TMRM fluorescence relative to control cells as measured by flow 
cytometry (117 ± 11u vs.  72 ± 6u for ramiprilat vs. control; n=3, P=0.004; mean 62% 
increase  in  fluorescence;  Figures  5.16  &  5.17),  i.e.  hyperpolarisation  of  the  inner 
Figure 5.15.  JC-1 aggregate/monomer (A:G) fluorescence ratio in C2C12 
myotubes incubated with vehicle, mClCCP or nigericin (10000 cells, N=3 
repeats), * P < 10
-7 ;  † P = 0.03 
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mitochondrial  membrane.    There  was  no  difference  in  Δψm  assessed  after  48  h 
incubation (with no further addition of ramiprilat).  C2C12 cells were also incubated with 
5 μM of the ACEi imidiprilat and perindoprilat (Figure 5.17).  Lipid solubilities of these 
ACEi were ramiprilat >> imidiprilat > perindoprilat, which concurs with previously 
reported  tissue  affinity  and  lipophilicity  data  (Dzau  et  al.  2001).  Δψm  at  24  hour 
followed this trend, with a mean percentage increase in TMRM fluorescence of 12.8% 
and -0.3% for imidiprilat and perindoprilat respectively.  Again, by 48 h, there was no 
difference in Δψm compared with vehicle treated cells. 
 
Figure  5.16.  Flow  cytometric  histogram  plot  demonstrating  TMRM  stained 
C2C12 myotubes which have been untreated or ramiprilat (10
-5M) 
treated for 24hours. THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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5.1.4.2.  JC-1 
Membrane potential assessed by JC-1 in C2C12 myotubes confirmed dose-dependent 
Δψm hyperpolarisation after 24h treatment with Ramiprilat, increasing at concentrations 
of Ramiprilat greater than 10
-7M (10±0.3% at 10
-7M; mean ±SD; N=3; P<0.05; Figure 
5.18). H9C2 cardiac blast cells showed a similar, dose-dependent hyperpolarisation of 
Δψm following incubation with 24hr ramiprilat. 
 
Adult rat primary cardiomyocytes were not ideally studied by flow cytometry as they 
tended to clump in the suspension. 
Figure 5.17. Mean change in TMRM dye fluorescence following incubation of 
C2C12 myotubes with different ACE inhibitors at 10
-5M for 24 - 48 
hours (N=3x 10000 cells) 
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Figure 5.18.  Ratio of JC-1 aggregate to monomer fluorescence of C2C12 myotubes 
incubated with increasing dose of ACEi Ramiprilat for 24 hours (n=3x 10000 cells). 
Figure 5.19.  Ratio of JC-1 aggregate to monomer fluorescence of H9C2 cardiac 
blast cells incubated with increasing dose of ACEi Ramiprilat for 24 hours  (n=2x 
10000 cells) 
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5.2  CONFOCAL ANALYSIS  
 
Cells were seeded at low density into several types of culture slides (Perspex and glass 
Petri dishes and chamber slides) to attempt their visualisation on an inverted microscope 
(Nikon  Eclipse  T100)  which  was  attached  to  the  confocal  system  (Bio-Rad 
Radiance2000).  Iwake round chamber slides had too large a surface area, allowing 
eddying of added drugs with incomplete admixture.  The fluorescence properties  of 
Perspex chamber slides did not allow good immunofluorescence imaging.  Quartz two-
chamber slides designed for immunofluorescence studies (Nunc™, Fisher Scientific, 
UK) were found to give the clearest imaging with the confocal microscope and also 
enabled sided-by-side treatment analyses. 
 
 
C2C12 myoblasts were seeded at low density (10
3 cells per well) into 2-well chamber 
slides.  Cells were allowed to adhere overnight and then serum deprived for at least 3 
days to stimulate differentiation into myotubes which were subsequently studied. 
 
Dose titrations with potentiometric dyes were  carried out to obtain optimal staining 
characteristics.  For TMRM, concentrations were used in the lower range in the linear 
phase of dye uptake according to Nernstian principles to prevent quenching (Section 
5.1.1.2).    Several  experiments  were  performed  to  obtain  optimal  laser  scanning 
conditions (see Table 5.1).  The settings were stored and the identical settings used for 
each comparative experiment. 
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Treatment  of  C2C12  myotubes  with  0.1  µM  TMRM  for  30  minutes  resulted  in 
characteristic  orange-red  staining  in  fibrillar  structures  (Figure  5.20).  Images  were 
stored and transferred to a workstation where cellular fluorescence was then quantified 
by posthoc analysis using LaserPix software (Bio-Rad, UK).  A region of interest (ROI) 
was drawn around each individual cell (first bluntly by edge recognition software, then 
optimised by dragging in the outline to the plasmamembrane edge).  Mean fluorescence 
signal  for  the  ROI  (mean  pixel  brightness)  was  calculated  on  a  256  grey-scale.  
Treatment with the uncoupler mClCCP caused a significant, immediate 58% reduction 
of mean cellular fluorescent signal (P = 0.0002 measured at 20 seconds; Figure 5.20d).  
Following the initial drop, the cellular fluorescence continued to reduce gradually for 
the next 280 seconds down to a 74.7% mean loss of TMRM fluorescence (P = 0.00002). 
 
Table 5.1.  Typical settings for confocal imaging. 
 
Probe  Laser  Power  Iris  Gain  Detection filter 
TMRM  Argon  5%  1  29%  515/30 
DCF  HeNe  30%  1   50%  590/70 
JC-1  Argon   15%  1  13%  515/30  
( using 560 dichroiic mirror) 
HeNe  13%  1  50%  590/70 
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Figure 5.20.  Confocal analysis of mitochondrial TMRM fluorescence in C2C12 myotubes (x20 magnification). 
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H9C2 cardiac blasts were seeded at 1x10
4 cells per chamber in quartz chamber-slides.  
Incubation with TMRM (0.1 μM for 30 minutes) showed dye uptake in mitochondria 
which were sinuous cytoplasmic structures (Figure 5.21) similar to the mitochondrial 
structures  previously  described  in  astrocytes  (Duchen  1999)  unlike  the  longitudinal 
arrangement in mature C2C12 myotubes or cardiomyocytes. 
 
 
Figure 5.21.  Grey scale confocal image of a cluster of H9C2 blasts which have 
been stained with TMRM, a potentiometric dye which is taken up preferentially in 
mitochondria  according  to  Δψm.    Note  the  dye  dropout  in  the  nucleus.  (x40 
magnification). 
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5.2.1.    The effect of ACE inhibition on Δψm assessed by CLSM 
 
5.2.1.1.   C2C12 skeletal myotubes 
C2C12 myotubes were incubated with 0.1 µM TMRM for 30 minutes.  Prior treatment 
with  10
-5M  ramiprilat  for  24  hours  resulted  in  a  significant  increase  in  TMRM 
fluorescence compared to vehicle treatment (Figure 5.22).  Treatment of cells with 20 
μM mClCCP resulted in a loss of fluorescence signal in both vehicle and ramiprilat 
treated cells, indicating that fluorescence was indeed located to mitochondria.    Further 
analyses were performed on low power fields (x20) taken from separate cultures of 
vehicle  and  ramiprilat-treated  C2C12  cells  (n  =  3).    As  can  be  seen  (Figure  5.23) 
ramiprilat treated cells again demonstrated an increase in Δψm, marked by a relative 
increase in TMRM fluorescence (P = 0.01; whole field analysis).  As can be seen, there 
was relative heterogeneity in cell morphology and cell response.   
 
5.2.1.2. Cardiac cells 
TMRM  fluorescence  of  H9C2  cardiac  blasts  was  also  significantly  increased  by 
ramiprilat treatment (P = 0.008, n = 4 cells; Figure 5.24).  As can be seen, there was 
heterogeneity in cell morphology.  Adult ventricular cardiomyocytes (primaries) were 
isolated from the rat as described in Methods 2.4.4.1 using collagenase digestion in a 
Langendorff perfusion.  Calcium tolerant cells were allowed to adhere to laminin-coated 
quartz chamber slides.  Non-adherent cells were subsequently  removed by washing.  
Cells in one chamber were treated with ramiprilat 10
-5M and the contra-lateral chamber 
treated with vehicle as an internal control. THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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Figure 5.22.  C2C12 myotubes stained with TMRM and analysed 
by confocal microscopy (magnification x40) 
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Figure 5.23.  Fields of C2C12 cells stained with TMRM and imaged with CLSM 
(X20 magnification) 
 
 
i.  Vehicle treated 24 hours    
ii. Ramiprilat 10
-5M for 24 hr 
1  3  2 
4  5  6 
0
500000
1000000
1500000
2000000
2500000
Vehicle Ramiprilat 10-5M
R
e
l
a
t
i
v
e
 
F
l
u
o
r
e
s
c
e
n
c
e
 
(
a
r
b
 
u
n
i
t
s
)
iii.   Relative TMRM fluorescence of fields of C2C12 cells treated 
with either vehicle or ramiprilat for 24hours (n=3) 
p=0.01 THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
  227 
Figure 5.24. H9C2 cardiac blasts stained with TMRM 
and analysed by confocal microscopy 
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A single rod-shaped cell was recorded from each of 10 fields, as depicted round each 
chamber  (Figure  5.25a).  Experiments  were  repeated  3  times,  giving  30  cells  per 
treatment. 
 
Cells treated with 100 nM TMRM displayed the characteristic banding pattern (Duchen 
et  al.  2003),  as  mitochondria  are  arrayed  along  the  cardiomyocyte  striations.  
Fluorescence quantification was adjusted to cell cross-sectional  area to give relative 
fluorescence  per  unit  area,  and  vehicle  treated  cells  indexed  to  a  mean  relative 
fluorescence of 100 (Figure 5.25c). 
 
A time series of vehicle vs. ramiprilat (10
-5M) was conducted with time points at 1, 6, 
12  and  24  hours.    There  was  no  difference  between  treatments  at  1  or  6  hours.  
Ramiprilat  treatment  after  12  hours  resulted  in  a  significant  increase  in  TMRM 
fluorescence  (100  nM),  with  relative  increases  of  50%  and  38%  for  12h  and  24  h 
respectively (both P < 0.000001). 
 
Analyses were possible on 1 sample of human adult right ventricular cardiomyocytes.  
The cells were isolated from the right ventricle of a 69 year old male patient with dilated 
cardiomyopathy undergoing cardiac transplantation.  The patient had been on long-term 
ACEi  maintenance  therapy.    Again,  cardiomyocytes  stained  with  100  nM  TMRM 
exhibited the typical striated patterning (Figure 5.26A).  Addition of 5 μM mClCCP 
resulted in slow loss of TMRM fluorescence (Figure 5.26A, Figure 5.27).  There was no 
difference in TMRM fluorescence between ACEi therapy for 24 hours with ramiprilat 
10
-5M and vehicle treated cells (Figure 5.28). THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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Figure 5.25. CLSM analysis of Δψm in rat adult ventricular primaries 
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Figures 5.28-28.  TMRM fluorescence in human adult ventricular cardiomyocytes 
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Figure  5.28  TMRM  fluorescence  in  human  right 
ventricular  cardiomyocytes  treated  with  either 
vehicle or ramiprilat (10
-5M) for 24 hours.  
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Figure 5.27. Time series in human cardiomyocyte after 
addition of 5μM mClCCP 
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Figure 5.26. Confocal images of mycotes 
stained with TMRM 
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5.2.2.    CLSM measurement of ROS in cardiomyocytes treated with ACEi 
TMRM has been shown to induce photodynamic damage with repetitive laser scanning 
(Zhang et al. 2001).  To test whether pre-treatment with the ACEi, ramiprilat had a 
beneficial effect on cellular reactive oxygen species (ROS) generation, adherent adult 
rat cardiomyocytes were incubated with either vehicle or Ramiprilat 10
-5M for 24 hours 
in  chambers  slides.    The  cells  were  then  incubated  with  TMRM  and  DCF-DA  to 
simultaneously  measure  mitochondrial  membrane  potential  and  ROS  (NO  and 
peroxynitrite).  The cells underwent sequential laser scanning every 1 minute for 15 
minutes using both Argon (488nm) and HeNe lasers and fluorescence signals detected 
at 560-650nm (560nm and 650nm dichroiic longpass mirrors and 590±70nm emission 
filter) for TMRM (red), and 515±30nm for DCF-DA green fluorescence (Figure 5.29).  
Cells treated with vehicle showed no significant change in TMRM fluorescence during 
this  period  (percentage  change  in  fluorescence  2±2%)  indicating  there  was  no 
significant photobleaching effect over this time.  However, there was an increase in 
DCF-DA  fluorescence  (12±3%).  
Pretreatment with ramiprilat resulted in a 
significant  difference  in  DCF-DA 
fluorescence  compared  to  vehicle 
(ramiprilat cells -9±8%, P = 0.009 vs. 
vehicle)  and  a  reduction  in  TMRM 
fluorescence(-25±13%,  P=0.009 
compared  with  vehicle;  Figure  5.29; 
N = 3). 
 
   
Figure 5.29.  Changes in TMRM 
and  DCF-DA  fluorescence  in 
vehicle  and  Ramiprilat  treated 
cardiomyocytes  after  sequential 
laser scanning.    
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Figure 5.30.  Relative TMRM and DCF-2A fluorescence of adult rat cardiomyocytes during repetitive laser scanning confocal microscopy.  
Cells were pretreated with either vehicle or ramiprilat 10
-5M for 24hr (n=2-4 cells) 
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5.3    CELLULAR OXYGEN CONSUMPTION 
 
C2C12  murine  myoblasts  were  grown  to  confluency  in  175cm
2  culture  flasks  and 
differentiated  into  myotubes  as  described  (Methods  2.1.2)  and  then  maintained  in 
culture for 5-7 days.  Cells were then treated with either vehicle or ramiprilat (10
-5M), 
LPS (1 µg.ml
-1) or Ang II (10
-7M) for 24 hour prior to resuspension in aerated Kreb‘s 
buffer.  Oxygen consumption was measured using the OxySpot system (Methods 2.3).   
 
Concentrations of C2C12 myocytes below 2-3x10
6 cells.ml
-1 did not measurably alter 
oxygen tension.  A cell concentration at 4x10
6 cells.ml
-1 gave a measurable reduction in 
oxygen tension with time (-7 ±0.6 mTorr.s
-1), but also tended to clump in solution.  As 
can be seen in  Figure  5.31, the addition  of 5μM  mClCCP resulted in  the expected 
increase in  oxygen consumption  (uncoupled respiration  -10 ±2 mTorr.s
-1 vs. vehicle 
above, N = 3, P=0.03). 
 
 
5.3.1.    C2C12 cells treated with LPS 
Treatment with LPS (1µg.ml
-1 for 24hr) resulted in a significant reduction in cellular 
respiration  (-7  ±0.6  mTorr.s
-1  vs.  -2  ±0.7  mTorr.s
-1  for  vehicle  vs.  LPS  treatment 
P=0.0008; Figure 5.29).  Treatment with uncoupler increased respiration rate in LPS 
treated cells (-9 ± 5.0mTorr.s
-1; P = 0.04; N=3).  There was no difference in uncoupled 
rates of respiration in vehicle and LPS treated cells (P = 0.9; Figure 5.29). 
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Figure 5.31.  Oxygen consumption measured in C2C12 myotubes pre-
treated  with  vehicle  or  lipopolysaccharide  (LPS;  1μg.ml
-1)  for  24 
hours.   Oxygen  consumption  was  lower in LPS treated  cells.  After 
addition  of  uncoupler  (arrow)  the  oxygen  tension  curves  run  in 
parallel.  (PO2 indexed to 100). 
 
Respiratory control ratio (RCR) was significantly higher in LPS treated cells compared 
to vehicle treated cells (2 ±0.1 vs. 6 ±0.1 for vehicle vs.  LPS; P = 0.0004; Figure 5.32). 
Figure 5.32.  Respiratory control ratio (RCR) in vehicle, LPS and angiotensin 
II treated C2C12 cells. 
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5.3.2.  C2C12 cells treated with ACE inhibitor 
In preliminary experiments, no difference in basal oxygen consumption was observed 
between vehicle and ramiprilat  (10
-5 M) treated cells  (-7 ±1.5  mTorr.s
-1 vs. -5 ±2.3 
mTorr.s
-1, respectively; P=NS; Figure 5.33). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.3.    C2C12 treatment with Angiotensin II  
Pre-treatment of C2C12 myocytes with Ang II (10
-7M) for 1 hour resulted in a significant 
increase in basal oxygen consumption in C2C12 myotubes (-7 ±0.6 mTorr.s
-1 vs. -23 
±8.2mTorr.s
-1  for  vehicle  vs.  Ang  II  treatment;  P=0.03;  n=3).  Treatment  with  an 
uncoupler  in  Ang  II  treated  cells  resulted  in  a  significant  increase  in  oxygen 
consumption (-169 ±63 mTorr.s
-1; P=0.02).   
Figure 5.33.  OxySpot graph depicting oxygen consumption in C2C12 myocytes 
treated with vehicle or Ramiprilat (10
-5M) for 24 hours (PO2 indexed to 100) 
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The respiratory control ratio was significantly higher in Ang II cells than in vehicle 
treated cells (1 ± 0.3 vs. 7 ± 0.2 for vehicle vs. Ang II; P = 0.0002; Figure 5.34).   
 
 
5.4  UCP3 mRNA EXPRESSION IN C2C12 MYCOCYTES. 
 
Primers were designed as previously described (Table 5.2) with a melting temperature 
(Tm) of 60ºC.  Primers were designed to either include an intronic sequence within the 
amplified sequence (thereby yielding a longer amplicon if DNA contamination were 
present and thus allowing differentiation from amplified RNA) or designed to straddle 
exon-exon boundaries (preventing contaminant DNA from being amplified altogether).  
PCR conditions were optimised using magnesium titrations in the range 3.0-5.0 mM to 
enable the same primers to be used for PCR amplification with the LightCycler™ if 
subsequently  required.    PCR  products  were  run  on  2%  agarose  gels  stained  with 
Figure 5.34.  Graph depicting oxygen consumption in C2C12 myocytes pre-treated 
with Angiotensin II (10
-7M) for 1 hour (PO2 indexed to 100) 
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ethidium bromide against a 1 kB DNA ladder (GibCo).  The mouse UCP3 cDNA was 
particularly difficult to amplify.  Four sets of primers were tried before amplification 
was achieved. 
 
In keeping with previous reports, the mRNA signal for UCP3 was greater than that for 
UCP2 in C2C12 myocytes.  The effect of 24 hours of ACEi treatment on UCP3 mRNA 
was assessed.  There were no gross differences in the UCP3 mRNA signal when PCR 
product was run on 2% agarose gels.   For a more accurate assessment, quantitative 
analysis by real-time RT-PCR was carried out. 
 
The  ratio  of  UCP3:GAPDH  was  quantified  using  RelQuant  software  as  previously 
described (Methods 3.4.5.) and was similar to previous reports (Shimokawa et al. 1998). 
 
Table 5.2.  Forward and reverse primers for RT-PCR and amplicon size 
 
Gene  Forward Primer  Reverse Primer 
Amplicon 
size (bp) 
mGAPDH  TGCATCCTGCAGCACCAACTG  CACAGCTTTCCAGAGGGGCCA  141 
mUCP3  CCCGATACATGAACGCT  AGATTCCCGCAGTACC  203 
mUCP2  GGTCCGCTTCCAGGCTCAGG  GCATTACGGGCAACATTG  138 
 
Incubation of C2C12 myotubes with increasing concentrations of ramiprilat for 24 hour 
resulted in no significant changes in UCP3 mRNA expression (Figure 5.33, n=3).  To 
test whether ACE inhibition would modify the effect of cell stress on myocyte UCP3 
mRNA expression, C2C12 cells were incubated within a hypoxic (37C, 5%CO2, 1% O2, 
94% N2) environment for 6 hours, with or without pre-treatment with ramiprilat 10
-5M 
for 24 hours (Figure 5.34).  Hypoxia resulted in an 11.6 fold decrease in UCP3 mRNA THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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expression at 6 hours (P=0.03; n=4) in both vehicle and ramiprilat pre-treated cells.  
There  was  no  effect  of  ramiprilat  treatment  on  the  hypoxia  induced  suppression  of 
UCP3 mRNA (P=0.5). 
 
Figure 5.35.   Quantitative  RT-PCR  analysis  of  UCP3:GAPDH  mRNA  transcript 
ratio in C2C12 myotubes treated with increasing concentration of the 
ACE inhibitor ramiprilat for 24 hours (mean ± SD of 3 experiments). 
 
R
a
t
i
o
 
o
f
 
m
U
C
P
3
:
G
A
P
D
H
 
m
R
N
A
 
(
1
0
4
)
 
 
* P < 0.05 vs. normoxia 
0.0
2.0
4.0
6.0
8.0
normoxia hypoxia hypoxia +ramiprilat
*  * 
R
a
t
i
o
 
o
f
 
U
C
P
3
:
G
A
P
D
H
 
m
R
N
A
 
(
x
1
0
4
)
 
0.0
2.0
4.0
6.0
8.0
10.0
12.0
vehicle -9 -8 -7 -6 -5
Concentration of ramiprilat (log 10) 
Figure 5.36   The effects of 6 hours of hypo xia and co-treatment with the ACE 
inhibitor ramiprilat on the UCP3:GAPDH mRNA transcript ratio 
in C2C12 myotubes analysed by quantitative RT-PCR (mean ± SD of 
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5.5  DISCUSSION 
 
Preliminary observations were carried out using cell lines which have the benefit of ease 
of  culture  and  rapid  growth.    However,  cell  lines  may  not  match  the  physiological 
characteristics  of  the  original  source  tissue  and  have  the  potential  to  transform  or 
subclone.  Primary cells were therefore preferred in later experiments examining Δψm.  
Myotubular  cells  (differentiated  C2C12  cells)  and,  in  particular,  adult  ventricular 
myocytes tended to clump and run slowly through the flow cytometer‘s fluidic system.  
In the case of C2C12 tubes, this problem was overcome with frequent rinsing of the 
fluidics with FACSafe liquid between samples.  Dye loading was carried out in Kreb‘s 
Buffer containing HEPES which is able to buffer fluctuations in environmental carbon 
dioxide as cells are moved from incubator for analysis.  This is particularly important 
since mitochondrial probe loading is pH dependent.   
 
The mitochondrial probe TMRM exhibited quenching above 1-2μM, with plateauing of 
the fluorescence-dose response curve.  Treatment with the uncoupler mClCCP below 
this threshold resulted in a characteristic loss of fluorescent signal, whereas, above this 
threshold,  uncoupling  resulted  in  an  increase  in  signal.    This  is  consistent  with 
observations by others (Duchen et al. 1998; Jacobson et al. 2001; Jacobson et al. 2002; 
Jacobson et al. 2002; Krieger et al. 2002; Duchen et al. 2003).  In order to use TMRM 
in a semi-quantitative manner for measuring alterations in was decided to use a low 
concentration of dye where the increase in fluorescence signal was proportional to an 
increase in dye uptake, which is directly related to Δψm according to the Nernst equation 
(Ehrenberg et al. 1988; Loew et al. 1993; Scaduto et al. 1999).    
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The use of JC-1 as an indicator of changes in Δψm was also examined.  JC-1 is known to 
form  aggregates  at  high  concentration,  which  have  different  spectral  properties  to 
monomer JC-1.  In contrast to TMRM, addition of uncoupler after incubation with JC-1 
resulted  in  no  significant  change  in  fluorescence  characteristics.    This  supports  the 
reported  findings  that  aggregates  tend  to  disassemble  slowly  in  response  to  rapid 
changes  in  Δψm  (Nicholls  &  Ward  2000).    To  examine  the  alterations  in  JC-1 
fluorescence associated with mitochondrial uncoupling, mClCCP was therefore added 
to cell suspensions for 15 minutes prior to dye loading.  This approach demonstrated 
that relatively high concentrations of dye were required to attain rapid equilibrium.  JC-
1 characteristics were similar to those observed by others (Reers et al. 1991; Smiley et 
al. 1991; Cossarizza et al. 1993; Di Lisa et al. 1995; Salvioli et al. 1997; Nuydens et al. 
1999; Collins et al. 2000; Mathur et al. 2000; Rakhit et al. 2001).  
 
Flow cytometric assessment of Δψm allowed a large sample of cells to be analysed 
quickly.    Without  direct  visualisation,  however,  the  assumption  is  made  that  the 
fluorescent signal is within mitochondria.  Loss of fluorescence signal with treatment 
with  low  dose  of  uncoupler  implies  that  dye  accumulation  is  dependent  on  Δψm, 
although  uncoupler  can  dissipate  plasma  membrane  potential,  albeit  at  higher 
concentrations.  With flow cytometry, simultaneous assessments of fluorescent signals 
can  be  recorded.    This  is  particularly  advantageous  in  the  case  of  JC-1,  allowing 
ratiometric measurement of Δψm.  It may also be possible to measure other aspects of 
mitochondrial physiology, such as ROS generation with a second fluorochrome.  CLSM 
is  also  flexible  in  this  regard.    Simultaneous  fluorescent  recordings  can  be  made.  
However, as with flow cytometry, spectral bleed-through is a potential hurdle.  The 
scanning software now allows sequential laser scanning from separate laser sources.  
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overlap can be made by using different dichroiic mirrors and bandwidth filters.  CLSM 
is  a  powerful  tool,  allowing  direct  visualisation  of  mitochondrial  signal  and 
physiological changes.  Four-dimensional imaging is possible, with superfusion time 
analysis  and  3D  reconstruction.    However,  fewer  cells  can  be  examined,  analysis 
software is not ‗user-friendly‘ and analysis, itself, time consuming.  
 
Treatment of all cell types with uncoupler resulted in collapse of Δψm as recorded by a 
loss  of  mitochondrial  probe  fluorescence.    This  was  seen  as  an  increase  in  cellular 
respiration, as recorded by OxySpot measurements in C2C12 cells.  Following collapse 
of  Δψm,  uncontrolled,  futile  cycling  of  the  ETC  occurs,  with  resultant  increase  in 
oxygen consumption.  However, there is no PMF to drive ATP synthesis, so ATP is 
generated within the cytoplasm by anaerobic glycolysis, although this ATP may, in turn, 
be rapidly depleted by reversal of ATP synthase (Nicholls et al. 2002). 
 
Treatment with the ACEi ramiprilat for 24 hours increased Δψm in both skeletal and 
cardiac blasts and myocytes as assessed by the two complementary techniques of flow 
cytometry and confocal microscopy.  The relative increase in fluorescence signal was 
38-50%  measured  in  primary  cardiomyocytes,  peaking  at  12  hours.    This  relative 
hyperpolarisation of the inner mitochondrial membrane would lead theoretically to a 
decrease in mitochondrial respiration rate (Nicholls et al. 2002), i.e. with an increase in 
Δψm, the ETC would be near equilibrium with a presumed lowering of the ADP/ATP 
ratio, thereby slowing the rate of respiration.  However, no alteration in basal respiratory 
rate  was  seen  in  C2C12  cells  treated  with  ramiprilat.    This  may  be  due  to  lack  of 
sensitivity of the assay to measure small changes in respiratory rate. 
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The increase in Δψm following ACEi treatment suggests an increase in the coupling 
between  mitochondrial  respiration  and  ATP  generation  and  the  delayed  increase 
suggested a gene-transcriptional event.  UCPs may uncouple oxidative-phosphorylation.  
Therefore, ACEi may decrease UCP expression and therefore increase mitochondrial 
coupling, or ACE inhibition may cause an increase in Δψm through another mechanism, 
with  resultant  increase  in  ROS  generation  triggering  a  protective  increase  in  UCP 
expression.    The  effect  of  ACE  inhibition  on  UCP3  mRNA  expression  in  skeletal 
myotubes  was  therefore  tested.    However,  no  significant  change  in  UCP3  gene 
transcription  was  observed  in  C2C12  myotubes  treated  with  ramiprilat  for  24  hours.  
There was a wide degree of variation of UCP3 mRNA transcript ratio in both treated 
and untreated myotubes.  This may be a reflection of the variability in UCP3 mRNA 
seen with degree of differentiation in this cell type (Shimokawa et al. 1998).  This may 
have prevented small changes in transcript ratio being observed.  Moreover, UCP2 and 
UCP3 undergo extensive post-transcriptional changes, so it may be more important to 
measure protein levels, but measuring protein has been hindered, until recently,  by the 
lack  of  specific  antibodies  available  (Pecqueur  et  al.  2001).    However,  neither  the 
amount of mRNA nor the protein may reflect the degree of activation of UCP, which 
depends on the presence of fatty acid or ROS (Echtay et al. 2002).   
 
The effect of the ACEi tested on Δψm followed the differences in lipophilicity of the 
respective  active  metabolite,  from  most  lipid  soluble  (ramiprilat)  having  a  greater 
response than imidiprilat (intermediate) which was greater than the most water soluble 
(perindoprilat) (Dzau et al. 2001).  This does suggest that the biological action of each 
ACEi may rely on its diffusion capacity into or across the lipid bilayer of either the 
plasma  or  mitochondrial  membrane,  to  ultimately  increase  the  bioavailability  of 
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Could alterations in NO• explain the effects of ACEi on Δψm?  NO• is a competitive 
inhibitor of oxygen at cytochrome oxidase (Brown et al. 1994; Cleeter et al. 1994), and 
therefore may be able to exert metabolic control over mitochondrial respiration (Shen et 
al. 1995; Clementi et al. 1999; Loke et al. 1999).  The concentration and source of NO• 
is  critical  (Kojda  et  al.  1999).    ACEi  reductions  in  oxygen  consumption  and 
improvements in contractility in cardiac tissue have been shown to be NO•-dependent 
(Zhang  et  al.  1997),  but  the  source  of  NO•  is  likely  to  be  eNOS  and  of  a  low 
concentration.  Persistent inhibition of respiration and contractile dysfunction can occur 
with higher concentrations of NO•, either provided by exogenously administered NO• 
donors (Beltran et al. 2000) or potent inducers of iNOS, such as endotoxin (Rosser et al. 
1998).  In these situations, oxygen consumption at cytochrome oxidase is inhibited and 
cellular ATP demand met by cytoplasmic anaerobic glycolysis, and reversal of ATP 
synthase and the adenine nucleotide translocator use this ATP to maintain a relative 
increase  in  Δψm  (Beltran  et  al.  2000;  Moncada  et  al.  2002).    In  keeping  with  this, 
treatment of C2C12 cells with endotoxin (LPS) for 24 hours significantly suppressed 
cellular oxygen consumption by 73%.  LPS has been shown to reduce cellular oxygen 
consumption in other cell types (James et al. 1995; Borutaite et al. 2001) in an NO•-
dependent manner (Borutaite et al. 2001).  Respiratory uncoupling by mClCCP was 
unaffected by the presence of LPS.  However, the RCR was significantly higher in LPS 
treated  cells,  therefore  implying  that  LPS  exerted  significant  metabolic  control  on 
mitochondrial respiration.   
 
Surprisingly, direct incubation of C2C12 cells with Ang II tended to also increase the 
RCR,  but,  in  contrast  to  LPS,  this  was  primarily  due  to  an  increase  in  uncoupled 
respiratory rate.  This effect was seen following 1 hour treatment with Ang II and has 
not been previously reported in the literature, and appears to be distinct from the NO• THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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modulation of respiration.  Chronic Ang II treatment in rats is known to alter resting 
oxygen consumption (Cassis et al. 2002) and result in cachexia (Brink et al. 1996).  
Ang II may be decreasing mitochondrial ETC coupling by increasing activity of UCPs, 
which  are  also  known  to  be  upregulated  in  skeletal  muscle  in  experimental  cancer 
cachexia (Bing et al. 2000). Alternatively, Ang II may be acting directly on the ETC 
complexes or via inhibition of NO• pathways. 
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 RESULTS CHAPTER SIX  
6  IS THERE AN ASSOCIATION BETWEEN VARIATION IN THE 
UCP3/UCP2 LOCUS AND CARDIOVASCULAR OR 
PERFORMANCE PHENOTYPES? 
 
I  hypothesised  that  some  of  the  observed  associations  between  ACE  genotype  and 
BDKRB2 genotype on LV growth, cardiovascular risk and on performance phenotypes 
may  be  due  to  metabolic  alterations  within  cardiac  and  skeletal  muscle.    The  data 
presented in Chapters 5 confirm that alteration of ACE activity can affect mitochondrial 
coupling in these cell types.  If this association holds true, then could common genetic 
variation in mitochondrial uncoupling proteins alter the same human cardiovascular and 
performance phenotypes as has been described for variation in the ACE and BDKRB2 
genes?  Any such association may strengthen the argument that mitochondrial function 
or dysfunction is the primary mover in these (patho)physiological states. 
 
The  UCPs  are  attractive  candidates  for  modulating  human  metabolic  rate  and 
performance.  Both UCP2 and UCP3 are also negative regulators of mitochondrial ROS 
generation  in-vitro  (Echtay  et  al.  2002)  and  in  animal  models  of  sepsis  and 
inflammation (Pecqueur et al. 2001; Sun et al. 2003).  The UCP2/3 genetic locus has 
been associated with differences in basal metabolic rate  (Bouchard et al. 1997) and 
body mass index in children (Yanovski et al. 2000) and in adults (Cassell et al. 1999; 
Esterbauer  et  al.  2001)  but  the  associations  have  not  been  replicated  in  all  studies 
(Dalgaard et al. 1999; Dalgaard et al. 2001).  A common, functional promoter variant 
has been described (Esterbauer et al. 2001), UCP2-866G>A, which is at the junction 
between negative and positive cis-acting DNA regions, and within a region containing 
binding sites for hypoxia, inflammation and pancreatic β-cell-specific binding factors.  6.  THE EFFECT OF ACE-INHIBITION ON MYOCYTE 
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The rare (A) allele has been associated with lower gene transcription (repression) in 
somatic non-β cells (Krempler et al. 2002), but more effective gene transcription in 
pancreatic β cells with reduced markers of β cell function (Krempler et al. 2002) as well 
as measures of reduced GSIS (Sesti et al. 2003).  The A allele has been associated with 
protection from obesity (Esterbauer et al. 2001), but is associated with the presence of 
diabetes in obese subjects (Krempler et al. 2002).  A common promoter variant has also 
been described in the UCP3 gene (-55C>T) (Cassell et al. 2000).  The variant allele has 
been associated with obesity in a recessive manner in several studies  (Cassell et al. 
2000; Otabe et al. 2000; Halsall et al. 2001). 
 
It could be anticipated that the UCP2-866A allele would be associated with lower UCP2 
activity in cardiac and skeletal muscle and thus both increased mitochondrial coupling 
(increased  ‗efficiency‘),  but  as  a  result,  increased  mitochondrial  ROS  generation.  
Similarly, the UCP3-55T allele may also represent a thrifty genotype, with enhanced 
mitochondrial coupling and preservation of substrate supply.  I hypothesised that these 
two  functional  variants  might  therefore  be  associated  with  prospective  changes  in 
cardiac muscle mass and indices of skeletal muscle performance, as well as prospective 
CHD risk, which itself may be related to excess mitochondrial ROS generation.  As 
such,  I  hypothesised  that  genetic  variation  at  the  UCP2/UCP3  locus  might  also  be 
associated  with  systemic  markers  of  oxidative  stress  amongst  a  cohort  of  diabetic 
patients and systemic markers of inflammation during strenuous exercise. 
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6.1  GENETIC VARIATION IN UCP2 AND UCP3  AND LV MASS  
The baseline characteristics of the 141/212 study subjects who completed army training 
in the prospective Big Heart 2 (Bassingbourn 2 ) study of the effects training on LV 
mass as assessed by CMR were described in Table 3.1. 
 
 
6.1.1  UCP2-866G>A genotype 
Of  the  study  subjects,  136/141  (97%)  were  successfully  genotyped  for  the  UCP2-
866G>A gene variant.  The genotype frequency (GG 36.0%, GA 50.7%, AA 13.2%) 
was consistent with the Hardy-Weinberg equilibrium (χ
2=0.67; P=0.41) and rare (A) 
allele  frequency  (0.386)  was  similar  to  previous  reports  (Esterbauer  et  al.  2000).  
UCP2-866AA homozygotes had higher systolic blood pressures (SBP) at baseline than 
G allele carriers (Table 6.1; ANOVA 3 way analysis P=0.04, AA vs. G allele ANOVA 
P = 0.015).  There was no difference between UCP2 genotypes and either BMI or lean 
body mass, but adipose tissue mass was significantly higher in UCP2AA homozygotes 
(3 way analyses ANOVA P = 0.03, linear trend P = 0.007; AA vs. G allele carriers  P = 
0.05). 
 
Before the onset of training, LV mass was independent of UCP2 genotype (Figure 6.1; 
Table 6.1).  Following training, however, the AA carriers had significantly higher LV 
mass than G allele carriers (204 ± 29 g vs. 190 ± 25 g vs. 192  ± 23 g for AA vs. GA vs. 
GG, respectively; P = 0.13 ANOVA; P < 0.05 for AA vs. G allele; Table 6.1).  The 
difference in LV mass persisted after correction for SBP, BSA, adipose and lean mass.  6.  THE EFFECT OF ACE-INHIBITION ON MYOCYTE 
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There was no significant association with training-related change in LV mass.    All data 
suggested a recessive effect of the A allele. 
 
 
6.1.2  UCP3-55C>T genotype 
The genotype frequency (CC 51.5%, CT 38.5%, TT 10.4%) was consistent with Hardy-
Weinberg equilibrium and rare allele frequency (0.296) was similar to previous reports 
(Cassell et al. 2000; Meirhaeghe et al. 2000).  Baseline characteristics were independent 
of UCP3-55C>T genotype: in particular there was no association between BMI, lean 
mass or adipose mass and genotype (Table 6.2).  LV mass indexed to lean body mass 
(LVMI
LM) was significantly higher in TT homozygotes after training.   
 
There was no evidence of LD between UCP2-866G>A and UCP3-55C>T genotypes (Δ 
=  0.23;  P =  0.14).   Haplotypic  analysis (combining  UCP2-866GG+GA and  UCP3-
55CC+CT)  provided  small  groups  for  comparison.    The  UCP2-866G+/UCP3-55C+ 
haplotype had the smallest mean LV mass before training and this was significant after 
training (P = 0.04 linear trend; Table 3.3; Figure 3.1) and reached greater statistical 
significance when indexed to lean mass (P = 0.03 for ANOVA; P = 0.01 for linear 
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Table 6.1.  Baseline characteristics of Big Heart 2 Study sample by UCP2-866G>A and UCP3-55C>T variants 
 
Trait 
UCP2 -866G>A Genotype  UCP3 -55C>T Genotype 
GG 
n = 49 
GA 
n = 69 
AA 
n = 18 
CC 
n = 69 
CT 
n = 52 
TT 
n = 14 
Age (years)  19.0 (1.7)  19.9 (2.7)  19.9 (3.1)  19.4 (2.3)  19.8 (2.7)  19.9 (2.8) 
Systolic blood pressure (mmHg)  118 (12)  116 (10)  125 (14)*  119 (13)  117 (10)  118 (12) 
Diastolic blood pressure (mmHg)  67 (13)  65 (9)  67 (11)  66 (11)  68 (11)  63 (9) 
Body mass index (kg.m
-2)  22.9 (1.9)  23.2 (2.3)  23.5 (2.7)  23.3 (1.9)  22.9 (2.5)  22.9 (2.1) 
Lean mass (kg)  59.2 (6.0)  58.5 (6.2)  59.0 (6.0)  58.9 (6.3)  58.8 (5.8)  58.3 (6.1) 
Adipose tissue mass (kg)  11.1 (2.9)  12.5 (4.2)  14.0 (4.1)†  12.2 (3.5)  12.1 (4.5)  11.7 (3.0) 
 
 
*P=0.04 for GG vs. GA vs. AA by ANOVA, P=0.015 for AA vs. G allele 
†P=0.03 for GG vs. GA vs. AA by ANOVA, P=0.007 for linear trend 
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Table 6.2  Training related changes in cardiac parameters by UCP2-866G>A and 
UCP3-55C>T genotypes and haplotypes 
Cardiac traits  
UCP2 -866G>A Genotype   
P 
ANOVA 
 
P 
G+ vs. AA 
GG  GA  AA 
LV mass pre-training (g)  184.2 (22.7)  182.7 (27.0)  191.2 (25.4)  0.45  0.67 
LVMI
LM pre-training (x10
-3)  3.11 (0.31)  3.17 (0.36)  3.29 (0.39)  0.19  0.13 
LV mass post training (g)  192.3 (22.7)  190.4 (24.8)  203.6 (28.6)  0.13  0.04 
LVMI
LM post training (x10
-3)  3.17 (0.32)  3.21 (0.34)  3.37 (0.39)  0.12  0.05 
Change in LV mass (%)  4.8 (8.8)  4.9 (7.9)  6.6 (6.7)  0.70  0.40 
Change in LV stroke volume 
(%)  10.4 (31.8)  6.8 (26.7)  18.0 (31.3)  0.24  0.09 
Change in RV stroke volume 
(%)  8.4 (19.6)  8.0 (22.7)  22.2 (25.9)  0.05  0.01 
  UCP3-55C>T Genotype 
P 
ANOVA 
P 
C+ vs. TT 
  CC  CT  TT 
LV mass pre-training (g)  186.5 (24.3)  179.8 (27.4)  188.4 (23.2)  0.29  0.52 
LVMI
LM pre-training (x10
-3)  3.17 (0.34)  3.15 (0.38)  3.26 (0.27)  0.61  0.34 
LV mass post training (g)  194.2 (24.8)  188.7 (24.7)  198.2 (26.3)  0.32  0.37 
LVMI
LM post training (x10
-3)  3.20 (0.35)  3.19 (0.33)  3.42 (0.27)  0.11  0.04 
Change in LV mass (%)  4.5 (8.0)  5.7 (8.6)  5.2 (4.3)  0.29  0.9 
Change in LV stroke volume 
(%)  13.0 (24.8)  7.7 (22.9)  3.9 (23.1)  0.71  0.3 
Change in RV stroke volume 
(%)  11.4 (23.6)  9.0 (22.3)  6.5 (17.3)  0.05  0.5 
  UCP2-886/UCP3-55 haplotypes 
P 
ANOVA 
P 
Linear 
trend    G+ / C+ 
N=106 
G+ / TT 
N=9 
AA / C+ 
N=14 
AA / TT 
N=4 
LV mass pre-training (g)  183.2 
(25.3) 
187.9 
(26.1) 
190.1 
(27.8) 
195.0 
(16.7)  0.62  0.19 
LVMI
LM pre-training (x10
-3)  3.15 (0.34)  3.31 (0.27)  3.32 (0.42)  3.20 (0.32)  0.25  0.11 
LV mass post training (g)  190.7 
(23.8) 
195.1 
(29.0) 
202.0 
(30.8) 
209.3 
(21.9)  0.22  0.04 
LVMI
LM post training (x10
-3)  3.17 (0.32)  3.50 (0.25)  3.38 (0.42)  3.34 (0.33)  0.03  0.01 6.  THE EFFECT OF ACE-INHIBITION ON MYOCYTE MITOCHONDRIAL FUNCTION 
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G+ = UCP2-866G allele; C+ = UCP3-55C allele 
 
 
Figure 6.1.  Pre and post left ventricular (LV) mass measured by cardiac MRI in healthy young men according to UCP2-866G>A and UCP3-
55C>T genotypes and combined haplotype. 
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6.2.  PROSPECTIVE CARDIOVASCULAR RISK AND GENETIC VARIATION OF 
UCP2 AND UCP3  
Subjects were drawn from the NPHSII study of healthy UK men (Methods 2.1.2) 
 
6.2.1  UCP2-866G>A (Dhamrait et al. 2004)  
A  total  of  2695  from  2775  study  subjects  with  DNA  available  (97.1%)  were  successfully 
genotyped, whose baseline characteristics by CHD event status (which did not differ from those 
in whom genotyping failed) are presented in Table 6.3.  Genotype distribution was consistent 
with Hardy-Weinberg equilibrium (χ
2=0.04; P=0.84), and both genotype distribution and rare 
(A) allele frequency of 0.37 (0.35 - 0.38) were similar to that of healthy controls previously 
reported (Esterbauer et al. 2001; Sesti et al. 2003).  Homozygosity for the A allele was more 
prevalent  amongst  obese  subjects  (64/375  obese  vs.  297/2316  non-obese;  P=0.03)  and  was 
associated with a significant elevation in baseline DBP.  All other baseline characteristics were 
independent of UCP2 genotype.   
 
CHD risk was substantially elevated amongst those of UCP2-866AA genotype (HR 2.22 [1.53 - 
3.22] for AA vs. GG genotype; P = 0.0002; Table 6.5).  The hazard ratios demonstrated a 
recessive effect of the A allele (HR 2.08 [1.49 – 2.86]; P < 0.0001 for AA vs. GA+GG).  The 
doubling in risk remained highly statistically significant even after adjustment for all baseline 
characteristics including BMI (HR 2.05 [1.28 – 3.26]; P = 0.003 for AA vs. GA+GG).  CHD 
risk  was  doubled  amongst  AA  homozygotes  without  traditional  risk  factors  for  CHD,  for 
example non-obese subjects, non-diabetic or normotensive subjects (Figures 6.2 A-C; Table 
6.6).  Amongst the small group of diabetics, 38.5% (5/13) UCP2-866AA carriers had a CHD 
event (HR 4.00 [1.55 – 10.31]; P = 0.004 for diabetic AA vs. non-diabetic AA; Figure 6.2C). 
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Table 6.3.  Baseline characteristics and genotype frequencies  by coronary artery disease event status for 2695 men from the Second 
Northwick Park Heart Study (NPHSII) genotyped for the UCP2-866G>A gene variant.  Data are mean (SD) unless otherwise stated. 
Trait 
Controls 
No CHD event 
n = 2491 
Cases 
CHD event 
n = 204 
Probability 
Age (years)  56.0 (3.4)  56.6 (3.5)  0.04 
Systolic Blood Pressure (mmHg)  138.0 (19.1)  143.8 (20.1)  <0.0001 
Diastolic Blood Pressure (mmHg)  84.3 (11.3)  87.8 (11.6)  <0.0001 
Body Mass Index (kg.m
-2)  26.4 (3.5)  27.1 (3.4)  0.004 
Current smoking % (n)  27.5% (685)  38.2 % (78)  0.001 
Diabetes % (n)  2.1% (51)  6.4% (13)  <0.0001 
Cholesterol (mmol.l
-1)  5.70 (1.00)  6.07 (1.01)  <0.0001 
Triglyceride (mmol.l
-1)*  1.77 (0.93 )  2.09 (1.12)  <0.0001 
CRP (mg.l
-1)* ; N=721  1.20 (1.33) N=623   4.65 (5.07) N=98  <0.0001 
Fibrinogen (g.l
-1)*  2.70 (0.51)  2.84 (0.50)  0.0003 
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Table 6.4.  Baseline characteristics in NPHS II by UCP2-866G>A genotype.  Data are mean (SD) unless otherwise stated. 
Trait 
UCP2 -866G>A Genotype 
GG 
n = 1088 
GA 
n = 1245 
AA 
n = 362 
Probability 
3 way 
Probability 
G+ vs. AA 
Age (years)  56.1 (3.4)  56.1 (3.4)  56.1 (3.5)  0.99  0.93 
Systolic blood pressure (mmHg)  138.5 (19.2)  138.1 (18.9)  139.7 (20.3)  0.38  0.19 
Diastolic blood pressure (mmHg)  84.2 (11.2)  84.4 (11.4)  86.2 (11.1)  0.01  0.003 
Body mass index (kg.m
-2)  26.5 (3.5)  26.4 (3.5)  26.7 (3.4)  0.4  0.22 
Current smoking  % (n)  28.0% (305)  28.9% (360)  27.1% (98)  0.76  0.57 
Diabetes n (%)  13 (0.012)  25 (0.020)  26 (0.024)  0.22  0.10 
Cholesterol (mmol.l
-1)  5.71 (1.02)  5.72 (1.00)  5.78 (1.01)  0.59  0.34 
Triglyceride (mmol.l
-1) *  1.78 (0.94)  1.78 (0.93)  1.88 (1.03)  0.2  0.07 
CRP (mg.l
-1)*; n  1.25 (1.48); n=295 
1.25 (1.37) 
n=321 
1.53 (1.76) 
n=105 
0.23  0.09 
Fibrinogen (g.l
-1)  2.71 (0.52)  2.70 (0.51)  2.71 (0.51)  0.79  0.64 
* geometric mean (approximate SD). IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 RECEPTOR AND PROSPECTIVE CARDIOVASCULAR PHENOTYPES? 
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Table 6.5.  CHD risk in NPHS II in subjects stratified by UCP2-866G>A genotype. 
 
UCP2-866G>A Genotype 
Number with CHD events  
/ total number (%) 
Hazard Ratio* 
(95% CI) 
Fully Adjusted Hazard Ratio† 
(95% CI) 
 
GG 
 
69 / 1088  (6.3 %) 
 
1 
 
1 
GA  87 / 1245  (7.0 %)  1.13  (0.82 – 1.55)  1.15  (0.71 – 1.87) 
AA  48 / 362  (13.3 %)  2.22  (1.53 - 3.22)  2.22  (1.29 – 3.82) 
Probability    0.0002  0.01 
 
GG + GA 
 
156 / 2333 (6.7%) 
 
1 
 
1 
AA  48 / 362  (13.3%)  2.08  (1.49 –  2.86)  2.05  (1.28 – 3.26) 
Probability    <0.0001  0.003 
 
* Adjusted for age, practice. 
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Table 6.6.  Relative risk of CHD event according to traditional risk factors of smoking, obesity, hypertension and diabetes for individuals 
stratified by UCP2-866G>A genotype. 
 
Characteristic 
UCP2 AG+GG 
Events / Total No. 
UCP2 AA 
Events / Total No. 
Relative Risk* 
[95% CI] 
Probability 
Non-smoker 
Smoker 
90 / 1668 (5.4%) 
66 / 665 (9.9%) 
36 / 264 (13.6%) 
12 / 98 (12.2%) 
2.71 [1.83 – 4.01] 
1.23 [0.66 -2.28] 
<0.001 
0.51 
BMI<30kg.m
-2 
BMI≥30kg.m
-2 
133 / 2019 (6.6%) 
23 / 311 (7.4%) 
32 / 297 (10.8%) 
16 / 64 (25.0%) 
1.77 [1.20 -2.61] 
3.17 [1.65 – 6.10] 
0.004 
0.001 
SBP<160mmHg 
SBP≥160mmHg 
123 / 2021 (6.1%) 
33 / 310 (10.7%) 
35 / 300 (11.7%) 
13 / 62 (21.0%) 
1.94 [1.33 -2.84] 
2.41 [1.26 – 4.60] 
0.001 
0.008 
DBP<95mmHg 
DBP≥95mmHg 
110 / 1934 (5.7%) 
46 / 396 (11.6%) 
35 / 283 (12.4%) 
13 / 79 (16.5%) 
2.23 [1.52 -3.28] 
1.57 [0.85 – 2.92] 
<0.001 
0.15 
* Adjusted for age & practice;  SBP Systolic blood pressure, DBP Diastolic blood pressure, BMI Body mass index IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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Figure 6.2.  Relative CHD risk in NPHSII by UCP2-866G>A genotype according to 
presence  or  absence  of  risk  factors:    A.  obesity;  B.  Systolic  hypertension;  C. 
diabetes 
 
BMI = Body mass index (kg.m
-2); G+ = G allele carriers 
SBP>160 = systolic blood pressure>160mmHg; NT=normotensive 
DM = diabetes mellitus 
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6.2.2  UCP3-55C>T  
Of  the  2775  study  subjects  with  DNA  available,  2694  (97%)  were successfully  genotyped.  
Genotype distribution was consistent with Hardy-Weinberg (χ
2 = 3.946, P = 0.05) and the rare 
(T) allele frequency of 0.23 (0.21 - 0.24) was similar to that in previous reports of European 
non-diabetic samples (Cassell et al. 2000; Meirhaeghe et al. 2000).  
 
All baseline characteristics were independent of UCP3 genotype (Table 6.7).  Contrary to a 
previous report (Meirhaeghe et al. 2000), there was no association with obesity, lipid parameters 
nor with presence of diabetes 
 
There was no association between UCP3-55C>T genotype and CHD risk (Table 6.8).  In the 
small number of obese or diabetic TT homozygotes there did appear to be an elevated CHD 
risk, but there was no significant evidence of statistical interaction between genotype and either 
presence of obesity or diabetes. 
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Table 6.7.  Baseline characteristics of study subjects in NPHS II by UCP3-55C>T genotype.   
 
 
 
 
 
 
 
 
 
 
 
Data are mean (SD) unless otherwise stated.    * Geometric means (approximate SD) 
Trait 
UCP3 -55C>T Genotype 
CC 
n = 1088 
CT 
n = 1245 
TT 
n = 362 
P 
Age (years)  56.0 (3.5)  56.2 (3.4)  55.7 (3.3)  0.17 
Systolic blood pressure (mmHg)  137.1 (18.8)  136.9 (18.8)  138.0(19.0)  0.78 
Diastolic blood pressure (mmHg)  84.4 (10.9)  84.6 (11.9)  85.2 (11.6)  0.67 
Body mass index (kg.m
-2)  26.3 (3.4)  26.2 (3.4)  25.9 (3.3)  0.38 
Current smoking  % (n)  29.0% (473)  27.9% (252)  22.6% (35)  0.23 
Diabetes n (%)  2.5% (40)  2.2% (20)  3.2% (5)  0.74 
Cholesterol (mmol.l
-1)  5.70 (1.01)  5.77 (1.01)  5.79 (1.01)  0.22 
Triglyceride (mmol.l
-1) *  1.79 (0.95)  1.81 (0.94)  1.77 (0.96)  0.90 
CRP (mg.l
-1)*; n  1.25 (1.48); n=295  1.25 (1.37) n=321  1.53 (1.76) n=105  0.23 
Fibrinogen (g.l
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Table 6.8.  CHD risk in NPHS II by UCP3-55C>T genotype 
 
 
 
 
 
 
 
 
 
* Adjusted for age, practice. 
† Adjusted for age, practice, BMI, DBP, smoking, cholesterol, triglycerides, fibrinogen, diabetes and CRP. 
 
 
 
UCP3-55C>T Genotype 
Number with CHD events  
/ total number (%) 
Hazard Ratio* 
(95% CI) 
Fully Adjusted Hazard Ratio† 
(95% CI) 
 
CC 
 
119 / 1634  (7.3 %) 
 
1 
 
1 
CT  78 / 905 (8.6%)  1.20  (0.90 – 1.59)  1.21  (0.91 – 1.62) 
TT  14 / 155 (9.0 %)  1.09  (0.62 – 1.91)  1.08  (0.61 – 1.91) 
Probability    0.48  0.43 IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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6.2.3  UCP3/2 haplotypes  
 
There was no evidence of LD between the UCP3-55C>T and UCP2-866G>A variants (Table 
6.9; Δ = 0.20, P < 0.001) and haplotype frequencies were similar to those from young male 
British army recruits from the Big Heart Study (section 6.1).  Those individuals who were 
UCP3-55TT/UCP2-866AA homozygotes had the highest CHD risk (compared to the common 
homozygote for both).  However, there was no evidence of interaction between genotypes in 
determining  CHD  risk  (P  =  0.2),  although  risk  appeared  to  rise  more  steeply  according  to 
UCP2-866G>A genotype amongst TT homozygotes (Figure 6.3).  When the risk conferred by 
particular haplotypes was considered amongst cases and controls (Table 6.10; Figure 6.4), a 
highly significant effect was observed overall (χ
2 test P < 0.00005).  The risk haplotype (more 
common amongst cases than controls) was UCP3-55T/UCP-866A (P =0.001) with the converse 
true of the common UCP3-55C/UCP2-866G haplotype (P = 0.005). 
 
 
Table 6.9.  UCP3/2 haplotype distribution in NPHSII 
 
 
 
 
 
 
 
 
 
NPHS2  UCP2-866G>A  
GG  GA  AA 
UCP3       
-55C>T 
CC  759  678  170 
CT  273  473  144 
TT  34  72  45 IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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Table 6.10.  UCP3/2 haplotype frequencies in cases and controls from NPHSII 
Haplotype  Frequency 
P 
UCP3-55  UCP2-866  All  Controls  Cases 
C  G  0.531  0.535  0.472  0.005 
C  A  0.244  0.242  0.271  0.19 
T  G  0.103  0.105  0.078  0.08 
T  A  0.122  0.117  0.177  0.001 
 
Figure 6.4.  UCP3/UCP2 haplotype frequencies in cases and controls from NPHS II 
 
Figure 6.3.  Relative CHD risk in NPHS II according to UCP3/UCP2 haplotypes.  
The relative risk (± 2 standard deviations) is shown for each haplotype. 
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6.3.   SKELETAL MUSCLE PERFORMANCE AND UCP GENOTYPES. 
The skeletal muscle efficiency study subjects were healthy male British army recruits 
undergoing basic army training and healthy female volunteers from the University of 
Staffordshire  who  underwent  an  endurance  training  programme  (Methods  2.1.4).  
Genotype and haplotype frequencies were also sought in elite runners drawn from the 
British Olympic Athletes study (Methods 2.1.5). 
 
6.3.1.  Skeletal muscle efficiency 
Data on those who had completed training and who were successfully genotyped for 
UCP2-866G>A (58/85; 68%) and UCP3-55C>T (61/85; 72%) are shown in Table 6.11.  
The  low  genotyping  rate  was  due  to  degradation  of  DNA  from  the  original  delta 
efficiency study.  There was no difference in baseline characteristics between those with 
and without genotype data.  There was no frequency difference in either UCP2-866 
G>A or UCP3-55C>T genotype between those who did and did not complete training.  
In subjects with complete data, both UCP2 and UCP3 genotypes were consistent with 
predicted  Hardy  Weinberg  frequencies,  with  the  rare  allele  frequencies  similar  to 
previous  reports  (Cassell  et  al.  2000;  Esterbauer  et  al.  2001)  and  to  the  genotype 
frequency found in Bassingbourn 2 and NPHSII studies. 
 
There  were  no  significant  associations  between  UCP3  genotype  and  any  baseline 
measurements including BMI and DE (Table 6.12).   
 
There  were  no  significant  associations  between  UCP2  genotype  and  baseline 
measurements, including DE (Table 6.12).  UCP2-866A allele carriers had significantly 
higher DE after training (Table 6.12) due to a greater increase in DE associated with IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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training (-0.2 ±3.6% vs. 1.7 ±2.8% vs. 2.3 ±3.7% for GG vs. GA vs. AA, respectively; P 
=  0.07  ANOVA;  P  =  0.03  by  linear  trend;  P  =  0.02  for  A  allele  carriers  vs.  GG 
homozygotes; Figure 6.5A).  In univariate analysis, UCP2-866 genotype and presence 
or  absence  of  the  UCP2-866A  allele  accounted  for  8.4%  and  7.4%  (adjusted  R
2, 
respectively) of the interindividual variability in the absolute change in DE associated 
with  endurance  training.    Of  note,  in  multivariate  analysis  there  was  a  significant 
interaction between UCP2-866G>A and UCP3-55C>T genotypes and their association 
with changes in DE with training (R
2 = 0.153; adjusted R
2 = 0.137, P for interaction = 
0.003; Figure 6.5B) which was independent of the effect of either single polymorphism 
and also baseline characteristics of gender, height and mass.  In a multivariate model, 
the  UCP2-866A  allele  and  the  interaction  between  UCP2  and  UCP3  genotypes 
accounted for 14.8% of the variation in training related change in DE (adjusted R
2). 
 
Table 6.11.  Baseline characteristics of the 131 subjects in the delta efficiency study 
 
Trait  Mean (SD) 
Age (years)  20.7 (4.4) 
Gender (proportion male)  67% 
Mass (kg)  70.4 (9.4) 
Height (m)  1.74 (0.08) 
Delta efficiency (%)  24.6 (2.6) 
UCP3-55C>T  CC / CT / TT (n) 
T allele frequency (95% C.I.) 
29 / 27 / 5 
0.303 (0.222 -0.385) 
UCP2-866G>A  GG / GA / AA (n) 
A allele frequency (95% C.I.) 
21 / 22 / 15 
0.448 (0.358-0.539) 
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Table  6.12.    Training  related  changes  in  delta  efficiency  according  to  UCP2-
866G>A and UCP3-55C>T genotypes 
 
   
 
UCP2-866G>A genotype 
Delta efficiency (%) 
 
Pre  Post  Absolute 
change (%) 
Proportional 
change (%) 
UCP2-866  GG (21)  24.6 ± 2.6  24.4 ± 2.8  -0.2 ± 3.6  0.2 ± 14.6 
  GA (22)  24.3 ± 3.0  26.1 ± 3.1  1.7 ± 2.8  7.9 ± 12.6 
  AA (15)  24.0 ± 2.2  26.2 ± 3.3  2.3 ± 3.7  10.1 ± 15.1 
  A allele  24.2 ± 2.7  26.1 ± 3.1  2.0 ± 3.1  8.8 ± 13.5 
P ANOVA  0.8  0.1  0.07  0.08 
P linear trend  0.9  0.07  0.03  0.03 
P GG vs. A allele  0.5  0.04  0.02  0.03 
UCP3-55  CC (29)  24.2 ± 2.8  25.8 ± 2.9  1.5 ± 3.3  7.1 ± 13.4 
  CT (27)  24.6 ± 2.7  25.3 ± 3.3  0.6 ± 3.5  3.3 ± 14.7 
  TT (5)  26.1 ± 1.1  24.9 ± 1.2  -1.2 ± 1.8  -4.3 ± 6.6 
P ANOVA  0.4  0.8  0.2  0.2 
P Linear trend  0.4  0.5  0.09  0.08 
 
Data are expressed as mean ± SD 
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Figure 6.5.  Training related changes in delta efficiency (mean ± SEM) 
A.  by UCP3-55C>T and UCP2-866G>A genotypes  
B.  by UCP3 and UCP2 haplotypes 
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Table 6.13.  UCP3-55C>T genotype distribution amongst 81 British Olympic 
athletes according to competitive distance event. 
 
 
 
6.3.2.  British Olympic Athletes 
Of those athletes with DNA available, 81/86 (94.1%) were successfully genotyped for 
the  UCP3-55C>T  gene  variant.    Genotype  distribution  was  in  Hardy-Weinberg 
equilibrium  (χ
2=  2.29;  P=0.13)  and  T  allele  frequency  (0.198  [0.136-0.259])  were 
similar  to  previous  reports.    There  was  no  difference  in  distance  running  event  by 
genotype (P=0.2 by gene counting for ≤200m vs. ≥400m; Table 6.13). 
UCP2-866G>A  genotyping  was  successful  in  81/86  (94.1%)  of  those  subjects  with 
DNA available.  Genotype distribution was in Hardy-Weinberg equilibrium (χ
2= 0.195; 
P=0.66) and the A allele frequency was similar to previous reports.   There was no 
difference in distance running event by genotype (P=0.15 for ≤200m vs. ≥400m; Table 
6.14).   
Running 
Distance 
UCP3-55C>T 
Total  T allele frequency 
CC  CT  TT 
 
≤200m 
 
13 
 
4 
 
 
17 
 
0.118 (0.009-0.226) 
400-3000m  19  12  1  32  0.219 (0.117-0.320) 
≥5000m  18  14    32  0.219 (0.117-0.320) 
 
Total 
 
50 
 
30 
 
1 
 
81 
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Table 6.14.  UCP2-866G>A genotype distribution amongst 81 British Olympic 
athletes according to competitive distance event. 
 
Running 
Distance 
UCP2-866G>A 
Total  A allele frequency 
GG  GA  AA 
 
≤200m 
 
12 
 
5 
 
1 
 
18 
 
0.194 (0.065-0.324) 
400-3000m  14  17  1  32  0.297 (0.185-0.409) 
≥5000m  14  13  4  31  0.339 (0.221-0.457) 
 
Total 
 
40 
 
35 
 
6 
 
81 
 
0.290 (0.220-0.360) 
 
 
 
UCP3/2  haplotype  distributions  are  shown  in  Tables  6.15  and  6.16.    The  common 
haplotype  was  UCP3-55C/UCP2-866G.    There  were  no  UCP3-55T/UCP2-866A 
carriers amongst the small number of Afro-Caribbean athletes.  There was no difference 
in  haplotype  frequencies  between  athletes  whose  competed  above  or  below  400m 
(Figure  6.6;  P=0.08).    The  common  haplotype  (UCP3-55C/UCP2-866G)  frequency 
decreased with distance run and the UCP3-55C/UCP2-866A haplotype increased with 
distance run, i.e. variation at the UCP2-866G>A locus in UCP3-55C allele carriers.  
Interestingly,  the  haplotype  frequencies  amongst  the  Caucasian  and  Afro-Caribbean 
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Table 6.15.  UCP3/2 haplotype distribution in the BOA study, both overall and 
amongst the greater number of Caucasian subjects.   
 
Overall  UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  27  20  1 
CT  12  13  4 
TT    1   
 
Figure 6.6.  UCP3-55C>T and UCP2-866G>A haplotype distribution according to 
running distance and ethnicity of British Olympic athletes. 
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Table 6.16.  UCP3/2 haplotype frequencies according to ethnicity and preferred running discipline amongst British Olympic track athletes.  
Haplotype frequencies from the Bassingbourn 3 study are included for comparison. 
 
 
Haplotype  Haplotype frequency 
UCP3-55  UCP2-866  BH3  Overall  Cauc  Afro-Car 
≤ 200 m  ≥ 400m 
Overall  Cauc  Afro-Car  Overall  Cauc 
C  G  0.509  0.613  0.595  0.75  0.787  0.796  0.786  0.563  0.560 
C  A  0.258  0.188  0.191  0.188  0.096  0.054  0.143  0.215  0.216 
T  G  0.126  0.105  0.103  0.063  0.066  0.054  0.071  0.117  0.113 
T  A  0.107  0.094  0.110  0  0.051  0.096  0  0.105  0.111 
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6.4  DIABETIC STUDY, OXIDATIVE STRESS AND UCP GENOTYPES (UDACS)  
(DHAMRAIT ET AL. 2004) 
 
CHD was present in 105 out of the 465 men (22.5%), whose mean age, plasma triglyceride and 
CRP levels were higher, and plasma TAOS significantly lower, than those without CHD (Table 
6.17).    A  significantly  higher  proportion  of  subjects  with  CHD  were  taking  ACEi,  statins, 
insulin and metformin- potentially accounting for their lower total cholesterol and BP.   
 
Of the 485 Caucasian diabetic men from UDACS, 465 (95.9%) were successfully genotyped for 
the UCP2-866G>A variant (Table 6.17).  The rare (A) allele frequency was 0.34 (0.31-0.37) 
and similar to that of healthy male cohorts from Big Heart 2 and NPHSII studies.  There was no 
genotype or allelic association with the presence of CHD (A allele frequency 0.34 in both those 
with and without CHD, P=0.99).   
 
The laboratory work regarding plasma markers of oxidative stress was conducted by Dr Jeffrey 
Stephens and is therefore shown in Appendix 4.  Of note, there was a significant association 
between  plasma  TAOS  and  UCP2-866G>A  genotype,  which  remained  significant  after 
adjustment for age, triglyceride, HDL-C, glucose, HbA1c and proteinuria, and with evidence of 
interaction with CHD status.  Diabetic men with CHD who had the UCP2-866AA genotype had 
the highest level of plasma ROS of all groups tested, as measured by plasma TAOS and F2-
isoprostanes.  There was no difference in any other baseline characteristics (including treatment 
or duration of diabetes) by UCP2 genotype (data not shown).   
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Table 6.17.  Baseline  characteristics  of  diabetic  Caucasian  men  recruited  in 
UDACS. 
 
Trait  No CHD (n=360)  CHD (n=105)  P 
Age (years)  59.2 (13.9)  67.5 (11.2)  <0.0001 
Systolic blood pressure (mmHg)*  130 (128-149)  136.5 (123-151)  0.49 
Diastolic blood pressure (mmHg)*  80 (75-87)  78 (70-84)  0.007 
Body mass index (kg.m
-2)*  30 (25.2-30.9)  29.1 (24.7-32.2)  0.03 
Current smoking % (n)  11.4 (41)  21.9 (23)  0.02 
Cholesterol (mmol.l
-1)*  5.0 (1.0)  4.5 (1.0)  <0.0001 
TC:HDL*  3.7 (3.1-4.7)  3.8 (3.1-4.6)  0.77 
Triglycerides (mmol.l
-1)*  1.5 (1.0 -2.3)  1.8 (1.2-2.7)  0.03 
CRP (mg.l
-1)*  1.41 (0.83 – 2.38)  2.02 (1.04-3.30)  0.004 
TAOS (%)  43.3 (13.2)  40.3 (13.7)  0.04 
Type 2 diabetes % (n)  70.6 (254)  95.2 (100)  <0.0001 
Duration of diabetes (years)†  11 (5-20)  12 (6-18)  0.67 
HbA1c (%)*  7.7 (6.7 -7.8)  7.5 (6.5-8.8)  0.62 
Creatinine (mmol.l
-1)*  93 (84 -109)  105 (88-124)  0.001 
Proteinuria (%)  10%  17%  0.05 
UCP2-866G>A Genotype frequency 
(GG/GA/AA)  154/165/41  44/51/10  0.820 
UCP2-866A allele frequency (95%CI)  0.34 (0.31-0.38)  0.34 (27-0.40)  0.99 
Drug Therapy       
Insulin (%)  34.6  47.3  0.05 
Sulphonylureas (%)  29.6  40.3  0.04 
Metformin (%)  42.4  63.6  <0.0001 
Aspirin (%)  39.6  77.1  <0.0001 
ACEI (%)  43.1  62.6  <0.0001 
Statins (%)  14.6  62.6  <0.0001 
Data are Mean (SD) or Median (IQR), Data transformed (*log, †square root) 
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6.5  ACUTE  INFLAMMATORY  RESPONSE  AND  CHANGES  IN  SERUM 
ACE ACTIVITY DURING INTENSE PHYSICAL EXERCISE 
 
Extreme exercise drives an acute phase response similar to that seen in sepsis (Castell et 
al. 1997), but more readily quantified and prospectively studied (Pedersen et al. 2000). 
This response is associated with a rise in C reactive protein (CRP) (Weight et al. 1991; 
Brull et al. 2003) and interleukin-6 (IL6) levels (Ostrowski et al. 1998) driving the 
associated  and  well-defined  rise  in  fibrinogen  concentration,  which  have  been 
associated with CHD (Ridker et al. 1997; Biasucci et al. 1999; Ridker et al. 2000; 
Lindmark et al. 2001; Danesh et al. 2005).  Just as in sepsis, the magnitude of this rise 
depends  upon  both  the  magnitude  of  environmental  stimulus  and  upon  individual 
genetic variation. 
 
The effect of an 11 week exercise training programme on serum ACE activity and its 
dependence  on  ACE  was  examined.    Any  association  between  UCP2-866G>A  or 
UCP3-55C>T genotypes and plasma markers of inflammation (IL-6, CRP, fibrinogen) 
during this training period was examined. 
 
Male army recruits were selected at random for the study (Brull et al. 2002).  Of these, 
DNA was available on 223/250 individuals, whose baseline characteristics are shown in 
Table 6.18. 
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Table 6.18.  Baseline characteristics of subjects from the Bassingbourn 3 Study 
 
Trait  Mean (SD) 
Age (years)  19.4 (2.2) 
Systolic blood pressure (mmHg)  122.7 (11.2) 
Diastolic blood pressure (mmHg)  71.4 (9.1) 
Body mass index (kg.m
-2)  22.5 (2.6) 
Current smokers (%)  48.9% 
C-reactive protein (mg.l
-1)*  0.45 (0.20 - 1.26) 
Interleukin-6 (pg.ml
-1)*  0.65 (0.40 – 1.04) 
Fibrinogen (g.l
-1)  2.61 (0.56) 
Serum ACE activity (nmol his-leu.ml
-1.min
-1)  29.7 (9.6) 
UCP3-55C>T  CC / CT / TT (n) 
T allele frequency (95% C.I.) 
132 / 76 / 13 
0.23 (0.191 – 0.270) 
UCP2-866G>A  GG / GA / AA (n) 
A allele frequency (95% C.I.) 
85 / 110 / 25 
0.36 (0.319 – 0.409) 
 
 
 
6.5.1  ACE genotype and serum ACE activity during training 
The objective was to select  twenty subjects of each ACE  genotype followed during 
training.  Due to prospective recruit drop-out, the final genotype distribution was ACE II 
17,  ACE  ID 21 and  ACE DD 23 (total  N=61).   Serum ACE activity  was  normally 
distributed for all three time points.  As anticipated, there were highly significant linear 
correlations in serum ACE activity between each time point (pre-mid, pre-post, mid-
post;  (correlation  coefficients  >  0.68;  all  P<10
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relationship between age and serum ACE activity (correlation coefficient -0.33; P<0.01 
for all time points; Figure 6.7A).  There were no correlations between blood pressure, 
BMI or smoking status and ACE activity.  There was no significant association between 
either absolute levels or changes in levels of IL-6, CRP or fibrinogen levels and serum 
ACE activity at any time point.   
 
Mean serum ACE activity increased significantly during training (Figure 6.7B; activity 
was  29 ±10nmol  his-leu.ml
-1.min
-1 pre-training, 31 ±10 nmol his-leu.ml
-1.min
-1 mid-
training and 33 ±11 nmol his-leu.ml
-1.min
-1 end of training; repeated measures analysis 
of effect of training on serum ACE activity P < 0.004).  There was a gradual increase in 
serum ACE activity, reaching statistical significance between the mid-point and end of 
training  (mean  ±SEM  increase  of  2  ±0.7  nmol  his-leu.ml
-1.min
-1;    P<  0.004)  and 
between the beginning and end of training (mean ±SEM increase of 3 ±1.1 nmol his-
leu.ml
-1.min
-1; P < 0.004).   
 
Serum ACE activity was highly ACE I/D genotype dependent at all time points (Figure 
6.8;  all  P<10
-6).    The  training  related  increases  were  greatest  in  the  order  of  ACE 
DD>ACE  II>ACE  ID,  although  repeated  measures  analysis  suggested  no  significant 
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Figure 6.7.  Serum ACE activity by quartile of age and by ACE I/D genotype during basic army training in 61 recruits. 
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Figure 6.8.  Absolute changes in serum ACE activity during basic army training 
according to ACE genotype. 
 
 
6.5.2  Serum markers and UCP3-55C>T gene variant  
Of the subjects, 221/223 (99.1%) were genotyped for the UCP3-55C>T variant (Table 
4.9).  The genotype frequency (CC 52.8%, CT 30.4% and TT 5.2%) was consistent with 
Hardy-Weinberg equilibrium (χ
2= 0.22; P=0.64) and the rare (T) allele frequency (0.23) 
was similar to previous reports in European non-diabetic samples (Cassell et al. 2000; 
Meirhaeghe et al. 2000).  BMI was lower amongst TT individuals in a recessive manner 
(CC 22.5 ± 2.7 kg.m
-2, CT 22.4 ± 2.4 kg.m
-2, TT 20.9 ± 2.1 kg.m
-2; P=0.10 by ANOVA; 
P = 0.03 for C allele vs. TT).  There was no other association between UCP3 genotype 
and other baseline characteristics. 
Data are mean ± SEM 
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Amongst the cohort of 61 individuals with serum ACE activity measured at all time 
points,  serum  ACE  activity  was  lower  at  all  timepoints  amongst  UCP3-55  TT 
homozygotes.    Serum  ACE  activity  was  therefore  assayed  retrospectively  on  stored 
samples to increase the sample size to see whether there was a significant association 
between serum ACE activity and UCP3 genotype.  Further samples were only available 
at  the  pre  and  post  time  points  (total  pre  n=154,  total  post  n=114).    UCP3-55TT 
genotype was significantly associated with lower mean serum ACE activity throughout 
training on repeated measures analysis (P = 0.03; Figure 6.9A). 
 
There  was  no  significant  differences  in  serum  markers  of  inflammation  by  UCP3-
55C>T genotype: CRP median [IQR]: 0.44 [0.23 - 1.58] mg.l
-1 vs. 0.44 [0.18 – 0.88] 
mg.l
-1 vs. 0.32 [0.18 – 1.24] mg.l
-1 for CC vs. CT vs. TT; P=0.33 and IL-6 median 
[IQR]: 0.65 [0.43 – 1.07] pg.ml
-1 vs. 0.70 [0.40 – 1.04] pg.ml
-1  vs. 0.39 [0.17 – 0.81] 
pg.ml
-1 for CC vs. CT vs.  TT; P=0.35). 
 
 
6.5.3  Serum markers and UCP2-866G>A gene variant 
Of the study subjects, 220/223 (98.7%) were genotyped for the UCP2-866G>A variant 
(Table 6.19).  The genotype frequency (GG 34%, GA 44%, AA 10%) was consistent 
with Hardy-Weinberg equilibrium (χ
2 = 1.42; P = 0.23) and the rare (A) allele frequency 
(0.36) was similar to the previous report in European non-diabetic samples (Esterbauer 
et al. 2001).  There were no significant differences in baseline characteristics or serum 
ACE activity by UCP2-866G>A genotype (Figure 6.9B).   
 
There was no evidence of linkage disequilibrium between UCP2-866G>A and UCP3-
55C>T variants (Δ = 0.11; P = 0.63; Table 6.19).  UCP3/UCP2 combined genotype IS THERE AN ASSOCIATION BETWEEN GENETIC VARIATION IN THE BRADYKININ B2 
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analysis  demonstrated  that  UCP2-866GG/UCP3-55TT  homozygotes  had  the  lowest 
mean serum ACE activity at all time points (Figure 6.9C), significant  after training 
(ANOVA P = 0.05; linear trend P = 0.03). 
 
 
 
Table 6.19.  UCP haplotype distribution and frequency in the two Bassingbourn studies 
 
 
 
 
 
 
 
 
 
 
Haplotype  Haplotype frequency 
UCP3-55  UCP2-866  Bassingbourn 3  Bassingbourn 2 
C  G  0.509  0.499 
C  A  0.258  0.245 
T  G  0.126  0.127 
T  A  0.107  0.128 
                 
 
P=NS for difference 
 
Bassingbourn 3  UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  54  66  10 
CT  27  35  14 
TT  3  9  1 
Bassingbourn 
(Big Heart) 2 
UCP2-866G>A  
GG  GA  AA 
UCP3-
55C>T  
CC  31  28  9 
CT  26  31  5 
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Figure 6.9.  Mean serum ACE activity during basic training stratified by: 
A.  UCP3-55C>T 
B.  UCP2-86G>A genotypes 
C.   UCP2/UCP3 haplotypes. 
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6.6  DISCUSSION 
 
6.6.1  LV mass 
The UCP2-866G>A variant was associated with CMR-determined LV mass after basic 
army training in the BH2 study.  The magnitude of the effect was smaller than that for 
the BDKRB2 (+9/-9) gene variant.  LV mass was higher in the AA homozygotes at 
baseline, and this difference reached statistical significance after training, matched by 
greater  changes  in  stroke  volumes  with  training.    UCP3-55TT  genotype  was  also 
associated with higher LV mass after training after indexing to lean body mass.  This 
may in part be due to the presence of UCP3 in skeletal muscle and possible associations 
of this genotype with skeletal muscle mass.  The UCP2-866AA/UCP3-55TT haplotype 
was associated with the highest left ventricular mass after training.   
 
This is the first report of an association between either UCP2 or UCP3 genotype and 
LV mass.  It is unclear whether the ‗risk‘ haplotype (UCP2-866AA/UCP3-55TT) is 
directly causal in the development of LV growth or facilitates its development.  The 
UCP2-866A allele has been associated with lower UCP2 mRNA expression in somatic 
cells (Krempler et al. 2002).  The UCP2-866A/UCP3-55T haplotype may therefore be 
associated with lower mitochondrial UCP2 and/or UCP3 protein expression, leading to 
decreased uncoupling and therefore enhanced mitochondrial ROS production.  ROS are 
known to mediate left ventricular growth (Amin et al. 2001; Bendall et al. 2002) and 
cardiac dysfunction (Ide et al. 2001; Suematsu et al. 2003).  This may explain the non-
significant differences observed at baseline, as ROS induced cardiac growth might be 
expected to accumulate over a life-time and accelerate during a period of physiological 
stress.    Alternatively,  genetically  determined  high  ROS  levels  may  decrease  aortic 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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compliance (Delles et al. 2008),  and this will result in LVH over time (Safar et al. 
1987).   
 
Alternatively, UCP2/3 phenotype may be associated with an alteration in the balance 
between cardiac glucose and fatty acid utilisation.  There is increasing evidence that 
cardiac substrate utilisation is critical for cardiac function.  Indeed, defects in enzymes 
involved  in  fatty  acid  oxidation  cause  childhood  cardiomyopathies,  and 
pharmacological inhibition of cardiac fatty acid import induces cardiac hypertrophy and 
causes rapid death in PPARa-knockout mice.  Transgenic mice that overexpress long-
chain acyl-CoA synthetase and take up excess long chain fatty acids initially exhibit 
cardiac hypertrophy, followed by LV dysfunction and death.  Fatty acids generate more 
ATP per mol of substrate but at the expense of a greater oxygen requirement per mol of 
ATP than either glucose or lactate (Nicholls et al. 2002) and also induce a proton leak 
across the inner mitochondrial membrane (Borst et al. 1962), increasing cardiac oxygen 
consumption  for  the  same  amount  of  cardiac  external  work  in  both  the  isolated 
(Challoner et al. 1966) and whole animal model (Mjos 1971), resulting in an even lower 
actual ratio of ATP:oxygen consumed than that predicted (Brand et al. 1994).  In vitro 
administration  of  fatty  acids  induce  UCP2  mRNA  expression  in  isolated  neonatal 
cardiomyocytes and both tri-iodothyronine and phenylephrine induced UCP2 mRNA 
expression in a fatty acid dependent manner (Van Der Lee et al. 2000).  However, 
elevation  of  serum  free  fatty  acids  (by  high  fat  feeding,  fasting  or  by  induction  of 
diabetes)  all  induce  cardiac  UCP3mRNA  in  the  rat  but  do  not  alter  cardiac  UCP2 
mRNA (Depre et al. 2000; Van Der Lee et al. 2000; Van der Lee et al. 2001).  
 
Both UCP2 and UCP3 mRNA and protein expression are either increased or decreased 
in the heart depending on the animal model of LVH or heart failure used (Fukunaga et 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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al. 2000; Boehm et al. 2001; Langdown et al. 2001; Noma et al. 2001; Young et al. 
2001).  UCP2, but not UCP3, mRNA is significantly reduced in the left ventricle of 
patients with dilated cardiomyopathy together with a switch to a foetal metabolic gene 
profile  (Razeghi  et  al.  2001)  in  keeping  with  a  switch  away  from  cardiac  lipid 
metabolism to more energy efficient glucose metabolism but this may be at the expense 
of increased cardiac ROS generation. 
 
 
6.6.2  Prospective CHD risk & oxidative stress 
This is the first report to demonstrate that a common functional variant in the UCP2 
gene is associated with both increased oxidative stress and with prospective CHD risk.  
Such data support a  role for UCP2 (and hence the mitochondrial  electron transport 
chain) in the regulation of ROS generation, and highlights its potential impact upon 
CHD  risk.    The  oxidation  of  vulnerable  cell  membrane  unsaturated  lipids  by  ROS 
(Evans et al. 2002) modulates diverse signal transduction pathways (Suzuki et al. 1997; 
Harrison  et  al.  2003),  leading  to  increased  expression  of  cell  adhesion  molecules, 
induction  of  pro-inflammatory  pathways,  activation  of  matrix  metalloproteinase, 
vascular smooth muscle cell proliferation and death, and endothelial dysfunction and 
lipid peroxidation (Chisolm et al. 2000) - factors implicated in atherogenesis, to which 
the formation of oxidized LDL (OxLDL) may contribute (Suzuki et al. 1997; St-Pierre 
et al. 2001; Witztum et al. 2001; Navab et al. 2002; Harrison et al. 2003).  Elevated 
OxLDL is independently associated with increased atherosclerotic burden and increased 
CHD risk (Toshima et al. 2000; Ehara et al. 2001; Weinbrenner et al. 2003). 
 
In  vitro,  UCP2  is  activated  by  ROS  (Echtay  et  al.  2002),  whilst  selective  down-
regulation  of  UCP2  increases  endothelial  cell  ROS  generation  (Duval  et  al.  2002).  7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
LOCUS AND CIRCULATING ACE ACTIVITY? 
  284 
Thus,  under  conditions  of  oxidative  stress  (OS),  increased  UCP2  expression  should 
prove vasculo-protective (Arsenijevic et al. 2000; Echtay et al. 2002), and in support, 
UCP2  protects  against  atherosclerosis  in  LDL-receptor  deficient  mice  (Blanc  et  al. 
2003).    
 
Diabetes is associated with increased OS (Cai et al. 2000; Brownlee 2001; Evans et al. 
2002), and thus  a fall in TAOS (Sampson et al. 2002).  In keeping with a causal role for 
ROS in atherogenesis, we found that plasma TAOS was significantly lower in diabetic 
men  with  CHD  than  those  without.    In  diabetic  men,  the  UCP2-866A  allele  was 
independently  associated  with  lower  TAOS,  suggesting  a  modulating  influence  of 
UCP2 genotype on OS burden, although it was not clear whether this was a recessive or 
dominant  effect.    Patients  with  the  UCP2-866AA  genotype  who  also  had  CHD, 
demonstrated the lowest levels of plasma TAOS of all groups tested, with TAOS 30% 
lower than those non-CHD AA subjects and 33% lower than non-CHD G allele carriers.  
In a subset of diabetic men with CHD matched for baseline characteristics (including 
age and treatment),  UCP2AA homozygosity was  associated with  40% lower TAOS 
mirrored  by  a  100%  increase  in  F2-isoprostane  concentrations.    UCP2  activity  and 
expression is induced by OS (Pecqueur et al. 2001; Echtay et al. 2002) (which is itself 
induced by CHD and its risk factors), thus protecting from further mitochondrial ROS 
generation.  This may explain the dependence of the observed genotypic effect on the 
presence /absence of CHD.  These data therefore suggest the UCP2-866A allele to be 
strongly associated with increased ROS burden.  Given the putative role of ROS in 
atherogenesis, we predicted a similar genotype association with prospective CHD risk, 
which  was  confirmed.    In  prospectively  studied  middle-aged  men,  CHD  risk  was 
doubled amongst  those  homozygous  for the  UCP2-866AA allele, even amongst  the 
normotensive, lean, non-smokers and non-diabetics.  However, the risk associated with 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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genotype was substantially increased by the presence of conventional CHD risk factors 
known to be associated with increased OS, such as hypertension, obesity and diabetes 
(Cai et al. 2000; Chisolm et al. 2000; Brownlee 2001; Witztum et al. 2001; Evans et al. 
2002; Harrison et al. 2003).  Indeed, the risk of CHD was elevated nearly eight-fold 
amongst  the  small  number  of  diabetic  subjects  of  UCP2-866AA  genotype,  when 
compared to non-diabetic G allele carriers and almost four-fold in obese AA compared 
to non-obese G allele carriers.    
 
The association of the UCP2-866A allele with reduced TAOS, increased esterified F2-
isoprostanes and with prospective CHD risk is mechanistically consistent, supporting 
the validity of our findings.  The UCP2-866G>A promoter variant is located within a 
multifunctional cis regulatory site, involving putative binding sites for pancreatic and 
hypoxia-induced transcription factors (Esterbauer et al. 2001).   The UCP2-866G>A 
polymorphism has been shown to be functional in vitro and in vivo.  The UCP2-866A 
allele has been associated with insulin resistance (Krempler et al. 2002; Sesti et al. 
2003) and with type 2 diabetes (Krempler et al. 2002), both being conditions associated 
with increased OS and CHD risk.  Although promoter constructs of the -866A allele are 
associated with greater transcriptional activity in pancreatic β cells, they are associated 
with greater repression of transcription in somatic non-β cells (Krempler et al. 2002).  It 
is  likely,  therefore,  that  the  UCP2-866A  allele  is  related  to  lower  inducible  UCP2 
expression within the vasculature or circulating immune cells.  As such, one would 
anticipate the A allele to be associated with increased OS and higher risk of CHD as 
demonstrated in these studies.  Furthermore, the -866G>A variant appears to be strongly 
associated with functionality across the gene cluster (Esterbauer et al. 2001).     
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At first sight, the lack of any significant difference in genotype distribution between 
those with and without CHD in the diabetic subjects would appear to conflict with the 
prospectively-derived data.  However, this is not the case.  Firstly, prospective gene-
association studies are more powerful than case-control studies (Humphries et al. 2003).  
Secondly, increased obesity, increased OS, inflammation, and hyperglycaemia might all 
overwhelm the UCP genotype ‗strength of signal‘ in diabetics.  Thirdly, case-control 
cross-sectional studies are prone to intrinsic bias, for example due to possible altered 
rates  of  disease  progression,  subsequent  progression  of  secondary  phenotypes,  or 
genotype associations with death or treatment changes.  Indeed, the presence of the A 
allele might be associated with both earlier disease presentation and earlier death in 
some, subsequently balanced by more aggressive secondary prevention strategies.  Such 
influences are well-recognised confounders (Risch 2000; Humphries et al. 2003; Sing et 
al. 2003). 
 
The number of diabetic men recruited to NPHSII is small, and confirmation of these 
findings should be sought in other diabetic groups. However, the substantially-increased 
CHD risk amongst diabetic men of UCP2-866AA genotype in NPHSII is congruent 
with the finding of increased markers of OS found in the plasma of diabetic men from 
UDACS.  The association of UCP2 genotype with altered markers of OS also requires 
examination in other ‗high ROS‘ groups and these observations should also be extended 
to those of other races, and to women.  In addition, further in vitro functional studies are 
required.  However, the conclusions from these two independent studies are consistent 
and statistically robust, and, if confirmed, will have important implications. There is a 
global epidemic of diabetes in which CHD is the major cause of mortality (Amos et al. 
1997), and diabetes is one of the major risk factors for CHD (Castelli et al. 1986).  
However, no more than 25% of the excess CHD risk in diabetes can be accounted for by 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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modulation of established risk factors (Pyorala et al. 1987), and a search for mechanistic 
understanding  may  thus  have  profound  implications  for  the  development  of  novel 
therapeutic options. These data suggest that modulation of UCP2 expression may be one 
such important mechanistic target.   
 
Larger  scale  studies  are  also  required  to  extend  our  observations  from  middle-aged 
Caucasian males to those of other racial origins and age ranges, as well as to women.  
Although  case-control  studies  may  be  confounded  by  population  stratification,  the 
prospective study design of NPHSII is much more robust, and it is extremely unlikely 
that  the  association  with  risk  we  see  here  could  be  explained  by  such  an  effect.  
Population stratification could be ruled out by genotyping the samples for a group of 
randomly distributed single nucleotide polymorphisms (SNPs) but, to date, of the more 
than  40  SNPs  where  we  have  genotype  data  in  NPHSII  no  statistically  significant 
evidence of population stratification has been obtained. 
These data extend our understanding of the mechanisms through which LVH and CHD 
are associated.  LVH is an independent cardiovascular risk factor (Levy et al. 1990).  
Extensive  animal  data  support  a  role  for  BDKRB2  activation  in  diminishing  this 
hypertrophic response (Linz et al. 1992) and implicate perturbations in both UCP2 and 
UCP3 in the abnormal metabolism associated with LVH (Fukunaga et al. 2000; Boehm 
et al. 2001; Langdown et al. 2001; Noma et al. 2001; Young et al. 2001).  I have 
presented novel associations between the BDKRB2(+9) allele (associated with reduced 
receptor mRNA expression) and both an enhanced prospective human left ventricular 
hypertrophic  response  and  with  prospective  coronary  artery  disease  only  amongst 
hypertensives,  as  well  as  novel  associations  between  a  new  risk  haplotype  (UCP3-
55T/UCP2-866A)  and  both  LV  mass  and  prospective  CHD  risk  as  well  as  the 
mechanistic  association  between  the  UCP2-866A  allele  and  plasma  markers  of 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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oxidative stress in high risk diabetic men.  These data suggest common mechanisms 
through which the deleterious effects of hypertension on left ventricular hypertrophy 
and CHD may be mediated and adds credence to the hypothesis that RAAS and UCP 
activity may be linked at the cellular level.   
 
6.6.3  Skeletal muscle efficiency & endurance phenotypes 
There were significant associations between genetic variation at the UCP2/3 locus and 
the efficiency of contraction of human skeletal muscle: there were no associations with 
DE at baseline in healthy sedentary young adults, but there were significant exercise 
training related changes.  The UCP2-866A allele carriers had significantly increases in 
DE  (absolute  increase  of  2%  DE)  after  training,  whereas  GG  homozygotes  had  no 
change in DE after training.  The small number of UCP3-55TT homozygotes tended to 
have lower DE after training.  There was significant evidence of interaction between the 
UCP2-866 and UCP-55 loci in determining changes in DE.   
 
The UCP2/3 locus was also associated with competitive distance running event amongst 
a small sample of elite, Olympic standard athletes.  UCP2-866A allele frequency tended 
to increase with running distance and this was reflected in an increased prevalence of 
UCP3-55C/UCP2-866A  haplotype  carriers  in  those  athletes  competing  in 
predominantly  endurance  events  and  an  increased  prevalence  of  UCP3-55C/UCP2-
866G haplotype carriers in sprinters.  There were very few UCP3-55T allele carriers 
amongst Afro-Caribbean athletes and this may have explained the overall increase in 
UCP3-55T allele frequency seen according to competing distance, as there was a shift 
towards shorter competing distance amongst Afro-Caribbean elite athletes, with no such 
athlete studied competing at longer distances.   There was not enough power in this 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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study to test whether there were significant allelic differences between Caucasian and 
Afro-Caribbean study subjects.  This will be looked at in more detail in Chapter 7. 
  
The  exact  role  of  UCP2  and  UCP3  in  myocyte  function  remains  unknown.    The 
UCP2/UCP3  locus  has  been  associated  with  basal  metabolic  rate  in  adult  humans 
(Bouchard et al. 1997).  These data support an association between the UCP2/UCP3 
gene locus and skeletal muscle efficiency.  Variation at the two SNPs studied accounted 
for 14.8% of the interindividual variation in exercise related gains in skeletal muscle 
efficiency  in  this  study.    It  is  however  difficult  to  delineate  which  gene  product  is 
responsible for the association as the UCP2 and UCP3 genes are separated by only 7kB 
in chromosomal region 11q13 (Solanes et al. 1997).  Much larger sample sizes and 
more SNPs would be required to decipher any association further.   
 
Skeletal muscle is a major determinant of resting and exercising metabolic rate (Zurlo et 
al. 1990).  UCP3 expression is highly tissue specific, being expressed predominantly in 
human skeletal muscle and, to a lesser extent, in cardiac muscle (Boss et al. 1997), 
whereas UCP2 mRNA expression is ubiquitous, being expressed at a lower level than 
UCP3  in  human  skeletal  muscle,  and  predominating  in  cardiac  muscle  (Boss  et  al. 
1997).   
 
The close sequence homology between UCP1 and both UCP2 and UCP3 has naturally 
led to the hypothesis that both UCP3 and UCP2 are able to increase skeletal muscle 
oxygen consumption by increasing mitochondrial proton conductance.  The evidence is 
still  divergent.    Proton  leak  (state  4  respiration)  was  reduced  in  skeletal  muscle 
mitochondria isolated from the UCP3(-/-) knockout mouse in some (Gong et al. 2000; 
Vidal-Puig et al. 2000)  but not all studies (Cadenas et al. 2002).  In whole animal 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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studies using NMR spectroscopy, UCP3 knockout mice had a doubling of the ATP 
synthesis rate in skeletal muscle without any increase in TCA cycle flux rate in the 
fasting  state  implying  increased  mitochondrial  coupling  (Cline  et  al.  2001).    UCP3 
overexpression in  yeast  (Gong et  al.  1997;  Zhang  et  al. 1999;  Harper et  al.  2002), 
proteoliposomes (Echtay et al. 2001) and mammalian cells (Boss et al. 1998) leads to 
artifactual  uncoupling  of  mitochondrial  respiration  (Cadenas  et  al.  2002),  possibly 
because of differences in insertion, folding or interaction within the inner mitochondrial 
membrane  compromising  membrane  integrity,  and  do  not  aid  in  understanding  the 
physiological function of UCP3. 
 
Both UCP2 and UCP3 mRNA are reduced between 40-70% by an 8 week endurance 
treadmill training program in rats in both fast twitch and slow twitch skeletal muscle 
fibres (Boss et al. 1998).  UCP3 protein expression does vary according to muscle fibre 
type in humans, being most abundant in type 2b fast-glycolytic fibres, to a lesser extent 
in type 2a fast-oxidative-glycolytic fibres and only moderately in type 1 slow-oxidative 
fibres  (Hesselink  et  al.  2001).    UCP3  protein  is  lower  in  the  skeletal  muscle  of 
endurance  trained  individuals  compared  to  untrained  subjects  (Russell  2003)  and  is 
lower in all fibre types compared to untrained muscle, although the same hierarchy 
exists.   
 
This data suggests that UCP2 and UCP3 may be associated with endurance training 
effects in skeletal muscle.  There is some debate as to the exact function of UCP3 in 
human  skeletal  muscle.    In  an  important  paper,  Schrauwen‘s  group  tested  whether 
physiological elevation of skeletal muscle UCP3 protein content in 6 human subjects 
altered the PCr resynthesis rate after PCr had been depleted by high-intensity exercise 
with limb blood flow occlusion (Hesselink et al. 2003).  The authors concluded that an 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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increase in UCP3 content within the physiological range did not affect mitochondrial 
coupling in vivo in human skeletal muscle.  There was a positive association between 
UCP3 protein content and PCr resynthesis rate overall, suggesting that the authors were 
measuring a surrogate marker of total mitochondrial protein or volume rather than the 
relative amount of UCP3.  Indeed, the relationship between UCP3 protein content and 
PCr resynthesis rate appeared to change during high fat feeding but the study was not 
powered to detect such a difference.  In support of this argument, it has been shown that 
during 6 weeks of endurance training, total UCP3 protein remains unchanged in human 
skeletal  muscle,  but  when  indexed  to  a  marker  of  mitochondrial  volume  (citrate 
synthase),  the  relative  amount  of  UCP3  protein  decreased  significantly  by  53% 
(Fernstrom et al. 2004).   
 
 
Most of the training and endurance associations in this study were due to variation at the 
UCP2-866  locus  with  sedentary  UCP2-866A  allele  carriers  benefiting  from  greater 
efficiency after training and elite athletes who were UCP2-866A carriers, more likely to 
compete at endurance distances.  The UCP2-866G>A polymorphism has been shown to 
be functional in vivo (Krempler et al. 2002; Sesti et al. 2003)  and in vitro.  Promoter 
constructs of the -866A allele are associated with greater repression of transcription in 
somatic cells (Krempler et al. 2002).  It is tempting to postulate that the UCP2-866A 
allele is associated with lower inducible UCP2 expression within skeletal muscle and 
therefore greater mitochondrial coupling.  As such, one would anticipate the A allele to 
be associated with the endurance phenotypes described.  Furthermore, the  -866G>A 
variant  appears  to  be  strongly  associated  with  functionality  across  the  gene  cluster 
(Esterbauer et al. 2001).   
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6.6.4  The effects of endurance training on serum ACE activity 
These are the first data to show that 11 weeks of an exercise training programme is 
associated with a small but significant increase in serum ACE activity (mean increase of 
3.3±1.10 nmol his-leu.ml
-1.min
-1).  Serum ACE increased to similar degrees in all ACE 
I/D genotype groups examined, with the relative differences between genotype groups 
remaining  highly  statistically  significant  at  all  time  points.    This  has  important 
implications.  Firstly, many of the phenotypes relating the ACE I/D polymorphism to 
endurance training phenotypes (such as DE) have relied on ACE I/D genotype related 
ACE activity remaining in the order of ACE DD>ID>II during training.  These data 
show that this hierarchy remains.  Secondly the inter-individual differences in ACE 
activity remained throughout training, permitting any causal differences in phenotypic 
expression, such as DE, to persist. 
 
It is unclear why serum ACE activity increased during training.  Very little is known 
about  the  regulation  of  ACE.    Serum  ACE  activity  increases  temporarily  during 
adolescence  (Cambien  et  al.  1988).    In  this  study  group,  there  was  a  negative 
relationship  between  increasing  age  and  serum  ACE  activity  as  the  subjects  were 
recruited in late adolescence and early adulthood during which time serum ACE activity 
drops back to adult range.  Thereafter, there is little change in serum ACE activity 
during adulthood.  This would imply that time itself could not act as a confounder and 
that  any  changes  observed  would  be  related  to  the  training  itself.    Shear  stress 
upregulates endothelial ACE (Gosgnach et al. 2000) and may release more endothelial 
bound ACE into the circulation during exercise resulting in a transient rise in serum 
ACE activity.  Against this notion, the mid-point ACE activity was measured during a 
period of convalescence.  Further studies are required to test whether the levels of serum 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
LOCUS AND CIRCULATING ACE ACTIVITY? 
  293 
ACE change during acute exercise and to examine the time course of any changes.  It 
would  also  be  important  to  test  if  there  were  serial  related  changes  in  tissue  ACE 
activity in metabolically active tissues such as skeletal muscle. 
 
There  was  no  association  between  serum  ACE  activity  and  any  other  baseline 
characteristic  measured,  including  blood  pressure.    Importantly,  there  was  also  no 
association  between  markers  of  systemic  inflammation,  such  as  CRP,  IL-6  and 
fibrinogen, measured at any time point with absolute or relative changes in serum ACE.  
 
It is intriguing that there was a significant association between serum ACE activity and 
UCP3-55C>T genotype and UCP2/UCP3 haplotypes amongst the recruits, with UCP3-
55TT and UCP2-866GG homozygotes achieving the lowest serum ACE activity.  This 
is the first example of genetic variation in an unrelated gene effecting regulation of the 
human ACE gene.  The UCP3/UCP2 gene cluster and ACE gene are coded on different 
chromosomes,  implying  that  direct  gene-gene  interaction  would  be  unlikely.    It  is 
plausible that the UCP2 or UCP3 gene product is influencing ACE gene transcription or 
ACE enzyme activity.  How might this occur?  Both ACE and the UCPs are thought to 
influence cell metabolism and UCP-induced mitochondrial uncoupling may provide a 
negative  feedback  loop  to  ACE.    UCPs  negatively  regulate  mitochondrial  ROS 
generation,  and  ROS  have  been  shown  to  inhibit  ACE  activity  (Chen  et  al.  1993; 
Michel et al. 2001).  The interaction between UCP and ACE will be the focus of more 
work in chapter 7.  
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 RESULTS CHAPTER SEVEN  
7  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 
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A  novel  association  between  genetic  variation  in  the  UCP3  gene  and  serum  ACE 
activity was described in chapter 4.  ACE is an ectoenzyme, bound to the cell surface at 
the C-terminus.  Endothelial-bound ACE is cleaved at the juxtamembrane stalk region 
by an unknown ‗ACE secretase‘ to yield circulating catalytically-active ACE (Ching et 
al.  1983).    Little  is  known  about  the  regulation  of  somatic  ACE,  and  no  cohesive 
pathway of its induction has been delineated.  Serum ACE activity rises rapidly during 
adolescence and then remains remarkably stable within adult individuals, rising only 
slowly with age (Cambien et al. 1988).  Circulating ACE is a highly heritable trait, with 
the majority of interindividual variability in ACE levels due to genetic variation in the 
ACE gene (Cambien et al. 1988; Keavney et al. 1998).  The ACE gene is polymorphic, 
with 78 varying sites found during whole gene sequencing in 11 individuals (Rieder et 
al. 1999).  In common with other genes, the sequence variation in ACE is greater in 
African populations (Rieder et al. 1999; Cox et al. 2002).  European populations can be 
divided into 3 major ACE clades (closely related haplotype branches).  The two most 
common (A and B), have contrasting alleles at many polymorphic sites which are in 
complete  LD, including  the  Alu  I/D variant.    It  appears that the  ACE  Alu insertion 
occurred, along with 17 other substitutions, some  time after the human/chimpanzee 
split  and  is  very  old  (>  1  million  years)  (Rieder  et  al.  1999).    The  next  two most 
common clades (C and D) probably occurred due to distinct ancestral recombination 
between clades A and B, between intron 5 and exon 6 and approximately 18kb away 
from this point, 3‘ of the last exon.  Approximately 36% of the variation in serum ACE 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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activity in Europeans can be assigned by this haplotype/clade approach (Keavney et al. 
1998).  It is suggested that the majority of the variation in the ACE QTL is associated 
with  variation  within  the  18kb  region  between  the  ancestral  break  points,  but  the 
extraordinary  degree  of  LD  between  these  two  points  in  Europeans  has  made  it 
impossible  to  detect  which  variants  are  functional  (Cox  et  al.  2002).   Recently, 
studying the greater sequence and haplotype diversity in a Nigerian sample, allowed the 
identification of four functional variants in the ACE gene, three within this 18kb region 
(A23495G, 31839insC and A31958G) and one in the promoter (A6138C) accounting 
for approximately 20% and 5% of the interindividual variation in serum ACE activity 
(Cox et al. 2002).  There have been no other reports of association between serum ACE 
activity and variation in any other gene. 
 
To test whether genetic variation at the UCP3/2 locus is associated with serum ACE 
activity,  I  extended  the  observed  association  in  the  BH3  study  by  retrospectively 
increasing the sample size and, not only genotyping the subjects for the UCP3-55C>T 
and UCP2-866G>A, but also for the UCP2 3‘UTR (exon 8) 45bp deletion/insertion 
(D/I) variant.   The  UCP2 D/I variant  is  associated with  alteration in UCP2 mRNA 
stability (Esterbauer et al. 2001), and has been associated with BMI (Cassell et al. 1999) 
(Yanovski  et  al.  2000)  and variably  with  basal metabolic rate  (Walder et  al. 1998; 
Yanovski et al. 2000).  Moreover, the UCP2-866G>A and UCP2 D/I variants were 
found to be in strong LD, and variation at the promoter SNP accounted for 71% of the 
variability in D/I mRNA transcript ratio in gene-promoter constructs (Esterbauer et al. 
2001).  Similarly, genetic association between these UCP3/2 genetic variants and serum 
ACE activity was sought in a healthy cohort of men drawn from a single tribe from the 
Republic of South Africa (RSA), and then differences in association between the two 
ethnic  groups  compared.    In  addition,  similar  associations  between  UCP3/2  genetic 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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variants  and  serum  ACE  activity  were  sought  in  two  samples  of  diabetic  patients 
(UDACS  and  a  sample  of  type  1  diabetic  patients  from  Denmark)  in  whom  OS  is 
elevated (Brownlee 2001), Chapter 3).  Any association between plasma TAOS (an 
inverse marker of OS) and ACE activity was also tested in UDACS. 
 
7.1  HEALTHY CAUCASIAN AND NATIVE SOUTH AFRICANS 
Of the 200 men recruited to the RSA study, 190 (95%) were successfully genotyped for 
the UCP3-55C>T variant, 191 (95.5%) for the UCP2-866G>A variant and 187 (93.5%) 
for  the  UCP2  Del/Ins  variant.    Results  from  the  RSA  study  were  compared  with 
analysis from the BH3 study, a Caucasian sample (Methods 2.16, Results 6.5).  The 
number  of  subjects  with  complete  data  in  the  BH3  study  was  enlarged  by 
retrospectively  enriching  the  number  of  subjects  in  whom  the  baseline  ACE  was 
measured.  Of the BH3 study subjects, 154 out of the 250 had baseline serum stored 
which could be analysed for post-hoc analysis of serum ACE activity.  The genotype 
distributions and rare allele frequencies for both RSA and BH3 are shown in Table 7.1.  
All  genotypes  were  within  Hardy-Weinberg  equilibrium.    The  rare  allele  for  all  3 
genotypes was found less frequently in the RSA study sample than in the BH3 study 
sample (P=0.0006, P=0.04, P=0.0000002 for UCP3-55T allele, UCP2-866A allele and 
UCP2 Ins allele, respectively).   
 
There was no significant LD between UCP3-55C>T and UCP2-866G>A genotypes in 
either ethnic group (Table 7.2).  However, there was highly significant and similar LD 
between the UCP2-866G>A and UCP2 Del/Ins in both ethnic samples (D‘0.54 – 0.58; 
P<0.0001;  Figure  7.1),  although  both  results  were  less  than  the  LD  (approx  0.75) 
between these two loci described previously for a Caucasian population (Esterbauer et 
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Table 7.1.  UCP3-55C>T, UCP2-866G>A and UCP2 Del/Ins genotype distributions for the RSA and BH3 studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RSA  BH3 
Comparison (Χ
2) 
P 
Genotype 
Genotype 
distribution 
Rare allele frequency 
(95% CI) 
Genotype 
distribution 
Rare allele frequency 
(95% CI) 
UCP3-55C>T  146 / 40 / 4  0.126 (0.093 – 0.160)  132 / 76 / 13  0.231 (0.191 – 0.270)  0.0006 
UCP2-866G>A  97 / 81 /13  0.280 (0.235 – 0.325)  85 / 110 / 25  0.364 (0.319 – 0.409)  0.04 
UCP2 Del/Ins  140 / 45 / 2  0.131 (0.097 – 0.165)  105 / 93 / 16  0.292 (0.249 – 0.335)  0.0000002 
Figure 7.1.  Linkage disequilibrium between  common variants in the UCP3/2 gene cluster in the RSA (D’ black) and BH3 (D’red) studies. 
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UCP2 Del/Ins  genotypes in BH3, as previously  described in a cohort from Chenai, 
South India (Cassell et al. 2000), but no LD between these 2 loci in the RSA study 
sample (Figure 7.1). 
 
These data suggest that there has been significant recombination between the UCP3-55 
and UCP2-866 sites in the evolutionary older African population, as has been reported 
for other genetic loci (Gabriel et al. 2002), but not between the two neighbouring UCP2 
polymorphisms.    In  the  European  sample,  the  UCP3-55C  allele  showed  allelic 
association with the UCP2 I allele, and the latter with the UCP2-866A allele. 
 
 
Table 7.2.  Distribution and linkage disequilibrium (D’) between UCP genotypes in 
the RSA and Bassingbourn (Big Heart) 3 studies 
 
 
RSA  UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  75  59  10 
CT  16  21  3 
TT  4  0  0 
 D‘ = 0; P=1.0           D‘=0.13; P=0.49     
 
 
RSA  UCP2 Del/Ins 
DD  DI  I I 
UCP3 
-55C>T  
CC  107  30  2  
CT  24  14  0  
TT  4  0  0 
D‘ = 0.06; P=0.95                    D‘= -0.31; P=0.0005                          
 
     
RSA  UCP2 Del/Ins 
DD  DI  I I 
UCP2 
-866G>A 
GG  91  2   0 
GA  38  37  2 
AA  7  5  0 
D‘ = 0.54; P<0.0001          D‘ = 0.58; P<0.0001 
 
Bassingbourn 
(Big Heart) 3 
UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  54  56  10 
CT  27  35  14 
TT  3  9  1 
Bassingbourn 
(Big Heart) 3 
UCP2 Del/Ins 
DD  DI  I I 
UCP3 
-55C>T  
CC  47  67  15 
CT  45  25  1 
TT  12  1  0 
Bassingbourn 
(Big Heart) 3 
UCP2 Del/Ins 
DD   DI  I I 
UCP2 
-866G>A 
GG  68  15  0 
CT  34  67  7 
TT  3  10  9 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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There was a highly significant difference in UCP3/2 haplotype distribution between the 
RSA and BH3 studies (P<0.0005; Table 7.3).  The observed difference between the two 
haplotype distributions was driven primarily by differences in LD between the UCP3 
promoter and UCP2 Del/Ins variants. 
 
ACE activity in serum was measured by a kinetic assay (Sigma Diagnostics, St Louis, 
MO, USA; Methods 2.1.9.). The within-assay and between-assay variabilities were 13% 
and 11%.  Serum ACE activity was weakly associated with increasing age in the RSA 
study (r = 0.16; P = 0.03), but with decreasing age in the BH3 study whose participants 
were of a younger age (r = -0.19; P = 0.02; Figure 7.2).  There was a highly statistically 
significant difference in mean serum ACE activity, despite correction for age, between 
the RSA and BH3 study samples (47.2 ±12.1 nmol His-Leu.ml
-1.min
-1 and 27.4 ±9.0 
nmol His-Leu.ml
-1.min
-1, respectively; P = 2x10
-48).   
 
Age-adjusted  ACE  activity  amongst  UCP3-55TT  homozygotes  was  lower  in  both 
studies by a mean difference of approximately 6 nmol His-Leu.ml
-1.min
-1 (Figure 7.3).  
Serum ACE activity was higher in the UCP2-866A allele carriers in the BH3 study.  
However, there appeared to be differential regulation of serum ACE activity in both 
studies according to UCP2 genotypes (Figure 7.3), but only significant differences by 
UCP2D/I  genotypes  in  the  BH3  study  (linear  trend  P=0.04;  I  allele  vs.    DD 
homozygotes P=0.02).  The statistical interaction between UCP2 genotypes accounted 
for up to 4.1% and 2.3% of the interindividual variation in serum ACE activity in the 
BH3 and RSA studies, respectively.  7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC LOCUS AND CIRCULATING ACE ACTIVITY? 
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Table 7.3.  Comparison of UCP haplotype distribution in the RSA and BH3 studies (graphic depiction of same on right) 
 
Haplotype  Haplotype frequency 
P 
difference 
UCP3 
-55 
UCP2 
-866 
UCP2  RSA  BH3 
C  G  Del  0.612  0.463  <0.0001 
C  A  Del  0.152  0.024  0.0002 
T  G  Del  0.094  0.120  0.11 
C  A  Ins  0.092  0.225  <0.0001 
T  A  Ins  0.023  0.009  0.62 
C  G  Ins  0.015  0.058  0.001 
T  A  Del  0.011  0.100  0.001 
T  G  Ins  0  0  N/A 
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Figure 7.2.  Scatter plots of serum ACE activity vs. age in the BH3 (left) and RSA (right).  Best fit correlation curves are shown with 95% 
confidence intervals. 
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Figure 7.3.  Serum ACE activity by UCP3 and UCP2 genotypes in the RSA and BH3 studies (P values are age-adjusted). 
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The expected phenotypic means according to estimated haplotypes for the two studies 
are  shown  in  Figure  7.4.  The  UCP3-55T/UCP2-866A/UCP2I  and  the  UCP3-
55T/UCP2-866G/UCP2I haplotype groups were too small for analysis.  There was not 
enough statistical power to detect a haplotypic effect in predicting serum ACE activity 
in either study (P = 0.24 for BH3 and P = 0.61 for RSA).  There was a significant 
difference in the haplotype effects in predicting serum ACE activity between the two 
groups (once adjusted for effect of study group on ACE activity P = 0.02), but statistical 
significance was  lost if the smaller  UCP3-55C/UCP2-866G/UCP2I haplotype  group 
was excluded.  A SNP change from the UCP3/2 CGD haplotype to CGI led to a mean 
increase in serum ACE activity of 5.2 nmol His-Leu.ml
-1.min
-1 in BH3 but to a mean 
decrease in  RSA of 11.9  nmol His-Leu.ml
-1.min
-1.  Again,  a SNP  change from the 
UCP3/2 CAD haplotype to CAI led to a mean increase in serum ACE activity of 7.1 
nmol  His-Leu.ml
-1.min
-1  in  BH3  but  to  a  mean  decrease  in  RSA  of  2.7  nmol  His-
Leu.ml
-1.min
-1.   
 
 
Figure  7.4.    Predicted  UCP3-55C>T,  UCP2-866G>A  and  UCP2D/I  haplotype 
effects on serum ACE activity in the BH3 and RSA study samples. Data are mean 
± 95% confidence intervals. 
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7.2  DIABETIC PATIENTS (UDACS)  
Of the 465 Caucasian male patients (mean age 61.113.7 years), 441 had serum ACE 
activity measured and this was normally distributed (mean serum ACE 23.1±10.7 nmol 
His-Leu.ml
-1.min
-1; Figure 7.5).  Amongst diabetics, serum ACE activity was inversely 
related to increasing age (correlation coefficient r= -0.19; P<0.0001; Figure 7.5).  No 
other baseline characteristic was associated with ACE activity, including duration of 
diabetes and HbA1c. 
 
 
 
Of  this  sample,  99/441  (22.4%)  were  type  1  diabetics.    There  was  a  significant 
difference in serum ACE activity according to type of diabetes: 26.2 ±11.8 nmol His-
Leu.ml
-1.min
-1 vs. 22.2±10.2 nmol His-Leu.ml
-1.min
-1, for type 1 and type 2 diabetics 
respectively; P = 0.001.  This difference was accounted for by the significant difference 
in mean age between the groups (mean age 48.1 ±12.1 yrs and 65.9 ± 10.8yrs for type 1 
and type 2 diabetics respectively; P < 1x10
-35).  After adjustment for age, there was no 
difference in serum ACE activity between type of diabetes (mean ACE activity ± SD 
Figure 7.5.  Distribution of serum ACE activity in male Caucasians drawn from UDACS 
and  negative  correlation  with  age  (linear  regression  curve  with  95%  confidence 
intervals; serum ACE =32.8 -0.15 * age nmol His-Leu.ml
-1.min
-1) 
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type 1 diabetics 23.8 ±11.7 nmol His-Leu.ml
-1.min
-1  and type 2 diabetics 22.9 ± 10.2 
nmol His-Leu.ml
-1.min
-1;
 P = 0.45).   
 
Less than half (48%) of the study group were treated with ACEi drug therapy (Figure 
7.6).  As expected, ACEi therapy was associated with lower mean serum ACE activity 
(no ACEi 24.7±10.8 nmol His-Leu.ml
-1.min
-1 vs. ACEi 21.8 ±10.2 nmol His-Leu.ml
-
1.min
-1 P = 0.003 for age adjusted data).  There was no significant difference in mean 
serum ACE activity in the 7% of patients taking ARBs (no ARB 23.0 ±10.4 nmol His-
Leu.ml
-1.min
-1 vs. ARB 25.1 ±11.8 nmol His-Leu.ml
-1.min
-1; P=0.3).  The 2 patients 
taking both an ACEi and ARB had the lowest serum ACE activity of all (Figure 7.6).  
There was a significant statistical interaction between ACEi and ARB medication in 
determining serum ACE activity (interaction term P = 0.002; 2% variability in levels).   
 
In patients who were not taking either ACEi or ARB, there was no relationship between 
TAOS and serum ACE activity overall, in type 1 or in type 2 diabetics (correlation 
coefficients r =0.058, 0.042, 0.125, respectively for age-adjusted data; Figure 7.8). 
 
All UCP3/2 genotype distributions tested were in Hardy-Weinberg equilibrium.  Rare 
allele frequencies are shown in Figure 7.7.  There was no statistical difference in any 
genotype distribution between UDACS type 1 and type 2 diabetics and between either 
diabetic subgroup and the BH3 control sample.   
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Figure 7.6.  Mean serum ACE activity in male Caucasian subjects from UDACS 
according to drug treatment with an ACE inhibitor (ACEi) or angiotensin type 1 
receptor blocker (ARB). Data are mean ± SEM. 
Figure 7.7.  Rare allele frequencies (±SD) for UCP3-55C>T, UCP2-866G>A and 
UCP2 I/D gene variants in the BH3 study and in the UDACS male Caucasian 
type 1 and type 2 sub-groups. 
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Figure 7.8.  The lack of correlation between serum ACE activity and TAOS in ACEi naive Caucasian men drawn from UDACS divided by 
type of diabetes (best fit correlation curves are shown with 95% confidence intervals). 
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There was significant LD across the UCP3/2  locus in the larger type 2 diabetics and 
there was similar association in the smaller type 1 diabetic sub-group, being significant 
only between the UCP2-866G>A and UCP2I/D polymorphisms (Table 7.4).  The LD 
was similar to that observed in the BH3 Caucasian study sample (Section 7.1; Figures 
7.1 & 7.9). 
 
There  were  no  genotype  associations  with  any  baseline  characteristic.    Genotype 
relationships with age-adjusted serum ACE activity were therefore tested in the study 
sample overall and also according to type of diabetes, but only in ACEi- and ARB naive 
patients  (Figure  7.10).  In  these  diabetic  patients,  there  were  no  clear  patterns  of 
associations between UCP genotypes and serum ACE activity.  The only statistically 
significant  genotype association  was  between the UCP2-866G>A variant  and serum 
ACE  activity  overall  and  specifically  in  type  1  diabetics  (age-adjusted  serum  ACE 
activity was 22.6 ±8.7 nmol His-Leu.ml
-1.min
-1 vs. 26.4 ±12.6 nmol His-Leu.ml
-1.min
-1 
vs.  22.6  ±8.7  nmol  His-Leu.ml
-1.min
-1  for  GG  vs.  GA  vs.  AA  overall;  P  =  0.04 
ANOVA).  
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Table 7.4.  UCP haplotype distribution and linkage disequilibrium (D’) in UDACS. 
 
D‘ = 0.23; P <0.0001         D‘= 0.21; P = 0.16     
 
 
Caucasian type 2 
diabetics 
UCP2 Del/Ins 
DD  DI  I I 
UCP3 
-55C>T  
CC  159  158  30 
CT  102  75  6 
TT  23  2  1 
D‘ = -0.19; P=0.0003                   D‘= -0.06; P = 0.97                       
     
 
Caucasian type 2 
diabetics 
UCP2 Del/Ins 
DD  DI  I I 
UCP2 
-866G>A 
GG  198  33  3 
GA  84  178  10 
AA  12  36  24 
D‘ = 0.60; P<0.0001          D‘ = 0.52; P<0.0001 
 
 
 
 
 
 
 
 
 
Caucasian type 2 
diabetics 
UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  164  156  27 
CT  57  92  35 
TT  1  18  7 
Caucasian type 1 
diabetics 
UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  47  37  5 
CT  16  26  9 
TT  4  4  2 
Caucasian type 1 
diabetics 
UCP2 Del/Ins 
DD  DI  I I 
UCP3 
-55C>T  
CC  47  37  4 
CT  30  19  2 
TT  7  2  1 
Caucasian type 1 
diabetics 
UCP2 Del/Ins 
DD   DI  I I 
UCP2 
-866G>A 
GG  60  10  3 
CT  26  48  1 
TT  4  8  4 
Figure  7.9.    Linkage  disequilibrium  between    common  variants  in  the  UCP3/2  gene 
cluster in UDACS type 1 (Black) and type 2 (red) diabetics.   
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Figure 7.10.  Mean serum ACE activity by UCP3 and UCP2 genotypes in ACEi- and ARB-naïve subjects from UDACS according to type of 
diabetes (data are age-adjusted). 
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7.3  TYPE 1 DANISH DIABETICS  
The study  consisted of 287 consecutive adult (≥ 18  years old; mean age 45.513.7 
years;  117  female)  type  1  diabetic  patients  drawn  from  the  outpatients  department 
Hillerød Hospital, Denmark by Pedersen-Bjergaard and colleagues.  These patients had 
had diabetes for more than 2 years, with type 1 diabetes defined as need for insulin 
treatment from the time of diagnosis and unstimulated C-peptide concentrations below 
300  pmol.L
-1  or  stimulated  (venous  blood  glucose  concentration  >  12mmol.L
-1)  C-
peptide concentrations below 600 pmol.L
-1 (Pedersen-Bjergaard et al. 2001). 
 
Serum ACE activity was normally distributed (mean serum ACE 41.2 ±19.6 nmol His-
Leu.ml
-1.min
-1;  Figure  7.11).    There  was  no  significant  difference  in  ACE  activity 
between men and women (mean serum ACE 45.9 ±21.0 nmol His-Leu.ml
-1.min
-1 and 
45.0  ±17.1  nmol  His-Leu.ml
-1.min
-1,  respectively;  P  =  0.75).    As  opposed  to  the 
Caucasian samples from BH3 and UDACS, serum ACE activity was weakly associated 
with increasing age (correlation coefficient r = 0.12; P = 0.04).   
 
 
 
 
 
Figure 7.11.  The distribution of serum 
ACE  activity  amongst  a  sample  of 
Danish  type  1  diabetics  (curve  fit 
represents normal distribution). 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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Those subjects treated with ACEi (n = 60) had significantly lower serum ACE activity 
(no ACEi 50.7 ±17.3 nmol His-Leu /ml /min and ACEi-treated 25.8 ±14.3 nmol His-
Leu  /ml  /min;  P  <  1x10
-21  age-adjusted;  Figure  7.12).    There  was  no  significant 
difference in serum ACE activity in the smaller number of patients taking ARBs alone 
or in combination with ACEi (n = 8 and 3, respectively) and no significant statistical 
interaction between ACEi and ARB treatment in determining serum ACE activity. 
 
 
UCP3-55C>T,  UCP2-866G>A  and  UCP2D/I  genotypes  were  in  Hardy  Weinberg 
equilibrium and rare allele frequencies were similar to those from a healthy Caucasian 
sample  (Bassingbourn  3,  NPHSII)  and  to  those  from  UDACS,  and,  as  with  those 
samples, there was significant positive LD between UCP3-55C>T and UCP2-866G>A 
and  between  UCP2-866G>A  and  UCP2D/I  and  significant  negative  LD  between 
UCP3-55C>T and UCP2D/I loci (Table 7.5, Figure 7.13).  There were no genotype 
associations with any baseline characteristic.   
 
With analyses restricted to those subjects who were both ACEi- and ARB-naïve, there 
were significant genotype associations with serum ACE activity, which followed the 
same pattern as those associations in the BH3 study (Figures 7.2 & 7.14):  UCP3-55TT 
homozygotes  had  significantly  lower  serum  ACE  activity,  UCP2-866AA  carriers 
tended to have higher serum ACE activity and UCP2II homozygotes had significantly 
higher serum ACE activity.  In multivariate analysis, statistical interaction between all 
three genotypes accounted for 5% of the interindividual variability in (age-adjusted) 
serum ACE activity, with the majority of this accounted for by the statistical interaction 
between  UCP2-866G>A  and  UCP2D/I  genotypes  (P=0.001).    This  effect  is 
demonstrated in Figure 7.15.    
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Figure 7.12.  Mean serum ACE activity in Danish type 1 diabetics according to 
drug  treatment  with  an  ACE  inhibitor  (ACEi)  or  angiotensin  type  1  receptor 
blocker (ARB). Data are mean ± SEM. 
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Table 7.5.  UCP haplotype distribution and linkage disequilibrium (D’) in the Danish type 1 diabetic patients. 
 
 
 
 
 
D‘= 0.23; P =0.005          D‘= - 0.26; P=0.001             D‘ = 0.38; P<0.0001     
 
 
 
 
 
 
 
 
 
Danish type 1 
DM 
UCP2 Del/Ins 
DD   DI  I I 
UCP2 
-866G>A 
GG  88  25  3 
CT  57  59  12 
TT  12  14  12 
Danish type 1 
DM 
UCP2 Del/Ins 
DD  DI  I I 
UCP3 
-55C>T  
CC  67  63  21 
CT  68  32  4 
TT  19  3  0 
Danish type 1 
DM 
UCP2-866G>A  
GG  GA  AA 
UCP3 
-55C>T  
CC  74  60  17 
CT  35  57  12 
TT  4  10  9 
Figure 7.13.  Linkage disequilibrium between  common variants in the UCP3/2 gene cluster in the Danish type 1 diabetics 
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Data are mean ±SEM;  
LT= linear trend analysis, II vs. D+ = ANOVA of II vs. D allele carriers 
 
 
 
 
 
 
 
Figure 7.14.  Serum ACE activity (adjusted for age) in ACEi/ARB naïve Danish type 
1  diabetic  patients  according  to  UCP3-55C>T,  UCP2-866G>A  and  UCP2D/I 
genotypes. 
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Figure 7.15.  The statistical interaction between UCP3-55C>T, UCP2-866G>A and 
UCP2D/I genotypes in determining serum ACE activity (adjusted for age) in Danish 
type 1 diabetic patients.  All 3 genotypes are shown in Figure A and data for just 
UCP2-866G>A and UCP2D/I haplotypes (number in each group shown at the base of 
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7.4  DISCUSSION 
 
The  UCP3-55C>T,  UCP2-866G>A  and  UCP2D/I  genotype  distributions  in  the 
Bassingbourn 3 study was similar to previous reports in Caucasians (Cassell et al. 1999; 
Dalgaard et al. 1999; Cassell et al. 2000; Meirhaeghe et al. 2000; Otabe et al. 2000; 
Dalgaard et al. 2001; Esterbauer et al. 2001; Kimm et al. 2002).  However, there have 
been  few  studies  to  date  in  African  populations  (Argyropoulos  et  al.  1998),  Afro-
Caribbean  (Chapter  4)  and  in  African-American  groups  (Argyropoulos  et  al.  1998; 
Kimm et al. 2002).  The UCP3-55C>T and UCP2-866G>A genotype distributions from 
the  RSA  study  were  not  dissimilar  to  the  much  smaller  group  of  Afro-Caribbean 
athletes in Chapter 4.  The RSA study consisted of 200 consecutive male recruits from 
the  Xhosa  ethnic  group.    This  sample  appeared  to  be  older  genetically  than  the 
Caucasian sample, with evidence of greater recombination:  the rare allele frequency 
was  significantly  less  for  each  genotype  in  the  RSA  group  than  those  from  the 
Bassingbourn 3 study.  Furthermore, there were significant differences in LD across the 
locus  between  the  RSA  and  Bassingbourn  3  studies,  exemplified  by  negative  LD 
(D‘=0.31)  between  UCP3-55C>T  and  UCP2D/I  in  Caucasians  and  no  LD  between 
these 2 sites in South Africans (the negative degree of LD between UCP3-55C>T and 
UCP2D/I had not been previously reported in Caucasians (Kimm et al. 2002)).  This 
resulted  in  highly  significant  differences  in  haplotype  distribution  between  the  two 
ethnic groups.  It has been demonstrated recently that African-origin populations exhibit 
substantially greater haplotype diversity than do Caucasian-origin populations (Reich et 
al. 2001; Gabriel et al. 2002).  
 
The resolution to detect functional polymorphisms in a fine mapping study is limited by 
the size of the population and the evolutionary history of the population (Cox et al. 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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2002) as well as the strength of association with the phenotype or complex trait.  The 
study of the ACE gene and its association with serum ACE activity has been described 
as one of the best human models to assess the genetics of a complex trait (Cox et al. 
2002), but the extraordinary degree of LD in the ACE gene in Europeans had made it 
impossible to detect which variants are functional (Cox et al. 2002).  Cox et al studied 
the  greater  sequence  and  haplotype  diversity  in  a  Nigerian  sample  to  improve  the 
identification of functional variants within the ACE gene (Cox et al. 2002).   
 
As was to be expected, serum ACE activity was much higher in the RSA group than the 
Caucasians,  despite  correction  for  confounders.  There  were  significant  but  weak 
associations between UCP3/2 genotypes and serum ACE activity in both the RSA and 
BH3 studies.  This is the first report of an association between common variation in a 
gene other than ACE and serum ACE activity.  Variation at the UCP3 promoter SNP 
resulted in a mean, age-adjusted difference of approximately 6 nmol His-Leu.ml
-1.min
-1 
in ACE activity in both Caucasians and South Africans Xhosans.  However, variation in 
UCP2 genotypes appeared to have opposite effects on serum ACE activity in the two 
ethnic groups.  The sample sizes and the strength of association were too small to detect 
overall  haplotypic  associations  with  serum  ACE  activity.    However,  there  was  a 
significant difference in haplotype effect between the ethnic groups, mostly explained 
by differential effects at the UCP2D/I variant.   
 
There were similar associations between serum ACE activity and UCP3/2 genotypes in 
the Danish type 1 diabetic cohort.  In this Caucasian sample, variation at the UCP3/2 
locus accounted for 5% of the variability in serum ACE activity between individuals.  
There was only weak association in the smaller male type 1 diabetic group drawn from 
UDACS  drawn  from  UDACS,  with  the  UCP2-866GG  homozygotes  having 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
LOCUS AND CIRCULATING ACE ACTIVITY? 
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significantly lower serum ACE activity than A allele carriers.  There was a similar, but 
borderline significant association in the BH3 study.  There were no such associations 
between any UCP genotype and ACE activity in the male type 2 diabetic group from 
UDACS. 
 
These data suggest that variation at the UCP3/2 genetic locus has a small but significant 
impact on serum ACE activity.  The differential association in the two ethnic groups 
studied  could  be  a  result  of  genetic  recombination  with  resultant  differences  in 
haplotype structure.  Only three genetic variants were examined, so it is difficult to draw 
firm conclusions as to which (if any) of these is functional or is associated with the 
greatest influence on ACE activity.  As previously discussed, the genetic variants or 
haplotypes  examined  may  not  be  functional  themselves,  but  may  mark  functional 
variation elsewhere in the cluster.  In order to unravel the association further, the sample 
sizes would need to be increased and more gene variants across the locus would need to 
be tested.  However, this process is limited by the strength of the association between 
UCP3/2 genotypes and serum ACE activity which reduces the power of any such study.   
 
The lack of association between serum ACE activity and UCP3 and UCP2 genotypes in 
the cross-section of type 2 diabetic men from UDACS may be due to the phenotypic 
complexity  of  this  group,  such  that  any  true  association  might  be  diluted  by 
confounders, such as drug therapy, duration of diabetes and presence of hypertension.  
 
The UCP3/UCP2 locus has been linked to resting metabolic rate (Bouchard et al. 1997) 
and is in a region that has been linked to diabetes and obesity (Fleury et al. 1997).  
However, I found no association between the UCP3 or UCP2 genotypes tested and the 
presence of diabetes or obesity.  This agrees broadly with most previous cross-sectional 7.  IS THERE AN ASSOCIATION BETWEEN THE UCP3/UCP2 GENETIC 
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studies in Caucasians, with no association between the UCP2D/I variant and obesity 
reported in 744 obese Danish men (Dalgaard et al. 1999) nor in British women (Cassell 
et  al.  1999).    In  contrast,  association  was  found  between  this  variant  and  fat 
accumulation in a small prospective study of Caucasian patients on peritoneal dialysis 
(Nordfors et al. 2000), childhood obesity (Yanovski et al. 2000), older (more than 45 
years old) Pima Indians (Walder et al. 1998) and a larger cross-sectional study of South 
Indian women (Cassell et al. 1999).  No association between UCP2D/I variant and the 
presence of type 2 diabetes was previously found (Cassell et al. 1999), but positive 
association was found between the UCP3-55T allele and diabetes in French Caucasians 
(Meirhaeghe et al. 2000) and with BMI in morbidly obese French Caucasians (Otabe et 
al. 2000), as well as the UCP2-866G allele and obesity (Esterbauer et al. 2001) and 
protection against diabetes (Krempler et al. 2002).  Differences in reported association 
may have been  caused  by differences in  ethnic group studied, sample  size  (smaller 
genetic studies may be more likely to report false positive association with a possibility 
of publication bias (Colhoun et al. 2003), or differences in the severity of the phenotype 
in  the  study  group  (for  example  morbid  obesity  rather  than  comparison  of  BMI  or 
childhood onset obesity rather than adult-onset).  
 
 
In summary, a significant genetic association between the UCP3/UCP2 locus and serum 
ACE  activity  has  been  described.    There  were  significant  ethnic  differences  in 
UCP3/UCP2 haplotype distribution and significant haplotypic associations with serum 
ACE activity.  The majority of this association appeared to be due to variation in the 
UCP2 gene.   
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Further work is required to delineate the proposed UCP3/UCP2 genetic association with 
ACE activity, with a larger sample size and an increase in the number of gene variants 
examined.   
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 RESULTS CHAPTER EIGHT  
8  DO UNCOUPLING PROTEINS 2 OR 3 ALTER ACE EXPRESSION 
IN HUMAN ENDOTHELIAL CELLS? 
 
 
8.1  UNCOUPLING PROTEINS ARE EXPRESSED AT THE MRNA LEVEL IN 
HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVECS) 
 
HUVECs were grown to sub-confluency in 175ml culture flasks and RNA harvested as 
described in Chapter 2.  Messenger RNA was isolated and target sequences amplified 
using forward and reverse primers (Table 8.1) as previously described.  Abundant UCP2 
and ACE mRNA were both identified, whereas UCP3 mRNA expression appeared to be 
low (Figure 8.1).  This is the first report of UCP expression in human endothelial cells.  
Shortly after this discovery, Duval et al published data in murine endothelial cells using 
antisense to UCP2 to increase cellular ROS generation; RT-PCR was not performed, 
and UCP3 antisense had no effect on endothelial ROS (Duval et al. 2002). 
 
 
8.2  MANIPULATION OF Δψm IN HUVECS 
Mitochondrial  membrane  potential  (Δψm)  was  measured  in  HUVECs  using  flow 
cytometry.  Cells were pre-treated with either 5 μM mClCCP for 30 minutes or 10 μM 
rotenone for 1 hour or 10 μM nigericin for 1 hour and then loaded with 5 μM JC-1 for 1 
hour prior to analysis of Δψm (Figure 8.2).  Uncoupling of mitochondrial respiration 
with the protonphore mClCCP resulted in collapse of Δψm (mean 95 ±0.1% reduction, P 
< 0.01). 
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Table 8.1.  Forward and reverse primers for RT-PCR and amplicon size.  Primers 
were designed to either include an intronic sequence within the amplified sequence 
(if genomic DNA were present as contaminant) or designed to straddle exon-exon 
boundaries. 
 
Gene  cDNA  accession no.  Primers  Amplicon 
size, bp 
hGAPDH  J04038 
F:  GGGGAAGGTGAAGGTCGGAGT 
228 
R:  CCTGGAAGATGGTGATGGGAT 
hUCP3  U84763 / 
AF050113 
F:  CCTCACTACCCGGATT 
235 
R:  GTTGACGATAGCATTCCT 
hUCP2  NM_003355 / 
AF019409 
F:  GCTTTGAAGAACGGGAC 
296 
R:  CTGTAACCGGACTTTAGCA 
hACE  J04144 
F:  ACCAATGACACGGAAAG 
207 
R:  GTGGGTTTCGTTTCGG 
 
Figure  8.1.    RT-PCR  of  mRNA  isolated  from  4  samples  of  HUVECs.    PCR  for 
GAPDH, UCP2, ACE and UCP3 were performed and products run on a 2% agarose 
gel against a 1kb DNA ladder. 
235 bp 
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The  ionophore  nigericin  caused  the  expected  hyperpolarisation  of  Δψm  (mean  107 
±26.1% increase P<0.01).  The complex 1 inhibitor rotenone had no effect on Δψm, 
confirming that the cells were maintaining their membrane potential through glycolytic 
metabolism, as they were in Krebs‘ solution with glucose as substrate.  
 
 
 
 
 
 
 
 
Figure  8.2.    Relative  JC-1  aggregate  to  monomer  (A:M)  fluorescence  in 
HUVECs pretreated with mClCCP, rotenone and nigericin. 
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8.3  ROS GENERATION IN HUVECS 
The  redox  cycler  menadione  (1  mM  for  1  hour)  caused  a  significant  increase  in 
mitochondrial superoxide production as measured with DHE fluorescence in HUVECs 
(76 ±2.6% increase, P = 0.009; Figure 8.3).  This appeared to be at the expense of 
mitochondrial  peroxynitrite,  as  demonstrated  by  a  significant  reduction  in  DCF-DA 
fluorescence (19 ±11.2% reduction P = 0.02).  This pattern was repeated with mClCCP 
(5 μM for 30 minutes) treatment, although the changes in fluorescence were greater 
(122 ±2.2% increase in DHE fluorescence, P = 0.001 and 56 ±16.4% reduction in DCF-
DA, P < 0.0001).  In contrast, rotenone (10 μM for 1 hour) led to a modest increase in 
both DHE and DCF fluorescence (29 ±1.3% increase, P = 0.01 and 31 ±22.9% increase, 
P = 0.04, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3.  Effect of addition of menadione, mClCCP and rotenone on the flow 
cytometric  measurement  of  intracellular  DCF-DA  (5μM)  and  DHE  (10μM) 
fluorescence in HUVECs. 
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8.4  THE  EFFECTS  OF  PROLONGED  HYPOXIA,  UNCOUPLING  AND 
HIGH  GLUCOSE  ON  Δψm  AND  SUPEROXIDE  GENERATION  IN 
CULTURED HUVECS 
 
HUVECs were incubated for 24 hours in different experimental conditions to induce 
cell  stress.    Superoxide  generation  and  Δψm  were  measured  by  flow  cytometric 
measurement of DHE and JC-1 cell fluorescence, respectively (Figure 8.4).  Control 
(vehicle-treated)  cells  were  incubated  in  standard  EBM  media  containing  5.6  mM 
glucose at 20% O2 and 5% CO2.   
 
In contrast to a previous report (Nishikawa et al. 2000), exposure to a high glucose 
concentration (30 mM) for 24 hours resulted in no change in either Δψm or superoxide 
generation (N = 5; Figure 8.4).  
 
Treatment with the respiratory uncoupler mClCCP for 24 hours (N = 3) resulted in a 
dose dependent decrease in Δψm (5 μM mClCCP: mean 71 ±17.5% reduction in JC-1 
A:M fluorescence; P = 0.003).  This profound, persistent uncoupling of respiration was 
also  associated  with  a  significant  dose-dependent  production  of  superoxide  (5  μM 
mClCCP: mean 232 ±40.0% increase in DHE fluorescence; P = 0.00002; Figure 8.4). 
 
HUVECs  incubated  in  hypoxic  conditions  for  24  hours  (5%  O2;  N  =  3)  exhibited 
significant cell stress with a reduction in Δψm (mean 12 ±3.6% reduction in JC-1 A:M 
fluorescence; P = 0.04) and increase in superoxide (mean 18 ±3.4% increase in DHE 
fluorescence; P = 0.006; Figure 8.4).  
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8.5  THE EFFECTS OF UCP ANTISENSE ON HUVEC MITOCHONDRIAL 
FUNCTION  
An  antisense  strategy  was  employed  to  selectively  downregulate  UCP2  and  UCP3 
mRNA expression in HUVECs, using a similar approach in murine endothelial cells as 
Duval et al (Duval et al. 2002).  Complementary oligonucleotide sequences (21mer) 
were designed to straddle the published transcription start sites of UCP1, UCP2 and 
UCP3 (Figure 8.5).  The sequences were entered into a Basic Local Alignment Search 
Tool  (BLAST;  National  Center  for  Biotechnology  Information  website 
http://www.ncbi.nlm.nih.gov/BLAST/) to rule out close sequence homology with other 
Figure 8.4.  Effects of 24 hours of high glucose, protonphore mClCCP and hypoxia 
(5% O2) on HUVEC Δψm and superoxide production (measured by JC-1 aggregate to 
monomer fluorescence ratio and DHE fluorescence, respectively) 
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human genomic sequences.  A randomly scrambled UCP2 antisense sequence which did 
not recognise any published human genomic sequence was also designed (Figure 8.5).  
 
Cells were then incubated with 2 ml serum-free media supplemented with 1-10 μM 
antisense oligonucleotide for a total of 48hours, with fresh media changed at 24 hours to 
maintain a more even concentration of oligonucleotide.  After this time, the supernatant 
was aspirated and stored at -80°C for subsequent analysis.  The cells were immediately 
either lysed for isolation of mRNA or washed in Krebs solution prior to assessment of 
Δψm or ROS status.   
 
 
 
Figure 8.5.  Nucleotide sequence of 21mer antisense strands designed to bind 
across  UCP1,  UCP2  and  UCP3  transcription  start  sites  and  of  a  UCP2 
‘scrambled’ antisense oligonucleotide 
hUCP2 5’- TCAGCATCATGGTTGGGTTCAAGGCCACA -
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Figure 8.6.  Mitochondrial membrane potential of HUVECs treated with antisense to 
UCP2  and  UCP3  using  flow  cytometric  assessment  of  cellular  JC-1  (5μM) 
fluorescence. 
Figure 8.7.  Dihydroethidium fluorescence in HUVECs incubated with antisense to 
uncoupling proteins for 48 hours. 
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There  was  no  significant  effect  of  any  antisense  oligonucleotide  on  resting  Δψm  in 
cultured HUVECs as assessed by JC-1 A:M fluorescence (Figure 8.6). 
 
UCP2  antisense  led  to  small,  but  significant  increase  in  superoxide  generation  in 
HUVECs (7 ±3.5% increase in DHE fluorescence; P = 0.01; Figure 8.7).  There was no 
effect  of  UCP3  or  scrambled  UCP2  antisense  on  DHE  fluorescence  compared  to 
vehicle. 
 
 
8.6  THE  EFFECT  OF  UCP  ANTISENSE  ON  ACE  EXPRESSION  IN 
ENDOTHELIAL CELLS 
 
HUVEC monolayers in 6 well culture plates were treated with vehicle, UCP2, UCP3 
and scrambled (UCP2) antisense for 48 hours.  After this time, total cellular mRNA was 
extracted and ACE mRNA was quantified using the LightCycler.  ACE activity was 
also measured in the supernatant as previously described. 
 
Treatment with UCP2 antisense resulted in a significant 40 ± 8.0% decrease in ACE 
mRNA expression (N = 4; P < 0.05 ANOVA; Figure 8.8).  There was no effect of 
scrambled antisense on ACE expression. 
 
There  were  no  measurable  alterations  in  ACE  activity  in  the  cell  culture  media 
following antisense treatments (Figure 8.9). 
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Figure 8.9.  ACE activity measured in the culture media of HUVECs following 
treatment with UCP antisense for 48 hours (N=7, data are mean ± SEM) 
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Figure  8.8.   ACE  mRNA expression in cultured HUVECs following treatment for 
48hr with 10mM UCP antisense (data are mean ± SEM). 
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8.7  DISCUSSION 
 
This is the first study to show expression of any UCP in human endothelial cells.  Such 
expression was alluded to, but not specifically sought, in one study of rat tissue (Prunet-
Marcassus et al. 1999).  UCP2 and UCP3 have now been localised, together with ACE, 
to a cell type that is central to the pathophysiology of atherosclerosis.  ACE protein was 
previously incidentally found within adrenal mitochondria (Peters et al. 1996) on the 
inner membrane, and this novel data may make regulatory or feedback control between 
ACE and uncoupling proteins plausible.   
 
Using  flow  cytometric  assays,  it  was  possible  to  measure  and  manipulate  Δψm  in 
HUVECs and also measure intracellular ROS generation.  Pre-incubation of HUVECs 
with the protonphore mClCCP led to collapse of Δψm with subsequent futile cycling of 
the ETC and generation of O2•
- (increased DHE fluorescence) probably from reverse 
electron transport and O2•
- generation from complexes I and III (Nicholls et al. 2002).  
This is in contrast to previous reports (Nishikawa et al. 2000).  There was a concomitant 
reduction  in  DCF-DA  fluorescence,  a  measure  of  ONOO
-  production  (Possel  et  al. 
2002; Roychowdhury et al. 2002).  Production of mitochondrial superoxide by HUVEC 
treatment with the redox cycler menadione led to a similar, but less extreme pattern of 
probe  fluorescence,  as  did  treatment  with  mClCCP.    This  may  be  as  a  result  of 
upregulation of Mn-SOD (as has been previously reported in glial cells (Roychowdhury 
et al. 2002)) with superoxide rapidly dismutased to H2O2 (and this reduced to H2O by 
glutathione reductase) rather than used to generate ONOO
- from NO•.  It is possible that 
respiratory  uncoupling  by  mClCCP  or mitochondrial  superoxide  generation  leads  to 
cellular  stress  and  a  reduction  in  cellular  NO•  production  and  thus  a  reduction  of 
ONOO
-  and  DCF-DA  fluorescence.    A  further  possibility  is  that  mitochondrial DO UNCOUPLING PROTEINS 2 OR 3 ALTER ACE EXPRESSION IN HUMAN 
ENDOTHELIAL CELLS? 
  333 
superoxide  production  in  endothelial  cells  reduces  the  bioavailability  of  molecular 
oxygen at complex IV, which is replaced by NO• (Brown et al. 1994; Cleeter et al. 
1994) and thus reducing NO• bioavailability for ONOO
- generation. 
 
The  addition  of  rotenone  to  HUVEC  cultures  led  to  modest  increases  in  both 
mitochondrial O2•
- and ONOO
- production.  Rotenone is a complex 1 inhibitor, binding 
to complex I downstream from its O2•
- production site, therefore generating O2•
- when 
electron transport through this complex is from NAD
+-linked substrates such as glucose 
(Nicholls et al. 2002).  It was suggested that rotenone inhibition of complex I could 
reduce O2•
- production from complex I (Duranteau et al. 1998; Pearlstein et al. 2002).  
However,  in  those  studies,  cells  were  exposed  to  hypoxia,  during  which  time 
glycolytically formed ATP is further depleted by reversal of the ATP synthase which 
maintains  Δψm  but  generates  O2•
-  from  complexes  I  and  III  by  reverse  electron 
transport.    Rotenone  treatment  during  cellular  hypoxia  therefore  binds  complex  I 
upstream from the site of O2•
- production, thereby reducing O2•
-.   (Parthasarathi et al. 
2002).  In ductus arteriosus endothelial cells, which are exquisitely sensitive to oxygen 
tension, rotenone has been shown to decrease cellular ROS production (Michelakis et 
al. 2002).  Furthermore, these cells have been shown to be insensitive to respiratory 
uncouplers such as cyanide (Michelakis et al. 2002).  This may demonstrate a difference 
in mitochondria and mitochondrial function between endothelial sub-types, but also that 
care  must  be  taken  in  interpretation  of  these  data  as  mitochondrial  function  varies 
considerably according to the experimental condition (Nishikawa et al. 2000). 
 
Chronic exposure of HUVECs to respiratory uncoupling led to a dose dependant loss of 
Δψm  and  a  dose  dependant  increase  in  superoxide  generation.    Similar  patterns  of 
change were demonstrated with chronic hypoxia (Pearlstein et al. 2002).  However, DO UNCOUPLING PROTEINS 2 OR 3 ALTER ACE EXPRESSION IN HUMAN 
ENDOTHELIAL CELLS? 
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high glucose concentration for 24 hours led to no change in either Δψm or superoxide 
generation, in contrast to previous findings (Nishikawa et al. 2000), although this study 
did not report the duration of incubation in these conditions.  It may be that more than 
24 hours of relative hyperglycaemia is required in order to cause an alteration of cellular 
ROS generation.  Of note, amongst diabetics, there was no association between TAOS 
and both HbA1c and random plasma glucose. 
 
Duval and colleagues subsequently reported the presence of UCP2 mRNA in murine 
endothelial cells and demonstrated its negative regulation using antisense (Duval et al. 
2002).  I therefore utilised a similar approach in human endothelial cells.  Treatment of 
HUVECs  with  antisense to  UCP2  for 48 hours led to  a significant  dose dependent 
increase  in  cellular  O2•
-  generation  as  measured  by  DHE  fluorescence,  without  a 
measurable  change  in  Δψm.    There  were  no  significant  changes  associated  with 
treatment of HUVECs with UCP3 antisense.  These data support the RT-PCR data that 
UCP2 is the predominant UCP in HUVECs. 
 
The same dose of UCP2 antisense led to a significant 40% decrease in ACE mRNA 
expression in cultured HUVECs without a measurable change in ACE activity in the 
culture media at 48 hours.  The assay for ACE activity may not have been sensitive 
enough to discriminate small changes of ACE activity in vitro.  UCP3 antisense had an 
almost identical effect on ACE mRNA, but without reaching statistical significance, 
which may have reflected the small sample size.  This borderline effect on ACE mRNA 
may have been directly as a result of a reduction in UCP3 protein activity or possibly as 
a result of inhibition of RNA polymerase binding 5‘ upstream at the UCP3/2 locus to 
generate UCP2. DO UNCOUPLING PROTEINS 2 OR 3 ALTER ACE EXPRESSION IN HUMAN 
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These  data  confirm  that  UCP2  is  involved  in  mitochondrial  ROS  generation  in 
HUVECs and that UCP2 is involved in regulation of endothelial ACE expression.  It is 
tempting to speculate that the two are linked by UCP2-mediated mitochondrial O2•
- 
generation.  ROS are mediators of many cell physiological processes, including cell 
growth (Nishio et al. 1997), angiotensin II- induced hypertrophy (Ushio-Fukai et al. 
1998;  Zafari  et  al.  1998)  and  oxygen  sensing  (Michelakis  et  al.  2002).    There  is 
accumulating evidence that UCPs may be negative regulators of oxidative stress in a 
variety of cell types (Negre-Salvayre et al. 1997; Lee et al. 1999; Arsenijevic et al. 
2000),  now  including  endothelial  cells  (Duval  et  al.  2002).    In  fact,  O2•
-  directly 
activates  mitochondrial  proton  conductance  via  UCP1,  2  and  3,  thereby  reducing 
mitochondrial ROS generation (Echtay et al. 2002).  However, against this hypothesis, 
there was no correlation between circulating ACE activity and TAOS in diabetic men. 
 
In summary, it has been shown that ACE, UCP2 and, to a lesser extent, UCP3 were 
expressed at the mRNA level in HUVECs.  Specific antisense to UCP2, but not UCP3, 
led  to  a  significant  increase  in  endothelial  (mitochondrial)  O2•
-  generation  and  to  a 
decrease in HUVEC ACE mRNA expression.  Further in vitro work will be required to 
dissect  the  putative  role  of  UCP2  or  UCP3  in  mitochondrial  ROS  generation  and 
HUVEC ACE expression.   Conclusion 
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 CHAPTER NINE  
9  CONCLUSIONS 
 
 
A genetic approach was used to test the hypothesis that kinins may be responsible for 
some of the observed associations between variation in the ACE gene and effects on 
both the cardiovascular system and skeletal muscle efficiency.  Such effects may rely on 
alterations in mitochondrial function.  In vitro assays were therefore established to test 
the hypothesis that ACE can influence mitochondrial coupling.   Novel mitochondrial 
uncoupling proteins (UCPs) have been discovered whose functions may include the 
regulation of mitochondrial respiratory chain coupling, mitochondrial ROS generation 
and mitochondrial substrate utilisation, and, as such, these proteins may be a subcellular 
target of ACE.  A genetic approach was used to test associations between common 
variation in the UCP3/2 locus and both cardiovascular pathophysiology and skeletal 
muscle efficiency.  These genetic studies suggested a novel regulatory pathway between 
circulating ACE protein activity and mitochondrial UCPs.  In vitro assays were used to 
explore such potential interactions between ACE and UCP within human endothelial 
cells. 
 
 
 
9.1.  GENETIC  VARIATION  IN  THE  BRADYKININ  β2  RECEPTOR 
(BDKRB2) GENE 
In vitro work has previously shown that the BDKRB2 -9 allele is associated with higher 
gene transcriptional activity (Braun et al. 1996), higher mRNA expression (Lung et al. 
1997)  and  increased  likelihood  of  angioedema  in  C1-esterase  deficiency,  a  disease Conclusion 
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characterised  by  high  kinin  activity  (Lung  et  al.  1997).    In  this  study,  there  were 
significant  associations  between  the  BDKRB2  -9  allele  and  lower  prospective  LV 
growth  as  well  as  a  protective  effect  from  prospective  hypertensive  CHD  risk.  
Prospective gene-environment studies are a useful tool in providing indirect answers to 
studies which have proved difficult to conduct in vivo in humans and are also useful in 
further hypothesis generation.  These first data in humans add credence to the long-held 
suspicions that the observed benefits of ACE inhibition on vascular risk may be, in part, 
due to reduced kinin degradation (Linz et al. 1995), as  kinetic studies have shown that 
bradykinin  is  the  preferred  substrate  of  ACE  (Jaspard  et  al.  1993).  In  this  study, 
individuals with the highest predicted kinin activity (ACE I BDKRB2-9 homozygotes) 
demonstrated no change in LV mass during the physiological challenge of 12 weeks of 
basic army training, whereas those individuals with the lowest predicted kinin activity 
(ACE D BDKRB2+9 homozygotes) had the highest gain in LV mass (15.7 ± 14.2g) 
during training.  Statistical analysis suggested that variation at the BDKRB2+9/-9 locus 
accounted for 4% of the interindividual variability in prospective LV growth. 
 
Could the beneficial (antitrophic) effects of kinins on LV growth and on hypertensive 
CHD risk be related?  Extensive animal and in vitro data support a role for BDKRB2 
activation in  diminishing blood pressure (Wang et al. 1997) and cardiac hypertrophic 
responses (Linz et al. 1993; Linz et al. 1995; Linz et al. 1996; Rosenkranz et al. 1999).  
Conversely,  BDKRB2  gene  knockout  mice  develop  hypertension  and  LVH  with 
exaggerated responses to salt and Ang II (Madeddu et al. 1997; Emanueli et al. 1999).  Conclusion 
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Hypertension  is  the  commonest  cause  of  LVH  and  is  associated  with  a  systemic 
(Koenig et al. 1999) and local vascular (Parissis et al. 2000) inflammatory response 
which, through interleukin-driven activation of NF-κβ, induces (potentially protective) 
vascular BDKRB1 expression (Ni et al. 1998).  Whether BDKRB2 expression may be 
similarly modulated is not known.  Both kinin receptor subtypes are expressed in the 
atheromatous plaque (Raidoo et al. 1997) and the BDKRB2-58C rather than -58T allele 
has been previously reported in excess amongst hypertensive (rather than normotensive) 
sufferers of acute MI (Aoki et al. 2001).  The beneficial effects of ACEi and ARBs on 
LV remodelling and function post MI are reduced in BDKRB2 knockout mice (Yang et 
al. 2001).  More broadly speaking, the KKS may afford vascular protection through a 
number  of  other  potential  mechanisms,  including  BDKRB2-mediated  local  NO• 
synthesis (Kichuk et al. 1996), coronary vasodilatation (Su et al. 2000) and inhibition of 
Figure 9.1.  Schematic summary of gene-environment studies conducting in this 
thesis.  Published data suggests that the BDKRB2-9 allele is associated with high β2 
receptor expression.  The stressor for each study is depicted with an open arrow.  The 
associated phenotype for each study is depicted alongside the proposed mechanism 
(boxed). Conclusion 
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vascular  smooth  muscle  cell  growth  (Murakami  et  al.  1999),  as  well  as  potent 
antithrombotic/antiplatelet effects (Colman et al. 1999; Schmaier 2000).   
 
Physiological cardiac hypertrophy in response to regular physical exercise (so called 
―athletes‘  heart‖)  is  associated  with  preserved  or  enhanced  cardiac  function  and  is 
distinct  from  pathological  cardiac  hypertrophy  secondary  to  pressure  or  volume 
overload,  which  is  associated  with  depressed  cardiac  function  and  an  increase  in 
morbidity  and  mortality.    At  the  molecular  level,  only  pathological  hypertrophy  is 
associated with an excess of cardiac fibrosis and extracellular matrix deposition and the 
two  processes  may  therefore  differ  in  their  subcellular  molecular  pathways.    The 
association of  the  ACE  I/D variant  and now the  BDKRB2  +9/-9 variant  with  both 
physiological LV growth and pathological states (e.g. hypertensive CHD risk) is highly 
suggestive of some commonality in the signalling pathways underlying both forms of 
LVH.   
 
A highly significant positive association between the BDKRB2 -9 allele and both human 
skeletal muscle metabolic efficiency and endurance athletic performance, and, as above, 
these associations were greatest amongst those individuals in whom one could predict 
the highest kinin activity (ACE I BDKRB2 -9 homozygotes).  Several genetic studies 
from  this  laboratory  have  shown  a  clear  association  between  the  ACE  I-allele  and 
markers  of  metabolic  efficiency,  such  as  increased  efficiency  of  skeletal  muscle 
contraction  (Williams  et  al.  2000)  and  endurance  performance  (Montgomery  et  al. 
1998;  Myerson et  al. 1999), but  these are the  first  data to  implicate a specific and 
plausible  underlying  mechanism.    Skeletal  muscle  contains  a  complete  KKS  with 
functional BDKRB2 (Figueroa et al. 1996; Mayfield et al. 1996; Rabito et al. 1996). 
Muscle blood flow and skeletal muscle glucose uptake may be influenced by bradykinin Conclusion 
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generated in situ (Wicklmayr et al. 1979; Langberg et al. 2002), levels of which are 
under  genetic  influence  (Murphey  et  al.  2000).    Bradykinin,  acting  through  the 
BDKRB2,  has  metabolic  effects  on  skeletal  muscle,  including  enhanced  insulin 
mediated  GLUT-4  translocation  (Taguchi  et  al.  2000),  activation  of  inositol  1,4,5-
triphosphate/calcium induced excitation-coupling (Foster 1994; Rabito et al. 1996) and 
alteration of mitochondrial oxygen utilisation via endogenous NO production (Shen et 
al. 1995; Zhang et al. 1997; Moncada et al. 2002).  ACE I/D genotype is associated with 
fibre type distribution (Zhang et al. 2003) and this may be caused by chronic differences 
in kinin activity influencing trophic changes in skeletal muscle.   
 
Skeletal and cardiac muscle share many of the described metabolic pathways, and it is 
possible that the cardioprotective effects of kinins are in large part metabolic in origin.  
ACEi and kininogen both increase NO• production and reduce oxygen consumption in 
isolated  myocardium,  in  a  BDKRB2-dependent  manner  (Zhang  et  al.  1997).  
Interestingly, these effects are preserved in explanted failing human heart (Loke et al. 
1999).    Bradykinin  perfusion  of  ischaemic,  isolated,  beating  rat  hearts  results  in  a 
reduction  in  LDH  and  CK  activity  and  in  myocardial  lactate  production,  with 
preservation of high energy phosphates and glycogen with concomitant improvements 
in cardiac haemodynamics (Schoelkens et al. 1992) suggesting a protective metabolic  
switch  towards  glucose  metabolism,  as  well  as  more  fundamental  changes  in 
mitochondrial function.  It is possible, therefore, that the observed association between 
the  low  ACE/low  kinin  haplotype  (ACE  I/BDKRB2-9)  and  low  prospective  cardiac 
growth is due to alterations in cardiac metabolism. 
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9.2.  ACE & MITOCHONDRIA 
 
Flow  cytometric  and  confocal  microscopic  assays  were  developed  using  fluorescent 
potentiometric dyes to indirectly measure Δψm in cultured live cells.  Treatment with the 
ACEi ramiprilat for 24 hours lead to a highly significant increase in Δψm in both skeletal 
and cardiac blasts and myocytes as assessed by the two complementary techniques.  
This relative hyperpolarisation of the inner mitochondrial membrane suggests increased 
coupling  between  mitochondrial  respiration  and  ATP  generation.    This  would  lead, 
theoretically, to a decrease in mitochondrial respiration rate (Nicholls et al. 2002), i.e. a 
reduction in proton leak in the basal state would lead to a lowering of the ADP/ATP 
ratio, which would slow the rate of oxygen consumption.  However, no alteration in 
basal respiratory rate was seen in C2C12 myocytes pretreated with ramiprilat.  This may 
be  due  to  lack  of  sensitivity  of  the  OxySpot  assay  to  measure  small  differences 
particularly in the resting state.  An increase in cellular activity such as with mechanical 
work may produce more pronounced and measurable differences in respiratory rate.   
 
Ramiprilat treatment resulted in a delayed increase in Δψm between 6 and 12 hours 
suggesting a gene-transcriptional event might be responsible for the putative increase in 
mitochondrial coupling.  However, no significant change in the dominant uncoupling 
protein,  UCP3,  gene  transcription  was  observed  in  C2C12  myotubes  treated  with 
ramiprilat  for  24  hours.    There  was  a  wide  degree  of  variation  of  UCP3  mRNA 
transcript ratio in both treated and untreated myotubes, possibly explained by the degree 
of  cultured  myocyte  differentiation  (Shimokawa  et  al.  1998),  and  this  may  have 
prevented small changes in transcript ratio being observed.  Moreover, UCP3 and UCP2 
undergo extensive post-transcriptional changes, so it may be more important to measure 
absolute protein levels  (Pecqueur et al. 2001), although neither the amount of mRNA or Conclusion 
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protein reflect the degree of activation of UCP, which can be altered by the presence of 
fatty acid or ROS (Echtay et al. 2002). 
 
ACEi increase the bioavailability of NO• which is thought to exert metabolic control 
over  mitochondrial  respiration  (Shen  et  al.  1995;  Clementi  et  al.  1999;  Loke  et  al. 
1999).  The concentration and source of NO• is critical (Kojda et al. 1999).  A biphasic 
inotropic  response  to  NO•  and  cGMP  is  seen  in  cardiac  myocytes  with  low 
(submicromolar)  concentrations  resulting  in  positive  inotropy  and  higher 
(submillimolar)  concentrations  resulting  in  negative  inotropy  (Mohan  et  al.  1996).  
Similar effects seem apparent in relation to mitochondrial function (Kojda et al. 1999), 
with  physiologically  relevant  submillimolar  concentrations  of  NO•  being  associated 
with  a  reduction  in  cardiac  oxygen  consumption  without  a  reduction  in  ATP  flux 
through the CK-PCr system (Decking et al. 2001).  ACEi-associated reductions in O2 
consumption and improvements in contractility in cardiac tissue have been shown to be 
NO•-dependent (Zhang et al. 1997), but the source of NO• is likely to be eNOS or 
mtNOS and of a much lower concentration that that induced by LPS activation of iNOS.  
It has been suggested that cytochrome c, modulated by the NO•:O2 ratio, acts as an O2 
sensor, and that constitutive low concentrations of NO• produced by eNOS or mtNOS is 
required by cells to exhibit control over O2 consumption, particularly as O2 tension 
decreases  (Clementi  et  al.  1999).  Regions  with  relatively  reduced  blood  flow  and 
oxygenation  would  have  enhanced  mitochondrial  complex  III  inhibition,  as  NO•-
dependent mitochondrial respiratory inhibition is greater at lower O2 tension.  It may be 
that the benefits in tissue contractile function and reductions in O2 consumption from 
ACEi treatment are due to improvements in tissue perfusion / consumption mismatch.  
ACEi induced vasodilatation would result in both a local increase in oxygen supply as 
well as an increase in NO• generation. Conclusion 
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Figure 9.2.  Cartoon depiction of the putative mitochondrial actions of ACE and its downstream effectors, bradykinin (BK) and angiotensin II (Ang II).  
BK acts via cell surface β2 receptors (BDKRB2) to increase intracellular NO· activity via NOS and also increases cellular glucose uptake, switching mitochondrial 
metabolism to more energetically favourable glucose metabolism, resulting in preservation of high energy phosphate bonds.  Similarly a mitochondrial RAAS or 
mitochondrial NOS may exist which may also directly or indirectly influence mitochondrial respiration (ETC) to decrease mitochondrial O2 utilisation at complex IV 
and increase Δψm.  There may be direct actions to limit UCP activity or indirect via reduction in mitochondrial ROS generation.  Ang II may have indirect, via 
NAPDH-oxidase ROS generation, or direct mitochondrial effects.  Mitochondrial AngII receptors may exist (ATR) which may mediate a direct increase in ETC O2 
utilisation or ETC ROS generation.  NADPH-oxidase related ROS may uncouple NOS leading to a vicious cycle of ROS generation and reduction in NO· which 
would result in an increase in complex IV O2 consumption, reduction in Δψm and compensatory activation of UCP (UCP*) to limit further ROS generation. 
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Pretreatment of C2C12 myotubes with LPS for 24 hours significantly suppressed cellular 
O2 consumption by 73%.  Maximal respiratory cycling caused by treatment with the 
uncoupler mClCCP was unaffected by pre-treatment  with  LPS, suggesting an intact 
ETC.  LPS has been shown to reduce cellular O2 consumption in other cell types (James 
et al. 1995; Borutaite et al. 2001) in an NO•-dependent manner (Borutaite et al. 2001).  
In  these  situations,  maximal  competitive  inhibition  of  complex  IV  and  of  O2 
consumption  at  cytochrome  oxidase  results  in  a  reduction  of  mitochondrial  ATP 
synthesis  (Brookes  et  al.  1999),  so  cellular  ATP  demand  is  met  by  cytoplasmic 
anaerobic  glycolysis.    The  cessation  of  flow  through  the  primary  proton  pump 
(complexes I-IV) results in reversal of the secondary proton pump ATP synthase (F1.Fo-
ATPase)  to  maintain  Δψm  (Section  1.5.1).  Glycolytic  ATP  enters  the  mitochondrial 
matrix through ‗reversal‘ of the adenine nucleotide translocator (ANT) and this matrix 
ATP is hydrolysed by ATP synthase, now a consumer of ATP, to pump H
+ into the 
intermembrane space to maintain a proton gradient (Beltran et al. 2000; Moncada et al. 
2002).  The initial block in electron transport at cytochrome c leads to a transition from 
state 3 to state 4 respiration and an increase in Δψm, and may lead to O2 utilisation at 
complexes  I  and  III  to  generate  superoxide  (O2•
-).    After  persistent  inhibition  of 
respiration by NO•, the depletion of glycolytic ATP and/or oxidative damage leads to a 
collapse in Δψm and cell death (Beltran et al. 2000). 
 
How  does  mClCCP  drive  cellular  O2  consumption  during  maximal  inhibition  of 
mitochondrial respiration by NO•?  This effect has not been previously reported.  It is 
possible  that  sudden  collapse  of  Δψm  with  a  low  dose  of  mClCCP,  leads  to  futile 
electron cycling through complexes I to III and consumption of O2 at complexes I and 
III to produce O2•
-, as demonstrated in HUVECs (vide infra).  Alternatively, mClCCP Conclusion 
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may decrease the bioavailability of NO•, possibly by ROS induced uncoupling of iNOS, 
and therefore allow O2 to compete at complex IV.   
 
An exciting novel finding was that Ang II directly increased the resting O2 consumption 
of C2C12 myocytes in vitro, which was distinct and opposite to the NO• modulation of 
respiration.  Chronic Ang II infusion in rats is known to alter resting O2 consumption 
(Cassis et al. 2002) and result in cachexia (Brink et al. 1996), and this may be through 
increased activity of mitochondrial UCPs which are also upregulated in skeletal muscle 
in experimental cancer cachexia (Bing et al. 2000).  Alternatively, Ang II may be acting 
directly on the ETC complexes through other novel mechanisms.  Ang II induction of 
cellular  ROS  via  NADPH  oxidase  may  result  in  ‗uncoupling‘  of  NOS  (eNOS  or 
mtNOS)  and  therefore  inhibition  of  endogenous  NO•  bioavailability  at  cytochrome 
oxidase  with  a  subsequent  increase  in  mitochondrial  O2  consumption  (Brown  et  al. 
1994; Cleeter et al. 1994).  The extra-mitochondrial NADPH oxidase pathway relies on 
activation  of  the  AT1R;  could  any  direct  mitochondrial  effect  of  Ang  II  rely  on 
mitochondrial angiotensin receptors? 
 
 
9.3.  UCP2 AND UCP3 AND THE CARDIOVASCULAR SYSTEM 
 
9.3.1.  UCPs and prospective cardiac growth 
 
The  mammalian  UCP1  homologues  UCP2  and  UCP3  were  discovered  by  reverse 
cloning (Boss et al. 1997; Fleury et al. 1997) and researchers have since struggled to 
find a plausible function for either of these proteins.  Both are expressed in the human 
myocardium  at  the  mRNA  and  protein  level,  but  their  precise  function  in  the Conclusion 
  346 
cardiovascular system was unknown at the onset of this work.  I used gene-environment 
studies to test the hypotheses that UCP2 and UCP3 are integral components of normal 
cardiovascular  physiology,  being  involved  in  cardiomyocyte  mitochondrial  function, 
substrate utilisation and oxidative stress and, as such, may be important in determining 
LV growth and prospective cardiovascular risk. 
 
This was the first report of an association of variation at the hUCP3/UCP2 locus and 
LV mass: significant associations were found between both the UCP2-866G>A and 
UCP3-55TT genotypes and CMR-determined LV mass in the BH2 study.  The rare 
UCP2-866AA/UCP3-55TT haplotype was associated with the highest LV mass after 
training, being a mean 19 g greater than in subjects who were UCP2-866G allele/UCP3-
55C allele carriers.  It is unclear whether this ‗risk‘ haplotype (UCP2-866AA/UCP3-
55TT) is directly causal in the development of LV growth, with higher UCP2 or UCP3 
activity being deleterious, or whether it relates to lower UCP2 or UCP3 activity which 
results in a permissive phenotype, facilitating the development of LVH. 
 
UCP2 mRNA is expressed at a higher level than UCP3 mRNA in the myocardium 
(Fleury et al. 1997; Razeghi et al. 2001; Young et al. 2001), but whether either UCP is 
expressed  at  the  protein  level  (in  rodents)  is  controversial  (Boehm  et  al.  2001; 
Langdown  et  al.  2001;  Pecqueur  et  al.  2001).    Both  UCP2  and  UCP3  mRNA  and 
protein expression can be increased or decreased in the heart depending on the animal 
model  of  LVH  or  heart  failure  studied  (Fukunaga  et  al.  2000;  Boehm  et  al.  2001; 
Langdown et al. 2001; Noma et al. 2001; Young et al. 2001).   
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Figure 9.3.  Schematic summary of gene-environment studies conducting in this thesis and 
in appendix 4.  It has been postulated that the UCP2-866A allele is associated with repression 
of  induction  of  UCP2  expression.    The  associated  phenotype  for  each  study  is  depicted 
alongside the proposed mechanism (boxed).  Haplotypic association is shown with the UCP3-
55C>T variant as shown.    
 
 
  
 
 
More recently,  both  UCP2 and UCP3 protein  have been detected  in  human cardiac 
tissue explanted at the time of coronary surgery, with significant positive correlations 
between both UCPs and circulating free fatty acid concentrations (Murray et al. 2004).  
UCP2/3  phenotype  may  therefore  be  associated  with  an  alteration  in  the  balance 
between cardiac glucose and fatty acid utilisation.  Fatty acids induce UCP2 mRNA in 
isolated  rat  neonatal  cardiomyocytes  (Van  Der  Lee  et  al.  2000)  and  induce  cardiac 
UCP3 mRNA in  the rat (Depre et al. 2000; Van Der Lee et al. 2000; Van der Lee et al. 
2001) via PPAR dependent and independent mechanisms (Van Der Lee et al. 2000; 
Young et al. 2001). 
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UCP induction may itself result in increased proton leak and O2 consumption at the 
expense  of  reduced  ATP  production  (reduced  mitochondrial  coupling).  It  has  been 
postulated  that  UCP2  and  3  may  be  directly  involved  in  fatty  acid  metabolism, 
facilitating  cycling  of  fatty  acid  anions  through  the  inner  mitochondrial  membrane 
(Boss  et  al.  2000).    But,  although  endurance  exercise  is  associated  with  enhanced 
muscle fat oxidative capacity, UCP2 and UCP3 mRNA expression is downregulated in 
cardiac and skeletal muscle, respectively (Boss et al. 1998).  Mitochondrial fatty acid 
oxidation, itself, is less metabolically efficient as it results in a lower ratio of ATP:O2 
consumed than pyruvate oxidation (Brand et al. 1994), thereby increasing cardiac O2 
consumption for the same amount of cardiac external work (Challoner et al. 1966; Mjos 
1971).    This  energy  deficient  cardiac  state  may  result  in  compensatory  cardiac 
hypertrophy  and  fibrosis.  A  similar  inefficient  state  is  also  seen  in  CCF,  with 
catecholamine induced lipolysis favouring cardiac fatty acid oxidation, together with 
impaired carbohydrate metabolism due to a reduction of GLUT4 expression, inhibition 
of pyruvate oxidation via fatty acid inhibition of the PDH complex (Stanley et al. 2002), 
insulin resistance and downregulation of glycolytic enzymes (Kalsi et al. 1999; Razeghi 
et al. 2001; Murray et al. 2004).   
 
Conversely, UCP upregulation in the heart may be protective.  It has been argued that 
UCP2 and UCP3 are upregulated in cardiac and skeletal muscle during acute rises in 
circulating free fatty acids, such as acute exercise, refeeding and acute cold exposure, as 
a  protective  measure  during  a  surplus  of  free  fatty  acid  supply  to  the  myocyte 
(Schrauwen  et  al.  2002).    In  this  model,  excess  free  fatty  acids  can  enter  the 
mitochondrial matrix, rather than using the CPT system, ‗flip-flopping‘ across the inner 
membrane where they may become protonated.   Neither neutral nor anionic fatty acids 
can be metabolised within the matrix.  UCP2 and UCP3 may therefore act as fatty acid Conclusion 
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anion  exporters  to  remove  excess  protonated  fatty  acid  whose  mitochondrial 
accumulation may result in toxicity (Schrauwen et al. 2002).  This mechanism may be 
particularly important in CCF. 
 
A  more  straightforward  hypothesis,  given  that  UCP2  and  UCP3  protect  against 
myocardial  ROS  production,  and  the  association  of  the  UCP2-866AA/UCP3-55TT 
haplotype with LVH risk, is that the haplotype is associated with lower mitochondrial 
UCP2  and/or  UCP3  protein  expression,  and  that  this  leads  to  either  decreased 
uncoupling and thus enhanced mitochondrial ROS production, or decreased protection 
from ROS.   The UCP2 -866A allele has been associated with lower dynamic UCP2 
mRNA expression in somatic cells (Krempler et al. 2002).  Redox-sensitive pathways 
are  known  to  mediate  LV  growth  (Amin  et  al.  2001;  Bendall  et  al.  2002),  cardiac 
dysfunction (Ide et al. 2001; Suematsu et al. 2003) and fibrosis (Bendall et al. 2002).  
ROS-mediated activation of mitogen activated protein kinases and of nuclear factor-κВ 
is involved in neurohormonal (e.g. angiotensin II, norepinephrine) and stretch-induced 
cardiomyocyte hypertrophy and can be inhibited by the administration of antioxidants in 
vitro  (Griendling  et  al.  2000;  Hirotani  et  al.  2002).    This  may  explain  the  non-
significant differences observed at baseline, as ROS induced cardiac growth might be 
expected to accumulate over a life-time and accelerate during a period of physiological 
stress.   
 
 
9.3.2.  UCPs and CHD risk 
This  was  the  first  report  of  a  highly  significant  association  between  a  common 
functional variant in the UCP2 gene and prospective CHD risk (Dhamrait et al. 2004).  
CHD risk was more than doubled amongst men of UCP2-866AA genotype  (HR 2.22 Conclusion 
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[1.53 - 3.22] for AA vs. GG genotype; P=0.0002) and this risk was amplified by the 
presence  of  conventional  risk  factors  which  are  associated  with  increased  oxidative 
stress,  such  as  hypertension  (x2),  smoking  (x2),  obesity  (x2)  and  diabetes  (x4).  
Although,  there  were  no  such  significant  associations  with  the  UCP3-55C>T  gene 
variant, there were highly significant associations between haplotype and prospective 
CHD risk when haplotype was assessed at the UCP3-55C>T and UCP2-866G>A loci.  
As was the case for prospective LV growth, the ‗risk‘ haplotype was the rare UCP3-55T 
/ UCP2-866A haplotype, which was found in 12.2% of men studied.  Perturbations in 
both UCP2 and UCP3 are implicated in the abnormal metabolism associated with LVH 
(Fukunaga et al. 2000; Boehm et al. 2001; Langdown et al. 2001; Noma et al. 2001; 
Young et al. 2001) and now may also be important in CHD risk.  This again suggests 
common  mechanisms  through  which  the  deleterious  effects  of  hypertension  on  left 
ventricular hypertrophy and CHD may be mediated.   
 
Contributory mechanistic data from joint work with Dr JW Stephens  (Appendix 4.) 
examined the association between plasma TAOS and UCP2-866G>A genotype.  The 
presence  of  diabetes  is  associated  with  increased  oxidative  stress  (Cai  et  al.  2000; 
Brownlee 2001; Evans et al. 2002), and thus  a fall in TAOS (Sampson et al. 2002).  In 
keeping with a role for ROS in atherogenesis, plasma TAOS was significantly lower in 
diabetic men with CHD than those without, an effect that was confirmed in health men 
in the NPHSII study (Stephens et al. 2006).  In the UDACS cohort, the risk UCP2-
866A allele was independently associated with lower TAOS, suggesting a modulating 
influence of UCP2 genotype on ROS burden.  In a smaller subset of diabetic men with 
CHD matched for baseline characteristics, UCP2AA homozygosity was associated with 
highly  significant  increases  in  markers  of  oxidative  stress,  with  40%  lower  TAOS 
mirrored by a 100% increase in F2-isoprostane concentrations (Dhamrait et al. 2004).   Conclusion 
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These data support a role for UCP2 (and hence the mitochondrial electron transport 
chain) in the regulation of ROS generation, and highlights its potential impact upon 
CHD  risk.    In  vitro,  UCP2  activity  and  expression  is  induced  by  oxidative  stress 
(Pecqueur et al. 2001; Echtay et al. 2002), whilst selective down-regulation of UCP2 
increases murine endothelial cell ROS generation (Duval et al. 2002).  O2•
- does not 
directly activate UCP, but releases iron from intramitochondrial  iron-sulphur centred 
proteins which then generates carbon-centered radicals on phospholipids that initiate 
lipid  peroxidation,  yielding  breakdown  products  that  activate  UCPs  (Murphy  et  al. 
2003).  Under conditions of oxidative stress, upregulation of UCP2 expression would 
decrease  Δψm,  thereby  protecting  from  further  mitochondrial  ROS  generation  and 
should  prove  vasculo-protective  (Arsenijevic  et  al.  2000;  Echtay  et  al.  2002).    In 
support,  UCP2  overexpression  protects  against  atherosclerosis  in  LDL-receptor 
deficient mice (Blanc et al. 2003). 
 
9.3.3.  UCPs and oxidative stress 
UCPs have not yet been localised to human atherosclerotic plaque.  This is the first 
report of UCP2 and UCP3 mRNA expression in human endothelial cells (HUVECs).  
Δψm and mitochondrial ROS were successfully manipulated in HUVECs and measured 
using flow cytometric assays.  Chronic exposure of HUVECs to respiratory uncoupling 
with mClCCP led to a dose-dependent loss of Δψm and a dose-dependent increase in 
O2•
- generation.  Similar patterns of change were demonstrated with chronic hypoxia as 
previously described (Pearlstein et al. 2002).  However, high glucose concentration for 
24  hours  led  to  no  change  in  either  Δψm  or  superoxide  generation,  in  contrast  to 
previous findings (Nishikawa et al. 2000), although the previous study by Nishikawa et 
al. did not report the duration of incubation and this may have lead to the observed Conclusion 
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differences.    Of  note,  amongst  diabetics  in  UDACS,  there  was  also  no  association 
between a marker of circulating redox state (TAOS) and either HbA1c or random plasma 
glucose (Appendix 4). 
 
Treatment of HUVECs with antisense to UCP2 for 48 hours led to a significant dose 
dependent  increase  in  cellular  O2•
-  generation  as  measured  by  DHE  fluorescence, 
without a measurable change in Δψm.  There were no significant changes associated 
with  treatment  of  HUVECs  with  UCP3  antisense  or  negative  controls.    These  data 
support the RT-PCR data that UCP2 is the predominant UCP in HUVECs.  A lack of a 
measurable  change in  Δψm may  be because of  a lack of sensitivity of  the assay or 
because UCPs may not be true uncouplers of respiration as has been suggested. 
 
The hypothesis  that  UCP2 is  functional  in  endothelial cell mitochondria and that it 
negatively regulates mitochondrial ROS generation is supported by these data, which 
are in agreement with previous reports in murine endothelial cells (Duval et al. 2002).  
It would be important to repeat these experiments, including the use of UCP activators, 
and  to  measure  UCP2  and  UCP3  protein  levels.  Moreover,  UCP2  has  also  been 
localised within macrophages (Kizaki et al. 2002) where it negatively regulates ROS 
(Arsenijevic et al. 2000) and NO• production (Kizaki et al. 2002).  These data have 
important implications on disease mechanisms and provides a putative role for UCP2 in 
atherogenesis as well as a potential novel therapeutic target.  
 
 
9.3.4.  UCPs and skeletal muscle efficiency 
There were significant associations between genetic variation at the UCP2/3 locus and 
endurance-training related changes in the efficiency of contraction of human skeletal Conclusion 
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muscle (DE).  The UCP2-866A allele carriers had significant gains in DE after training, 
whereas the small number of UCP3-55TT homozygotes tended to have lower DE after 
training.  There was evidence of significant statistical interaction between the UCP2-
866G>A and UCP-55C>T genotypes in determining changes in DE, explaining up to 
14.8% of the interindividual training related changes in DE.  It is however difficult with 
the small sample size to delineate which gene product is responsible for this association 
as the UCP2 and UCP3 genes are separated by only 7kB in chromosomal region 11q13 
(Solanes et al. 1997), and the two SNPs show strong LD.  Much larger sample sizes and 
more SNPs would be required to disentangle any association further.   
 
There were no significant associations between UCP2/3 haplotypes and competitive 
distance  running  event  amongst  a  sample  of  elite,  Olympic  standard  UK  athletes, 
probably partly due to the small sample size and the low frequency of the rare alleles.  
The UCP2-866A allele frequency tended to increase with running distance, reflected in 
an  increased  prevalence  of  UCP3-55C/UCP2-866A  haplotype  carriers  amongst 
endurance events athletes coupled with an increased prevalence of UCP3-55C/UCP2-
866G haplotype carriers in sprinters.  In this small sample of athletes, there were no 
Afro-Caribbean  elite  athletes  competing  at  longer  distances.    There  were  very  few 
UCP3-55T allele carriers amongst Afro-Caribbean athletes and this may have explained 
the  overall  increase  in  UCP3-55T  allele  frequency  seen  according  to  competing 
distance.  The UCP3-55C>T and UCP2-866G>A genotype distributions in the small 
group of Afro-Caribbean athletes was similar to that found in the RSA Study sample, 
suggesting that sampling error was unlikely.   
 
The exact role of UCP2 and UCP3 in skeletal myocyte function is controversial.  The 
close sequence homology between UCP1 and both UCP2 and UCP3 has naturally led to Conclusion 
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the  hypothesis  that  both  UCP3  and  UCP2  are  able  to  increase  skeletal  muscle  O2 
consumption by increasing mitochondrial proton conductance.  The evidence is still 
divergent.  In favour of an uncoupling effect, the UCP2/UCP3 locus has been linked to 
basal metabolic rate in adult humans (Bouchard et al. 1997) and both UCP2 and UCP3 
mRNA is reduced significantly in all skeletal muscle fibre types in endurance training 
rats  (Boss  et  al.  1998).    There  is  a  positive  association  between  UCP3  protein 
expression  and  degree  of  training  and  muscle  fibre  fatiguability  in  humans:  UCP3 
protein content is lower in endurance trained individuals compared to untrained subjects 
(Russell 2003) and is most abundant in type 2b fast-glycolytic fibres (Hesselink et al. 
2001).   Proton leak  (state 4 respiration)  is reduced in  skeletal  muscle  mitochondria 
isolated from the UCP3(-/-) knockout mouse in some (Gong et al. 2000; Vidal-Puig et 
al. 2000) but not all studies (Cadenas et al. 2002).  In whole animal studies using NMR 
spectroscopy, UCP3 knockout mice had a doubling of the ATP synthesis rate in skeletal 
muscle in the fasting state, without any increase in TCA cycle flux rate, implying an 
increase  in  mitochondrial  coupling  (Cline  et  al.  2001).    Conversely,  UCP3 
overexpression studies in yeast (Gong et al. 1997; Zhang et al. 1999; Harper et al. 
2002), proteoliposomes (Echtay et al. 2001) and mammalian cells (Boss et al. 1998) 
leads  to  artifactual  uncoupling  of  mitochondrial  respiration  and  add  little  to  the 
understanding of the physiological function of UCPs (Cadenas et al. 2002). 
 
In an important but small study, Schrauwen‘s group used high-intensity exercise with 
limb blood flow occlusion as a model to deplete skeletal muscle of the energy reserve 
compound PCr in 9 healthy men on a low fat diet and then measured the rate of PCr 
resynthesis during subsequent recovery once limb blood flow was reinstated (Hesselink 
et al. 2003).  The rate of PCr resynthesis  (from mitochondrial generated ATP) is a 
surrogate marker of mitochondrial respiratory coupling.  The study was repeated after Conclusion 
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one week ingestion of a high fat diet to induce a significant ‗physiological‘ increase in 
skeletal  muscle  UCP3  protein.    There  was  no  statistical  difference  in  PCr  content 
measured over time between the two groups, so the authors concluded that a high fat 
diet-induced  physiological  increase  in  UCP3  content  did  not  affect  mitochondrial 
coupling in vivo in human skeletal muscle.  However, this study has been criticised by 
others (Fernstrom et al. 2004).  Looking at the data more closely, there was a positive 
linear  association  between  UCP3  protein  content  and  PCr  resynthesis  rate  overall, 
suggesting  that  the  authors  were  in  fact  measuring  a  surrogate  marker  of  total 
mitochondrial mass per unit of muscle rather than the relative amount of UCP3.  Of 
note,  this  linear  relationship  was  steeper  during  low  fat  feeding,  i.e.  for  any  given 
mitochondrial mass there was more rapid PCr resynthesis, suggesting tighter coupling 
of mitochondrial respiration in the low fat fed state.  In support of this argument, it has 
been  shown  that  absolute  UCP3  protein  content  per  amount  of  tissue  apparently 
remained unchanged in human skeletal muscle after 6 weeks of endurance training, but 
when  taking  into  account  the  training-induced  increase  in  mitochondrial  mass  by 
indexing  to  a  marker  of  mitochondrial  volume  (citrate  synthase),  the  relative 
mitochondrial  content  of  UCP3  protein  in  fact  decreased  significantly  by  53% 
(Fernstrom et al. 2004), thereby potentially contributing to training related increases in 
mitochondrial efficiency.   
 
Most of the training and endurance associations in this study were due to variation at the 
UCP2-866  locus  with  sedentary  UCP2-866A  allele  carriers  benefiting  from  greater 
efficiency after training and elite athletes who were UCP2-866A carriers, more likely to 
compete at endurance distances.  It is tempting to postulate that the UCP2-866A allele 
is  associated  with  lower  inducible  UCP2  expression  within  skeletal  muscle  and Conclusion 
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therefore greater mitochondrial coupling.  As such, one would anticipate the A allele to 
be associated with the endurance phenotypes described.  
 
The UCP3/UCP2 locus is within a region that has been linked to diabetes and obesity 
(Fleury et al. 1997).  However, I found no association between any UCP3 or UCP2 
genotypes  tested  and  the  presence  of  diabetes  or  obesity.    This  agrees  with  some 
(Cassell et al. 1999; Dalgaard et al. 1999), but not the majority of published studies 
(Walder et al. 1998; Cassell et al. 1999; Meirhaeghe et al. 2000; Nordfors et al. 2000; 
Otabe et al. 2000; Yanovski et al. 2000; Esterbauer et al. 2001; Krempler et al. 2002), 
although  many  of  these  studies  examined  extreme  phenotypes  or  subsets  of  racial 
groups.    Differences  in  reported  association  may  therefore  have  been  caused  by 
differences in ethnic group studied, sample size, as smaller genetic studies may be more 
likely  to  report  a  false  positive  association  with  a  possibility  of  publication  bias 
(Colhoun et al. 2003), or differences in the severity of the phenotype in the study group, 
for example morbid obesity and childhood onset obesity rather than comparison of BMI 
in adults. 
 
 
9.4.  UCP AND ACE 
 
9.4.1.  Genetic studies 
An intriguing, significant association between serum ACE activity and variation in the 
UCP3/UCP2 locus was found amongst male army recruits in the Bassingbourn 3 study: 
UCP3-55TT  and  UCP2-866GG  homozygotes  were  found  to  have  the  lowest  serum 
ACE  activity.    This  is  the  first  example  of  genetic  variation  in  an  unrelated  gene 
effecting regulation of the human ACE gene.  There were similar associations between Conclusion 
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serum  ACE  activity  and  UCP3/2  genotypes  in  the  Danish  type  1  diabetic  cohort, 
variation at the UCP3/2 locus accounting for 5% of the interindividual variability in 
serum ACE activity. 
 
The  ACE-UCP  phenotype-genotype  interaction  was  examined  further  in  Chapter  7, 
increasing the variants tested and extending the ethnic diversity in an attempt to tease 
out which gene variant was functional, in a process previously described for the ACE 
gene (Cox et al. 2002).  The RSA study group sampled from the South African Xhosan 
Tribe appeared more ancient (genetically) than the Caucasian sample, with evidence of 
greater recombination and significant differences in LD across the locus between the 
two ethnic groups, exemplified by significant (negative) LD (D‘=0.31) between UCP3-
55C>T  and  UCP2D/I  in  Caucasians  and  no  LD  between  these  two  sites  in  South 
African Xhosans.  The greater observed haplotype diversity amongst the RSA sample is 
consistent with recent reports in black African samples (Reich et al. 2001; Gabriel et al. 
2002).  There were significant associations between UCP3/2 genotypes and serum ACE 
activity  in  both  the  RSA  and  BH3  studies.    Variation  at  the  UCP3  promoter  SNP 
resulted in a mean, age-adjusted difference of approximately 6 nmol His-Leu.ml
-1.min
-1 
in ACE activity in both Caucasians and South Africans Xhosans.  However, variation in 
UCP2 genotypes appeared to have opposite effects on serum ACE activity in the two 
ethnic groups, mostly explained by differential effects at the UCP2D/I variant.   
 
 
The data suggests that variation at the UCP3/2 genetic locus has a small but significant 
impact on serum ACE activity.  Only three genetic variants were examined, so it is 
difficult  to  draw  firm  conclusions  as  to  which  (if  any)  of  these  is  functional  or  is 
associated  with  the  greatest  influence  on  ACE  activity.    The  resolution  to  detect Conclusion 
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functional polymorphisms is limited by the size of the population and the evolutionary 
history of the population.  The differential association in the two ethnic groups studied 
could  be  a  result  of  genetic  recombination  with  resultant  differences  in  haplotype 
structure.    As previously discussed, the genetic variants or haplotypes examined may 
not  be  functional  themselves,  but  may  mark  functional  variation  elsewhere  in  the 
cluster.  In order to unravel the association further, the sample sizes would need to be 
increased and more gene variants across the locus would need to be tested.  However, 
this process is limited by the strength of the association between UCP3/2 genotypes and 
serum ACE activity which reduces the power of any such study.   
 
 
 
9.4.2.  In vitro work 
In vitro work sought to examine the mechanism of the ACE-UCP association.  It was 
first demonstrated that ACE, UCP2 and UCP3 were all co-expressed at the mRNA level 
in human endothelial cells (HUVECs).  Incubation of HUVECs with UCP2 antisense 
led to a significant 40% decrease in ACE mRNA expression as well as a significant 
increase in cellular ROS generation.  There was no measurable change in ACE activity 
in the culture media, although the assay for ACE activity may not have been sensitive 
enough to discriminate small changes of ACE activity in vitro.  UCP3 antisense did not 
have a significant effect on ACE mRNA and ROS generation.  These data confirm that 
UCP2 may regulate both mitochondrial ROS generation and ACE gene expression in 
endothelial cells, although there was no correlation between circulating ACE activity 
and TAOS measured in diabetic men. 
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9.5.  STUDY LIMITATIONS & FUTURE DIRECTIONS 
 
In general, the genetic studies presented here would benefit from an increase in sample 
size and further replication in independent studies, to confirm the observed associations.  
However, the prospective nature of the NPHSII, BH2 and BH3 studies tends to reduce 
the  impact  of  confounders  such  as  survivor  selection  and  difficulties  in  control 
matching, which are inevitable in larger case-control cross-sectional genetic association 
studies (Humphries et al. 2003).  Statistically robust small gene-environment studies are 
possible by matching a small number of carefully chosen individuals with or without a 
known common gene-variant, who are then challenged by an environmental stimulus 
and in  whom pathophysiological  responses are  observed  (Montgomery  et  al. 2003). 
This is exemplified by the effects of exercise on physiological LV growth in young 
male  army  recruits  by  ACE  genotype  (Montgomery  et  al.  1997;  Brull  et  al.  2001; 
Myerson et al. 2001) and in the highly significant differences in two plasma markers of 
ROS which required only 20 closely matched UCP2-866G>A homozygotes from the 
UDACS study (Dhamrait et al. 2004).    
 
Further genetic studies are required to confirm these observations and to extend our 
observations from middle-aged Caucasian males to those of other racial origins and age 
ranges, as well as to women.  It would be interesting to extend the association studies to 
pathological  LVH,  including  regression  of  LVH  following  surgical  relief  of  aortic 
stenosis, as well as to patients with established CHD, such as survivors of myocardial 
infarction, including those with LV dysfunction.  Following myocardial infarction, the 
vast majority of patients receive long-term treatment with either an ACEi or ARB, and 
any prospective pharmacogenomic interaction should be sought.   
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Ideally,  both  the  BDKRB2  gene  and  UCP3/2  locus  should  be  screened  for  further 
polymorphisms and the common haplotypes assessed in different racial groups, as some 
of the genetic variants so far tested may not be functional themselves, but may be in 
strong  LD with  other  nearby  functional variants.  With this  knowledge, the genetic 
association studies should be extended to include these haplotypes in order to test which 
variant(s)  are  functional  or  causal  in  LV  growth,  CHD  risk  and  in  the  association 
between the UCP3/2 locus and serum ACE activity.  For such haplotype studies in 
search  of  functionality,  larger  sample  sizes  may  well  be  required  depending  on  the 
frequency of the rarer haplotypes. 
 
Further assessment of the functionality of the gene variants under study should be made.  
For instance, HUVECs could be isolated according to homozygosity for the  UCP2-
866G>A  variant  and  then  studied  in  vitro  for  assessments  of  Δψm,  ROS,  O2 
consumption  and  ATP  content  at  baseline  and  in  response  to  treatment  with 
hydroxynonenal, fatty acids, ACEi, Ang II and LPS.  Similar work could be carried out 
with  isolated  monocytes  taken  from  volunteers  of  known  genotype.    In  this  case, 
manipulations could be undertaken to induce potential changes in gene expression, such 
as consumption of a high fat diet or vaccination to induce a systemic inflammatory 
reaction or euglycaemic hyperinsulinaemic clamp in diabetic patients. 
 
It would be important to perform immunostaining of human atherosclerotic plaque to 
identify  whether  and  where  UCP2  and  UCP3  are  expressed,  predicting  expression 
within  both  endothelium  and  macrophage/foam  cells.    If  such  expression  was 
confirmed, in vivo assessment of culprit coronary plaque temperature could be made 
according to UCP2 genotype in patients presenting with unstable angina and acute MI 
using  a  thermography  catheter  (Stefanadis  et  al.  1999).    Further  ACE/UCP Conclusion 
  361 
colocalisation studies could be carried out in atherosclerotic plaque as well as more 
specifically in HUVECs in culture using immunofluorescence.   
 
The major finding of this thesis was direct mitochondrial effects of ACE inhibition in 
cultured cells.  There were differential effects according to the lipophilicity of the ACEi 
tested, suggesting an intracellular action.  ACE protein has been previously localised to 
adrenal mitochondria in the rat by electron microscopy (Peters et al. 1996), and this 
study should be repeated in human cardiac and skeletal muscle, with co-localisation 
with UCP2 and UCP3.  The direct activation of cellular O2 consumption by Ang II, 
might  suggest  direct  activation  of  mitochondrial  angiotensin  receptors,  and  their 
presence,  as  well  as  the  presence  of  kinin  receptors  should  be  sought  within 
mitochondria,  both  with  electron  microscopy  and  with  protein  isolation  from 
mitochondrial  subfractions.  If  the  presence  of  a  mitochondrial  RAAS  and  their 
receptors is confirmed, then further work would be required to understand the post-
translational trafficking and targeting of these components to the mitochondria.  ACE 
protein does not have a mitochondrial targeting sequence. 
 
Further  studies  are  required  on  isolated  skeletal  and  cardiac  mitochondria  to  assess 
direct  effects  of  ACEi,  kinins,  angiotensins  and  their  agonists  on  mitochondrial 
respiratory rate.  State 4 respiration could  be assessed in  the presence  of GDP and 
palmitate to inactivate or activate UCPs respectively.  Similar experiments could be 
carried out in tissues isolated from UCP2ko and UCP3ko animals as well as utilising 
both  antisense  and  siRNA  technology  in  isolated  cells  in  order  to  tease  out  UCP 
dependent mechanisms of action. 
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9.6.  SUMMARY 
 
This thesis has used human genetic and in vitro studies to show novel mitochondrial 
effects  of  components  of  the  RAAS  and  a  novel  regulatory  system  involving 
mitochondrial uncoupling proteins and ACE.  This interaction suggests that many of the 
observed non-pressor effects of ACEi on cardiac pathophysiology might be metabolic in 
origin.  Furthermore, genetic studies confirmed for the first time that both bradykinin 
and  the  uncoupling  proteins  have  a  significant  role  in  left  ventricular  hypertrophy, 
cardiovascular risk and skeletal muscle performance.  These studies suggest that UCP2 
and UCP3 could be potential novel targets in cardiovascular biology.   
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APPENDIX 1:  Published manuscripts arising from this thesis 
 
 
 
1.  Bradykinin  B2BKR  receptor  polymorphism  and  left-ventricular  growth 
response. 
   
Brull D, Dhamrait S, Myerson S, Erdmann J, Regitz-Zagrosek V, World M, Pennell D, 
Humphries SE, Montgomery H.   
 
Lancet 2001; 358: 1155–1156 
 
Angiotensin-converting-enzyme (ACE) activity regulates left ventricular growth. The 
deletion (D), rather than the insertion (I), ACE gene variant is associated with increased 
ACE activity and kinin degradation, and the absence (-) rather than the presence (+) of a 
9 bp deletion in the gene encoding the bradykinin 2 receptor (B2BKR) is associated 
with greater gene expression. We determined the ACE and B2BKR genotype of 109 
male army recruits, and measured their physiological left ventricular growth response to 
a 10-week physical training programme. Mean left-ventricular growth was 15.7 g (SE 
3.5) in those with ACE genotype D/D and B2BKR genotype +9/+9, but -1.37 g (4.1) in 
those with ACE genotype I/I and B2BKR genotype  -9/-9 (p=0.003 for trend across 
genotypes). These results suggest that kinins regulate left-ventricular growth, mediating 
some of the effects of ACE in this regard. 
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2.    Variation  in  bradykinin  receptor  genes  increases  the  cardiovascular  risk 
associated with hypertension. 
 
Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, Hawe E, Palmen JM, 
Wootton PTE, Miller GJ, Humphries SE, Montgomery HE. 
 
European Heart Journal 2003; 24: 1672–1680 
 
Aims. The contribution of kinins to the beneficial effects of angiotensin I converting 
enzyme (ACE) inhibition in cardiovascular risk reduction remains unclear. The genes 
for the kinin inducible B1 receptor (B1R) and constitutive B2 receptor (B2R) contain 
functional variants: the B1R−699C (rather than G) and the B2R(−9) (rather than +9) 
alleles  are  associated  with  greater  mRNA  expression  and  the  B2R(−9)  allele  with 
reduced left ventricular hypertrophic responses. We tested whether these gene variants 
influenced hypertensive coronary risk in a large prospective study. 
 
Methods and results. Two thousand, seven hundred and six previously healthy UK 
men (mean age at recruitment 56 years; median follow-up 10.8 years) were genotyped 
for the kinin receptor variants. The coronary risk attributable to systolic hypertension 
(SBP≥160 mmHg) was significantly higher only in B1R−699GG homozygotes (HR 2.14 
[1.42–3.22]; P<0.0001) and B2R(+9,+9) individuals (HR 3.51 [1.69–7.28]; P=0.001) but 
not  in  B1R−699C  allele  carriers  (HR  0.82  [0.28–2.42];  P=0.76)  or  in  B2R(−9,−9) 
homozygotes (HR 1.25 [0.51-3.04]; P=0.63). 
 
Conclusions.  Common  variation  in  the  genes  for  the  kinin  B1  and  B2  receptors 
influences prospective hypertensive coronary risk. These are the first reported human 
data to suggest a role for the B1R in human coronary vascular disease, and the first 
prospective study to demonstrate a similar role for the B2R. 
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3. Cardiovascular risk in healthy men and markers of oxidative stress in diabetic 
men are associated with common variation in the gene for uncoupling protein 2. 
 
Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Manic AR, Moore K, Miller GJ, 
Humphries SE, Hurel SJ, Montgomery HE. 
 
European Heart Journal. 2004; 3: 1–8 
 
Background. Oxidative stress reduces total antioxidant status (TAOS) and is implicated 
in  atherogenesis.  Mitochondrial  uncoupling  protein  2  (UCP2)  negatively  regulates 
reactive oxygen species generation. The UCP2 gene demonstrates a common functional 
promoter variant (-866G>A). 
 
Methods and results. Amongst 465 diabetic men (age 61.7±13.3 years), an association 
of the UCP2-866A allele with significantly lower TAOS in those without CHD was 
even more pronounced in those with CHD (TAOS 30.1±16.1% vs. 41.6±12.4% for AA 
vs. GG; P=0.016). In a sample of 20 diabetic men selected for homozygosity for the 
UCP2-866G>A  variant,  matched  for  baseline  characteristics,  plasma  markers  of 
oxidative  stress  in  those  with  CHD  were  significantly  higher  in  AA  genotype  men 
(TAOS 31.7±7.3% vs. 52.6±6.3%; P=0.001 and F2-isoprostanes 220.6±37.2 pg.ml
-1 vs. 
109.9±51.1  pg.ml
-1;  P=0.005  for  AA  vs.  GG).  Amongst  2695  healthy  men  (age 
56.1±3.5 years) prospectively studied for a median 10.2 years, AA homozygotes had a 
highly significant doubling in CHD risk after adjustment for established risk factors 
(HR 1.99 [1.37–2.90]; P=0.002). Risk associated with this genotype was substantially 
increased by the presence of other risk factors (obesity, hypertension and diabetes). 
 
Conclusions.  This  study  provides  the  first  in  vivo  evidence  of  a  role  for  UCP2  in 
modifying oxidative stress and CHD risk in humans. 
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4. Bradykinin receptor gene variant and human physical performance. 
 
Williams AG,  Dhamrait SS, Wootton PTE, Day SH, Hawe E, Payne JR, Myerson SG, 
World M, Budgett R, Humphries SE, Montgomery HE. 
 
 
J Appl Physiol. 2004; 96: 938–942. 
 
Accumulating  evidence  suggests  that  athletic  performance  is  strongly  influenced  by 
genetic variation. One such locus of influence is the gene for angiotensin-I converting 
enzyme (ACE), which exhibits a common variant [ACE insertion (I)/deletion (D)]. ACE 
can drive formation of vasoconstrictor ANG II but preferentially degrades vasodilator 
bradykinin. The ACE I allele is associated with higher kinin activity. A common gene 
variant in the kinin β2 receptor (B2R) exists: the -9 as opposed to +9 allele is associated 
with higher receptor mRNA expression. We tested whether this variant was associated 
with the efficiency of muscular contraction [delta efficiency (DE)] in 115 healthy men 
and women, or with running distance among 81 Olympic standard track athletes. We 
further  sought  evidence  of  biological  interaction  with  ACE  I/D  genotype.  DE  was 
highly significantly associated with B2R genotype (23.84 ± 2.41 vs. 24.25 ± 2.81 vs. 
26.05 ± 2.26% for those of +9/+9 vs. +9/-9 vs. -9/-9 genotype; n = 25, 61, and 29, 
respectively;  P  =  0.0008  for  ANOVA  adjusted  for  sex).  There  was  evidence  for 
interaction with ACE I/D genotype, with individuals who were ACE II, with B2R -9/-9 
having the highest DE at baseline. The ACE I/B2R -9 ―high kinin receptor activity‖ 
haplotype was significantly associated with endurance (predominantly aerobic) event 
among elite athletes (P = 0.003). These data suggest that common genetic variation in 
the B2R is associated with efficiency of skeletal muscle contraction and with distance 
event of elite track athletes and that at least part of the associations of ACE and fitness 
phenotypes is through elevation of kinin activity.  
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APPENDIX 2:  Published letters arising from this thesis 
 
1. In search of genetic precision 
 
Humphries SE, Hawe E, Dhamrait SS, Miller GJ, Talmud PJ 
Lancet. 2003; 361: 1908-1909. 
 
Sir—We  have  previously  suggested  the  existence  of  an  interaction  between  the 
apolipoprotein ε4 allele and cigarette smoking in determining risk of coronary heart 
disease.
1  In  their  Research  letter,  Bernard  Keavney  and  colleagues  (Feb  1,  p  396)
2 
dispute our finding, while your accompanying Editorial (p 357)
3 calls into question the 
value of association studies in biomedical research. 
 
Keavney and colleagues, collaborators in the International Study of Infarct Survival 
(ISIS), misrepresent our data. We reported 146 (not 115, as stated) prospective cases of 
coronary heart disease and stated that smoking caused a significant increase in risk ―in 
men of all genotypes but particularly in men carrying the ε4 allele‖, not, as Keavney 
and co-workers assert ―only among carriers of the ε4 allele‖.  
 
We question the genotyping methods reported by Keavney and colleagues, given that 
our  Madge  method
1  is  referenced  as  being  used  in  their  study.  Furthermore,  their 
negative  finding  does  not  perhaps  carry  the  weight  with  which  it  is  credited.  All 
candidate gene association studies are not the same, and cross-sectional case-control 
studies, such as ISIS,
4 have major weaknesses. More than half of all cases will have 
been unavailable for study in ISIS, since up to 40% of individuals with myocardial 
infarction  do  not  survive  to  reach  hospital,
5  and  in  addition,  those  ineligible  for 
thrombolysis, and a further 14·5% of early deaths were all excluded from analysis in 
ISIS. If smokers carrying the ε4 allele were at increased risk of sudden or early death or 
less suitable for thrombolysis, this would make any further analysis unreliable. The 
same  would  hold  true  if  smokers  with  the  ε4  allele  contributed  significantly  to  the 
18·1% who were excluded from ISIS because they did not respond to the questionnaire. 
 
Such generic weaknesses of case-control gene-environment studies of candidate genes 
are further compounded by specific methodological flaws. Retrospective assessment of   APPENDICES 
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the  magnitude  of  the  environmental  stimulus  (in  Keavney  and  colleagues‘  study 
smoking  history  was  sought  6  months  after  the  event)  may  prove  unreliable. 
Meanwhile, a proportion of the controls in Keavney and colleagues‘ study were first-
degree  relatives  of  the  cases,  thus  sharing  inherited  factors  and,  potentially, 
environmental factors such as passive smoking. It is usual (and genetically appropriate) 
for  individuals  with  the  ε3/3  genotype  to  be  used  as  the  reference  group,  whereas 
Keavney and co-workers use those with the ε3/2 genotype. Keavney and colleagues also 
excluded, for no apparent reason, individuals with the ε2/2 genotype and those with the 
high  risk  ε4/4  genotype  from  their  Table  1.  By  contrast,  in  Table  2  they  include 
individuals homozygous for the ε3 and ε4 alleles.  
 
We reanalysed data from Keavney and colleagues‘ Table 2 (we excluded individuals 
with the ε2/4 genotype) to calculate the risk of coronary heart disease by apolipoprotein 
E (APOE) genotype and smoking status in ISIS (Figure). Our reanalysis confirms that 
smokers with the ε4 allele have a significantly greater than additive risk of coronary 
heart disease, with a relative excess  risk of interaction of 1·62 (95% CI 0·4–2·97). 
Furthermore, although Keavney and colleagues state that there was no difference in the 
proportion  of  survivors  between  the  APOE  genotypes,  individuals  with  the  ε3/4 
genotype had a lower survival rate in the 6 months after myocardial infarction (p=0·06) 
and  individuals  with  the  ε4/4  genotype,  with  anticipated  low  survival  rates,  were 
inexplicably excluded from this analysis. 
 
Bigger is not always better: smaller prospective studies of gene-environment interaction 
are generally more robust and reliable than somewhat larger case-control studies. The 
comments by Keavney and colleagues, which are affirmed in your Editorial, through 
confusion, risk throwing a healthy baby out due to the presence of some tainted bath 
water. We would counsel against such a response.  
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2.  ACE Genotype and Performance 
 
Montgomery HE, Dhamrait SS.    
J Appl Physiol 2002; 92: 1774–1775. 
 
 
To  the  Editor:  The  angiotensin-converting  enzyme  (ACE)  insertion/deletion  (I/D) 
polymorphism has previously been associated with measures of training response and 
human endurance performance. A recent article (4) concluded that such an association 
was weak or spurious. However, this conclusion is erroneous, being derived from flaws 
in the gene-environment model used. The application of four different training regimes 
to nine subgroups of race and sex in a sample of only 117 individuals will per force 
prevent the identification of any such association. The rationale for this contention is 
discussed. 
Gene-environment  interaction  (GEI)  studies  relate  the  magnitude  of  physiological 
response  to  a  uniform  environmental  stimulus  with  variation  in  a  candidate  gene. 
However,  response  magnitude  depends  on  stimulus  nature  and  scale  and  on  the 
subject‘s physical and genetic characteristics. The ideal GEI study thus seeks 1) subject 
homogeneity (similar individuals of identical race and sex), 2) stimulus homogeneity 
(nature,  magnitude,  and  duration),  and  3)  selection  of  an  appropriate  phenotype  to 
assess.  
Sonna et al. (4) report such a GEI study: candidate gene was ACE, variant was I/D 
polymorphism, subjects were army recruits, environmental stimulus was exercise, and 
phenotypic responses were performance measures. However, their conclusion that the 
ACE  gene  exerts  minor  or  spurious  effects  on  performance  characteristics  is  not 
justified.  
Subjects  were  not  homogeneous.  The  use  of  nine  combinations  of  race  and  sex  is 
disadvantageous. 1) Associations of phenotype with race confound association with x 
genotype if polymorphism frequency also varies dramatically (as here) with race. 2) 
Phenotype  is  influenced  by  genes  associated  with  race  and  gender.  Left  ventricular 
growth  is  greater  in  men  and  those  of  African  descent  (3),  and  some  performance 
responses will also be influenced by race and sex. 3) The influence of a polymorphism 
on phenotypic response will, as the authors acknowledge, differ as a function of the 
genetic  background  of  the  population  under  study.  Mixing  such  backgrounds  by   APPENDICES 
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inclusion of diverse race and sex combinations is thus detrimental. 4) Polymorphism 
functionality  may  itself  vary  with  race.  Fundamental  to  this  study,  the  ACE  I/D 
polymorphism  is  used  as  a  marker  of  tissue  ACE  activity.  Such  an  association  is 
unexplored and unproven among non-Caucasians. However, its association with serum 
ACE activity in Caucasians may be absent among African-Americans (1), thus negating 
the very rationale for the use of the polymorphism as a marker of ACE activity in such 
groups entirely.  
The complex effects of race and sex on the gene-environment interaction cannot be 
modeled when 117 subjects are divided into nine potential combinations of race and sex 
themselves spread over three genotypes. Furthermore, detecting a 20% difference in 
phenotypic response (far greater than that reported in any gene-environment association 
studies of mixed race-sex cohorts so far) with 80% power requires (they suggest) 30 
subjects in each group, which is far more than is found for any race-sex combination 
here. Thus, with only 37 African-Americans starting training (3 of II genotype, roughly 
one-half likely to be women) and a reported cohort dropout rate of 20.4%, even fewer 
subjects are left for analysis.  
The problem cannot be overcome by ―lumping together‖ those of one sex (and different 
race) or those of different race, as performed in the Sonna et al. study (4) for the three 
non-African-American/Caucasian  groups.  Furthermore,  conclusions  cannot  be  drawn 
from the study of Caucasians alone. Data for only 117 (61 women) individuals were 
studied, of 147 ―starters,‖ and, of the original cohort, only 57% were Caucasian. If we 
assume no race and sex selection in passing training (an additional confounder that we 
cannot  judge  from  the  data  presented),  then  there  would  have  been  only  29  male 
Caucasians  of  three  genotypes  in  the  final  analysis,  which  is  again  far  too  few  for 
meaningful comparisons with other race-sex groups.  
Training stimulus was inhomogeneous. Training stimulus was inhomogeneous, differing 
according to four ability groups whose racial or gender composition, genotype mix, and 
―pass rate‖ may have also differed.  
Choice of phenotype. An association of ACE genotype with training-related change in 
maximal O2 uptake has never been shown. Other measures (such as pressups and sit-
ups) may require mixed strength and endurances. The association of the I allele with the 
latter and the D allele with the former (2) would confound allele association with such 
measures.  
Furthermore, raw data were adjusted for age and sex to provide a ―score‖ in a range of 
0–100, the effect being to ―reduce the statistical impact of outliers without excluding   APPENDICES 
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them from analysis‖ (4), a major problem when the genetic variation being examined 
may account for such outliers.  
In addition, lack of association of genotype with such measures (even if statistically 
valid)  cannot  be  used  to  discount  past  association  with  different  measures  of 
performance in other more homogeneous groups. Nor can such data be used to infer 
anything of the validity of other studies of entirely other types (e.g., candidate gene-
association studies of elite athletes).  
Thus a heterogeneous (four group) environmental stimulus has been applied to nine 
combinations of race and sex with three genotypes among only 117 individuals. The 
conclusion that ―the apparent association described by some is due to a minor effect of 
the  ACE  gene  on  physical  performance  that  is  important  only  under  selected 
circumstances‖ (4) is thus questionable.  
Putative race and sex dependence of the strength of association of a polymorphism with 
a given phenotypic trait remains an important issue to address. This study did not set out 
to (and could not) do this. In addition, analysis of mixed training in such small mixed-
sex and race groups does not prove, or disprove, the impact of any given polymorphism 
in any population, mixed or otherwise. 
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3. ACE gene, physical activity, and physical fitness 
 
Williams AG, Day SH, Dhamrait S.   
J Appl Physiol. 2002; 93(4): 1561-2 
 
To the Editor: We read with interest the recent article on the topic of the angiotensin-
converting enzyme (ACE) gene by Fuentes and colleagues (2). We see some value in 
aspects of their study, for example, as an investigation of the effect of the ACE insertion 
(I)/deletion (D) polymorphism on blood pressure in a specific population. However, we 
were  disturbed  at  elements  of  both  the  introduction  section  and  the  discussion  and 
conclusion. 
An  introduction  section  is  traditionally  used  to  outline  the  theoretical  basis  for  the 
investigation  being  presented.  In  this  case  (2),  a  major  focus  of  the  study  was  the 
possible association of the ACE gene with self-reported moderate-intensity leisure time 
physical activity. The theoretical basis presented for such an association was weak in 
the extreme, for two reasons. 
First, no literature was cited by Fuentes et al. (2) to support the premise that a greater 
fitness level and/or trainability will encourage greater physical activity in adulthood 
(regardless of any influences of specific genes). Yet this was the premise underpinning a 
major part of the study (see Table 2 in Ref. 2). 
Second, even if appropriate literature supporting the premise that greater fitness and/or 
trainability  produces  greater  activity  in  adulthood  had  been  cited,  there  are  strong 
reasons why seeking an effect of the ACE gene in this regard is likely to prove fruitless. 
Specifically, the research on the ACE gene has suggested possible beneficial effects of 
both alleles on the response to physical training. Growing evidence associates the D 
allele with the growth of muscle in humans (1, 6, 9) and elite performance in power 
events (8). Furthermore, evidence from a nonhuman model associates angiotensin II 
(the product of the action of ACE on angiotensin I) with skeletal muscle growth (4). 
Thus evidence suggests that the D allele might predispose an individual to successful 
performance in particular sporting events. Although we acknowledge that there is some 
important  contradictory  evidence  (10,11),  there  is  also  considerable  evidence 
associating the I allele with certain endurance phenotypes (5, 12, 13) and with elite 
endurance status (3, 7, 8). Hence, evidence suggests that the I allele, in addition to the D 
allele, might predispose an individual to successful performance in particular sporting 
events. Consequently, an effect of the ACE gene on activity in adulthood due to effects   APPENDICES 
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on fitness and/or the response to training is highly unlikely. Even more importantly, the 
lack of association of the ACE I/D polymorphism with adulthood activity is used (2) to 
―confirm‖ reports of no association between ACE I/D and physical fitness in both the 
concluding paragraph of the article and the abstract. The lack of association reported by 
Fuentes et al. (2) does not confirm anything of the sort. Single-question self-reported 
moderate-intensity leisure time physical activity is not a recognized fitness phenotype 
suitable for investigating gene and gene-environment effects. Thus the data presented by 
Fuentes  et  al.  add  nothing  to  the  debate  on  the  effect  of  the  ACE  gene  on  fitness 
phenotypes and should not be used to ―confirm‖ results of one sort or another in that 
field. 
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APPENDIX 4:  Assessment of circulating oxidative stress in the University College 
Diabetes and Cardiovascular disease Study (UDACS) (Dhamrait et al. 2004) 
 
Assays were performed by Dr JW Stephens.  Plasma total anti-oxidant status (TAOS), 
which is inversely related to ROS generation, was measured by Sampson‘s modification 
of Laight‘s photometric microassay (Sampson et al. 2002), using 2.5l citrated plasma 
samples in  96-well ELISA plates.  Inter- and intra-assay coefficients of variation were 
14.1%  and  4.3%  respectively.    In  addition,  plasma  esterified  F2-isoprostanes  were 
measured using gas  chromatography and mass spectroscopy as previously described 
(Morrow et al. 1994; Ferraro et al. 2003) in 20 UCP2-866G>A homozygous subjects (5 
GG and 5 AA with CHD and 5 GG and 5AA without CHD), with the mean for each 
group closely matched for baseline characteristics including drug treatment as shown in 
Table  8.1.  Results  were  calculated  by  reference  to  deuterated  8-iso-PGF2α  internal 
standards.   Analyses were confined to Caucasian diabetic (type 1 and 2) men only 
(n=465; mean age 61.113.3 years).  The relationships between baseline parameters and 
plasma TAOS were tested by Spearman rank correlation co-efficient.  An ANOVA was 
also performed to test the association between genotype and TAOS after adjustment for 
the potential confounders using multiple regression analysis to obtain a residual.   
 
 
Plasma  TAOS  was  independent  of  pharmacotherapy,  but  correlated  positively  with 
plasma  HDL-cholesterol,  and  negatively  with  triglyceride,  glucose,  HbA1c  and 
proteinuria (correlation co-efficient r =0.12, -0.15, -0.11, -0.10 and -0.07, respectively; 
all P<0.05).  Plasma TAOS was significantly associated with UCP2-866G>A genotype, 
with  subjects  homozygous  for  the  A  allele  having  the  lowest  values  (TAOS 
44.3±12.7%, 41.8±14.0%, 40.2±12.4% for GG, GA, AA respectively; ANOVA P=0.07, 
GG vs. A allele, P=0.03).  When results were stratified by CHD status (Figure 8.1),   APPENDICES 
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there was a small but significant difference between genotype and plasma TAOS in men 
without CHD (45.1±12.8%, 42.1±14.1%, 42.7±10.0% for GG, GA, AA respectively;  
 
Figure  10.1.    Plasma  TAOS  in  465  diabetic  Caucasian  men  recruited  to  the 
UDACS according to CHD status and stratified by UCP2 -866G>A genotype. 
 
 
 
Footnote:    *  P=0.04  for  GG  vs.  A  allele  carriers;  †  P=0.01  for  G  allele  vs.  AA 
homozygotes; numbers of subjects are shown at the base of each column. 
 
 
ANOVA P=0.13, GG vs. A allele, P=0.04), which remained significant after adjustment 
for age, triglyceride, HDL-C, glucose, HbA1c and proteinuria (GG vs. A allele, P=0.04).  
These genotypic differences in plasma TAOS were more pronounced amongst men with 
CHD (41.6±12.4%, 41.03±13.9%, 30.1±16.1% for GG, GA, AA respectively; ANOVA 
P=0.049, G allele vs. AA P=0.01).  Diabetic men with CHD who had the UCP2-866AA 
genotype had the lowest plasma TAOS level of all groups tested.  There was evidence   APPENDICES 
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of interaction between UCP2-866G>A genotype and CHD status in determining plasma 
TAOS (P=0.025 for G allele vs. AA). 
 
To  further  corroborate  these  data,  20  men  from  UDACS  were  selected  for 
homozygosity  for  the  UCP2-866G>A  variant  and  closely  matched  for  baseline 
characteristics (Table 8.1).  There were non-significant differences in plasma markers of 
OS between the presence/absence of CHD; with TAOS lower (CHD 42.2±12.7% vs. no-
CHD 48.4±12.9%; P=0.22) and F2-isoprostanes higher (CHD 168.3±74.2pg.ml
-1 vs. no-
CHD 111.7±79.1pg.ml
-1; P=0.05).  However, there were highly significant differences 
in plasma TAOS between AA and GG homozygotes overall (AA 36.9±8.4% vs. GG 
53.6±10.5%;  P<0.0001),  in  those  without  CHD  (AA  42.1±6.1%  vs.  GG  54.7±7.0; 
P=0.016) and in those with CHD (AA 31.7±7.3%
 vs. GG 52.6±6.3%; P=0.001).  AA 
homozygotes  with  CHD  had  the  lowest  TAOS  of  all  groups  (Figure  8.2a).  In 
accordance with this, plasma F2-isoprostane concentrations were highly significantly 
elevated  in  AA  homozygotes  both  overall  (AA  175.4±64.5pg.ml
-1  vs.    GG 
104.6±72.8pg.ml
-1; P=0.011) and in those with CHD (AA 220.6±37.2pg.ml
-1 vs. GG 
109.9±51.1pg.ml
-1; P=0.005), but not significantly in AA homozygotes without CHD 
(AA 119.1±40.2pg.ml
-1 vs. GG 105.9±27.5pg.ml
-1; P=0.58; Figure 8.2b).  There was 
evidence of significant interaction between genotype and CHD status in determining F2-
isoprostanes (P=0.014) but not plasma TAOS (P=0.19). 
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Table 10.1.  Plasma TAOS and esterified F2-isoprostanes in relation to UCP2-866G>A genotype and CHD status in the UDACS substudy. 
 
  No CHD  CHD 
  AA (n=5)  GG (n=5)  P  AA (n=5)  GG (n=5)  P 
Age (years)  64.6 (4.4)  65.4 (5.3)  0.80  64.0 (6.2)  65.1 (7.2)  0.79 
BMI (kg.m
-2)  32.7 (6.9)  29.6 (4.8)  0.43  30.34 (3.7)  36.2 (19.0)  0.52 
Duration DM (years)  6 (0.5-20.5)  6 (4-12)  0.78  12 (7.5-21)  10 (8-17)  0.64 
HbA1c (%)  6.5 (0.7)  7.5 (1.3)  0.19  8.4 (2.1)  8.6 (1.5)  0.88 
Glucose (mmol.l
-1)  9.2 (5.0-15.7)  8.1 (7.2-10.1)  0.47  9.6 (6.8-16.6)  9.2 (7.5-16.2)  0.99 
Cholesterol (mmol.l
-1)  5.1 (0.8)  5.5 (1.0)  0.50  4.5 (0.3)  4.6 (0.9)  0.90 
LDL (mmol.l
-1)  2.8 (0.6)  3.4 (1.0)  0.28  2.2 (0.6)  2.4 (0.5)  0.65 
HDL (mmol.l
-1)  1.3 (0.4)  1.4 (0.3)  0.93  1.1 (0.2)  1.2 (0.1)  0.27 
Tg (mmol.l
-1)  2.1 (0.6)  2.3 (1.5)  0.81  3.3 (1.4)  2.2 (1.7)  0.30 
TAOS (%)  42.06 (6.12)*  54.68 (6.99)  0.02  31.70 (7.27)*  52.6 (6.25)  0.001 
F2 isoprostanes (pg. ml
-1)  119.1 (40.2)**  105.9 (27.48)  0.58  220.6 (37.2)**  109.9 (51.1)  0.005 
Systolic BP (mmHg)  141 (12)  145 (12)  0.63  136 (20)  148 (27)  0.46 
Diastolic BP (mmHg)  81.2 (8.4)  80.4 (8.1)  0.88  81 (9)  82 (7)  0.57 
% Proteinuria  30  % (n=3)  40% (n=4)  0.64  60 % (n=3)  60 % (n=3)  1.00 
% Smokers  20 % (n=1)  20 % (n=1)  1.00  0 % (n=0)  20% (n=1)  0.29 
% on insulin  20 % (n=1)  20 % (n=1)   1.00  40 % (n=2)  60 % (n=3)   0.53 
% on Aspirin  20 % (n=1)  40 % (n=2)  0.49  60 % (n=3)  80 % (n=4)   0.49 
% on Statin  20 % (n=1)  0 % (n=0)  0.29  100 % (n=5)  80 % (n=4)  0.29 
% on ACEI  40 % (n=2)  20 % (n=1)  0.49  60 % (n=3)  80 % (n=4)   0.49 
Mean (SD) shown or Median (IQR); Compared with Student‘s t-test/ Mann-Whitney/ Chi-squared test 
 
Genotype groups were closely matched for baseline characteristics. 
Comparing AA (No CHD v CHD) 
*P<0.05 
**P<0.01   APPENDICES 
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Figure 10.2.  Plasma TAOS and F2-isoprostane in UDACS substudy of 20 diabetic 
closely matched men selected for homozygosity for UCP2-866G>A genotype and 
stratified by CHD status. 
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